{"data":{"build_date":"2026-05-07","cohort":{"mid_n":100,"tail_n":492,"top_n":10,"total":602},"dataset_version":"jhtv-portfolio@2026-Q2","engine_version":"1.0.0","methodology_version":"methodology@2026-05-07","mid":[{"biomarker_overlap":"PAD4 activity; anti-PAD4 serum levels","composite_score":0.66,"cr_rationale":"Anti-PAD4 mAb in RA with lung fibrosis comorbidity targets a subset with poor SoC options.","description_excerpt":"Value PropositionSelective monoclonal antibody therapy to treat lung fibrosis.Directly targets immune cells to promote a pro-inflammatory pathway that reduces fibrosis.High serum levels are associated with less severe lung disease, decreased fibrosis, and improved survival in a subset of rheumatoid ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"rheumatoid_arthritis","indication_free_text":"lung fibrosis; high serum levels associated with less severe disease in rheumatoid arthritis patients","mechanism_class":"anti-PAD4 monoclonal antibody","modality":"monoclonal_antibody","objectID":"53603","rationale_one_line":"Recombinant anti-PAD4 antibody; description explicitly states 'high serum levels are associated with less severe lung disease...in a subset of rheumatoid arthritis patients', making RA the best-fit supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53603","subscores":{"clinical_relevance":0.6,"ira_exposure":0.85,"modality_pos":0.9,"whitespace":0.5},"target":"PADI4","title":"Recombinant anti-PAD4 antibodies as a treatment for lung fibrosis"},{"biomarker_overlap":"extracellular DNA (cell-free DNA)","composite_score":0.66,"cr_rationale":"DNase1L3-enhancing antibody reduces inflammatory cfDNA with a mechanism distinct from existing RA DMARDs.","description_excerpt":"Value Proposition\r\n·        Autoantibody that promotes DNA degradation to diminish inflammation\r\n·        Enhances endonuclease DNase1L3 activity\r\n·        Avoids kidney-mediated inflammatory response\r\n \r\nUnmet Need\r\n·        Extracellular DNA, also called cell-free DNA, released from dying cells or","dev_stage":"unknown","exclusivity_status":"unknown","indication":"rheumatoid_arthritis","indication_free_text":"Inflammatory bowel disease, cystic fibrosis, and arthritis; promoting DNA degradation to diminish inflammation via DNase1L3 enhancement","mechanism_class":"DNase1L3-enhancing autoantibody","modality":"monoclonal_antibody","objectID":"52852","rationale_one_line":"Taxonomy includes Inflammation > Arthritis among the indications and the antibody enhances DNase1L3 to reduce inflammatory cell-free DNA; arthritis maps to rheumatoid_arthritis as the closest supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52852","subscores":{"clinical_relevance":0.6,"ira_exposure":0.85,"modality_pos":0.9,"whitespace":0.5},"target":"DNase1L3","title":"Antibody for DNA Degradation"},{"biomarker_overlap":null,"composite_score":0.6539818946831569,"cr_rationale":"NHE3 peptide nanoparticles target severe IBD diarrhea beyond systemic SoC.","description_excerpt":"Value Proposition:\r\n·        Nanoparticle-based delivery of therapeutic that enhances intestinal sodium absorption \r\n·        Broad clinical applications in severe diarrhea, whether acute or chronic\r\n·        Effective treatment across heterogeneous presentations of diarrhea \r\n·        Appropriate f","dev_stage":"unknown","exclusivity_status":"unknown","indication":"crohns","indication_free_text":"Severe diarrhea including in Crohn's disease, ulcerative colitis, and inflammatory bowel disease; nanoparticle-NHE3 peptide to enhance intestinal sodium absorption","mechanism_class":"NHE3 activating peptide","modality":"peptide","objectID":"52511","rationale_one_line":"Taxonomy explicitly tags Crohn's Disease and Ulcerative Colitis; source describes nanoparticle delivery of NHE3 peptide for diarrhea in IBD; crohns is selected as the lead supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52511","subscores":{"clinical_relevance":0.65,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":1},"target":"NHE3","title":"Nanoparticle-NHE3 Peptide to Treat Diarrhea"},{"biomarker_overlap":null,"composite_score":0.651901695779676,"cr_rationale":"Gene-edited myeloid cells target immune exclusion limiting checkpoint efficacy.","description_excerpt":"Value Proposition:\r\n·      Gene-editing approach creates myeloid cells polarized into a pro-inflammatory phenotype.\r\n·      Engineered cells persist even in an immune-suppressive environment. \r\n·      High potential as anti-cancer therapy, as cells are present in all tissues and can easily infiltrat","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer (broad, all tissue types)","mechanism_class":"Gene-edited myeloid cell immunotherapy","modality":"gene_therapy","objectID":"58654","rationale_one_line":"Gene-editing approach creating pro-inflammatory myeloid cells that infiltrate tumors; primary innovation is gene editing; broad oncology not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/58654","subscores":{"clinical_relevance":0.7,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Proinflammatory Immature Myeloid Cells and Their Use in Treatment of Cancer"},{"biomarker_overlap":"cancer-specific mutations (PAM site absence in healthy tissue)","composite_score":0.651901695779676,"cr_rationale":"Tumor-specific CRISPR guide RNAs reduce off-target toxicity, a key limitation of pan-cancer gene editing.","description_excerpt":"Value Proposition: - Specific targeting of mutations can treat any cancer with the specified mutations. - Selective cell killing spares healthy tissue while eliminating cancer cells.  - Pan-cancer efficacy as guide RNAs are developed to target a wide breadth of cancer-specific mutations. - Lack of p","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"pan-cancer including pancreatic cancer","mechanism_class":"CRISPR/Cas9 tumor-specific guide RNA","modality":"gene_therapy","objectID":"54191","rationale_one_line":"CRISPR/Cas9 with tumor-specific guide RNAs is a gene therapy modality; pan-cancer platform without a single primary supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54191","subscores":{"clinical_relevance":0.7,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"CRISPR/Cas9 and Tumor-Specific Guide RNAs as a Specific and Selective Cancer Cell Killing Biologic Platform"},{"biomarker_overlap":"NF1 gene mutations (RASopathies)","composite_score":0.651901695779676,"cr_rationale":"NF1 GRD gene therapy targets MPNST without approved targeted options.","description_excerpt":"Unmet Need\r\nNeurofibromatosis type 1 (NF1) is a common genetic disorder that affects approximately 1 in 3,000 individuals worldwide. Patients with NF1 have DNA alterations to the neurofibromin 1 gene which cause RASopathies, a family of diseases caused by altered Ras signaling. RASopathies can inclu","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Neurofibromatosis type 1 (NF1), RASopathies, malignant peripheral nerve sheath tumors (MPNST)","mechanism_class":"Membrane-targeting NF1 GAP-related domain (GRD) to suppress RAS activity","modality":"gene_therapy","objectID":"35359","rationale_one_line":"Membrane-targeting NF1 GRD construct to suppress RAS activity in NF1-related MPNST and other RASopathies — gene therapy; rare genetic disease outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35359","subscores":{"clinical_relevance":0.7,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"RAS / NF1 GRD","title":"A Membrane-targeting Construct of NF1 GAP-related Domain (GRD) that Suppresses RAS Activity in NF1-related MPNST, NF1 and other Rasopathies"},{"biomarker_overlap":null,"composite_score":0.651901695779676,"cr_rationale":"Biological pacemaker gene therapy addresses patients ineligible for device pacemakers.","description_excerpt":"Spontaneous cellular electrical rhythms govern numerous biological processes from the autonomous beating of the heart, to respiratory rhythms and insulin secretion. For instance, abnormal pacing in the heart leads to various forms of electrical disorders that necessitate conventional pharmacologic i","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cardiac arrhythmia and biological rhythm disorders (pacemaker engineering)","mechanism_class":"bio-electrical rhythm modulator (gene engineering of pacemaker activity)","modality":"gene_therapy","objectID":"24627","rationale_one_line":"Gene therapy engineering approach to modulate bio-electrical rhythms for cardiac arrhythmias; cardiovascular indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24627","subscores":{"clinical_relevance":0.7,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Modulation of Bio-electrical Rhythms Via a Novel Engineering Approach"},{"biomarker_overlap":null,"composite_score":0.651901695779676,"cr_rationale":"AAV-miR-26a addresses HCC where systemic SoC historically offered poor survival.","description_excerpt":"C10912: A plasmid to produce recombinant adeno-associated virus (AAV) that expresses microRNA-26a and green fluorescent proteinValue Proposition: \r\n\n&#8226; miR-26a, cloned into the short intron that is part of the EF1a promoter unit, thus allowing simultaneous production of eGFP and miR-26a from a ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"hepatocellular carcinoma / liver cancer (miR-26a gene therapy)","mechanism_class":"AAV-delivered microRNA (miR-26a)","modality":"gene_therapy","objectID":"18740","rationale_one_line":"scAAV plasmid expressing miR-26a with eGFP reporter, classified under Liver Cancer and Gene Therapies; liver cancer is outside the supported indication enum, maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/18740","subscores":{"clinical_relevance":0.7,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"miR-26a","title":"scAAV.EF1a.miR26a.eGFP Plasmid"},{"biomarker_overlap":null,"composite_score":0.651901695779676,"cr_rationale":"HIF-1alpha stabilization for ischemia; no approved gene therapy SoC for cardiac/limb ischemia, high unmet need.","description_excerpt":"C03416: HIF-1aDP, A Constitutively-Expressed form of Hypoxia-Inducible Factor 1a\r\n\t\t\tTechnical Details:\r\n\t\t\tIt has previously been demonstrated that a truncation of HIF-1alpha after amino acid residue 390 results in a constitutively expressed form of the protein. The purpose of this work was to iden","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cardiovascular / ischemia (HIF-1alpha stabilization)","mechanism_class":"HIF-1alpha constitutive expression construct","modality":"gene_therapy","objectID":"18718","rationale_one_line":"Constitutively-expressed HIF-1alpha construct for cardiovascular applications via gene therapy/biologics; cardiovascular indication is outside the supported enum, maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/18718","subscores":{"clinical_relevance":0.7,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"HIF-1alpha","title":"C03416: HIF-1aDP, A Constitutively-Expressed form of Hypoxia-Inducible Factor 1a"},{"biomarker_overlap":null,"composite_score":0.6243988269794721,"cr_rationale":"Malaria has limited approved preventive biologics; high-titer antibody vectored immunoprophylaxis addresses major unmet need.","description_excerpt":"Invention novelty: an improved antibody-based malarial therapy\r\nValue Proposition\r\nMalaria remains one of the world’s major causes of death, especially in Africa. Ninety percent of malaria mortalities occur in Africa, where it accounts for about one in five childhood deaths. WHO reported that there ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"malaria (Plasmodium falciparum)","mechanism_class":"vectored immunoprophylaxis / antibody-based anti-malarial","modality":"monoclonal_antibody","objectID":"24284","rationale_one_line":"Antibody-based vectored immunoprophylaxis to generate 'high-titer Plasmodium Falciparum circumsporozoites antibodies' for malaria; monoclonal antibody modality targeting an infectious disease outside the enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24284","subscores":{"clinical_relevance":0.8,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"Plasmodium falciparum circumsporozoite protein (CSP)","title":"Antibody-based Vectored Immunoprophylaxis Provides High-titer Plasmodium Falciparum Circumsporozoites Antibodies"},{"biomarker_overlap":null,"composite_score":0.6119016957796761,"cr_rationale":"Brain-penetrating nanoparticle for GBM gene therapy; addresses major delivery barrier in fatal disease.","description_excerpt":"Unmet Need\r\nGlioblastomas account for 45% of all brain cancers, and affect nearly 11,000 men, women and children every year. They are the most debilitating, complex, and treatment-resistant brain tumors. They can become widespread quickly and can grow in multiple areas at once making them difficult ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Glioblastoma (brain tumor)","mechanism_class":"GRAS-material brain-penetrating nanoparticle gene delivery","modality":"gene_therapy","objectID":"36712","rationale_one_line":"GRAS material-based large brain-penetrating nanoparticles for widespread gene therapy distribution in glioblastoma — gene delivery platform for a brain tumor indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36712","subscores":{"clinical_relevance":0.6,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Entirely GRAS Material-based Large Brain-Penetrating Nanoparticles for Widespread Therapeutic Distribution in Healthy and Tumor-bearing Brain Tissues"},{"biomarker_overlap":null,"composite_score":0.6119016957796761,"cr_rationale":"TSC2-mTOR T cell enhancement for cancer immunotherapy; durable T cell persistence addresses key SoC limitation.","description_excerpt":"Unmet Need\r\nImmunotherapies that boost T cell responses have demonstrated therapeutic efficacy in numerous cancers. To improve the efficacy and expand the clinical utility of immunotherapy, improved methods of stimulating T cell responses are needed. mTORC1 is a critical regulator of T cell activati","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer immunotherapy (broad oncology — T cell-based)","mechanism_class":"mTOR/TSC2 modification for T cell activation enhancement","modality":"gene_therapy","objectID":"36513","rationale_one_line":"New method of mTOR regulation via TSC2 modification to enhance T cell immunotherapy across cancers — gene/cell therapy approach for broad oncology immunotherapy without a single supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36513","subscores":{"clinical_relevance":0.6,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"mTORC1 / TSC2","title":"New Method of mTOR Regulation by TSC2 Modification"},{"biomarker_overlap":null,"composite_score":0.6119016957796761,"cr_rationale":"Gene delivery aAPCs for metastatic melanoma immunotherapy; tumor antigen presentation approach vs checkpoint SoC.","description_excerpt":"Unmet Need\r\n Melanoma is an aggressive form of skin cancer that is characterized by high multidrug resistance and low survival rates. The median survival time for metastatic melanoma patients is approximately 8-9 months with a 3-year overall survival rate of less than 15%. As such, there is a compel","dev_stage":"unknown","exclusivity_status":"unknown","indication":"melanoma","indication_free_text":"Metastatic melanoma","mechanism_class":"Gene delivery particles inducing tumor-derived antigen-presenting cells","modality":"gene_therapy","objectID":"35363","rationale_one_line":"Gene delivery particles to induce tumor-derived antigen-presenting cells for melanoma immunotherapy — 'Melanoma is an aggressive form of skin cancer' explicitly stated; gene delivery modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35363","subscores":{"clinical_relevance":0.6,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Gene Delivery Particles to Induce Tumor-Derived Antigen Presenting Cells"},{"biomarker_overlap":null,"composite_score":0.6119016957796761,"cr_rationale":"Theranostic gene therapy for HCC; combined imaging and therapy vs sequential diagnostic/sorafenib SoC.","description_excerpt":"Unmet Need\r\nHepatocellular carcinoma (HCC) is the third leading cancer in the US with a ~twenty percent (20%) survival rate. HCC develops typically in the inflammatory environment of the liver caused by infections or liver disease. Therefore, it is essential to have highly targeted anti-cancer thera","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Hepatocellular carcinoma (HCC)","mechanism_class":"Transcriptionally targeted CpG-free plasmid gene therapy (theranostic)","modality":"gene_therapy","objectID":"34787","rationale_one_line":"Transcriptionally targeted, CpG-free plasmid for theranostic gene therapy of hepatocellular carcinoma — gene therapy; liver/HCC indication is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/34787","subscores":{"clinical_relevance":0.6,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Transcriptionally Targeted and CPG-free Plasmid for Theranostic Gene Therapy"},{"biomarker_overlap":null,"composite_score":0.6119016957796761,"cr_rationale":"Focal calcium channel gene therapy offers targeted cardiac modulation beyond systemic drug SoC.","description_excerpt":"C04144: Genetic Calcium Channel Blocking Therapy\r\n\r\nNovelty: \r\n\r\nThis technology involves genetic therapy for focal modulation of calcium channel activity, effectively preventing, treating and reducing the severity of many calcium channel related disorders.\r\nValue Proposition: \r\nCalcium channels are","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"calcium channel-related cardiovascular disorders","mechanism_class":"genetic calcium channel blocker","modality":"gene_therapy","objectID":"16260","rationale_one_line":"Gene therapy for focal modulation of calcium channel activity in cardiovascular disorders; cardiovascular indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16260","subscores":{"clinical_relevance":0.6,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"voltage-gated calcium channels","title":"Genetic Calcium Channel Blocking Therapy"},{"biomarker_overlap":null,"composite_score":0.6119016957796761,"cr_rationale":"Periocular gene therapy for ocular neovascularization could extend durability beyond monthly anti-VEGF injections.","description_excerpt":"C03994: Therapeutic for Ocular-related Diseases\r\n\r\nNovelty: \r\n\r\nA method of prophylactically or therapeutically treating an ocular disorder associated with abnormal neovascularization.\r\nValue Proposition: \r\nAn overwhelming majority of the worlds population will experience some degree of vision loss ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"ocular diseases associated with abnormal neovascularization","mechanism_class":"periocular gene transfer (anti-angiogenic)","modality":"gene_therapy","objectID":"16232","rationale_one_line":"Periocular gene transfer for retinal and choroidal diseases caused by ocular neovascularization; ophthalmology indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16232","subscores":{"clinical_relevance":0.6,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Periocular Gene Transfer For Retinal and Choroidal Diseases"},{"biomarker_overlap":null,"composite_score":0.6119016957796761,"cr_rationale":"Thrombomodulin gene therapy for vein grafts targets a high-failure-rate intervention with no pharmacologic SoC.","description_excerpt":"C03579: Genetic Engineering of Autologous Vein Grafts with thrombomodulin-Expressing Vectors to Resist thrombosis, Neointimal Hyperplasia and Atherosclerosis\r\n   \r\n\r\nTechnical Details: \r\n\r\nAutologous vein grafts are the most widely used conduits for coronary and peripheral arterial bypass surgery. C","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"vascular graft thrombosis / atherosclerosis (cardiovascular)","mechanism_class":"thrombomodulin gene therapy (vein graft)","modality":"gene_therapy","objectID":"16164","rationale_one_line":"Genetic engineering of autologous vein grafts with thrombomodulin-expressing vectors to resist thrombosis and atherosclerosis; cardiovascular indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16164","subscores":{"clinical_relevance":0.6,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"thrombomodulin","title":"Genetic Engineering of Autologous Vein Grafts with thrombomodulin-Expressing Vectors to Resist thrombosis, Neointimal Hyperplasia and Atherosclerosis"},{"biomarker_overlap":"C9ORF72 hexanucleotide repeat expansion","composite_score":0.5911460629132439,"cr_rationale":"C9ORF72 ASO targets a defined genetic cause of ALS/FTD with no approved disease-modifying therapy.","description_excerpt":"Invention novelty: This technology is the use of antisense oligonucleotides (ASO) as a therapeutic for specific neurodegenerative diseases. The technology could also be used in development of a biomarker assay to monitor the efficacy of the ASO therapy.   \r\nValue Proposition: Current therapeutic eff","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) / C9ORF72 hexanucleotide expansion disorders","mechanism_class":"antisense oligonucleotide (ASO) therapy","modality":"nucleic_acid","objectID":"50211","rationale_one_line":"ASO therapy targeting C9ORF72 for FTD and ALS; classified under Biologics / Gene Therapies; ALS/FTD not in the 11 indication enums so maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50211","subscores":{"clinical_relevance":0.9,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"C9ORF72","title":"Antisense oligonucleotide therapy and biomarker assay for C9ORF72 hexanucleotide expansion disorders"},{"biomarker_overlap":"MART-1 antigen expression; HLA-DR1 restriction","composite_score":0.585981894683157,"cr_rationale":"Melanoma phosphopeptide vaccine targets MART-1; active SoC exists but immunotherapy combination potential is meaningful.","description_excerpt":"C10691: Novel Peptides as a Melanoma Vaccine\r\n    Value Proposition: \r\n\n&#8226; Phosphopeptides for use as vaccines for therapy and prevention of melanoma\n\n\n&#8226; Phosphopeptides for robust, diverse, and long-lasting anti-tumor immunity\n\n\n&#8226; Specific activity against whole melanoma tumor cell","dev_stage":"unknown","exclusivity_status":"unknown","indication":"melanoma","indication_free_text":"melanoma (phosphopeptide vaccine)","mechanism_class":"melanoma phosphopeptide vaccine (HLA-DR1 restricted)","modality":"peptide","objectID":"16735","rationale_one_line":"Description explicitly states 'Phosphopeptides for use as vaccines for therapy and prevention of melanoma'; melanoma is a supported indication; peptide modality confirmed by taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16735","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.84},"target":"MART-1","title":"MART-1 Phosphopeptides Restricted by HLA-DR1 for use as Melanoma Vaccines"},{"biomarker_overlap":null,"composite_score":0.5843988269794721,"cr_rationale":"Anti-HCV E2 mAb may prevent reinfection where DAAs do not protect.","description_excerpt":"Value Proposition:\r\n·      Comprehensive panel of monoclonal and broadly-neutralizing antibodies against HCV\r\n·      Potential treatment for HCV infection\r\n·      Key bNAb-E2 interactions identified\r\n·      Candidates for discovery of HCV vaccine antigens\r\nUnmet Need\r\nHepatitis C virus (HCV) is a bl","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Hepatitis C virus (HCV) infection","mechanism_class":"Broadly neutralizing anti-HCV antibody (bNAb)","modality":"monoclonal_antibody","objectID":"59582","rationale_one_line":"Broadly neutralizing monoclonal antibodies targeting HCV E2 glycoprotein; mAb modality; HCV infection not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59582","subscores":{"clinical_relevance":0.7,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"HCV E2","title":"Human Broadly Neutralizing Monoclonal Antibodies associated with Hepatitis C Virus Clearance"},{"biomarker_overlap":"KCNK9 overexpression","composite_score":0.5843988269794721,"cr_rationale":"Anti-KCNK9 mAb targets tumors lacking approved therapy against this channel.","description_excerpt":"Value Proposition - First-in-Class Targeting of a Novel Oncogenic Ion Channel: Inhibiting KCNK9 represents a new therapeutic modality in cancers where traditional approaches - Tumor-Specific Overexpression Enables Selectivity: KCNK9 is overexpressed in various tumors (e.g., breast, gastric, lung) bu","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"Breast cancer, gastric cancer, lung cancer (KCNK9-overexpressing tumors)","mechanism_class":"KCNK9 ion channel inhibitor (antibody)","modality":"monoclonal_antibody","objectID":"57104","rationale_one_line":"Therapeutic antibody targeting KCNK9 oncogenic ion channel overexpressed in breast, gastric, and lung tumors; breast_cancer is the first supported enum match.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/57104","subscores":{"clinical_relevance":0.7,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"KCNK9","title":"Therapeutic KCNK9 Antibody"},{"biomarker_overlap":"low-level viremia / viral load","composite_score":0.5843988269794721,"cr_rationale":"HIV control antibodies for functional cure address major gap since ART requires lifelong adherence.","description_excerpt":"Value Proposition\r\n·      Target associated with viral load reduction identified from a large pool of study participants who had low level viremia\r\n·      Potential to reduce disease severity in at-risk populations\r\n·      Proactive approach to lower viral load in individuals who could become infect","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"HIV infection / viral load control","mechanism_class":"HIV-control antibody","modality":"monoclonal_antibody","objectID":"53710","rationale_one_line":"Taxonomy classifies under Therapeutic Antibodies; antibodies associated with HIV viral load control — monoclonal_antibody modality; HIV is outside the supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53710","subscores":{"clinical_relevance":0.7,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":null,"title":"Antibodies associated with HIV control"},{"biomarker_overlap":"prion-like alpha-synuclein aggregates","composite_score":0.5843988269794721,"cr_rationale":"Alpha-synuclein nanobody targets aggregation in Lewy body dementia where no approved disease-modifying therapy exists.","description_excerpt":"Unmet Need\r\nLewy bodies dementia (LBD) is one of the most common causes of dementia, including Parkinson&#39;s disease with dementia (PDD) and dementia with Lewy bodies (DLB). Both clinical and experimental observations support the hypothesis of prion-like α-syn driving α-synucleinopathy, hence targ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Alpha-synucleinopathies including Lewy body dementia, Parkinson's disease with dementia, and dementia with Lewy bodies","mechanism_class":"anti-alpha-synuclein nanobody","modality":"monoclonal_antibody","objectID":"53104","rationale_one_line":"Source describes novel nanobodies as therapy for alpha-synucleinopathies targeting prion-like alpha-syn; nanobodies map to monoclonal_antibody; neurodegenerative indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53104","subscores":{"clinical_relevance":0.7,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"alpha-synuclein","title":"Novel Nanobodies as therapy for α-synucleinopathies"},{"biomarker_overlap":null,"composite_score":0.5843988269794721,"cr_rationale":"Converts inhibitory TME signals to stimulatory; could address checkpoint-refractory tumors.","description_excerpt":"Unmet Need:\r\nOne of the largest obstacles to overcome in cancer immunotherapy is the suppressive actions of the tumor microenvironment. Combination therapies that activate an immune response as well as block inhibitory pathways have potential in creating a prolonged and effective anti-tumor response","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer immunotherapy (tumor microenvironment)","mechanism_class":"immune checkpoint signal converter (inhibitory-to-stimulatory antibody)","modality":"monoclonal_antibody","objectID":"24896","rationale_one_line":"Antibody-based combination immunotherapy converting tumor microenvironment inhibitory signals to stimulatory signals; broad oncology indication outside the 11 supported enums so mapped to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24896","subscores":{"clinical_relevance":0.7,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":null,"title":"Converting immune inhibitory signal into immune stimulatory signal"},{"biomarker_overlap":null,"composite_score":0.5843988269794721,"cr_rationale":"Tumor-targeting bacteria plus checkpoint blockade combination may enhance response in resistant solid tumors.","description_excerpt":"Invention novelty: This technology is a combination therapy method including a tumor-specific bacterium and antibodies that boost tumor immune response.\r\nValue Proposition\r\nWorldwide cancer affects more than 12 million people each year. This number is expected to increase to 14 million each year by ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"solid tumor malignancies","mechanism_class":"anti-CTLA-4 / anti-PD-1 checkpoint blockade combined with tumor-specific bacteria","modality":"monoclonal_antibody","objectID":"24286","rationale_one_line":"Combination of tumor-targeting bacteria with 'anti-CTLA-4 and/or anti-PD-1 antibodies' to treat solid tumors; dominant modality is monoclonal antibody checkpoint blockade; no single enumerated solid-tumor indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24286","subscores":{"clinical_relevance":0.7,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"CTLA4, PDCD1","title":"Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies"},{"biomarker_overlap":null,"composite_score":0.5843988269794721,"cr_rationale":"PD-1/PD-L1 blockade plus vaccine for pancreatic cancer addresses indication with historically poor immunotherapy response.","description_excerpt":"Novel Combination Therapy for Pancreatic Cancer Treatment\r\nJHU REF: C12915\r\nInvention Novelty: The technology is the novel combination of PD1/PD-L1 blockade antibody and vaccine-based immunotherapy to treat pancreatic cancer.\r\n \r\nValue Proposition:\r\nPancreatic cancer is one of the top cancer killers","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"pancreatic cancer","mechanism_class":"anti-PD-1/PD-L1 checkpoint blockade combined with vaccine","modality":"monoclonal_antibody","objectID":"20837","rationale_one_line":"Combination of 'PD1/PD-L1 blockade antibody and vaccine-based immunotherapy to treat pancreatic cancer'; dominant modality is monoclonal antibody checkpoint blockade for pancreatic cancer, outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/20837","subscores":{"clinical_relevance":0.7,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"PDCD1 (PD-1), CD274 (PD-L1)","title":"PD-1/PD-L1 Blockade together with Vaccine Therapy Facilitates Effector T Cell Infiltration into Pancreatic Tumors"},{"biomarker_overlap":null,"composite_score":0.5843988269794721,"cr_rationale":"HSV-2 lacks effective curative therapy; antibody-toxin fusion offers potential beyond suppressive antivirals.","description_excerpt":"Treatment and Preventative for Herpes Simplex Virus-2\r\nJHU REF: 12627\r\n \r\nInvention Novelty: This technology is an antibody-toxin fusion therapeutic for treatment and prevention of HSV-2.\r\n \r\nValue Proposition:\r\nHSV infects 85% of the global population and 73% of the American population. Currently, ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"herpes simplex virus-2 (HSV-2) infection","mechanism_class":"antibody-toxin fusion","modality":"monoclonal_antibody","objectID":"20819","rationale_one_line":"Llama-derived single-domain antibody fused to a toxin targeting HSV-2 glycoprotein D for treatment and prevention of HSV-2 — infectious disease outside enum, antibody-toxin fusion closest to monoclonal_antibody.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/20819","subscores":{"clinical_relevance":0.7,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"Glycoprotein D (HSV-2 gD)","title":"Isolation and Application of a Llama-derived Single Domain Antibody Binding to Glycoprotein D of HSV-2"},{"biomarker_overlap":null,"composite_score":0.5843988269794721,"cr_rationale":"TGF-beta/AT1 blockade addresses Marfan aortic complications with no approved disease-modifying therapy.","description_excerpt":"Unmet Need: \r\nMarfan syndrome is a disorder of the body&#39;s connective tissues. One out of every 5,000 people in the world has Marfan syndrome, or a related connective tissue disorder. Features of the disease include, emphysema (which frequently results in spontaneous lung rupture), eye problems, ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Marfan syndrome / connective tissue disorder (emphysema, cardiovascular, skeletal)","mechanism_class":"TGF-beta antagonist / AT1 receptor blocker","modality":"monoclonal_antibody","objectID":"16437","rationale_one_line":"TGFbeta antagonists including AT1 blockers for Marfan syndrome multi-system pathogenesis; rare genetic connective tissue disorder outside supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16437","subscores":{"clinical_relevance":0.7,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"TGFB1","title":"TGFbeta Antagonists, Including AT1 Receptor Blockers, Rescue the Multisystem Pathogenesis of Marfan Syndrome & Associated Mouse Model"},{"biomarker_overlap":"LINE-1 ORF1p overexpression (~50% of human malignancies)","composite_score":0.5719016957796761,"cr_rationale":"Pan-solid-tumor gene therapy targeting LINE-1 ORF2p; broad oncology with modest SoC differentiation.","description_excerpt":"Unmet Need\r\nA substantial portion (~50%) of human malignancies overexpress a protein encoded by a genomic repeat, the Long INterspersed Element-1 (LINE-1)-encoded ORF1p. These include colon, pancreatic, lung, ovarian, breast and prostate cancers. LINE-1 is a retrotransposon that codes for both RNA a","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Solid tumors overexpressing LINE-1 ORF1p (colon, pancreatic, lung, ovarian, breast, prostate cancers)","mechanism_class":"LINE-1 retrotransposon ORF2p translation enhancer","modality":"gene_therapy","objectID":"38588","rationale_one_line":"Gene therapy approach to enhance translation of LINE-1 ORF2p for broad solid tumor indications — pan-oncology target spanning multiple cancer types not individually supported by the 11 enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/38588","subscores":{"clinical_relevance":0.5,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"LINE-1 ORF2p","title":"Enhancing Translation of LINE-1 Encoded ORF2p for Cancer Therapeutics"},{"biomarker_overlap":null,"composite_score":0.5719016957796761,"cr_rationale":"Nonviral suprachoroidal gene transfer enables safer delivery route; clinical outcome depends on payload.","description_excerpt":"Unmet Need:\r\nGene transfer with adenoassociated viral (AAV) or lentiviral vectors can provide long-term expression in cells that have appropriate receptors for transduction. However, viral vectors induce an immune response making repeated administration impossible and also have limitations to cargo ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"ophthalmology (suprachoroidal gene transfer)","mechanism_class":"nonviral suprachoroidal gene transfer","modality":"gene_therapy","objectID":"28645","rationale_one_line":"Nonviral gene transfer to the suprachoroidal space for ophthalmology; gene therapy modality explicitly stated; ophthalmic indication not in the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28645","subscores":{"clinical_relevance":0.5,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Nonviral gene transfer to the suprachoroidal space"},{"biomarker_overlap":null,"composite_score":0.5719016957796761,"cr_rationale":"Suicide gene therapy adenovirus packaging approach offers targeted cancer killing but modality is early-stage.","description_excerpt":"The invention provides a packaging cell line for production of diphtheria toxin (DT) expressing, non-replicating adenovirus for use in suicide gene therapy of cancer cells, as well as production of immunotoxins. Also provided are methods for producing diphtheria toxin (DT) expressing, non-replicatin","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (suicide gene therapy); immunotoxin production","mechanism_class":"diphtheria toxin-expressing adenovirus packaging cell line","modality":"gene_therapy","objectID":"24200","rationale_one_line":"Packaging cell line produces diphtheria toxin-expressing non-replicating adenovirus 'for use in suicide gene therapy of cancer cells'; gene therapy modality for broad oncology, outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24200","subscores":{"clinical_relevance":0.5,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"DPL: Packaging Cell Line For Diphtheria Toxin Expressing Non-replicating Adenovirus"},{"biomarker_overlap":"PSMA expression","composite_score":0.5719016957796761,"cr_rationale":"PSMA-retargeted oncolytic adenovirus for prostate cancer; gene therapy approach in a setting with active SoC.","description_excerpt":"C11155: Method of developing targeted therapeutic agents for cancer using adenovirus\r\nValue Proposition: &bull; Addresses a major patient need. &bull; Specific for the target. &bull; Enhances adenoviral gene therapy. &bull; Has therapeutic and diagnostic applications. \r\nTechnical Details: \r\nJHU scie","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer (PSMA-retargeted adenoviral gene therapy)","mechanism_class":"PSMA-retargeted oncolytic adenovirus","modality":"gene_therapy","objectID":"16846","rationale_one_line":"Described as a strategy to 'optimize' adenoviral gene therapy targeted via PSMA to prostate cancer; gene_therapy modality confirmed; prostate cancer is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16846","subscores":{"clinical_relevance":0.5,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"PSMA","title":"PSMA-retargeted adenovirus"},{"biomarker_overlap":"PSMA expression","composite_score":0.5719016957796761,"cr_rationale":"Oncolytic adenovirus/RNAi enters prostate cancer space with active SoC.","description_excerpt":"C10910: Use of RNA Interference and Adenovirus Therapy against Prostate Cancer\r\nValue Proposition: &bull; Addresses a major patient need &bull; Enhances the therapeutic efficacy of CRAd strategy &bull; Creates the bases to develop enhanced oncolytic viral gene therapies with shRNA \r\nTechnical Detail","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer (oncolytic adenovirus + RNAi gene therapy)","mechanism_class":"oncolytic adenovirus with shRNA (CRAd strategy)","modality":"gene_therapy","objectID":"16784","rationale_one_line":"Described as 'RNA Interference and Adenovirus Therapy against Prostate Cancer' using shRNA-enhanced oncolytic adenoviruses; gene_therapy modality confirmed; prostate cancer is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16784","subscores":{"clinical_relevance":0.5,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"PSMA","title":"Host Defense Turned Viral Offense; Engineering the Next Generation of Oncolytic Adenoviruses"},{"biomarker_overlap":null,"composite_score":0.5719016957796761,"cr_rationale":"GDEPT suicide gene therapy for broad cancer; targeted prodrug activation offers SoC selectivity advantage.","description_excerpt":"Unmet Need: Gene-directed enzyme prodrug therapy (GDEPT; also known as “suicide gene therapy”) is an emerging gene therapy strategy against cancer. A prodrug is systemically administered but only activated in cancer cells that have previously been modified to express an enzyme capable of activating ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (gene-directed enzyme prodrug therapy / suicide gene therapy)","mechanism_class":"gene-directed enzyme prodrug therapy (GDEPT) using protein switches","modality":"gene_therapy","objectID":"16669","rationale_one_line":"Described as 'suicide gene therapy' (GDEPT) selectively activating prodrugs in cancer cells via protein switches; gene_therapy modality confirmed; broad cancer indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16669","subscores":{"clinical_relevance":0.5,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Selective Prodrug Activation in Cancer Cells Using Protein Switches"},{"biomarker_overlap":"p53 pathway status","composite_score":0.5719016957796761,"cr_rationale":"PUMA/p53 pathway activation is broadly relevant but competes with established chemotherapy regimens.","description_excerpt":"C04140: PUMA Mediates the Apoptotic Response to p53\r\n   \r\n\r\nTechnical Details: \r\n\r\nThe p53 pathway is inactivated in the great majority of human cancers. Of the many physiologic effects of p53 that have been described, current evidence suggests that apoptosis is critical for its tumor suppressor act","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (p53 pathway apoptosis)","mechanism_class":"PUMA / p53 apoptosis pathway activator","modality":"gene_therapy","objectID":"16259","rationale_one_line":"PUMA mediates apoptotic response to p53 tumor suppressor; broad oncology p53 pathway — no specific PhaseFolio-supported indication named.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16259","subscores":{"clinical_relevance":0.5,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"TP53","title":"PUMA Mediates the Apoptotic Response to p53"},{"biomarker_overlap":"androgen receptor status","composite_score":0.5719016957796761,"cr_rationale":"Oncolytic adenovirus in prostate cancer offers a complementary mechanism to hormonal and PARP inhibitor SoC.","description_excerpt":"Unmet Need: Prostate cancer is a multi-focal disease with clones of androgen-sensitive and androgen-refractory cells, yet, the specific role androgen receptors (ARs) may play in prostate cancer in not clear. There remains an unmet need for new specific treatment modalities that selectively target di","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer","mechanism_class":"oncolytic adenovirus (E1A modification)","modality":"gene_therapy","objectID":"16252","rationale_one_line":"Adenoviral oncolytic activity enhanced by E1A modification for prostate cancer; prostate cancer is not among the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16252","subscores":{"clinical_relevance":0.5,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"androgen receptor","title":"Enhancement of Adenoviral Oncolytic Activity by Modification of the E1A Gene Product"},{"biomarker_overlap":null,"composite_score":0.5719016957796761,"cr_rationale":"HSC-based immune tolerance induction is mechanistically promising but platform-stage with no clinical comparison.","description_excerpt":"Technical Details:\r\n\t\t\tThe initiation of T cell-dependent immune responses depends on presentation of antigens by bone marrow-derived antigen-presenting cells such as dendritic cells. Tolerance induction depends on expression of antigens by tolerizing antigen presenting cells. Immunotherapy approach","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer / autoimmune (immune tolerance modulation)","mechanism_class":"hematopoietic stem cell gene transduction for antigen presentation","modality":"gene_therapy","objectID":"16210","rationale_one_line":"Hematopoietic stem cells transduced with antigen-encoding genes for systemic immune modulation in cancer and tolerance induction; broad platform outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16210","subscores":{"clinical_relevance":0.5,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Modulation of systemic Immune Responses by Transplantation of Hemotopoietic Stem Cells Transduced with Genes Encoding Antigens and Antigen Presenting Cell Regulatory Molecules"},{"biomarker_overlap":null,"composite_score":0.5643988269794721,"cr_rationale":"Nav nanobody targets channelopathies with limited treatment options beyond symptomatic management.","description_excerpt":"Unmet Need \r\nGlobally, millions of patients are affected by diseases caused when mutations affect the normal function of voltage gated sodium channels (Nav). These mutations have been implicated in several human genetic diseases such as hypokalemic periodic paralysis, myotonia and Brugada syndrome. ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Genetic channelopathies caused by mutations in voltage-gated sodium channels; including hypokalemic periodic paralysis, myotonia, and Brugada syndrome","mechanism_class":"Nav channel nanobody","modality":"monoclonal_antibody","objectID":"53262","rationale_one_line":"Source describes high affinity nanobodies specific for voltage gated sodium channels classified under Antibodies; nanobodies map to monoclonal_antibody; genetic channelopathies are outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53262","subscores":{"clinical_relevance":0.65,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"Nav (voltage-gated sodium channels)","title":"High Affinity Nanobodies Specific for Voltage Gated Sodium Channels"},{"biomarker_overlap":null,"composite_score":0.5643988269794721,"cr_rationale":"IL-2 antibody fusion may expand immune effectors more safely than high-dose IL-2.","description_excerpt":"Unmet Need\r\nGlobal revenue from the cytokine therapeutics market was valued at approximately $16.5 billion in 2018, and cytokine immunotherapy is a promising field of anti-cancer treatments for a broad range of cancer types. In particular, interleukin-2 (IL-2) therapy is shown to stimulate anti-canc","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer broadly; engineered cytokine-antibody fusion for targeted expansion of immune effector cells via IL-2 pathway","mechanism_class":"IL-2 cytokine-antibody fusion","modality":"monoclonal_antibody","objectID":"52646","rationale_one_line":"Source describes engineered cytokine-antibody fusion leveraging IL-2 for anti-cancer immunity across a broad range of cancer types; taxonomy confirms Antibodies; broad oncology without specific cancer type maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52646","subscores":{"clinical_relevance":0.65,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"IL-2","title":"Engineered Cytokine-antibody Fusion for Targeted Expansion of Immune Effector Cells"},{"biomarker_overlap":null,"composite_score":0.563981894683157,"cr_rationale":"ALS and FTD have no approved disease-modifying therapies; peptide reducing toxic protein pathology is high-value.","description_excerpt":"Value Proposition - Treatment readily acts via subcutaneous injection and crosses the blood-brain barrier without extra formulation or drug delivery mechanism. - Treatment significantly reduces pathological and behavioral phenotypes from toxic proteins coded by genetic defects in amyotrophic lateral","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)","mechanism_class":"toxic pathway peptide inhibitor","modality":"peptide","objectID":"55689","rationale_one_line":"Taxonomy classifies under Peptides; treatment 'significantly reduces pathological and behavioral phenotypes from toxic proteins' in ALS/FTD — neurological indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55689","subscores":{"clinical_relevance":0.8,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Method to Inhibit Toxic Pathways Activated in Genetic ALS/FTD"},{"biomarker_overlap":"PSA, PSMA, hK2 expression","composite_score":0.563981894683157,"cr_rationale":"PSMA-targeted thapsigargin prodrug offers potent cytotoxicity for PSMA-expressing prostate cancer beyond standard androgen blockade.","description_excerpt":"Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific membrane antigen (PSMA), prostate specific antigen (PSA) or human glandular kallikrein 2 (hK2). Various embodiments relate more specifically to PSA,","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Prostate cancer (PSMA/PSA/hK2-targeted prodrug)","mechanism_class":"PSA/PSMA/hK2-activated peptide prodrug","modality":"peptide","objectID":"48584","rationale_one_line":"Radiolabeled thapsigargin analogs in PSMA/PSA/hK2-activated peptide prodrugs for prostate cancer; classified under Peptides; prostate cancer not in the 11 enums so maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48584","subscores":{"clinical_relevance":0.8,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"PSMA","title":"Radiolabeled Thapsigargin Analogs Incorporated into Protease Activated Prodrugs"},{"biomarker_overlap":null,"composite_score":0.563981894683157,"cr_rationale":"Fibrolamellar HCC peptide vaccine addresses rare cancer lacking targeted SoC.","description_excerpt":"Unmet Need\r\nFibrolamellar carcinoma (FLC) is an extremely rare form of cancer. It affects both men and women in approximately 1 in 5,000,000 people with greater frequency among young adults with a median age of diagnosis of 25. Unfortunately, there is no standard of care therapy for this cancer, and","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"fibrolamellar hepatocellular carcinoma (FLC)","mechanism_class":"peptide vaccine (tumor antigen)","modality":"peptide","objectID":"40046","rationale_one_line":"Peptide vaccine for fibrolamellar hepatocellular carcinoma; liver cancer (rare subtype) does not map to a supported indication enum; modality is peptide vaccine.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/40046","subscores":{"clinical_relevance":0.8,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Peptide vaccine for patients with fibrolamellar hepatocellular carcinoma"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Targeted miRNA nanoparticles address poor medulloblastoma outcomes despite chemoradiation SoC.","description_excerpt":"Value Proposition - Targets specifically to medulloblastoma - Reduces tumorigenicity in vitro and in vivo - Nanoparticle encapsulation is capable of enhanced miRNA delivery\r\nUnmet Need:\r\nMedulloblastoma is a malignant embryonal tumor of the cerebellum and brainstem that accounts for roughly 15–20% o","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"Medulloblastoma (pediatric brain tumor)","mechanism_class":"miRNA replacement therapy","modality":"nucleic_acid","objectID":"61071","rationale_one_line":"Nanoparticle-encapsulated miRNA for medulloblastoma; modality is nucleic_acid; indication is other as medulloblastoma is not in the supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/61071","subscores":{"clinical_relevance":0.8,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A microRNA for treatment of childhood medulloblastoma"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"RelA inhibitor targeting persister-cell stress resistance directly addresses AMR where last-resort antibiotics are failing.","description_excerpt":"Value Proposition:\r\n·        Unique mechanism of action that targets antibiotic-resistant infections\r\n·        Ability to target multiple stress resistance mechanisms in bacteria\r\n·        Broad range of application \r\n \r\nTechnology Description\r\n·        Researchers at Johns Hopkins have developed an","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Antibiotic-resistant bacterial infections","mechanism_class":"RelA inhibitor (antibacterial)","modality":"small_molecule","objectID":"60529","rationale_one_line":"Small molecule RelA inhibitor targeting bacterial stress resistance mechanisms; infectious disease/AMR is not in the indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60529","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"RelA","title":"RelA Inhibitor as a Anti-microbial Therapy"},{"biomarker_overlap":"GNAQ mutation","composite_score":0.5511460629132439,"cr_rationale":"Sturge-Weber / capillary malformations have no approved targeted therapy; GNAQ-specific approach addresses true unmet need.","description_excerpt":"Value Proposition:  \r\n \r\n·      Antibiotic treatment strategy for capillary malformations and Sturge-Weber Syndrome. \r\n·      Selectively targets endothelial cells with the pathogenic GNAQ mutations using puromycin \r\n·      Inhibits cell proliferation and reduces cell survival via activation of TRP6","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"capillary malformations and Sturge-Weber Syndrome","mechanism_class":"GNAQ mutation-targeted antibiotic","modality":"small_molecule","objectID":"55032","rationale_one_line":"Uses puromycin (antibiotic/small molecule) to selectively target GNAQ-mutant endothelial cells; rare disease indication outside the supported enum set.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55032","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GNAQ","title":"Antibiotic Treatment Strategy for Capillary Malformations and Sturge-Weber Syndrome"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"ALS/Alzheimer's/Huntington's have no approved CHMP7-pathway therapies; ESCRT targeting addresses nuclear envelope failure.","description_excerpt":"Value Proposition - Novel Target: CHMP7, a nuclear pore protein, identified as a key driver in ALS, offers a new therapeutic approach. - Disease-Modifying Method: Targets the root cause of nuclear pore complex injury and neural injury, aiming to alter disease progression. - Druggable Target: CHMP7 c","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurodegeneration including ALS, Alzheimer's, Huntington's disease","mechanism_class":"ESCRT pathway / CHMP7 inhibitor","modality":"other","objectID":"54986","rationale_one_line":"Target CHMP7 identified; modality described as 'small molecule, gene, and peptide' options — no single modality designated; neurodegeneration indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54986","subscores":{"clinical_relevance":0.8,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"CHMP7","title":"Mitigation of Nuclear Pore defect in Neurodegeneration: ESCRT Pathway Inhibition"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Novel oxazolidinone addresses M. abscessus AMR with limited approved options.","description_excerpt":"Value Proposition\r\n·        Higher efficacy and lower toxicity oxazolidinone compounds\r\n·        Positive activity demonstrated against M. abscessus\r\n·        MIC values are the same or better than the current antibiotics in the market\r\n \r\nUnmet Need\r\n The prevalence of antimicrobial resistance (AMR","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"bacterial infections including M. abscessus / antimicrobial resistance","mechanism_class":"oxazolidinone antibacterial","modality":"small_molecule","objectID":"54316","rationale_one_line":"Novel oxazolidinone small molecules with antibacterial activity; infectious disease / antibacterial indication is outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54316","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Oxazolidinone Antibacterials and the Synthetic Routes to Them"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Novel oxazolidinone scaffold addresses drug-resistant TB beyond linezolid limitations.","description_excerpt":"Value Proposition\r\n·        Belong to the same chemical family as Zyvox, marketed by Pfizer, but shows better efficacy\r\n·        Positive activity demonstrated against M. tuberculosis\r\n·        MIC values the same or better than the current antibiotics in the market\r\n \r\nUnmet Need\r\n The prevalence o","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"bacterial infections including M. tuberculosis / antimicrobial resistance","mechanism_class":"oxazolidinone antibacterial","modality":"small_molecule","objectID":"54313","rationale_one_line":"Novel oxazolidinones in the same chemical family as Zyvox (linezolid); small molecule antibacterials for bacterial infections including TB — outside the supported enum set.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54313","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Oxazolidinones for Treatment of Bacterial Infections"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Pancreatic ductal adenocarcinoma has <10% 5-year survival and no effective second-line SoC.","description_excerpt":"Unmet Need\r\nPancreatic cancer is a highly lethal malignancy and it is the fourth leading cause of cancer-related death in the United States (see Uptodate). Surgical resection is currently the only potential treatment to cure pancreatic cancer that could result in significant improvement in survival,","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"pancreatic cancer (pancreatic ductal adenocarcinoma)","mechanism_class":"selective cell killing therapeutic","modality":"other","objectID":"54291","rationale_one_line":"Taxonomy classifies under Cell Therapies + Targets; description is a broad 'selective and specific cell killing tool' for pancreatic cancer — pancreatic cancer is outside the supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54291","subscores":{"clinical_relevance":0.8,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Selective and Specific Cell Killing Tool"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Haploinsufficiency disorders largely lack approved therapies; mRNA intensifier restoring expression is mechanistically direct.","description_excerpt":"Unmet Need / Invention Novelty: Haploinsufficiency occurs when one gene allele is inactivated and the amount of gene product expressed from the remaining active allele is insufficient for proper gene function. Targeted restoration of mRNA expression and translation may offer a therapeutic window.  \r","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"haploinsufficiencies (genetic diseases caused by single-allele inactivation)","mechanism_class":"mRNA intensifier / haploinsufficiency restorer","modality":"nucleic_acid","objectID":"54169","rationale_one_line":"Taxonomy classifies under Gene Therapies; mRNA intensifier to restore expression in haploinsufficiency conditions — rare/genetic diseases outside the supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54169","subscores":{"clinical_relevance":0.8,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"mRNA Intensifier to treat Haploinsufficiencies"},{"biomarker_overlap":"SYNGAP1 mutation / haploinsufficiency","composite_score":0.5511460629132439,"cr_rationale":"SYNGAP1-related ID/ASD/epilepsy has no approved disease-modifying therapy; ASO restoration is precision and direct.","description_excerpt":"Unmet Need: \r\nRecent human genetic studies have suggested that mutations in the SYNGAP1 gene are linked to intellectual disability (ID), autism spectrum disorders (ASD), neurodevelopmental disorders, high rates of epilepsy, and schizophrenia. SYNGAP1 is a gene that encodes SynGAP, a GTPase-activatin","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"SYNGAP1-related intellectual disability, autism spectrum disorder, epilepsy, schizophrenia","mechanism_class":"antisense oligonucleotide (ASO)","modality":"nucleic_acid","objectID":"53601","rationale_one_line":"SYNGAP antisense oligonucleotide (ASO) is a nucleic_acid modality; indication is neurodevelopmental disorders (SYNGAP1-related ID/ASD), outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53601","subscores":{"clinical_relevance":0.8,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SYNGAP1","title":"SYNGAP antisense oligonucleotide as therapy for human cognitive disorders"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Anti-fentanyl vaccine targets opioid addiction with no equivalent immunological prophylaxis approved.","description_excerpt":"Value Proposition:\r\n·      Elicits production of anti-Fentanyl antibodies\r\n·      Leads to long-lasting anti-opioid responses without toxicity\r\n·      Exhibits 1000-fold increase in antibody production over conventional drug vaccines\r\n \r\nTechnology Description\r\nResearchers at Johns Hopkins have deve","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Opioid addiction; anti-fentanyl vaccine for prevention of opioid use disorder","mechanism_class":"polymeric anti-fentanyl vaccine","modality":"other","objectID":"53486","rationale_one_line":"Source describes a polymeric fentanyl vaccine that elicits anti-opioid antibodies; vaccines are not in the 9 supported modality enums; addiction/pain indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53486","subscores":{"clinical_relevance":0.8,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"fentanyl (hapten)","title":"Robust Vaccine Against Opioid Addiction"},{"biomarker_overlap":"DNA repair loss (40-50% of breast, lung, ovarian cancer patients)","composite_score":0.5511460629132439,"cr_rationale":"POLQ inhibition exploits DNA-repair deficiency in breast/ovarian cancer beyond PARP inhibitor coverage.","description_excerpt":"Unmet Need\r\nLoss of DNA repair is an early and frequent event in the growth of tumors, occurring in 40 to 50% of breast, lung and ovarian cancer patients. The inability to repair damaged DNA provides a selective growth advantage to tumor cells as this results in genetic instability and enhanced muta","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"Breast, lung and ovarian cancer (DNA repair-deficient tumors)","mechanism_class":"DNA polymerase theta (Pol theta) inhibition","modality":"small_molecule","objectID":"51177","rationale_one_line":"Invention identifies mechanism of DNA Polymerase Theta inactivation for tumors with DNA repair loss; breast cancer is the first-listed indication and maps to the enum; classified under Gene Therapies / Cell Therapies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/51177","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"POLQ","title":"Identification of DNA Polymerase Theta Inactivation Mechanism"},{"biomarker_overlap":"TLR4 overexpression in premature infants","composite_score":0.5511460629132439,"cr_rationale":"TLR4 inhibition targets NEC, which lacks approved pharmacologic prevention.","description_excerpt":"Unmet Need / Invention Novelty: TLR4 (Toll-like receptor 4) is the most upstream receptor in the pro-inflammatory cascade for endotoxin lipopolysaccharide (LPS). While normally downregulated gradually after full-term birth, high levels of TLR4 expression in infants born prematurely is associated wit","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Necrotizing enterocolitis (NEC) in premature infants","mechanism_class":"TLR4 inhibitor","modality":"small_molecule","objectID":"48326","rationale_one_line":"Novel small molecule TLR4 inhibitors to treat and prevent NEC in premature infants; classified under Small Molecules; NEC / pediatric indication not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48326","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TLR4","title":"Novel small molecule TLR4 inhibitors to treat and prevent NEC"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Gene-agnostic retinal cell therapy covers mutations gene augmentation cannot.","description_excerpt":"Unmet Need / Invention Novelty: Gene augmentation therapy, the current technology for treatment of inherited retinal diseases, is limited by its 1) small cargo capacity which challenges the delivery of larger genes 2) ability to target only a single genetic mutation, and thus disease subtype, at a t","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Inherited retinal diseases (universal stem cell-based therapy)","mechanism_class":"universal stem cell-based gene-agnostic retinal therapy","modality":"other","objectID":"46440","rationale_one_line":"Universal stem cell-based therapy for inherited retinal diseases overcoming limitations of gene augmentation; classified under Cell Therapies; ophthalmic indication not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/46440","subscores":{"clinical_relevance":0.8,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel universal stem cell-based therapy for the treatment of retinal diseases"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"T1D has no disease-modifying SoC; tolerogenic aAPC-mediated Treg expansion targets root autoimmunity.","description_excerpt":"Unmet Need\r\nGlobal incidence of autoimmune disease is on the rise, and currently one in twelve Americans (including one in 9 women) suffer from autoimmune disease. Particularly, Type 1 Diabetes (T1D) represents a highly prevalent autoimmune disease, affecting over 20 million people. These diseases o","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"Type 1 Diabetes and autoimmune disease","mechanism_class":"tolerogenic artificial antigen-presenting cell","modality":"other","objectID":"45002","rationale_one_line":"Engineered cell-based platform for Treg expansion targeting T1D/autoimmunity; cell therapy / delivery platform modality does not cleanly map to a supported enum; T1D is not type2_diabetes.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45002","subscores":{"clinical_relevance":0.8,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Engineered Tolerogenic Artificial Antigen-presenting Cells for Specific Expansion of Regulatory T Cells"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"AIF/Trx2-targeted small molecule for arrhythmogenic cardiomyopathy; no approved disease-modifying SoC exists.","description_excerpt":"Unmet Need\r\nAbout 400,000 to 460,000 people die each year from sudden cardiac death (SCD). Patients with Arrhythmogenic Cardiomyopathy (ACM) are at increased risk for heart failure and SCD triggered by exercise. Common ACM driver mutations occur in about 1 out of every 10,000 people. However, the ph","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Arrhythmogenic Cardiomyopathy (sudden cardiac death)","mechanism_class":"AIF/thioredoxin-2 signaling activator","modality":"small_molecule","objectID":"44660","rationale_one_line":"Small molecule targeting AIF/thioredoxin-2 signaling to prevent myocardial loss in Arrhythmogenic Cardiomyopathy; cardiovascular indication does not map to any supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44660","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"AIFM1","title":"Preventing Myocardial Loss and Sudden Death in Patients with Arrhythmogenic Cardiomyopathy via Rescuing of AIF/thioredoxin-2 Signaling"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"H3K27 demethylase inhibitor for pediatric osteoporosis; genetic skeletal disorder with no approved targeted SoC.","description_excerpt":"Unmet Need\r\nChildhood and adolescence are critical periods for bone growth and mineral accrual. Bone mass and strength in this period are influenced by genetic/epigenetic factors, activity, nutrition, and hormones. For children with genetic skeletal disorders or chronic disease, bone growth and mine","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"pediatric and juvenile osteoporosis (genetic skeletal disorders)","mechanism_class":"H3K27 demethylase inhibitor","modality":"small_molecule","objectID":"44279","rationale_one_line":"Small molecule H3K27 demethylase inhibitor for pediatric/juvenile osteoporosis; musculoskeletal indication does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44279","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"KDM6A","title":"Therapeutic application of H3K27 demethylase inhibitor for pediatric and juvenile osteoporosis"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Small molecule for NEC in neonates; life-threatening condition with no approved pharmacologic SoC.","description_excerpt":"Unmet Need: Necrotizing enterocolitis (NEC) is the acute onset of inflammation in the gut of babies, and is the leading cause of premature infant mortality from gastrointestinal disease. The mortality of NEC is over 30%, and those infants who do survive suffer significant deficiency due to the effec","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Necrotizing Enterocolitis (NEC) / inflammatory disorders in children","mechanism_class":"small molecule agonist (anti-inflammatory)","modality":"small_molecule","objectID":"42098","rationale_one_line":"Small molecule agonist to treat inflammatory disorders including NEC in children; pediatric gastroenterology indication does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/42098","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Small Molecule Agonist to Treat Inflammatory Disorders in Children"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Novel triazole anticonvulsant for LGS; refractory seizures with limited approved options and high unmet need.","description_excerpt":"Unmet Need\r\nLennox-Gastaut Syndrome (LGS) is rare and severe form of childhood-onset epilepsy associated with various types of seizures and cognitive dysfunction that persist into adulthood; yet, to date, LGS management is challenged by the lack of reliable diagnostic tests and potentially grave sid","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Lennox-Gastaut Syndrome / severe or refractory seizure (epilepsy)","mechanism_class":"triazole anticonvulsant","modality":"small_molecule","objectID":"39155","rationale_one_line":"Novel triazole small molecules for LGS and refractory seizures; rare neurological/epilepsy indication does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/39155","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel TriazoleCompounds to Treat Severe or Refractory Seizure"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Biologic to prevent opioid respiratory depression; naloxone SoC requires co-administration and has short duration.","description_excerpt":"Description:\r\nUnmet Need\r\n The opioid epidemic continues to be a public health crisis, with about 130 Americans dying every day from an opioid overdose. Opiate-mediated respiratory suppression (ORS) is the primary cause of opiate-associated deaths, and obesity greatly increases opiate-related mortal","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"opiate-induced respiratory depression (opioid overdose)","mechanism_class":"respiratory depression prevention (biologic)","modality":"other","objectID":"39091","rationale_one_line":"Novel biologic method to prevent opiate-induced respiratory suppression; respiratory/addiction indication does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/39091","subscores":{"clinical_relevance":0.8,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel method to prevent opiate-induced respiratory depression"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"iPSC corneal cells may reduce transplant burden and donor scarcity.","description_excerpt":"Unmet Need\r\nFuchs’ dystrophy, a progressive, hereditary disease of the cornea, is the leading cause of corneal transplants both in the US and worldwide. The disease results in the dysregulation and destruction of corneal endothelial cells which are responsible for keeping the eye properly hydrated. ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Fuchs' dystrophy (progressive corneal disease)","mechanism_class":"PBMC-derived iPSC-derived corneal endothelial cell therapy","modality":"other","objectID":"36531","rationale_one_line":"Generation of iPSC-derived corneal endothelial cells for treating Fuchs' dystrophy — a cell therapy for an ophthalmic rare disease outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36531","subscores":{"clinical_relevance":0.8,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Generation of PBMC-Originated, iPSC-Derived Corneal Endothelial Cells"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"NEC in newborns has no approved pharmacotherapy; high mortality defines major unmet need.","description_excerpt":"Unmet need\r\nNecrotizing enterocolitis (NEC), a condition of newborns in which a portion of the bowel dies. NEC affects one in 1000-4000 births, or about 10% of preterm children and is associated with an overall mortality of up to 40%. NEC is thought to be caused by defective bacterial-host signaling","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"necrotizing enterocolitis (NEC) in newborns","mechanism_class":"enteric nervous system enhancer","modality":"small_molecule","objectID":"34513","rationale_one_line":"Small molecule compounds targeting necrotizing enterocolitis; NEC is not among the 11 supported indications so mapped to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/34513","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Discovery of Novel Compounds that Enhance Enteric Nervous System Function"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Retinal photoreceptor regeneration addresses irreversible vision loss with no restorative SoC available.","description_excerpt":"Unmet Need\r\nApproximately 253 million people worldwide live with vision impairment. Of those with vision impairment, approximately 15% are blind. Most human blindness is caused by the dysfunction or death of retinal photoreceptors. For many eye disorders, there is no way to reverse photoreceptor los","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"vision impairment / retinal photoreceptor loss (ophthalmology)","mechanism_class":"stem cell-derived retinal photoreceptor generation","modality":"other","objectID":"29826","rationale_one_line":"Generation of retinal photoreceptors from stem/progenitor cells for vision loss; ophthalmology cell therapy is not in the supported indication or modality enums; mapped other/other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/29826","subscores":{"clinical_relevance":0.8,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Efficient generation of retinal photoreceptors from stem/progenitor cells."},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"NEC prevention addresses high neonatal mortality with no approved therapy.","description_excerpt":"Unmet Need \r\nNecrotizing enterocolitis (NEC) is the leading cause of death and disability in premature infants. The disease is characterized by a bacterial infection in the intestines that quickly progresses to organ death if untreated. Current treatment of NEC entails surgically removing the diseas","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"necrotizing enterocolitis (NEC) in premature infants","mechanism_class":"NEC prevention small molecule","modality":"small_molecule","objectID":"29043","rationale_one_line":"Small molecule compositions for treatment or prevention of NEC in premature infants; NEC is not in the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/29043","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel compositions for the treatment or prevention of necrotizing enterocolitis in premature infants"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"AHR agonist targeting TLR4 for NEC prevention addresses neonatal disease with no approved pharmacotherapy.","description_excerpt":"UNMET NEED: Necrotizing enterocolitis (NEC) is the leading cause of death from gastrointestinal disease in premature infants. The main risk factors for the development of NEC are prematurity, bacterial colonization and administration of formula feeds, which in the setting of an abnormal microbiome l","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"necrotizing enterocolitis (NEC) in premature infants","mechanism_class":"AHR agonist (TLR4 signaling modulator)","modality":"small_molecule","objectID":"26026","rationale_one_line":"AHR agonist small molecules to prevent NEC by modulating TLR4 signaling in premature infants; NEC is not in the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/26026","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"AHR (aryl hydrocarbon receptor), TLR4","title":"Use of AHR Agonists to Prevent or Treat NEC in Premature Infants"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"High mortality fungal infections in immunocompromised with limited, toxic SoC options.","description_excerpt":"Unmet Need\r\nIndividuals with impaired immunity, including those with advanced HIV infection, organ transplants, and on immunosuppressive regimens are susceptible to major fungal pathogens, such as Cryptococcus neoformans and Candida albicans.  Cryptococcus neoformans is particularly problematic for ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"fungal infections (Cryptococcus neoformans, Candida albicans) in immunocompromised patients","mechanism_class":"antifungal inhibitor","modality":"small_molecule","objectID":"24887","rationale_one_line":"Novel small molecule antifungal inhibitors targeting major fungal pathogens in immunocompromised patients; infectious disease indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24887","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Anti-fungal Inhibitors"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Phenobarbital-resistant neonatal seizures have essentially no approved alternative therapy.","description_excerpt":"Technology Overview\r\nThe invention provides novel pharmaceutical interventions that convert phenobarbital (PB)-resistant seizures into phenobarbital responsive seizures in neonates. We have shown that unlike in adult brains, expression of a transport protein in the neonatal brain is much lower and u","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"neonatal refractory seizures / epilepsy (phenobarbital-resistant)","mechanism_class":"NKCC1 transporter modulator (converting PB-resistant to PB-responsive seizures)","modality":"small_molecule","objectID":"24713","rationale_one_line":"Small molecule modulating neonatal NKCC1 to convert phenobarbital-resistant seizures to responsive; preclinical data referenced; epilepsy/seizure outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24713","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"NKCC1","title":"Method for Treating Refractory Seizures Using a Novel Therapeutic Approach"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"HAT SoC is highly toxic; novel chelator addresses significant unmet need.","description_excerpt":"Membrane Activated Chelators (MACs) are proprietary neuroprotective drugs [D-PHARM LTD; Rehovot Isreal] that modulate cell membrane metal ion homeostasis by adopting an inactive conformation outside only in the lipid environment of cell membranes. In this environment, the drugs are able to unable to","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Human African Trypanosomiasis (sleeping sickness)","mechanism_class":"membrane active chelator (metal ion homeostasis modulator)","modality":"small_molecule","objectID":"24656","rationale_one_line":"Membrane Active Chelators (MACs) as chemotherapeutic agents for Human African Trypanosomiasis; parasitic infectious disease outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24656","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Membrane Active Chelators (MACs) as Chemotherapueutic Agents for Treatment of Human African Trypanosomiasis (HAT)"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Acute liver failure has no approved cell-based rescue beyond transplant.","description_excerpt":"Acute Liver Failure (ALF), typically due to drug poisoning or viral hepatitis, accounts for around 10,000 deaths per year in the United States.  Treatment options are severely limited: supportive observation in the hopes of spontaneous recovery or liver transplant.  Liver transplant is an imperfect ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"acute liver failure (due to drug poisoning or viral hepatitis)","mechanism_class":"bone marrow-derived stem cell mobilization (cell therapy)","modality":"other","objectID":"24644","rationale_one_line":"Biologic/cell therapy mobilizing bone marrow-derived stem cells to treat acute liver injury and hepatic failure; hepatology indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24644","subscores":{"clinical_relevance":0.8,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Treatment of Acute Liver Injury and Hepatic Failure by Mobilization of Bone Marrow Derived Stem Cells"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"DXP synthase inhibitors address MDR TB with limited effective options.","description_excerpt":"Invention novelty:  novel class of chemical inhibitors targeting DXP synthase with increased selectivity to pathogens\r\n \r\nValue Proposition: Development of anti-infectives has direct impact on infectious diseases such as malaria and tuberculosis. The long term goal is to develop novel, potent and br","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"malaria and tuberculosis; bacterial and parasitic infections","mechanism_class":"DXP synthase inhibitor (anti-infective)","modality":"small_molecule","objectID":"23438","rationale_one_line":"Chemical inhibitors targeting DXP synthase 'with increased selectivity to pathogens' for malaria and tuberculosis; small molecule anti-infective for infectious diseases outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/23438","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"DXPS (1-deoxy-D-xylulose-5-phosphate synthase)","title":"Novel inhibitors of DXP synthase as anti-infective drugs"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Novel mechanism active against drug-resistant TB addresses critical global unmet need with inadequate SoC.","description_excerpt":"Unmet Need\r\nAlthough effective therapy exists for TB caused by drug-susceptible mycobacterium tuberculosis, this therapy requires daily administration of multiple drugs for a minimum of 6 months. The consequence of noncompliance with the existing TB treatment leads to the development of drug-resista","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"tuberculosis (drug-susceptible and drug-resistant TB)","mechanism_class":"anti-TB compound (novel mechanism)","modality":"small_molecule","objectID":"21362","rationale_one_line":"Compounds for 'Treatment of both Drug-susceptible and Drug-Resistant TB'; small molecule anti-infective for tuberculosis, outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/21362","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Compounds for Treatment of both Drug-susceptible and Drug-Resistant TB"},{"biomarker_overlap":"sickle hemoglobin (HbS) polymerization","composite_score":0.5511460629132439,"cr_rationale":"HbS polymerization inhibition targets SCD root cause; current SoC (HU, voxelotor) only partially effective.","description_excerpt":"INVENTION NOVELTY: This technology is a set of RNA aptamers capable of reducing sickle hemoglobin (HbS) polymerization, which has therapeutic potential in reducing vaso-occlusion and ischemia in sickle cell disease patients.\r\n \r\nVALUE PROPOSITION: Sickle cell anemia is a genetically inherited diseas","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"sickle cell anemia","mechanism_class":"RNA aptamer","modality":"nucleic_acid","objectID":"20823","rationale_one_line":"RNA aptamers targeting HbS polymerization for sickle cell anemia — sickle cell disease is not in the supported indication enum so maps to other; nucleic_acid modality from the aptamer approach.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/20823","subscores":{"clinical_relevance":0.8,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HbS","title":"Aptamer Based Sickle Cell Anemia Therapeutic"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Artemisinin-resistant malaria strains threaten global SoC; novel analogs directly address a life-threatening resistance gap.","description_excerpt":"C11864: Novel Artemisinin Analog Antimalarial Drugs\r\nNovelty: \r\nThe inventors have created several semisynthetic analogs of artemisinin with antimalarial properties.\r\nValue Proposition: \r\nIn 2010, malaria affected over 216 million people, and while treatments for malaria exist, malaria parasites hav","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"malaria (Plasmodium parasite, artemisinin-resistant)","mechanism_class":"artemisinin analog antimalarial","modality":"small_molecule","objectID":"17079","rationale_one_line":"Semisynthetic thioacetal trioxane analogs of artemisinin with antimalarial properties against resistant Plasmodium strains — malaria outside supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17079","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Antimalarial Thioacetal Trioxanes in the Artemisinin Family"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Novel beta-lactamase inhibitors address critical AMR crisis; beta-lactam resistance causes significant mortality.","description_excerpt":"C11674: Novel Beta-Lactamase Inhibitors\r\nNovelty: \r\nThis technology comprises of a series of compounds based on a novel scaffold that selectively inhibits the enzyme, beta lactamase with high affinity thereby providing a potential solution to beta-lactam resistance in bacteria.\r\nValue Proposition: \r","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"beta-lactam resistant bacterial infections","mechanism_class":"beta-lactamase inhibitor","modality":"small_molecule","objectID":"17018","rationale_one_line":"Novel scaffold beta-lactamase inhibitors to overcome beta-lactam antibiotic resistance in bacteria — bacterial infectious disease outside supported indication enum; small_molecule per taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17018","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"beta-lactamase","title":"High Affinity Beta Lactamase Inhibitors"},{"biomarker_overlap":null,"composite_score":0.5511460629132439,"cr_rationale":"Single-dose artemisinin trioxane for drug-resistant malaria; resistance to frontline ACTs is a life-threatening gap.","description_excerpt":"C11486: Oral Single Dose Therapeutic for Malaria\r\nNovelty: \r\nThe combination of a novel oral drug with Mefloquine administered as a single oral dose demonstrates anti-malarial activity.\r\nValue Proposition: \r\nMalaria is responsible for a million deaths each year and some treatments are not very effec","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"malaria (Plasmodium, drug-resistant)","mechanism_class":"trioxane antimalarial (combination with mefloquine)","modality":"small_molecule","objectID":"16956","rationale_one_line":"Monomeric trioxane amide sulfur compounds combined with mefloquine as a single oral dose anti-malarial — malaria outside supported indication enum; small_molecule per taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16956","subscores":{"clinical_relevance":0.8,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Monomeric Trioxane Amide Sulfur Compounds"},{"biomarker_overlap":"Amyloid beta","composite_score":0.5443988269794721,"cr_rationale":"Validated anti-amyloid mAb in crowded Alzheimer's space; differentiation remains incremental.","description_excerpt":"Unmet Need\r\nAccording to the CDC, approximately 5.8-million individuals aged 65+ in the United States were living with Alzheimer’s disease in 2020 (see CDC). Alzheimer’s disease leads to memory impairment that progressively affects the ability of individuals to conduct daily tasks and worsens with t","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Alzheimer's disease","mechanism_class":"Amyloid beta antibody (research/therapeutic)","modality":"monoclonal_antibody","objectID":"60683","rationale_one_line":"Biotin-labeled amyloid beta antibody for Alzheimer's diagnosis/therapy; mAb modality confirmed; Alzheimer's is not in the indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60683","subscores":{"clinical_relevance":0.6,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"amyloid beta","title":"Biotin Labeled Amyloid Beta Antibody (bio-IB3)"},{"biomarker_overlap":null,"composite_score":0.5443988269794721,"cr_rationale":"Anti-metastasis mAb targets cancer mortality driver, though indication specificity is lacking.","description_excerpt":"Unmet Need\r\n·      It is projected that there will be about 1.9 million cancer cases, and 6 thousand cancer deaths within the US in the year 2023 (Siegel, 2021). mAb immunotherapy has been found to be less damaging and less invasive to rapidly dividing normal tissues when compared to current tumor t","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer metastasis (general)","mechanism_class":"Anti-metastasis monoclonal antibody","modality":"monoclonal_antibody","objectID":"59665","rationale_one_line":"Monoclonal antibody targeting cancer metastasis; mAb modality confirmed; no specific indication from the 11 enums identified in the description.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59665","subscores":{"clinical_relevance":0.6,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":null,"title":"Monoclonal Antibody for Cancer Metastasis"},{"biomarker_overlap":"KCNK9 overexpression","composite_score":0.5443988269794721,"cr_rationale":"KCNK9 is a novel target in breast/lung cancer with limited approved therapies addressing it directly.","description_excerpt":"Unmet Need:\r\nKCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"breast, lung, skin, and other cancers","mechanism_class":"K2P channel antagonist","modality":"monoclonal_antibody","objectID":"57102","rationale_one_line":"Title explicitly states 'monoclonal antibody inhibitors targeting potassium channel KCNK9'; breast cancer is the primary listed indication in the taxonomy path.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/57102","subscores":{"clinical_relevance":0.6,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"KCNK9","title":"Novel monoclonal antibody inhibitors targeting potassium channel KCNK9"},{"biomarker_overlap":"Anti-CCAR1 autoantibody (negatively associated with cancer in dermatomyositis patients)","composite_score":0.5443988269794721,"cr_rationale":"Dermatomyositis-associated cancer protection/screening addresses a clinically significant gap with limited current options.","description_excerpt":"Brief Description\r\nStanford and JHU researchers identify an autoantibody response in dermatomyositis patients that is protective of cancer, which may have applications in cancer screening and treatment.\r\nTechnology Summary \r\nResearchers at Stanford University and Johns Hopkins University have identi","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer (dermatomyositis-associated cancer protection / screening and treatment)","mechanism_class":"CCAR1 autoantibody","modality":"monoclonal_antibody","objectID":"51128","rationale_one_line":"Antibody against CCAR1 identified in dermatomyositis patients as protective against cancer; general oncology with no specific enum-mapped indication; classified under Therapeutic Antibodies / Immunotherapies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/51128","subscores":{"clinical_relevance":0.6,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"CCAR1","title":"Antibodies Against CCAR1 Confer Protection Against Cancer"},{"biomarker_overlap":null,"composite_score":0.5443988269794721,"cr_rationale":"CXCR4/CCR5 antibodies blocking HIV entry offer a novel mechanism complementing antiretroviral SoC.","description_excerpt":"C03243: Monoclonal antibodies (and their Production) against HIV and SIV co-receptors: Chemokine receptors\r\n    \r\n   \r\n\r\nTechnical Details: \r\n\r\nThese monoclonal antibodies are specific for the chemokine receptors CXCR4 and CCR5, which mediate entry of HIV and SIV into susceptible cells.","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"HIV / SIV infection","mechanism_class":"anti-CXCR4 / anti-CCR5 monoclonal antibody","modality":"monoclonal_antibody","objectID":"16125","rationale_one_line":"Monoclonal antibodies against chemokine receptors CXCR4 and CCR5 mediating 'entry of HIV and SIV into susceptible cells'; infectious disease indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16125","subscores":{"clinical_relevance":0.6,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"CXCR4; CCR5","title":"Monoclonal antibodies (and their Production) against HIV and SIV co-receptors: Chemokine receptors"},{"biomarker_overlap":null,"composite_score":0.5439818946831569,"cr_rationale":"GsMTx-4 targets schwannomatosis pain mechanistically where no approved therapy exists and opioids provide inadequate relief.","description_excerpt":"Value Proposition:\r\n·      First Non-Surgical Therapy for Schwannomatosis Pain: Introduces the first targeted, injectable, mechanism-based treatment for schwannoma-associated pain, replacing the current reliance on tumor resection for pain control.\r\n·      Mechanosensitive Ion Channel (MSC) Inhibiti","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Schwannomatosis-induced chronic neuropathic pain","mechanism_class":"Mechanosensitive ion channel (MSC) inhibitor","modality":"peptide","objectID":"59786","rationale_one_line":"GsMTx-4, a peptide toxin blocking mechanosensitive ion channels for schwannomatosis pain; peptide modality confirmed by taxonomy; schwannomatosis not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59786","subscores":{"clinical_relevance":0.75,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"mechanosensitive ion channels","title":"GsMTx-4 as a Treatment for Schwannomatosis-Induced Pain"},{"biomarker_overlap":null,"composite_score":0.5319016957796762,"cr_rationale":"ERCP-based liver gene delivery platform; procedural delivery innovation without defined therapeutic endpoint.","description_excerpt":"Unmet Need\r\nGene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of gene therapy trials has been steadily increasing in the United States, with around 170 trials taking place in 2015. All of these trials aim to treat the causes of differe","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Genetic disorders and diseases treatable by liver-directed gene therapy (broad platform)","mechanism_class":"Liver-directed gene delivery via ERCP hydrodynamic injection","modality":"gene_therapy","objectID":"36532","rationale_one_line":"Liver-directed gene delivery via endoscopic retrograde cholangiopancreatography (ERCP) hydrodynamic injection — a gene therapy delivery platform without a single supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36532","subscores":{"clinical_relevance":0.4,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Liver-directed gene delivery via endoscopic retrograde cholangiopoancreatograpy (ERCP) directed hydrodynamic injection"},{"biomarker_overlap":null,"composite_score":0.5319016957796762,"cr_rationale":"Non-viral gene delivery platform without disease-specific therapeutic indication.","description_excerpt":"Non-viral vectors are widely investigated due to their ability to safely and effectively deliver exogenous genes and potentially cure diseases of genetic origin. Much portion of the ongoing research in the field is also dedicated to further optimize the existing vectors for in vivo applications. Thi","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gene and drug delivery (non-viral vector platform)","mechanism_class":"PEG-PBAE-PEG non-viral gene delivery vector","modality":"gene_therapy","objectID":"24796","rationale_one_line":"PEG-PBAE-PEG polymer for non-viral gene and drug delivery; gene therapy delivery platform without a disease-specific indication among the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24796","subscores":{"clinical_relevance":0.4,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Synthesis of poly(β-amino ester)-co-polyethylene glycol (PEG-PBAE-PEG) polymer for gene and drug delivery"},{"biomarker_overlap":null,"composite_score":0.5319016957796762,"cr_rationale":"Biodegradable gene vector platform; no disease-specific SoC.","description_excerpt":"JHU researchers have formulated compact, colloidally stable gene carriers that have a dense surface coverage of hydrophilic and neutrally charged PEG. These gene vectors stably retain their physicochemical characteristics over at least a week in aqueous solution and are highly stable in physiologica","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gene delivery platform (non-viral gene vectors overcoming biological barriers)","mechanism_class":"PEG-coated biodegradable non-viral gene vector","modality":"gene_therapy","objectID":"24768","rationale_one_line":"Compact PEG-coated biodegradable gene vectors stable in physiological conditions for gene delivery; gene therapy delivery platform without a specific disease indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24768","subscores":{"clinical_relevance":0.4,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Formulation Method and Use of Highly Stable Biodegradable Gene Vector Platforms Capable of Overcoming Various Biological Barriers"},{"biomarker_overlap":null,"composite_score":0.5319016957796762,"cr_rationale":"Brain-penetrant gene vector platform; therapeutic impact depends on specific application.","description_excerpt":"Unmet Need:\r\nGene delivery to the central nervous system (CNS) has potential as a means for treating numerous debilitating neurological diseases. Viral gene delivery, though relatively efficient, has been limited by immunogenicity, low packaging capacity and difficulties in manufacture and scale-up.","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"CNS neurological diseases (non-viral gene delivery to the central nervous system)","mechanism_class":"synthetic brain-penetrating non-viral gene vector","modality":"gene_therapy","objectID":"24744","rationale_one_line":"Engineered synthetic non-viral gene vectors for CNS gene delivery to treat neurological diseases; gene therapy delivery platform without a specific supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24744","subscores":{"clinical_relevance":0.4,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Engineering Synthetic Brain Penetrating Gene Vectors"},{"biomarker_overlap":null,"composite_score":0.5311460629132438,"cr_rationale":"Non-opioid neuropathic pain therapy addresses efficacy and addiction limits of SoC.","description_excerpt":"Unmet Need\r\nChronic pain affects around 50-million adults within the United States (see CDC). Currently the dominant treatment option for moderate to severe pain are opioids, which have a range of associated adverse effects as well as the potential for abuse. Despite the development of abuse-deterre","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Chronic neuropathic pain","mechanism_class":null,"modality":"small_molecule","objectID":"60454","rationale_one_line":"Small molecule therapeutic approach for neuropathic pain as opioid alternative; pain is not in the indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60454","subscores":{"clinical_relevance":0.75,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"New therapeutic approach for the treatment of neuropathic pain"},{"biomarker_overlap":"MDSC levels","composite_score":0.5311460629132438,"cr_rationale":"Epigenetic-checkpoint combination targets MDSC resistance in poorly immunogenic cancers.","description_excerpt":"Value Proposition\r\n·      Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers\r\n·      Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer (metastatic, poorly immunogenic — targeting MDSCs)","mechanism_class":"HDAC inhibitor + DNA methyltransferase inhibitor combination with checkpoint blockade","modality":"small_molecule","objectID":"60329","rationale_one_line":"Epigenetic modulators (HDAC/DNMT inhibitors) combined with anti-PD-1/CTLA-4 to overcome MDSC-mediated resistance; primary novel component is small molecule; broad oncology not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60329","subscores":{"clinical_relevance":0.75,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HDAC","title":"Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment"},{"biomarker_overlap":"SYNGAP1 mutation","composite_score":0.5311460629132438,"cr_rationale":"Perampanel repurposing addresses SYNGAP1, a rare disorder without approved treatment.","description_excerpt":"Value Proposition:\r\n·      First Targeted Pharmacologic Therapy for SYNGAP1 (MRD5): Introduces the first mechanism-driven treatment strategy for SYNGAP1-related neurodevelopmental disorders, addressing sleep and behavioral dysfunction at the synaptic circuitry level.\r\n·      Repurposing of an FDA Ap","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"SYNGAP1-related neurodevelopmental disorders (MRD5)","mechanism_class":"AMPA receptor antagonist (drug repurposing)","modality":"small_molecule","objectID":"59851","rationale_one_line":"Repurposing Perampanel (FDA-approved AMPA antagonist) for SYNGAP1-related disorders; small molecule; neurodevelopmental disease not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59851","subscores":{"clinical_relevance":0.75,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SYNGAP1","title":"Repurposing Perampanel to treat SYNGAP1-related disorders"},{"biomarker_overlap":"UHRF1 expression, DNA methylation","composite_score":0.5311460629132438,"cr_rationale":"mRNA-UHRF1 inhibition targets epigenetic silencing not addressed by current SoC.","description_excerpt":"Value Proposition - Reversal of colorectal cancer-specific DNA hypermethylation - mRNA-based strategy for UHRF1 inhibition - A lipid nanoparticle-based delivery platform\r\nUnmet Need\r\n1 out of 24 people will develop colorectal cancer. Current technologies do not maximize the bodies’ native ability to","dev_stage":"unknown","exclusivity_status":"unknown","indication":"colorectal_cancer","indication_free_text":"Colorectal cancer","mechanism_class":"mRNA-based UHRF1 inhibitor (LNP-delivered)","modality":"nucleic_acid","objectID":"58326","rationale_one_line":"mRNA-based strategy using LNP delivery to inhibit UHRF1 and reverse colorectal cancer-specific DNA hypermethylation; nucleic_acid modality; colorectal_cancer confirmed.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/58326","subscores":{"clinical_relevance":0.75,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"UHRF1","title":"A method for inhibiting UHRF1 in colorectal cancer"},{"biomarker_overlap":null,"composite_score":0.5311460629132438,"cr_rationale":"hPSC-Schwann cell therapy addresses Charcot-Marie-Tooth with no disease-modifying treatment currently approved.","description_excerpt":"Unmet Need\r\nPermanent peripheral nerve damage can be caused by acute traumatic injury, or peripheral neuropathy may develop gradually, secondary to hereditary disorders (i.e. Charcot-Marie-Tooth), chronic diseases (i.e., diabetes) and aging-related demyelination symptoms. The prevalence of periphera","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Peripheral neuropathy and Schwann cell-related degenerative diseases including Charcot-Marie-Tooth disease","mechanism_class":"hPSC-derived Schwann cell therapy","modality":"other","objectID":"53496","rationale_one_line":"Source describes derivation of Schwann cells from hPSCs for cell-based therapy in peripheral neuropathy; cell therapy subtype is not among the 9 supported modality enums; indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53496","subscores":{"clinical_relevance":0.75,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Direct Derivation of Functional Schwann Cells from Human Pluripotent Stem Cells (hPSCs) as a Source for Cell-based Therapy to Schwann Cell-related Degenerative Diseases"},{"biomarker_overlap":null,"composite_score":0.5311460629132438,"cr_rationale":"Cardiac regeneration via circadian gene modulation addresses severe heart failure where regenerative SoC is absent.","description_excerpt":"Value Proposition: - This technology provides a therapeutic approach for the regrowth of permanently damaged heart muscle. - This could improve health outcomes for patients with severe heart failure.\r\nTechnology Description\r\nResearchers at Johns Hopkins have discovered that the manipulation of circa","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Heart failure; regeneration of cardiac muscle in severe heart failure patients","mechanism_class":"circadian gene modulation for cardiomyocyte regeneration","modality":"other","objectID":"53440","rationale_one_line":"Source describes manipulation of circadian genes to induce cardiac muscle regeneration for heart failure; no clear supported modality enum applies and heart failure is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53440","subscores":{"clinical_relevance":0.75,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Regeneration of cardiac muscle for the treatment of heart failure"},{"biomarker_overlap":"PD-L1 expression","composite_score":0.5293393790641335,"cr_rationale":"Multispecific PD-L1 downregulation antibody addresses checkpoint resistance, a key gap in IO SoC.","description_excerpt":"Unmet Need: It is estimated that in 2018 there were more than 17 million new cases of cancer worldwide (see ACS). Immune checkpoint therapies have become a powerful treatment route for a wide variety of cancer types and have increased the life expectancy for patients whose disease is refractory to a","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"various cancer types (immune checkpoint therapy)","mechanism_class":"PD-L1 downregulation multispecific antibody","modality":"bispecific","objectID":"55780","rationale_one_line":"Title says 'Multispecific Antibodies' targeting PD-L1 downregulation; multispecific maps to bispecific in the enum; broad cancer indication does not map to a single supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55780","subscores":{"clinical_relevance":0.7,"ira_exposure":0.85,"modality_pos":0.331131263547112,"whitespace":0.5},"target":"CD274","title":"Multispecific Antibodies that Induce Downregulation of Programmed Death-ligand 1"},{"biomarker_overlap":null,"composite_score":0.5293393790641335,"cr_rationale":"Bispecific targeting metastasis in TNBC addresses poor prognosis where SoC remains limited.","description_excerpt":"Description: \r\nUnmet Need. In the United States, 40% of males and 38% of females will develop cancer in their lifetimes. Many types of cancers, including triple negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC), have devastatingly low five year survival rates, even after the ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"triple negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC)","mechanism_class":"bispecific antibody targeting tumor metastasis","modality":"bispecific","objectID":"34759","rationale_one_line":"Title states 'Engineered Bispecific Antibodies' and description cites TNBC as primary oncology indication; PDAC is secondary and maps outside supported enums so breast_cancer is the closer supported fit.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/34759","subscores":{"clinical_relevance":0.7,"ira_exposure":0.85,"modality_pos":0.331131263547112,"whitespace":0.5},"target":null,"title":"Engineered Bispecific Antibodies for Targeted Inhibition of Tumor Metastasis"},{"biomarker_overlap":null,"composite_score":0.5239818946831569,"cr_rationale":"Needle-free HPV peptide vaccine could expand coverage where cold-chain access limits SoC.","description_excerpt":"Value Proposition:\r\n\t\t\t• A broadly protective vaccine against HPV.\r\n\t\t\t• Can be delivered without needles.\r\n\t\t\t• Can be chemically synthesized at low cost.\r\n\t\t\tTechnical Details:\r\n\t\t\tHuman papillomavirus (HPV) infections are the most common sexually transmitted infection in the United States. Infect","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"HPV infection and HPV-associated oncogenic diseases","mechanism_class":"Peptide-based broadly protective HPV vaccine","modality":"peptide","objectID":"60515","rationale_one_line":"Chemically synthesized peptide HPV vaccine deliverable without needles; modality is peptide; HPV/cervical cancer not in the indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60515","subscores":{"clinical_relevance":0.7,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"HPV","title":"Novel HPV Vaccine"},{"biomarker_overlap":null,"composite_score":0.5239818946831569,"cr_rationale":"Long-acting HIV treatment remains a priority; self-assembling prodrug depot approach improves adherence vs. daily SoC.","description_excerpt":"Unmet Need / Invention Novelty: The need for long-acting HIV drugs arises from challenges such as pill burden, side effects, and stigma, which contribute to inconsistent use and reduced effectiveness. A long-acting antiretroviral formulation could enhance treatment adherence, reduce disease transmis","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"chronic HIV infection / Hepatitis B","mechanism_class":"self-assembling antiviral prodrug","modality":"peptide","objectID":"54558","rationale_one_line":"Taxonomy classifies under Peptides; self-assembling antiviral prodrug for long-acting HIV treatment — HIV is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54558","subscores":{"clinical_relevance":0.7,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Self-Assembling Antiviral Prodrugs for Long-Acting Treatment of Chronic HIV Infections"},{"biomarker_overlap":null,"composite_score":0.5239818946831569,"cr_rationale":"Norrin/LGR6 dendrite growth stimulation for ALS/PD/HD; no disease-modifying SoC exists for these neurodegeneration targets.","description_excerpt":"Unmet Need\r\nAstroglial dysfunction is associated with the development of numerous central nervous system (CNS) diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and Huntington’s disease (HD). Astroglia are the homeostatic cells of the central nervous system and play ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"CNS diseases including ALS, Parkinson's disease, Huntington's disease, Alzheimer's disease, neurodegeneration","mechanism_class":"Norrin/LGR6 signaling stimulation for dendrite growth and spine formation","modality":"peptide","objectID":"35349","rationale_one_line":"Stimulation of dendrite growth and spine formation by Norrin and LGR6 for CNS injury and neurodegeneration including ALS, PD, HD — peptide/protein; neurodegenerative disease outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35349","subscores":{"clinical_relevance":0.7,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"LGR6 / Norrin","title":"Stimulation of Dendrite Growth and Spine Formation by Norrin and LGR6: A Target for Therapy in CNS Injury and Degeneration"},{"biomarker_overlap":"HPV E7 antigen","composite_score":0.5239818946831569,"cr_rationale":"HPV E7-targeted immunotherapy for cervical cancer offers disease-modifying potential over chemoradiation SoC.","description_excerpt":"Unmet need\r\nHuman papillomavirus (HPV) causes the majority of cases of cervical cancer, which affects approximately 500,000 women worldwide each year. Additionally, HPV has been associated with other cancers including penile, vaginal, vulvar, anal, and head and neck cancers. Currently, there are lim","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"cervical cancer caused by human papillomavirus (HPV)","mechanism_class":"fusion protein cancer immunotherapy","modality":"peptide","objectID":"34446","rationale_one_line":"Annexin V-HPV E7 fusion protein for cervical cancer treatment; cervical cancer is not in the 11 supported indications so mapped to other; fusion protein is closest to peptide modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/34446","subscores":{"clinical_relevance":0.7,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"HPV E7","title":"Annexin V-HPV E7 Fusion Protein for Cancer Treatment"},{"biomarker_overlap":null,"composite_score":0.5239818946831569,"cr_rationale":"Plasmodium-derived anti-invasion peptides for malaria address blood-stage disease where SoC resistance is growing.","description_excerpt":"Novel Peptide Targeting for Malaria Therapeutic ApplicationsJHU REF: C12845\r\n \r\nInvention Novelty: Use of Plasmodium-derived peptides to reduce red blood cell invasion of Plasmodium parasites for the prevention and treatment of malaria\r\n \r\nValue Proposition: Malaria is an infectious disease caused b","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"malaria; Plasmodium parasite red blood cell invasion","mechanism_class":"Plasmodium-derived peptide anti-invasion agent","modality":"peptide","objectID":"20836","rationale_one_line":"Plasmodium-derived peptides to 'reduce red blood cell invasion' for malaria prevention and treatment; peptide modality for malaria, an infectious disease outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/20836","subscores":{"clinical_relevance":0.7,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"Plasmodium invasion ligands","title":"A novel Malaria vaccine candidate"},{"biomarker_overlap":null,"composite_score":0.5239818946831569,"cr_rationale":"Antigenic peptide coating renders ovarian tumors immunogenic; platinum-resistant OC has no effective SoC.","description_excerpt":"C11613: Novel Immunotherapy for Ovarian Cancer\r\nNovelty: \r\nThis invention is an immunotherapy that coats tumor cells with foreign antigenic peptide thereby rendering the coated tumor cells susceptible to immune recognition and elimination.\r\nValue Proposition: \r\nCancer is the second most common cause","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"ovarian cancer","mechanism_class":"antigenic peptide coating (tumor cell immunotherapy)","modality":"peptide","objectID":"16993","rationale_one_line":"Immunotherapy coating tumor cells with foreign antigenic peptide to render them susceptible to CD8+ T cell killing in ovarian cancer — ovarian cancer outside supported enum; peptide/immunotherapy modality, peptide maps closest.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16993","subscores":{"clinical_relevance":0.7,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"CD8+ T cell antigen recognition (tumor-specific)","title":"Selectively Targeted Coating of Tumor Cells with Foreign Antigenic Peptide Renders Tumor Cells Susceptible to Antigen-specific CD8+ T Cell-mediated Killing"}],"rubric_version":"rubric@2026-Q2-v3","rubric_weights":{"clinical_relevance":0.4,"modality_pos":0.3,"whitespace":0.3},"schema_version":1,"tail_full":[{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Mechanosignaling modulator targets unaddressed mucus-viscosity driver in COPD/CF/IPF where SoC lacks disease-modifying options.","description_excerpt":"Value Proposition\r\n·      Restoration of pro-repair cell dynamics: targets the high mucus viscosity that drives exacerbation of muco-obstructive lung diseases (COPD, CF, IPF)\r\n·      Addresses biophysical mechanism of disease development: disrupts the counter-reparative mechanosignaling pathway acti","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Muco-obstructive lung diseases (COPD, CF, IPF)","mechanism_class":"Mechanosignaling pathway modulator","modality":"other","objectID":"60938","rationale_one_line":"Targets high mucus viscosity-driven mechanosignaling in COPD/CF/IPF; no specific modality class stated; COPD/CF/IPF not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60938","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Treatment of mucus-related diseases via modulation of mechanosignaling pathways activated by high mucus viscosity"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Oncolytic virus targets NF1 neurofibromas lacking approved systemic therapy.","description_excerpt":"Value Proposition\r\n·      Tumor-selective oncolysis: T‑VEC is an engineered oncolytic HSV‑1 that preferentially replicates in and lyses tumor cells, providing direct cytolytic reduction of cutaneous neurofibromas in preclinical models\r\n·      Local, anti-tumor immune activation: preclinical evidence","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cutaneous neurofibromas (NF1-associated)","mechanism_class":"Oncolytic virus immunotherapy","modality":"other","objectID":"60923","rationale_one_line":"T-VEC is an engineered oncolytic HSV-1 — oncolytic virus is not among the 9 modality enums; neurofibromas are not in the indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60923","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Targeted T-VEC immunotherapy for cutaneous neurofibromas"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Dendrimer-GCPII inhibitor targets muscle atrophy with no approved pharmacological DMARD-equivalent; meaningful unmet need.","description_excerpt":"Value Proposition\r\n·      GCPII inhibitor has a low IC50 (&lt;5 nM), suggesting greater potency and less systemic toxicity.\r\n·      Functional improvements after treatment include 95% preservation of muscle mass, 96% preservation of grip strength, 25% greater isometric force.\r\n·      Decreased decli","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"Muscle atrophy","mechanism_class":"GCPII inhibitor","modality":"small_molecule","objectID":"60655","rationale_one_line":"Dendrimer-conjugated GCPII inhibitor (IC50 <5 nM) preserving muscle mass; small molecule therapeutic; muscle atrophy not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60655","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GCPII","title":"Dendrimer-conjugated GCPII Inhibitors to Delay Loss of Muscle Mass and Strength"},{"biomarker_overlap":"Activated microglia, tumor-associated macrophages","composite_score":0.5111460629132438,"cr_rationale":"Dendrimer-DON may overcome toxicity in CNS tumors with few effective options.","description_excerpt":"Value Proposition\r\n·      Deliver glutamine antagonists to the CNS without GI and systemic toxicity assiated with free DON.\r\n·      High specificity for activated microglia and tumor-associated macrophages, providing therapeutic precision across neuroinflammatory and oncologic indications. \r\n·      ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"CNS neuroinflammation and oncologic indications (brain tumors)","mechanism_class":"Glutamine antagonist (dendrimer-conjugated)","modality":"small_molecule","objectID":"60618","rationale_one_line":"Dendrimer-conjugated glutamine antagonist (DON analog) for CNS/tumor delivery; small molecule therapeutic; no single supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60618","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Dendrimer Conjugated Glutamine Antagonists for Targeted Brain and Tumor Delivery"},{"biomarker_overlap":"SMN2 copy number","composite_score":0.5111460629132438,"cr_rationale":"ASO combinations may boost SMN where nusinersen leaves residual SMA burden.","description_excerpt":"Unmet Need\r\nSpinal muscular atrophy (SMA) is a devastating neuromuscular disease that predominantly affects children and is the most common cause of hereditary infant mortality. The disease is caused by low levels of survival motor neuron (SMN) protein, due to recessive mutations in the SMN1 gene. I","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Spinal muscular atrophy (SMA)","mechanism_class":"Antisense oligonucleotide (ASO) combination","modality":"nucleic_acid","objectID":"60518","rationale_one_line":"Combinations of ASOs to modulate SMN expression in SMA patients; nucleic_acid modality; SMA not in the indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60518","subscores":{"clinical_relevance":0.7,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SMN2","title":"Combinations of ASOs for the Modulation of SMN Expression in SMA Patients"},{"biomarker_overlap":"Pro-inflammatory cytokines","composite_score":0.5111460629132438,"cr_rationale":"GAS6 EVs target IBD inflammation where biologic nonresponse remains substantial.","description_excerpt":"Value Proposition\r\n·      Superior Anti-Inflammatory Potency: This membrane-associated GAS6 demonstrates over 10-fold higher anti-inflammatory activity compared to equivalent amounts of soluble recombinant GAS6 proteins. \r\n·      Dual Mechanism of Action: Inhibits pro-inflammatory cytokine productio","dev_stage":"unknown","exclusivity_status":"unknown","indication":"crohns","indication_free_text":"Crohn's Disease, Ulcerative Colitis, and other inflammatory conditions","mechanism_class":"GAS6-modified extracellular vesicle anti-inflammatory","modality":"other","objectID":"59849","rationale_one_line":"GAS6-modified EVs with dual anti-inflammatory mechanism targeting Crohn's Disease and Ulcerative Colitis; EVs do not fit any of the 9 modality enums; indication mapped to crohns (first listed).","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59849","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"AXL","title":"GAS6-Modified Extracellular Vesicles (EVs) for Anti-Inflammatory Therapy"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Targeted chemo-immunotherapy addresses recurrent glioma, where SoC offers minimal survival.","description_excerpt":"Value Proposition - Enhanced effect of immunotherapy - Treatment for recurrent or metastatic disease - Improved glioma treatment \r\nUnmet Need - Immunotherapy represents a new paradigm in cancer treatment. Molecules that effectively reverse the immune suppressing nature of cancer have the potential t","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Glioma (recurrent or metastatic)","mechanism_class":"Chemo-immunotherapy combination","modality":"small_molecule","objectID":"59788","rationale_one_line":"Targeted delivery of chemo-immunotherapy agents to enhance immune response in glioma; primary component is small molecule immunomodulator; glioma not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59788","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Targeted chemo-immunotherapy delivery"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Liver cancer has poor SoC beyond sorafenib/IO; EV delivery showing survival benefit is meaningful.","description_excerpt":"Value Proposition\r\n·       Effective: animal studies showed increased survival and decreased tumor burden in liver cancer model.\r\n·       Fewer side effects: no immunological reactions or off-target effects\r\n·       Multiple targets: targets the cancer-stroma interactions\r\nUnmet Need\r\n·       Many c","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"liver cancer (cancer-stroma interactions)","mechanism_class":"extracellular vesicle-mediated nucleic acid delivery","modality":"nucleic_acid","objectID":"56209","rationale_one_line":"Technology delivers nucleic acid cargo via extracellular vesicles; 'animal studies showed increased survival and decreased tumor burden in liver cancer model' confirms preclinical stage.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/56209","subscores":{"clinical_relevance":0.7,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Extracellular Vesicle mediated nucleic acid treatment in vivo"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"MS lacks truly disease-modifying metabolite therapies; indole lactate mechanism is mechanistically distinct.","description_excerpt":"Unmet Need\r\n2.8 million people are estimated to be living with multiple sclerosis (MS) worldwide (35.9 per 100,000 population) (Walton et al.). The gold standard of care consists of symptom relieving remedies as well as disease modifying therapies. However, there are no curative therapies for MS, an","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"multiple sclerosis","mechanism_class":"indole lactate metabolite therapy","modality":"small_molecule","objectID":"55712","rationale_one_line":"Indole Lactate is a small molecule metabolite; indication is multiple sclerosis, which is outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55712","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Indole Lactate for the Treatment of Multiple Sclerosis"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Gut-restricted SERT inhibitor avoids CNS side effects of systemic SSRIs, a meaningful improvement for IBS-C.","description_excerpt":"Value Proposition\r\n·       Potent inhibition of serotonin transporter (SERT) in GI system\r\n·       Luminally and or/peripherally-restricted SERT inhibitors\r\n·       Result in enhanced action of serotonin in stimulation of GI motility\r\n·       Spares the body of systemic and CNS effects\r\nUnmet Need\r\n","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"constipation-predominant IBS / gastrointestinal motility disorders","mechanism_class":"gut-restricted SERT inhibitor","modality":"small_molecule","objectID":"55163","rationale_one_line":"Small molecule serotonin transporter (SERT/SLC6A4) inhibitors restricted to the GI lumen; indication is IBS/constipation, outside the supported enum set.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55163","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SLC6A4","title":"Gut-specific serotonin transporter inhibitors for treatment of constipation"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Diabetic wounds remain high-need; regenerative therapy could improve care beyond wound management.","description_excerpt":"Value Proposition: - Provides a slow, sustained release of a combination therapy to reverse cellular senescence and enhance collagen production in proliferating and senescent primary dermal fibroblasts. - Utilizes a thermosensitive and biodegradable hydrogel for sustained release of nanoparticles an","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"diabetic wound healing / cellular senescence","mechanism_class":"thermosensitive hydrogel-nanoparticle combination therapy","modality":"other","objectID":"55110","rationale_one_line":"Taxonomy path explicitly includes 'Clinical and Disease Specializations > Diabetes'; technology addresses wound healing in a diabetic context, making type2_diabetes the best-fit supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55110","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Thermosensitive Hydrogel-Nanoparticle System to Reverse Cellular Senescence and Enhance Collagen Production"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Overcoming DNMT inhibitor resistance addresses a key failure mode in hematologic malignancy treatment.","description_excerpt":"Unmet Need\r\nGenome stability is regulated by a variety of mechanisms. One such mechanism is DNA methylation. DNA methylation can alter the manner in which genes are expressed, and aberrations in methylation management are well documented as features of cancer cells. DNA methylation is regulated in p","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancers with intrinsic resistance to nucleoside DNMT inhibitors","mechanism_class":"DNMT inhibitor combination therapy","modality":"small_molecule","objectID":"54444","rationale_one_line":"Taxonomy classifies under Small Molecules; targets DNA methyltransferases (DNMTs) to overcome cancer resistance — broad oncology without a single supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54444","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"DNMT","title":"Combination therapy targets intrinsic cancer resistance to nucleoside DNA methyltransferase inhibitors."},{"biomarker_overlap":"ceramide levels","composite_score":0.5111460629132438,"cr_rationale":"nSMase2 inhibition for Alzheimer's/MS addresses exosome-mediated pathology spread without current SoC equivalent.","description_excerpt":"Unmet Need\r\nNeutral sphingomyelinase 2 (nSMase2) is expressed in neurons and hydrolyzes sphingomyelin, producing the lipid ceramide, which functions in stress responses leading to apoptosis, cell growth arrest, and differentiation.  Increased levels of ceramides have been associated with many neurol","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurological disorders including Alzheimer's disease and multiple sclerosis","mechanism_class":"nSMase2 inhibitor","modality":"small_molecule","objectID":"54231","rationale_one_line":"Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2/SMPD3) for neurological disorders; neurology indication is outside the supported enum set.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54231","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SMPD3","title":"Small Molecule Neutral Sphingomyelinase 2 (nSMase2) Inhibitors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Novel nSMase2 inhibitors for neurodegeneration address propagation mechanism absent from current SoC.","description_excerpt":"Unmet Need\r\nIn the brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increased activity and expression of this enzyme has been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Inhi","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurodegenerative diseases including Alzheimer's disease and multiple sclerosis","mechanism_class":"nSMase2 inhibitor","modality":"small_molecule","objectID":"54229","rationale_one_line":"Novel small molecule nSMase2 inhibitors for neurodegeneration; Alzheimer's and MS are outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54229","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SMPD3","title":"Novel nSmase2 Inhibitors to Treat Neurodegenerative Disease"},{"biomarker_overlap":"PSMA expression","composite_score":0.5111460629132438,"cr_rationale":"PSMA-targeted myeloid CAR therapy for prostate cancer addresses CRPC where taxane/ARSI SoC has limited durability.","description_excerpt":"Unmet Need: Prostate cancer remains one of the leading causes of cancer-related death among men. Clinical translation of PSMA-CAR-T cell therapies under investigation is hindered by questions as to their tumor infiltration, efficacy, and durability. Immature myeloid cells deficient in the p50-subuni","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer (PSMA-targeted)","mechanism_class":"PSMA CAR-modified myeloid cell therapy","modality":"other","objectID":"53983","rationale_one_line":"PSMA chimeric antigen receptor-modified proinflammatory myeloid cells — a cell therapy but distinct from CAR-T (myeloid cells, not T-cells); prostate cancer is outside the supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53983","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"FOLH1","title":"PSMA Chimeric Antigen Receptor-Modified Proinflammatory Myeloid Cells"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Adoptive myeloid therapy for prostate/pancreatic cancer targets immunosuppressive microenvironment beyond current SoC.","description_excerpt":"Unmet Need: Prostate cancer is one of the most often diagnosed cancers in the male population; roughly one out of ten men will be diagnosed at some point in their lives. Despite extending survival, androgen depravation therapy invariably leads to the development of lethal castration resistant prosta","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer and pancreatic ductal carcinoma","mechanism_class":"adoptive myeloid cell therapy","modality":"other","objectID":"53982","rationale_one_line":"Adoptive proinflammatory myeloid cell therapy for prostate/pancreatic cancer; cell therapy modality does not fit defined enums (not CAR-T); indications outside supported set.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53982","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Adoptive Proinflammatory Myeloid Cell Therapy for Cancer"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Dysautonomia has no approved targeted therapy; novel diagnostic/therapeutic target represents genuine unmet need.","description_excerpt":"Value Proposition:\r\n·        Diagnostic target for broad primary dysautonomia screening.\r\n·        Broadly applicable therapeutic target for symptom relief in primary and secondary dysautonomia patients.\r\nTechnology Description\r\nResearchers at Johns Hopkins have identified a potential diagnostic and","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"primary and secondary dysautonomia","mechanism_class":"dysautonomia diagnostic and therapeutic target","modality":"small_molecule","objectID":"53968","rationale_one_line":"Taxonomy classifies under Small Molecules; targets a novel diagnostic/therapeutic pathway for dysautonomia — autonomic nervous system disorder outside the supported enum set.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53968","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Diagnostic and therapeutic target for primary dysautonomia"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"TRM T cells could reverse fibrosis where current SoC only slows progression.","description_excerpt":"Value Proposition:\r\n·        Cellular therapy for the treatment of lung fibrosis with potential to stop and reverse underlying disease pathology.\r\n·        Improved efficacy and accessibility compared to status-quo therapies.\r\n·        Potential autologous therapy, as peripheral T cells can be used ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"lung fibrosis","mechanism_class":"tissue-resident memory T cell therapy","modality":"other","objectID":"53891","rationale_one_line":"Cellular therapy using peripheral T cells to induce tissue-resident memory subsets for lung fibrosis; respiratory/fibrosis indication is outside the supported enum set.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53891","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel cell therapy to Stop and Reverse Lung Fibrosis"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Glutamine antagonist JHU083 addresses AKI prevention in transplant recipients where no approved prophylactic agent exists.","description_excerpt":"Unmet Need: \r\nIt is estimated that 13.3 million people worldwide are affected by acute kidney injury (AKI) (see Bjornstad et. al). AKI is an especially prevalent condition in kidney transplant recipients, with one study showing that 35% of recipients had at least one episode of AKI (see Palmisiano e","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Acute kidney injury (AKI); prevention in kidney transplant recipients and other AKI populations","mechanism_class":"glutamine antagonist (JHU083)","modality":"small_molecule","objectID":"53438","rationale_one_line":"Taxonomy confirms Small Molecules and the compound is named JHU083; indication is acute kidney injury which is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53438","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Preventing Acute Kidney Injury Using JHU083"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Bioreducible ocular delivery enables gene therapy for IRDs, improving on subretinal injection SoC accessibility.","description_excerpt":"Unmet Need\r\nInherited retinal diseases (IRDs) are a group of disorders with genetic and clinical heterogeneity and are the leading cause of vision loss. [1, 20] ] Collectively, IRDs have an estimated incidence of 1:2000. [1] Gene therapies targeting IRD, including FDA approved Luxturna, are injected","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Inherited retinal diseases (IRDs); vision loss due to genetic disorders of the retina","mechanism_class":"bioreducible polymer for ocular nucleic acid delivery","modality":"nucleic_acid","objectID":"53437","rationale_one_line":"Source describes a polymer enabling nucleic acid delivery to eyes for inherited retinal diseases; nucleic acid delivery vehicle maps to nucleic_acid modality; ophthalmic indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53437","subscores":{"clinical_relevance":0.7,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Bioreducible Polymer for Nucleic Acid Delivery to Eyes and Beyond"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"TB vaccine could shorten treatment where BCG and antibiotics remain inadequate.","description_excerpt":"Unmet Need\r\nTuberculosis (TB) is one of the leading causes of death globally. A vaccine to prevent TB has not been approved since the development of the BCG vaccine in the early 20th century. New treatment paradigms using small molecule antibiotics have led to cures in a large proportion of individu","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Tuberculosis (TB); reducing treatment time with a vaccine approach","mechanism_class":"TB vaccine","modality":"other","objectID":"53265","rationale_one_line":"Taxonomy explicitly tags Vaccines for Tuberculosis; vaccines are not among the 9 supported modality enums; TB is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53265","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"Mycobacterium tuberculosis","title":"A Vaccine to Reduce Treatment Time for Tuberculosis"},{"biomarker_overlap":"alpha-synuclein aggregates","composite_score":0.5111460629132438,"cr_rationale":"Nanozyme targeting alpha-synuclein prion-like pathology addresses Parkinson's/LBD where no disease-modifying SoC exists.","description_excerpt":"Unmet Need\r\nOxidative stress and subsequent prion-like pathology is an essential driver n the pathogenesis of neurodegenerative diseases, including Parkinson’s Disease (PD and Alzheimer’s disease (AD). Currently, only symptomatic treatments are available, and there is a great unmet need to develop a","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Alpha-synucleinopathies including Parkinson's disease and Alzheimer's disease; targeting prion-like alpha-synuclein pathology","mechanism_class":"nanozyme (catalytic nanoparticle) for alpha-synuclein degradation","modality":"other","objectID":"53108","rationale_one_line":"Source describes novel nanozymes to treat alpha-synucleinopathies targeting prion-like alpha-syn; nanozymes are not among the 9 supported modality enums; neurodegenerative indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53108","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"alpha-synuclein","title":"Novel Nanozymes to treat α-synucleinopathies"},{"biomarker_overlap":"alpha-synuclein aggregates","composite_score":0.5111460629132438,"cr_rationale":"Nanozyme for alpha-syn aggregation in Parkinson's addresses misfolded protein clearance with no approved SoC equivalent.","description_excerpt":"Description: \r\nUnmet Need\r\n Parkinson’s disease (PD) is the second most common neurodegenerative disorder characterized with misfolded α-synuclein (α-syn) accumulation in Lewy bodies (LB). Although some α-syn mutations have been associated with familial PD, the majority cases are sporadic with unkno","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Alpha-synucleinopathies such as Parkinson's disease; misfolded alpha-synuclein accumulation in Lewy bodies","mechanism_class":"nanozyme therapy for alpha-synuclein aggregation","modality":"other","objectID":"52896","rationale_one_line":"Source describes novel nanozyme therapy for alpha-synucleinopathies targeting misfolded alpha-syn; nanozymes are not among the 9 supported modality enums; neurodegenerative indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52896","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"alpha-synuclein","title":"Novel Nanozyme therapy for α- Synucleinopathies such as PD"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Fungal vector control targets malaria mortality where vaccines remain incomplete.","description_excerpt":"Invention novelty: This material is a transgenic fungus which targets the sporozoites that cause malaria in the salivary glands of mosquitoes. The fungus is taken up by direct contact with the mosquito and inhibits Plasmodium development. \r\nValue Proposition: Unmodified, Metarhizium anisopliae kills","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Malaria; transgenic fungus targeting Plasmodium sporozoites in mosquito salivary glands","mechanism_class":"transgenic entomopathogenic fungus for malaria vector control","modality":"other","objectID":"52672","rationale_one_line":"Source describes a transgenic fungus that kills malaria parasites in mosquitoes via vector control; this is a biocontrol/infectious disease approach not among the 9 supported modality enums; malaria is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52672","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"Plasmodium sporozoites","title":"Transgenic Fungi that Kill Malaria Parasites in Mosquitoes"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Oral insulin biologic delivery removes injections, a meaningful convenience advantage.","description_excerpt":"Technology Description\r\n·        Researchers at Johns Hopkins have developed methods for delivering oral formulations of traditionally parenteral medications (e.g., insulin, infliximab).\r\n·       After oral delivery, autonomous microscale injectors are triggered by physiological cues in the intestin","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"Diabetes; oral delivery of biologics including insulin and infliximab using ingestible microinjectors","mechanism_class":"ingestible microinjector oral biologic delivery platform","modality":"other","objectID":"52626","rationale_one_line":"Taxonomy tags Diabetes and the description specifically mentions oral delivery of insulin; diabetes maps to type2_diabetes as the closest supported enum; microinjector delivery platform maps to other for modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52626","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Oral Delivery of Biologics Using Ingestible Microinjectors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"No approved pharmacologic adjunct for post-stroke neuroplasticity; psychedelic-assisted recovery targets clear unmet need.","description_excerpt":"Unmet Need\r\nImpairment of neuronal function in adults is challenging to treat. No pharmaceutical interventions have shown promise in restoring cognitive and motor function after acute neurologic injury, as is the case in recovery following transient ischemic attack or stroke. Treatment of neurologic","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Stroke / transient ischemic attack / neurologic injury (adjunct therapy with psychedelics)","mechanism_class":"psychedelic / serotonergic agonist (repurposed)","modality":"small_molecule","objectID":"50969","rationale_one_line":"Repurposed psychedelic adjunct therapy for neurologic recovery post-stroke/TIA; classified under Repurposed Drugs; stroke is not among the 11 indication enums so maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50969","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Adjunct Therapy with Psychedelics"},{"biomarker_overlap":"Copy number alterations, protein-coding gene mutations (avg 11 per tumor)","composite_score":0.5111460629132438,"cr_rationale":"Medulloblastoma in children has high mortality and limited targeted options; target discovery is clinically meaningful.","description_excerpt":"Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high density microarrays and sequenced all known protein-coding genes and miRNA genes using Sanger sequencing. We found tha","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Medulloblastoma (malignant brain tumor in children)","mechanism_class":"therapeutic target identification (genetic alterations in MB)","modality":"other","objectID":"50280","rationale_one_line":"Identification of therapeutic targets via genetic alteration mapping in medulloblastoma; primarily a target/biomarker discovery; medulloblastoma not in enum so maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50280","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Medulloblastoma Therapeutic Targets"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"HNO donors show positive inotropy without tolerance; addresses heart failure gap beyond standard neurohormonal blockade.","description_excerpt":"Technology Overview\r\nThe invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides met","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Congestive heart failure / ischemia-reperfusion injury (HNO donor)","mechanism_class":"HNO donor (nitroxyl donor)","modality":"small_molecule","objectID":"50279","rationale_one_line":"N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives as stabilized HNO donors for cardiovascular conditions; small molecule; cardiovascular not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50279","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"N-Acyloxysulfonamide and N-Hydroxy-N-acylsulfonamide Derivatives as Stabilized HNO Donors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Bis-acylated HNO donors with improved stability offer inotropic benefit unmet by existing heart failure SoC.","description_excerpt":"Technology Overview\r\nThe invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compoun","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Congestive heart failure / ischemia-reperfusion injury (HNO donor)","mechanism_class":"HNO donor (nitroxyl donor)","modality":"small_molecule","objectID":"50278","rationale_one_line":"Bis-acylated hydroxylamine derivatives as HNO donors for cardiovascular conditions; small molecule; cardiovascular indication not in the 11 enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50278","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Bis-Acylated Hydroxylamine Derivatives as Physiologically Useful HNO Donors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"N-hydroxylsulfonamide HNO donors address unmet inotropic need in heart failure beyond current SoC.","description_excerpt":"Technology Overview\r\nThe invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failu","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Heart failure and ischemia/reperfusion injury (nitroxyl therapy)","mechanism_class":"HNO donor (nitroxyl donor)","modality":"small_molecule","objectID":"50277","rationale_one_line":"N-hydroxylsulfonamide derivatives donate nitroxyl (HNO) for heart failure and ischemia/reperfusion injury; classified under Small Molecules; cardiovascular not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50277","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"HNO donors provide inotropic effect without tolerance, meaningful advantage over existing heart failure agents.","description_excerpt":"Technology Overview\r\nThe invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failur","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Heart failure and ischemia/reperfusion injury (nitroxyl therapy)","mechanism_class":"HNO donor (nitroxyl donor)","modality":"small_molecule","objectID":"50276","rationale_one_line":"N-hydroxysulfonamide derivatives as physiologically useful nitroxyl donors for heart failure; classified under Small Molecules; cardiovascular not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50276","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"N-Hydroxysulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Novel HNO donor chemistry for cardiovascular disease addresses inotropic gap not covered by standard SoC.","description_excerpt":"Technology Overview\r\nThe disclosed subject matter provides certain N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provide","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cardiovascular diseases (nitroxyl / HNO donor therapy)","mechanism_class":"HNO donor (nitroxyl donor)","modality":"small_molecule","objectID":"50241","rationale_one_line":"N-substituted hydroxylamine derivatives with carbon-based leaving groups as HNO donors for cardiovascular diseases; classified under Small Molecules; cardiovascular not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50241","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"N-Substituted Hydroxylamine Derivatives with Carbon-Based Leaving Groups as Physiologically Useful Nitroxyl (HNO) Donors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"HNO donor with pyrazolone leaving group offers inotropic benefit absent from standard heart failure SoC.","description_excerpt":"Unmet Need\r\nAn estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths (see WHO). Nitroglycerin has been used as a vasodilator to treat heart conditions for over 130 years. It wasn&#39;t until 2003 that scientists realized the beneficial effect ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cardiovascular diseases / congestive heart failure (HNO donor)","mechanism_class":"HNO donor (nitroxyl donor)","modality":"small_molecule","objectID":"48841","rationale_one_line":"O-substituted hydroxamic acids with pyrazolone leaving groups as HNO donors for cardiovascular conditions; classified under Small Molecules; cardiovascular not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48841","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"O‐substituted hydroxamic acids with pyrazolone leaving groups as\nnovel physiologically useful HNO donors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"N-hydroxylsulfonamide HNO donor addresses positive inotropic gap in heart failure not met by current agents.","description_excerpt":"Unmet Need\r\nAn estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths (see WHO). Nitroglycerin has been used as a vasodilator to treat heart conditions for over 130 years. It wasn&#39;t until 2003 that scientists realized the beneficial effect ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cardiovascular diseases (HNO / nitroxyl donor)","mechanism_class":"HNO donor (nitroxyl donor)","modality":"small_molecule","objectID":"48840","rationale_one_line":"N-hydroxylsulfonamide derivatives as nitroxyl donors for cardiovascular diseases; classified under Small Molecules; cardiovascular not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48840","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"N-hydroxylsulfonamide Derivatives as Nitroxyl Donors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"N-substituted hydroxamic acid HNO donor targets heart failure with novel mechanism beyond existing SoC.","description_excerpt":"Unmet Need\r\nAn estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths (see WHO). Nitroglycerin has been used as a vasodilator to treat heart conditions for over 130 years. It wasn&#39;t until 2003 that scientists realized the beneficial effect ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cardiovascular diseases (HNO donor)","mechanism_class":"HNO donor (nitroxyl donor)","modality":"small_molecule","objectID":"48839","rationale_one_line":"N-substituted hydroxamic acids with carbon-based leaving groups as HNO donors for cardiovascular diseases; cardiovascular not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48839","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"New N-substituted Hydroxamic Acids with Carbon-based Leaving Groups as Efficient HNO Donors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Pyrazolone-derived nitroxyl donors offer positive inotropy without tolerance, clinically meaningful vs heart failure SoC.","description_excerpt":"Unmet Need\r\nAn estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths (see WHO). Nitroglycerin has been used as a vasodilator to treat heart conditions for over 130 years. It wasn&#39;t until 2003 that scientists realized the beneficial effect ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cardiovascular diseases (HNO / nitroxyl donor)","mechanism_class":"HNO donor (nitroxyl donor)","modality":"small_molecule","objectID":"48838","rationale_one_line":"Pyrazolone derivatives as nitroxyl donors for cardiovascular diseases; classified under Small Molecules; cardiovascular not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48838","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Pyrazolone Derivatives as Nitroxyl Donors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Barbituric acid-derived HNO donors provide unexpected inotropic mechanism beyond neurohormonal heart failure SoC.","description_excerpt":"Unmet Need\r\nAn estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths (see WHO). Nitroglycerin has been used as a vasodilator to treat heart conditions for over 130 years. It wasn&#39;t until 2003 that scientists realized the beneficial effect ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cardiovascular diseases / congestive heart failure (HNO donor)","mechanism_class":"HNO donor (nitroxyl donor)","modality":"small_molecule","objectID":"48837","rationale_one_line":"Hydroxylamine-substituted alkyl barbituric acid derivatives as unexpected HNO donors for heart failure; classified under Small Molecules; cardiovascular not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48837","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Hydroxylamine-substituted Alkyl Barbituric Acid Derivatives as Unexpected HNO Donors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Alpha-particle radiotherapy via dendrimer addresses GBM, a high-mortality cancer with no curative SoC.","description_excerpt":"Unmet Need\r\nGlioblastoma accounts for 49.1 percent of all primary malignant brain tumors. Although current standard of care, which includes surgery, followed by radiotherapy, and chemotherapy, may prolong survival, the five-year survival rate for glioblastoma patients is only 6.8 percent, and the av","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Glioblastoma and other brain cancers (dendrimer-delivered alpha-particle radiotherapy)","mechanism_class":"dendrimer-delivered alpha-particle radiotherapy","modality":"other","objectID":"48479","rationale_one_line":"Dendrimer-delivered alpha-particle radiotherapy for glioblastoma; classified under Therapeutic Delivery Platforms; glioblastoma/brain cancer not in the 11 enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48479","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Dendrimer-delivered alpha-particle radiotherapy for treatment of glioblastoma and possibly of other cancers in the brain"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"eIF2alpha kinase inhibition targets integrated stress response in neurodegeneration with no available disease-modifying SoC.","description_excerpt":"Unmet Need / Invention Novelty:  Few kinases have been identified that phosphorylate eukaryotic initiation factor 2 alpha (eIF2α) and control translation in response to protein unfolding stress, a common cause of various neurodegenerative diseases. There is an unmet need to identify novel eIF2α kina","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Neurodegenerative diseases (eIF2alpha kinase / integrated stress response)","mechanism_class":"eIF2alpha kinase inhibitor","modality":"small_molecule","objectID":"47863","rationale_one_line":"Novel eIF2alpha kinase target and small molecule inhibitors for modulating translation and stress response in neurodegenerative diseases; classified under Small Molecules; neurodegeneration not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/47863","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"EIF2AK","title":"Novel eIF2α kinase target and small molecule inhibitors for modulating translation and the stress response"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Stem-cell retinal repair addresses vision loss with limited disease-modifying SoC.","description_excerpt":"Unmet Need / Invention Novelty: Currently, there are limited options for patients diagnosed with degenerative macular diseases, with available options reducing the rate of degeneration rather than repairing the diseased retinal tissue. There is an unmet need to develop a novel therapeutic for macula","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Degenerative macular diseases (retinal and macular repair)","mechanism_class":"stem cell-based retinal/macular repair therapy","modality":"other","objectID":"46441","rationale_one_line":"Novel stem cell-based therapeutic for retinal and macular repair in degenerative macular diseases; classified under Cell Therapies; ophthalmic indication not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/46441","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel stem-cell based therapeutic for retinal and macular repair"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Tonabersat targets connexin hemichannels in ALS, a disease with no approved neuroprotective standard of care.","description_excerpt":"Unmet Need\r\nAmytrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, and results in muscle atrophy and loss of motor control. ALS affects approximately 17,000 people in the United States and 450,000 worldwide at any given time, and the average life ex","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Amyotrophic lateral sclerosis (ALS)","mechanism_class":"connexin hemichannel blocker (repurposed)","modality":"small_molecule","objectID":"45471","rationale_one_line":"Tonabersat as a neuroprotective compound for ALS; repurposed small molecule connexin hemichannel blocker; ALS not in the 11 indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45471","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GJA1","title":"Tonabersat as a Neuroprotective Compound for Amyotrophic Lateral Sclerosis"},{"biomarker_overlap":"KRAS activation; miR-21","composite_score":0.5111460629132438,"cr_rationale":"miR-21 targets PDAC KRAS signaling in a lethal, underserved cancer.","description_excerpt":"Unmet Need\r\nPancreatic ductal adenocarcinomas (PDAs) are the most prevalent neoplastic disease of the pancreas. PDAs account for more than 90% of all pancreatic malignancies and are the fourth most frequent cause of cancer-related deaths worldwide. Almost all PDAs develop following the activation of","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Pancreatic ductal adenocarcinoma (PDA)","mechanism_class":"miRNA therapy (miR-21)","modality":"nucleic_acid","objectID":"45431","rationale_one_line":"miR-21 as therapy to intercept pancreatic ductal adenocarcinoma downstream of KRAS activation; classified under Diagnostics Biomarkers / Therapeutic Targets; pancreatic cancer not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45431","subscores":{"clinical_relevance":0.7,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"KRAS","title":"miR-21 as a Therapy to Intercept Pancreatic Ductal Adenocarcinoma"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Sequential hormonal regimen targets ADT resistance in CRPC, a clinically significant gap beyond abiraterone/enzalutamide.","description_excerpt":"Unmet Need / Invention Novelty: Men with prostate cancer develop resistance to androgen deprivation therapy (castration resistant prostate cancer) and must rely on less defined subsequent lines of therapy. Increasing resistance develops with each subsequent line of hormonal therapy. There exists an ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Castration resistant prostate cancer (CRPC)","mechanism_class":"sequential hormonal therapy regimen","modality":"other","objectID":"45168","rationale_one_line":"Sequential treatment regimen to overcome resistance to androgen deprivation therapy in castration resistant prostate cancer; a treatment strategy; prostate cancer not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45168","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"AR","title":"Sequential treatment regimen for men with castration resistant prostate cancer"},{"biomarker_overlap":"BRCA1/BRCA2 deficiency","composite_score":0.5111460629132438,"cr_rationale":"POLB covalent inhibitor exploits synthetic lethality in BRCA-deficient breast cancer beyond PARP inhibitor SoC.","description_excerpt":"Unmet Need / Invention Novelty: Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors are known synthetic lethal partners for breast cancer gene (BRCA) 1- and 2-deficient cancers. However, not all BRCA-deficient cancers are susceptible to PARP1 inhibitors and others develop resistance. Furthermore, DNA p","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"BRCA-deficient breast cancer (and other BRCA-deficient cancers)","mechanism_class":"DNA polymerase beta covalent inhibitor / synthetic lethality","modality":"small_molecule","objectID":"44797","rationale_one_line":"Selective covalent inhibitors of DNA polymerase beta exploiting synthetic lethality in 'BRCA-deficient cancer'; primary category is Oncology > Breast Cancer.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44797","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"POLB","title":"Novel selective, covalent inhibitors of DNA polymerase beta, and synthetic lethality in BRCA-deficient cancer"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Oral LNP costimulatory blockade targets immune tolerance unmet by T1D SoC.","description_excerpt":"Unmet Need\r\nType 1 diabetes (T1D) affects 1.25 million Americans currently and by 2050, this number is expected to reach 5 million. Though a currently untreatable autoimmune disease, one of the more promising approaches has been a costimulatory blockade of malfunctioning immune cells via administrat","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Type 1 Diabetes (autoimmune disease)","mechanism_class":"lipid nanoparticle oral immunotherapy delivery","modality":"other","objectID":"44792","rationale_one_line":"Lipid nanoparticle oral vehicle for costimulatory blockade immunotherapy in T1D; T1D is not type2_diabetes; modality is a delivery platform, not a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44792","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Lipid Nanoparticles as Oral Vehicles of Immunotherapy"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Cell therapy for peripheral nerve regeneration; no approved regenerative SoC, only supportive management.","description_excerpt":"Unmet Need\r\nAn estimated 250,000 peripheral nerve injuries occur annually in the US alone, which accounts for 42% of the global burden. Peripheral nerve injury (PNI) can occur from trauma, surgical complications, medication, toxins, and diet. Severe peripheral nerve injury is customarily treated wit","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"peripheral nerve injury","mechanism_class":"cell therapy for nerve regeneration","modality":"other","objectID":"44305","rationale_one_line":"Cell therapy strategy for accelerated nerve regeneration in peripheral nerve injuries; indication and cell therapy modality do not map to supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44305","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel therapeutic strategy for accelerated nerve regeneration in peripheral nerve injuries"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Prevention of anesthetic neurotoxicity in children; meaningful unmet need with no approved neuroprotective SoC.","description_excerpt":"Unmet Need\r\nEvery year in the United States more than one million children under the age of five undergo a surgical procedure that requires anesthesia. Children who have had multiple early exposures to anesthesia are at greater risk of developing learning disabilities and disorders of attention and ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"anesthetic-induced neurocognitive dysfunction (children)","mechanism_class":null,"modality":"small_molecule","objectID":"44246","rationale_one_line":"Small molecule for prevention of anesthetic-induced neurocognitive dysfunction in pediatric patients; psychiatric/neurological indication does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44246","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Prevention of Anesthetic-Induced Neurocognitive Dysfunction"},{"biomarker_overlap":"NF1 mutation","composite_score":0.5111460629132438,"cr_rationale":"Mebendazole repurposing for NF1; rare disease with no approved tumor-preventive SoC and strong preclinical rationale.","description_excerpt":"Unmet need\r\nNeurofibromatosis 1 (NF1) is a common genetic disorder affecting 1 in 3000 individuals worldwide (see CTF). NF1 patients are at a markedly increased risk for the development of benign and malignant tumors that often disfigure the faces of children by the time they are teenagers. Furtherm","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Neurofibromatosis 1 (NF1) — benign and malignant tumors","mechanism_class":"mebendazole (anthelmintic repurposing)","modality":"small_molecule","objectID":"43871","rationale_one_line":"Repurposed mebendazole (small molecule) to prevent malignancies in Neurofibromatosis 1; rare disease indication does not match a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/43871","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Preventative Effect of Mebendazole Against Malignancies in Neurofibromatosis 1"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Arachidonic acid pathway inhibition for ALS; major unmet need, riluzole/edaravone SoC provides minimal OS benefit.","description_excerpt":"Unmet Need\r\nAmyotrophic Lateral Sclerosis (ALS) affects as many as 30,000 people in the United States alone, with 5,000 new cases diagnosed every year. ALS is a fatal neuromuscular disease that is characterized by a progressive degeneration of the motor nerve cells and spinal cord. There are only tw","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Amyotrophic Lateral Sclerosis (ALS)","mechanism_class":"arachidonic acid pathway inhibitor","modality":"small_molecule","objectID":"43243","rationale_one_line":"Pharmacological intervention targeting the arachidonic acid pathway as a repurposed/new small molecule approach for ALS; rare neurological disease does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/43243","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Pharmacological Intervention of the Arachidonic Acid Pathway to Cure Amyotrophic Lateral Sclerosis"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"CFTR modulator repurposing for ADPKD; significant unmet need with no approved disease-modifying SoC.","description_excerpt":"Unmet Need: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the progressive enlargement of multiple renal cysts, leading to chronic pain, hypertension, and decline in renal function and renal failure in a substantial subset of patients. Fluid enters the cysts via a cAMP-depe","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","mechanism_class":"CFTR modulator","modality":"small_molecule","objectID":"43014","rationale_one_line":"Repurposed CFTR modulators (small molecules/biologics) for ADPKD; renal indication does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/43014","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"CFTR","title":"Use of CFTR Modulators for the Treatment of ADPKD"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Cervicovaginal microbiome transplant for BV; recurrence-prone condition with antibiotic SoC that doesn't restore microbiome.","description_excerpt":"Approximately one-third of all women currently have bacterial vaginosis (BV), a condition where the vaginal microbiota is not dominated by lactobacilli. Another one-third of women have mixed vaginal microbiota (intermediate BV), and only one-third of women have healthy, lactobacilli-dominated microb","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"bacterial vaginosis / vaginal microbiota dysbiosis","mechanism_class":"cervicovaginal secretion transplant (microbiome restoration)","modality":"other","objectID":"43013","rationale_one_line":"Cervicovaginal secretion transplant to restore healthy vaginal microbiota in bacterial vaginosis; women's health / microbiome indication and modality do not match supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/43013","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Method for Cervicovaginal Secretion Transplants to Restore Healthy Vaginal Microbiota"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Tankyrase inhibitor-derived vascular progenitors for diabetic retinopathy; anti-VEGF SoC doesn't restore vasculature.","description_excerpt":"Unmet Need\r\nIn the United States, approximately 14.6 million Americans are estimated to suffer from diabetic retinopathy by the year 2050 (see CDC). Diabetic retinopathy is a debilitating condition defined by the loss of vision due to leaky blood vessels of the retina. The current standard of care i","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"diabetic retinopathy / ischemic retina","mechanism_class":"tankyrase inhibitor (Wnt/naive iPSC reprogramming)","modality":"small_molecule","objectID":"40209","rationale_one_line":"Tankyrase inhibitor-regulated naive diabetic human iPSC-derived vascular progenitors for retinal revascularization; ophthalmology/diabetic retinopathy does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/40209","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TNKS","title":"Vascular progenitors generated from tankyrase inhibitor-regulated naïve diabetic human iPSC potentiate efficient revascularization of ischemic retina"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Novel Pks13 inhibitor for TB addresses drug-resistant strains with high unmet need.","description_excerpt":"Unmet Need\r\nTuberculosis (TB) is an infectious disease caused by the bacteria Mycobacterium tuberculosis (Mtb), which typically impacts the lungs. In 2016, there were 10.4 million new cases of TB and 1.7 million deaths worldwide, with approximately one-fourth of the world’s population infected. As a","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Tuberculosis (TB) caused by Mycobacterium tuberculosis","mechanism_class":"Pks13 inhibitor","modality":"small_molecule","objectID":"39008","rationale_one_line":"Novel coumestan derivatives identified as Pks13 inhibitors against Mycobacterium tuberculosis — small molecule antibiotic; TB is an infectious disease outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/39008","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"Pks13","title":"Identification of Novel Coumestan Derivatives as Pks13 Inhibitors against Mycobacterium Tuberculosis"},{"biomarker_overlap":"Long noncoding RNAs as diagnostic and therapeutic markers across MB molecular subgroups (WNT, SHH, Group 3, Group 4)","composite_score":0.5111460629132438,"cr_rationale":"lncRNA therapeutics for medulloblastoma; pediatric brain cancer has very limited SoC options.","description_excerpt":"Unmet Need\r\nMedulloblastoma (MB) is the most common pediatric brain tumor and requires aggressive therapy in high-risk cases. MB is frequently resistant to treatment and is associated with high morbidity and mortality in affected individuals. There are four distinct molecular subgroups of MB (WNT, S","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Medulloblastoma (pediatric brain tumor)","mechanism_class":"Long noncoding RNA (lncRNA) therapeutic and diagnostic marker","modality":"nucleic_acid","objectID":"37606","rationale_one_line":"Long noncoding RNAs as therapeutic and diagnostic markers for medulloblastoma — nucleic acid modality; pediatric brain cancer is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/37606","subscores":{"clinical_relevance":0.7,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Long Noncoding RNAs as Therapeutic and Diagnostic Markers for Childhood Cancer Medulloblastoma"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Tolerogenic aAPCs for antigen-specific tolerance in autoimmunity; mechanistically distinct from broad immunosuppressants.","description_excerpt":"Unmet Need\r\n Autoimmune diseases are often treated with immunosuppressants that weaken the entire immune system, leaving patients vulnerable to infection. An ideal autoimmune therapy would establish immune tolerance to a specific self-antigen, while the rest of the immune system remains intact. One ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Autoimmune diseases (broad — immune tolerance to self-antigens)","mechanism_class":"Tolerogenic artificial antigen-presenting cell","modality":"other","objectID":"36544","rationale_one_line":"Tolerogenic artificial antigen-presenting cells to establish antigen-specific immune tolerance for autoimmune diseases — a cell therapy/delivery platform for broad autoimmunity, no specific supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36544","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Tolerogenic Artificial Antigen-Presenting Cells"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Locoregional HCC chemotherapy claiming higher efficacy than SoC sorafenib/lenvatinib.","description_excerpt":"Unmet Need\r\nOver 800,000 people are diagnosed with liver cancer annually. As the leading cause of cancer death worldwide, liver cancer accounts for more than 700,000 deaths annually. Recently, Johns Hopkins researchers have developed new chemotherapeutic drugs to treat liver cancer that demonstrate ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Liver cancer (hepatocellular carcinoma)","mechanism_class":"Locoregional chemotherapy for liver cancer","modality":"small_molecule","objectID":"36533","rationale_one_line":"New chemotherapeutic drugs for locoregional treatment of liver cancer with 'higher efficacy than the current standard of care' — small molecule modality; liver cancer is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36533","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Locoregional Chemotherapy for Liver Cancers"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Epigenetic TGFB2 targeting for scleroderma; no approved disease-modifying therapy exists for systemic sclerosis.","description_excerpt":"Unmet Need\r\nScleroderma disorders comprise a heterogeneous group of conditions linked by the presence of thickened, sclerotic skin lesions. These conditions result in a poor quality of life and have a poor prognostic outcome. In particular, systemic sclerosis (SSc) has a 10 year mortality rate of ap","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Scleroderma / systemic sclerosis (autoimmune fibrotic disease)","mechanism_class":"Epigenetic therapy targeting distal regulatory element of TGFB2","modality":"other","objectID":"36150","rationale_one_line":"Epigenetic therapy targeting the distal regulatory element of TGFB2 expression for scleroderma/systemic sclerosis — autoimmune fibrotic disease outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36150","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TGFB2","title":"Epigenetic Therapy Against Distal Regulatory Element of TGFB2 Expression"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"SARM1 inhibition for TBI; no approved neuroprotective therapy exists for traumatic brain injury.","description_excerpt":"Unmet Need\r\nTraumatic brain injury (TBI) is regarded as one of the major causes of death and disability in the United States, contributing to 30% of all injury-related deaths. Over 150 people die daily from consequences of a TBI and those that survive often face difficulties and disabilities that ca","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Traumatic brain injury (TBI) and neurodegenerative disease","mechanism_class":"SARM1 inhibition or deletion for neuroprotection","modality":"other","objectID":"35354","rationale_one_line":"SARM1 inhibition or deletion as treatment for traumatic brain injury and neurodegenerative disease — target/small molecule approach; neurological indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35354","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SARM1","title":"SARM1 Inhibition or Deletion as Experimental Treatment of Traumatic Brain Injury and Neurodegenerative Disease"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"GPR54 antagonist restoring insulin secretion for T2D; novel hepatic mechanism distinct from GLP-1/SGLT2/metformin SoC.","description_excerpt":"Unmet Need\r\nGlucagon and insulin work together to keep blood glucose levels balanced. Glucagon stimulates the liver to secrete glucose while insulin suppresses glucose release. If the body does not regulate glucose levels properly, Type 2 diabetes mellitus (T2DM) will develop. Type 2 diabetes mellit","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"Type 2 diabetes mellitus (T2DM) and prediabetes","mechanism_class":"Kisspeptin receptor (GPR54) antagonist","modality":"small_molecule","objectID":"35326","rationale_one_line":"GPR54 antagonist targeting hepatic kisspeptin to restore insulin secretion for treatment of 'prediabetes and diabetes mellitus' — small molecule; explicitly type 2 diabetes in the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35326","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GPR54 (KISS1R)","title":"Hepatic Kisspeptin Secretion Impairs Insulin Secretion from Pancreatic Bets Cell. Kisspeptin Receptor GPR54 Antagonist for Treatment of Prediabetes and Diabetes Mellitus in Humans."},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Alpha-particle radiopharmaceutical for HCC; curative systemic options remain very limited in advanced HCC.","description_excerpt":"Unmet Need\r\nHepatocellular carcinoma (HCC) is the fifth most common cancer type worldwide and a leading cause of cancer related deaths. HCC is clinically silent in its early stages, leading to diagnosis at more advanced stages when only non-surgical, palliative treatment is available. One treatment ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"hepatocellular carcinoma (HCC) / liver cancer","mechanism_class":"alpha particle radiopharmaceutical","modality":"small_molecule","objectID":"30475","rationale_one_line":"Alpha particle formulations for treatment of solid tumors including HCC; liver cancer is not among the 11 supported indications; radiopharmaceutical is closest to small_molecule given the category.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/30475","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Alpha particle formulations for treatment of solid tumors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Novel transpeptidase inhibitors for TB target drug-resistant strains where treatment options are critically limited.","description_excerpt":"Unmet need\r\nb-lactam antibacterial agents target peptidoglycan biosynthesis and are used for treatment of infection, but have been ineffective in treatment of Tuberculosis (TB). This lack of activity has been attributed to the presence of b-lactamase and limited penetration of the thick mycolate coa","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"tuberculosis (TB) and bacterial infections","mechanism_class":"transpeptidase inhibitor antibacterial","modality":"small_molecule","objectID":"28109","rationale_one_line":"New antibacterials targeting D,D- and L,D-transpeptidases for tuberculosis treatment; infectious disease indication is not in the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28109","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"D,D- and L,D-transpeptidases","title":"New Antibacterials Against D,D- and L,D-Transpeptidases"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Carbapenem plus avibactam for MDR-TB addresses a critical antimicrobial resistance unmet need.","description_excerpt":"UNMET NEED\r\nMultidrug-resistant (MDR) pathogens, e.g. Mycobacterium tuberculosis (TB) are a growing threat with significant economic ramifications. In particular, TB is one of the top 10 causes of death worldwide, with an estimated 10.4 million people infected, globally. An estimated 1.8 million dea","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"multidrug-resistant tuberculosis (MDR-TB) and bacterial infections","mechanism_class":"carbapenem + avibactam beta-lactamase inhibitor combination","modality":"small_molecule","objectID":"27063","rationale_one_line":"Carbapenem and avibactam combination for MDR-TB and bacterial infections; infectious disease indication is not in the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/27063","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"beta-lactamase","title":"A Combination of Carbapenem and Avibactam for Treatment of Bacterial Infections"},{"biomarker_overlap":"Semaphorin 3D and Plexin D1 expression","composite_score":0.5111460629132438,"cr_rationale":"Semaphorin-Plexin D1 targeting addresses PDAC with poor survival under SoC.","description_excerpt":"Unmet Need: Most patients with pancreatic ductal adenocarcinoma (PDA) present with metastatic disease at the time of diagnosis or will recur with metastases after surgical treatment. \r\nTechnology Overview: Semaphorin-plexin signaling mediates the migration of neuronal axons during development and of","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"pancreatic ductal adenocarcinoma (PDA) / pancreatic cancer","mechanism_class":"semaphorin-plexin signaling inhibitor","modality":"other","objectID":"25120","rationale_one_line":"Semaphorin 3D and Plexin D1 as therapeutic targets for pancreatic cancer; pancreatic cancer is not in the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/25120","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"Semaphorin 3D, Plexin D1","title":"Semaphorin 3D and Plexin D1 as New Therapeutic Targets for Pancreatic Cancer Treatment"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"HAND has no approved disease-modifying therapy; genuine high unmet need.","description_excerpt":"Some glutamine antagonists have been shown to have anti-cancer activities in multiple preclinical and clinical studies. However the toxicity of the glutamine antagonists at doses necessary for their anticancer effects have hampered their clinical development.  Herein we describe a completely novel u","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"HIV-associated neurocognitive disorders and oncology (glutamine antagonist repurposing)","mechanism_class":"glutamine antagonist","modality":"small_molecule","objectID":"24837","rationale_one_line":"Novel use of glutamine antagonists for HIV-associated neurocognitive disorders and immunology; preclinical studies referenced; indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24837","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Glutamine Antagonists as Therapeutics in Oncology and Immunology"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"No approved cell therapy regenerates cardiac muscle; addresses unmet regenerative gap.","description_excerpt":"Unmet Need:\r\nPluripotent stem cells (PSCs) are capable of becoming all types of patients’ body cells and thus, provide unprecedented opportunities for disease modeling and personalized medicine. With the capability, current cardiac regenerative medicine focuses on utilizing PSCs for modeling heart d","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cardiac disease / cardiac regenerative medicine (heart muscle generation from pluripotent stem cells)","mechanism_class":"pluripotent stem cell-derived cardiomyocyte generation","modality":"other","objectID":"24829","rationale_one_line":"Cell therapy/research tool for generating adult heart muscle from human pluripotent stem cells; cardiovascular indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24829","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Generation of Adult Heart Muscle from Human Pluripotent Stem Cells"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Local HIF-1 inhibition addresses glioblastoma hypoxia resistance with dismal SoC.","description_excerpt":"Value Proposition:\r\n·       Intracranial wafers deliver anti-cancer drugs directly to the tumor, circumventing pharmacokinetic barriers.\r\n·       Repurposes acriflavine and polymers, both with other FDA approvals, for malignant glioma.\r\n·       High-efficacy treatment option to prolong survival for ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"malignant glioma / brain cancer","mechanism_class":"HIF-1 inhibitor (acriflavine) intracranial wafer delivery","modality":"small_molecule","objectID":"24778","rationale_one_line":"Polymer-based acriflavine wafers for intracranial local delivery in malignant glioma; brain/glioma cancer is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24778","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Polymer-based Acriflavine Wafers for the Treatment of Malignant Brain Cancer"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Plk1 combination directly targets gemcitabine resistance with no approved analogous strategy.","description_excerpt":"Unmet Need: Gemcitabine resistance is a widespread problem. A large proportion of cancer patients end up receiving gemcitabine at some point of their care (as is approved in lung, pancreatic, breast and ovarian cancer), and although efficacious in a third of the cases, most do not respond, and even ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gemcitabine-resistant cancers (lung, pancreatic, breast, ovarian)","mechanism_class":"Plk1 inhibitor combination with gemcitabine","modality":"other","objectID":"24632","rationale_one_line":"Combination therapy of gemcitabine with Plk1 inhibitor to overcome resistance across multiple cancer types; pan-oncology indication without a single supported enum match.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24632","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PLK1","title":"Combination Therapy to Treat Gemcitabine-Resistant Cancers"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"No approved cardiac cell therapy post-MI; bioreactor approach maintains cell viability.","description_excerpt":"UNMET NEED\n\nHeart failure after myocardial infarction (MI) is a common and morbid condition that affects millions worldwide.  While there are multiple therapies that help the heart adapt and compensate for the damage incurred in an MI, there remains no method by which injured heart muscle may be rep","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"heart failure after myocardial infarction (stem cell therapy via implantable bioreactor)","mechanism_class":"implantable bioreactor cell pouch for cardiac stem cell therapy","modality":"other","objectID":"24378","rationale_one_line":"Implantable bioreactor with non-static cell pouch for stem cell-based cardiac repair after MI; cardiovascular/device platform outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24378","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Implantable Bioreactor with a Non-Static Cell Pouch"},{"biomarker_overlap":"DNA hypomethylation","composite_score":0.5111460629132438,"cr_rationale":"ARDS has no approved DMARD equivalent; Treg epigenetic targeting addresses real unmet need.","description_excerpt":"Acute respiratory distress syndrome (ARDS) is a devastating inflammatory lung disease for which there are no effective targeted therapies.  In experimental models of acute lung inflammation and injury, regulatory T cells (Tregs) orchestrate a pro-repair program; Tregs themselves are highly dependent","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"acute respiratory distress syndrome (ARDS)","mechanism_class":"DNMT inhibitor / AMPK activator (repurposed)","modality":"small_molecule","objectID":"24345","rationale_one_line":"Description targets ARDS via Treg epigenetic mechanisms; classified under Small Molecules and Repurposed Drugs; preclinical experimental models cited.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24345","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A Promising Pharmacotherapy for Acute Respiratory Distress Syndrome"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Electrospun scaffold for spinal cord injury addresses indication with no approved regenerative SoC.","description_excerpt":"Value Proposition:\r\nThe multilayer 3D conduit is a superior candidate for nerve repair and clinical regeneration applications.\r\n• The novel wall structure made of double-sided fibers increases the opportunities for cell migration so that more cells populate the regenerating tissue faster in order to","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"spinal cord injury; neuronal regeneration","mechanism_class":"electrospun fiber scaffold for nerve regeneration","modality":"other","objectID":"24221","rationale_one_line":"Implantable multilayer 3D scaffold of aligned electrospun fibers for 'neuronal regeneration applications'; a medical device / regenerative scaffold — modality maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24221","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Implantable Multilayer 3D Scaffold Consisting of Highly Aligned Electrospun Fibers for Neuronal Regeneration Applications"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"GLS inhibitor nanoparticle delivery for PDAC addresses indication with very poor SoC outcomes.","description_excerpt":"Invention novelty: An improved glutaminase (GLS) inhibitors delivery system to enhance efficacy and prolong glutaminase inhibitor drug levels in tumor for improve treatment of pancreatic cancer.\r\nValue Proposition: Currently available glutaminase inhibitors are generally poorly soluble, metabolicall","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"pancreatic cancer (pancreatic ductal adenocarcinoma)","mechanism_class":"glutaminase (GLS) inhibitor nanoparticle delivery","modality":"small_molecule","objectID":"24187","rationale_one_line":"GLS inhibitor delivery system for 'improve treatment of pancreatic cancer'; small molecule with nanoparticle delivery for pancreatic ductal adenocarcinoma, outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24187","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GLS (glutaminase)","title":"Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for Cancer Therapy"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Nav isoform-selective inhibitor targets refractory seizures where existing AEDs have limited efficacy.","description_excerpt":"Unmet Need\r\nAbnormal behavior of sodium (Nav) channels is linked to a variety of epilepsy syndromes, movement disorders, and neuropathic pain. While researchers continue to elucidate the roles of different Nav channel isoforms within a variety of neurological disorders, current therapeutics influenc","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"epilepsy; neuropathic pain; movement disorders linked to sodium channel dysfunction","mechanism_class":"Nav channel isoform-selective inhibitor (triazole)","modality":"small_molecule","objectID":"24076","rationale_one_line":"Novel triazole compounds selectively target Nav channel isoforms to treat 'severe or refractory seizure'; small molecule Nav inhibitor for epilepsy/neuropathic pain, outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24076","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SCN (Nav channels)","title":"Novel TriazoleCompounds to Treat Severe or Refractory Seizure"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Companion Nav triazole for refractory epilepsy addresses substantial unmet need beyond current AED options.","description_excerpt":"Unmet Need\r\nAbnormal behavior of sodium (Nav) channels is linked to a variety of epilepsy syndromes, movement disorders, and neuropathic pain. While researchers continue to elucidate the roles of different Nav channel isoforms within a variety of neurological disorders, current therapeutics influenc","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"epilepsy; severe or refractory seizure","mechanism_class":"Nav channel isoform-selective inhibitor (triazole)","modality":"small_molecule","objectID":"24075","rationale_one_line":"Companion to 24076 — novel triazole compounds for 'severe or refractory seizure' via Nav channel selectivity; small molecule for epilepsy, outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24075","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SCN (Nav channels)","title":"Novel Triazole Compounds to Treat Severe or Refractory Seizure"},{"biomarker_overlap":"SOX2 overexpression; COX2/YAP1 co-expression","composite_score":0.5111460629132438,"cr_rationale":"COX2/YAP/SOX2 axis targets cancer stem cells in bladder cancer where recurrence SoC is inadequate.","description_excerpt":"UNMET NEED\r\nChronic environmental exposure induces cancer stem cells (CSCs) with SOX2 overexpression, one of the most important CSC factor for urothelial cancer (UC). COX2 and YAP1 coordinately regulate SOX2 expression, and mutually compensate for the reduction of expression of SOX2 to maintain CSCs","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"urothelial cancer / bladder cancer; cancer stem cells with SOX2 overexpression","mechanism_class":"COX2/YAP/SOX2 axis inhibitor","modality":"small_molecule","objectID":"23512","rationale_one_line":"Targets 'COX2/YAP/SOX2 signaling axis' to eliminate cancer stem cells in urothelial/bladder cancer; small molecule for a cancer outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/23512","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PTGS2 (COX2), YAP1, SOX2","title":"PHARMACEUTICAL AGENTS TARGETING CANCER STEM CELLS"},{"biomarker_overlap":"ER-negative, PR-negative, HER2-negative (triple negative)","composite_score":0.5111460629132438,"cr_rationale":"siRNA gene silencing for TNBC targets subtype with limited SoC options beyond chemotherapy.","description_excerpt":"Invention Novelty: The given invention proposes an efficient technology for the treatment of triple negative breast cancer\r\n \r\nValue Proposition: Often associated with rapid progression and poor outcomes, Triple Negative Breast Cancer (TNBC) refers to any breast cancer that does not express the gene","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"triple negative breast cancer (TNBC)","mechanism_class":"gene silencing / siRNA","modality":"nucleic_acid","objectID":"23435","rationale_one_line":"Technology described as 'gene silencing technology for the treatment of triple negative breast cancer'; nucleic acid (siRNA) modality targeting TNBC, an enumerated indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/23435","subscores":{"clinical_relevance":0.7,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Gene silencing technology for the treatment of triple negative breast cancer"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"SAVA delivery targets GBM YAP/TAZ where effective SoC is limited.","description_excerpt":"Unmet Need: Brain tumors including aggressive Glioblastoma (GBM) remain a large societal burden due to the large number of affected patients and overall poor survival rates. A promising FDA-approved drug verteporfin (VP) was identified that directly targets transcription factors upregulated in GBM, ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"glioblastoma (GBM); brain cancer","mechanism_class":"self-assembling verteporfin amphiphile (SAVA) delivery platform","modality":"other","objectID":"21898","rationale_one_line":"Self-assembling verteporfin amphiphiles for 'localized cancer therapy' of GBM by targeting transcription factors upregulated in glioblastoma; a therapeutic delivery platform — glioblastoma is outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/21898","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"YAP/TAZ transcription factors","title":"Self-Assembling Verteporfin Amphiphiles (SAVA) for Localized Cancer Therapy"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Oxazolidinone for drug-resistant TB addresses serious unmet need where linezolid toxicity limits SoC.","description_excerpt":"TITLE:    An Oxazolidinone for Treatment of Infections with Mycobacterium Tuberculosis and Gram Positive Bacteria\r\n \r\nCASE NUMBER: C13966\r\n \r\nUNMET NEED\r\nTuberculosis (TB) is still one of the most difficult infectious diseases to treat, and the second most frequent cause of death due to infectious d","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"tuberculosis (TB) and gram-positive bacterial infections","mechanism_class":"oxazolidinone antibiotic","modality":"small_molecule","objectID":"21546","rationale_one_line":"Oxazolidinone for 'Treatment of Infections with Mycobacterium Tuberculosis and Gram Positive Bacteria'; small molecule antibiotic for infectious disease outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/21546","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"An Oxazolidinone for Treatment of Infections with Mycobacterium Tuberculosis and Gram Positive Bacteria"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Non-classical transpeptidase inhibitors address antimicrobial resistance where existing antibiotics are failing.","description_excerpt":"Novel Inhibitors of Bacterial GrowthJHU REF: C13624\r\n \r\nInvention novelty: Novel antibacterials that inhibit non-classical transpeptidases.\r\n \r\nValue Proposition: Resistance to existing antibacterials is being reported at an alarming rate. Therefore, new antibacterials that work by inhibiting novel ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"bacterial infections (broad); novel antibacterials targeting non-classical transpeptidases","mechanism_class":"non-classical transpeptidase inhibitor","modality":"small_molecule","objectID":"20999","rationale_one_line":"Novel antibacterials that 'inhibit non-classical transpeptidases' to address resistance; small molecule anti-infective for bacterial infections outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/20999","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Inhibitors of Bacterial Growth"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Dopaminergic neuron conversion for Parkinson's; no curative SoC exists, high unmet need in neurodegeneration.","description_excerpt":"Conversion of human stem cells to dopaminergic neurons using a single, high-efficiency factor\n\nJHU REF: [C12596]\n\n \n\nInvention novelty: To convert human stem cells into dopaminergic neurons at high efficiency.\n\n \n\nValue Proposition\n\nAs many as one million Americans suffer from Parkinson&#39;s diseas","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Parkinson's disease / neurodegeneration","mechanism_class":"stem cell differentiation (dopaminergic neuron conversion)","modality":"other","objectID":"20365","rationale_one_line":"Method to convert human stem cells to dopaminergic neurons for Parkinson's disease — cell-conversion research tool / potential cell therapy, Parkinson's not in enum, modality is a stem-cell platform not a standard biologic.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/20365","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Method for highly efficient conversion of human stem cells to lineage-specific neurons."},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"PBX1 inhibition targets drug-resistant ovarian cancer with no approved SoC for resistance setting.","description_excerpt":"Invention novelty: Panel of newly-synthesized small molecule antagonists of PBX1-DNA interaction for the treatment of different cancers and other non-neoplastic diseases. \r\nValue Proposition: Pre-B-cell leukemia homeobox-1 (PBX1) is a homeodomain transcription factor that interacts with DNA and othe","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"drug-resistant cancers (ovarian cancer primary focus)","mechanism_class":"PBX1-DNA interaction inhibitor","modality":"small_molecule","objectID":"20022","rationale_one_line":"Panel of small molecule antagonists of PBX1-DNA binding to treat drug-resistant cancers with ovarian cancer emphasis — ovarian cancer not in enum, maps to other; small_molecule per taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/20022","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PBX1","title":"Small Molecule Inhibitors Targeting PBX1-DNA Binding to Treat Drug Resistant Cancers"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Novel mechanism glideosome inhibitors for drug-resistant malaria; artemisinin resistance is a critical gap.","description_excerpt":"C12661: Novel Anti-Malarial Compounds and Compositions\r\nNovelty: \r\nThis technology provides new classes of anti-malarial compounds and a method to identify such compounds.\r\nValue Proposition: \r\nNearly half the worlds population is at risk of acquiring malaria, which is caused by the Plasmodium famil","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"malaria (Plasmodium parasite infection)","mechanism_class":"malarial aldolase-trap enhancer / glideosome inhibitor","modality":"small_molecule","objectID":"17289","rationale_one_line":"Small molecule malarial aldolase-trap enhancers and glideosome inhibitors for Plasmodium infection — malaria is an infectious/parasitic disease outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17289","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"Plasmodium aldolase / glideosome","title":"Small Molecule Malarial Aldolase-trap Enhancers and Glideosome Inhibitors"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Low-voltage defibrillation could reduce shock pain and ICD morbidity; meaningful improvement over high-energy SoC.","description_excerpt":"C12013: Method for Cardiac Low-Voltage Defibrillation\r\n    Value Proposition: \r\nDefibrillation by strong electric shock remains the only clinically proven method to terminate\nventricular fibrillation (VF) and to prevent sudden cardiac death. The defibrillation of atrial fibrillation (AF) on the othe","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cardiac fibrillation (atrial and ventricular fibrillation, ventricular tachycardia)","mechanism_class":"low-voltage electrical defibrillation method","modality":"other","objectID":"17131","rationale_one_line":"Method for low-voltage cardiac defibrillation converting fibrillation to tachycardia then terminating — a medical device / electrophysiology method, not a drug; cardiovascular outside supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17131","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A method for cardiac low-voltage defibrillation by converting cardiac fibrillation to cardiac tachycardia followed by termination of cardiac tachycardia"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"GBM intracellular pH therapy targets high unmet need beyond TMZ.","description_excerpt":"C11679: Novel Therapeutics for Glioblastoma and Other Cancers\r\n\r\nNovelty: \r\n\r\nThis invention uses 5-Nonloxytryptamine (5-NOTO) and other intracellular pH acidifiers for the treatment of glioblastoma (GBM). It can serve as a platform for using PH acidifiers to treat other cancers as well.\r\nValue Prop","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"glioblastoma (GBM) and other cancers","mechanism_class":"intracellular pH acidifier","modality":"small_molecule","objectID":"17023","rationale_one_line":"5-Nonyloxytryptamine and other intracellular pH acidifiers for glioblastoma and other cancers — glioblastoma/brain tumor is outside supported indication enum; small_molecule per taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17023","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"5-Nonyloxytryptamine and Other Intracellular pH Acidifiers for the Treatment and Prevention of Cancer."},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Cardioprotective agent limiting cardiomyocyte loss in MI; reperfusion alone is standard, adjunctive cytoprotection unmet.","description_excerpt":"Novelty: \r\nThe outlined invention features the novel therapeutic implications of a drug in preventing cardiac cell loss that occurs in myocardium infraction.\r\nValue Proposition: \r\nThe technology describes the application of a drug to treat a major public health problem for which there is no current ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"myocardial infarction (heart attack) / cardiac cell loss","mechanism_class":"cardioprotective agent (cardiac cell preservation)","modality":"small_molecule","objectID":"16998","rationale_one_line":"Novel drug application preventing cardiac cell loss in myocardial infarction — cardiovascular indication outside supported enum; small_molecule per taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16998","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"C11620: Novel Treatment for Heart Attack"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Ethoxyquin analog prevents CIPN; no approved drug prevents chemotherapy-induced neuropathy, high unmet need.","description_excerpt":"Peripheral neuropathies are a group of neurodegenerative disorders affecting the peripheral nerves. Currently there is no effective therapy that prevents nerve degeneration except in cases of autoimmune peripheral neuropathies. Wehave now identified a compound, ethoxyquin (EQ), that prevents nerve d","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"chemotherapy-induced peripheral neuropathy","mechanism_class":"neuroprotective agent (ethoxyquin analog)","modality":"small_molecule","objectID":"16992","rationale_one_line":"Ethoxyquin (EQ) prevents nerve degeneration in chemotherapy-induced peripheral neuropathy — peripheral neuropathy is a neurology indication outside supported enum; small_molecule per taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16992","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Compounds to Treat Peripheral Neuropathy"},{"biomarker_overlap":"PSMA expression","composite_score":0.5111460629132438,"cr_rationale":"PSMA theranostic addresses metastatic prostate cancer with combined imaging and treatment advantage over SoC.","description_excerpt":"C11482: PSMA-based Theranostic Imaging of Metastatic Cancer\r\n\r\nNovelty: \r\n\r\nThis invention is a pharmaceutical composition and method for the effective imaging, targeting, and treatment of metastatic tumor cells.\r\nValue Proposition: \r\nIn the United States, prostate cancer (PCa) is the second leading","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"metastatic prostate cancer (PSMA-based theranostic imaging and treatment)","mechanism_class":"PSMA-targeted theranostic","modality":"other","objectID":"16954","rationale_one_line":"Classified as 'other' for both indication and modality because the invention is a theranostic delivery platform (imaging + treatment) for prostate cancer, which maps outside the supported indication and modality enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16954","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PSMA","title":"PSMA-based Theranostic Imaging of Metastatic Cancer"},{"biomarker_overlap":"E7 antigen expression","composite_score":0.5111460629132438,"cr_rationale":"CRT/E7 vaccine targets HPV-driven cervical cancer with limited curative SoC.","description_excerpt":"Technical Details:\r\n\t\t\tThe Vac-CRT/E7 vaccine can be employed to deliver chimeric CRT/E7 gene into the host cells in order to generate potent E7-specific CD8+ T cell immune responses and antitumor effects against E7- expressing tumors.\r\n\t\t\t\r\nLooking for Partners:\r\n\t\t\tCervical cancer vaccine\r\n\t\t\t\r\nPu","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cervical cancer (E7-expressing tumors)","mechanism_class":"therapeutic vaccine (CRT/E7 chimeric antigen)","modality":"other","objectID":"16790","rationale_one_line":"Described as a 'cervical cancer vaccine' delivering CRT/E7 chimeric antigen for E7-specific CD8+ T cell responses; vaccine modality maps to 'other'; cervical cancer is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16790","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HPV E7","title":"Vac-CRT/E7 and Vac-CRT"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Transmission-blocking malaria vaccine addresses a major global unmet need with no approved transmission-blocking SoC.","description_excerpt":"Technical Details:\r\n\t\t\tMalaria is a disease caused by parasites of the genus Plasmodium. It affects near 2 billion people worldwide and results in 1-2 million deaths every year. Transmission-blocking vaccines (TBV) have received attention as potentially effective strategy in the fight against malari","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"malaria (transmission-blocking vaccine)","mechanism_class":"transmission-blocking malaria vaccine (Pfs 48/45 antigen)","modality":"other","objectID":"16680","rationale_one_line":"Described as 'a malaria vaccine based on CH-rPfs 48/45 antigen' for transmission blocking; vaccine modality maps to 'other'; malaria is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16680","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"Pfs 48/45","title":"A Malaria Vaccine Based on CH-rPfs 48/45 Antigen and Adjuvant Formulations to Stop Malaria Transmission"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Keratin aggregation inhibitor for EBS addresses a rare disease with no approved disease-modifying SoC.","description_excerpt":"Value Proposition: Advantages: &bull; Uses known natural chemicals to effectively prevent or diminish skin blistering &bull; Represents a safe, effective, and affordable therapy &bull; Has a wider application as the basis for a therapy of keratin-based diseases \r\nTechnical Details: \r\nEpidermolysis b","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"epidermolysis bullosa simplex (EBS) and keratin-based diseases","mechanism_class":"keratin aggregation inhibitor (natural chemicals)","modality":"small_molecule","objectID":"16581","rationale_one_line":"Described as 'uses known natural chemicals to effectively prevent or diminish skin blistering' in epidermolysis bullosa; small molecule modality confirmed; EBS is a rare genetic skin disease outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16581","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"C10069: Treatment of Epidermolysis Bullosa Simplex and Related Diseases"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"E. coli sepsis vaccine addresses high-mortality condition with no approved prophylactic.","description_excerpt":"Value Proposition: E. coli is the most common gram-negative organism causing nosocomial bacteremia related infection in elderly patients. The mortality and morbidity associated with E. coli bacteremia is substantial. E. coli sepsis is associated with an estimated 40,000 deaths each year at a cost of","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"E. coli bacteremia and sepsis","mechanism_class":"bacterial vaccine","modality":"other","objectID":"16457","rationale_one_line":"Vaccine against E. coli bacteremia/sepsis; vaccines map to 'other' modality and infectious disease is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16457","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"C04942: Vaccine against E. Coli Bacteremia and sepsis"},{"biomarker_overlap":"CFTR mutation","composite_score":0.5111460629132438,"cr_rationale":"CFTR rescue in cystic fibrosis addresses root cause; complements but predates modulators like ivacaftor.","description_excerpt":"UNMET NEED\r\nThere is understanding that mutations in the cystic fibrosis transmembrane regulator (CFTR) protein can lead to life-threatening illness. When functioning normally, CFTR is thought to be a necessary cAMP-activated chloride channel. In CF, this channel is thought to be misprocessed and re","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cystic fibrosis","mechanism_class":"proteasome inhibitor (CFTR corrector)","modality":"small_molecule","objectID":"16424","rationale_one_line":"PS-341 (bortezomib-related proteasome inhibitor) rescues mutant CFTR from ER-mediated degradation in cystic fibrosis; rare genetic lung disease outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16424","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"CFTR","title":"PS-341 Rescues Cystic Fibrosis Transmembrane Regulator (CFTR) from Endoplasmic Reticulum Mediated Degradation"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"HCV vaccine targets cure vs. viral eradication; meaningful differentiation from DAA treatment.","description_excerpt":"C04630: Use of Consensus Sequence as Vaccine Antigen to Enhance Recognition of Virulent Viral Variants\r\n  \r\nTechnical Details: \r\nVaccines for diverse viruses will be most effective when they direct the recipient?s response to recognize the most virulent form of the organism. Scientists at JHU have f","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"hepatitis C virus infection","mechanism_class":"consensus sequence vaccine antigen","modality":"other","objectID":"16373","rationale_one_line":"Consensus sequence vaccine strategy for hepatitis C virus to target most virulent circulating strains; vaccine modality and infectious disease indication both outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16373","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Use of Consensus Sequence as Vaccine Antigen to Enhance Recognition of Virulent Viral Variants"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"Cross-neutralizing HPV vaccine expands protection beyond Gardasil-covered strains, reducing cervical cancer risk.","description_excerpt":"Technical Details:\r\n\t\t\tHigh risk Human Papillomavirus (HPV) infection is a common cause of cervical cancer. Researchers at JHU have found that vaccination with the N terminus of HPV16 and bovine papillomavirus 1 can induce cross neutralizing antibodies that inhibit in vitro generated pseudovirus inf","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"HPV infection / cervical cancer","mechanism_class":"L2 epitope-based cross-neutralizing vaccine","modality":"other","objectID":"16367","rationale_one_line":"Vaccine using HPV16 N-terminus and BPV1 induces cross-neutralizing antibodies against multiple papillomavirus types; vaccine modality and HPV/cervical cancer outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16367","subscores":{"clinical_relevance":0.7,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HPV L2","title":"Unexpected Cross-neutralization of Cutaneous & Mucosal Papillomavirus Types with Anti-Sera to a Novel L2 Epitopes"},{"biomarker_overlap":null,"composite_score":0.5111460629132438,"cr_rationale":"mitoKATP openers prevent ischemic organ injury in a setting with no approved cytoprotective SoC.","description_excerpt":"C03742: Neuroprotection and Inhibition of Apoptosis by Mitrochondrial Potassium Channel Openers\r\n   \r\n\r\nTechnical Details: \r\n\r\nMitochondria can either enhance or suppress cell death. Cytochrome C release triggers apoptosis, but activation of mitochondrial ATP-sensitive potassium (mitoPotassiumATP) c","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"ischemic cardiac/neurological injury (neuroprotection)","mechanism_class":"mitoPotassiumATP channel opener","modality":"small_molecule","objectID":"16186","rationale_one_line":"Mitochondrial potassium channel openers prevent 'lethal ischemic injury in vivo' for neuroprotection/cardioprotection; cardiovascular/neurology indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16186","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"mitochondrial ATP-sensitive potassium channel","title":"Neuroprotection and Inhibition of Apoptosis by Mitrochondrial Potassium Channel Openers"},{"biomarker_overlap":null,"composite_score":0.51,"cr_rationale":"Novel mAb for RA/fibrosis spectrum where biologic SoC has significant non-responder populations.","description_excerpt":"Unmet Need\r\nAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, s","dev_stage":"unknown","exclusivity_status":"unknown","indication":"rheumatoid_arthritis","indication_free_text":"inflammatory diseases including pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis","mechanism_class":"immunotherapy for autoinflammatory disease","modality":"monoclonal_antibody","objectID":"56145","rationale_one_line":"Taxonomy classifies under Antibodies + Biologics; rheumatoid arthritis is the supported-enum indication explicitly named among the target diseases.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/56145","subscores":{"clinical_relevance":0.6,"ira_exposure":0.85,"modality_pos":0.9,"whitespace":0},"target":null,"title":"Novel Immunotherapy for Pulmonary Remodeling Diseases"},{"biomarker_overlap":null,"composite_score":0.51,"cr_rationale":"Anti-autoinflammatory mAb for RA/COPD/heart failure addresses conditions with unmet biologic gaps.","description_excerpt":"Unmet Need\r\nAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, s","dev_stage":"unknown","exclusivity_status":"unknown","indication":"rheumatoid_arthritis","indication_free_text":"chronic inflammatory diseases including pulmonary hypertension, COPD, heart failure, COVID-19","mechanism_class":"anti-autoinflammatory monoclonal antibody","modality":"monoclonal_antibody","objectID":"56144","rationale_one_line":"Title states 'Monoclonal Antibody to Treat Autoinflammation'; rheumatoid arthritis is the best-fit supported enum among the autoinflammatory diseases listed in the taxonomy path.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/56144","subscores":{"clinical_relevance":0.6,"ira_exposure":0.85,"modality_pos":0.9,"whitespace":0},"target":null,"title":"Monoclonal Antibody to Treat Autoinflammation Associated with Chronic Diseases"},{"biomarker_overlap":"severity prediction markers for COVID-19","composite_score":0.5043988269794721,"cr_rationale":"Anti-SARS-CoV-2 antibody with severity prediction; monoclonal antibodies lost relevance with variant evolution.","description_excerpt":"Unmet Need\r\nThe spectrum of COVID-19 symptomatic infection ranges from mild to critical. Severe illness can occur in healthy individuals of any age, but it predominantly occurs in adults with advanced age or certain underlying medical comorbidities (e.g. cardiovascular disease, diabetes, hypertensio","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"COVID-19 (infection severity prediction and antibody treatment)","mechanism_class":"anti-SARS-CoV-2 antibody","modality":"monoclonal_antibody","objectID":"44285","rationale_one_line":"Antibody-based treatment for COVID-19 with severity prediction component; classified under Antibodies; indication (COVID-19) does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44285","subscores":{"clinical_relevance":0.5,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":null,"title":"Predicting infection severity and antibody treatment"},{"biomarker_overlap":"ZnT8 expression","composite_score":0.5043988269794721,"cr_rationale":"Anti-ZnT8 mAb for T2D; novel target but T2D has multiple effective drug classes as SoC.","description_excerpt":"Unmet Need\r\nType 2 diabetes (T2D) is a growing worldwide public health issue affecting over 500 million people while creating a $1 trillion economic burden on global healthcare economies. Many current and new therapeutics demonstrate varying degrees of effectiveness, but no single agent or combinati","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"Type 2 Diabetes","mechanism_class":"anti-ZnT8 monoclonal antibody","modality":"monoclonal_antibody","objectID":"42846","rationale_one_line":"Highly specific monoclonal antibodies for human ZnT8 developed explicitly for T2D; categories confirm Diabetes > Type 2 Diabetes and Therapeutic Antibodies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/42846","subscores":{"clinical_relevance":0.5,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"ZnT8","title":"Highly Specific Monoclonal Antibodies for Human ZnT8"},{"biomarker_overlap":null,"composite_score":0.5043988269794721,"cr_rationale":"Neuritin antibody for tumor immunotherapy; novel target but no clinical endpoint differentiation demonstrated.","description_excerpt":"Unmet Need\r\nCancer immunotherapy is a therapeutic approach that has revolutionized advanced cancer treatment. In particular, the use of therapeutic blocking antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein (PD-1) has achieved routine clinical use in numerous i","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Tumor immunotherapy / autoimmunity (cancer immunotherapy and T cell tolerance)","mechanism_class":"Neuritin-targeting antibody for tumor immunotherapy and T cell tolerance","modality":"monoclonal_antibody","objectID":"35366","rationale_one_line":"Neuritin impacts T cell tolerance induction and is a target for tumor immunotherapy — monoclonal antibody approach spanning autoimmunity and broad oncology without a single supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35366","subscores":{"clinical_relevance":0.5,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"Neuritin","title":"Neuritin Impact T Cell Tolerance Induction and Maintenance and is a Target for Tumor Immunotherapy"},{"biomarker_overlap":null,"composite_score":0.5043988269794721,"cr_rationale":"Novel antibodies spanning scleroderma/cancer immunotherapy; dual indication without focused clinical differentiation.","description_excerpt":"Unmet Need\r\nEpidemiological studies have shown that patients with scleroderma, a type of autoimmune rheumatic disease affecting the skin and connective tissues, have an increased risk of developing cancer relative to the general population. The exact etiology of scleroderma is still unknown. The Scl","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Scleroderma / cancer immunotherapy (autoimmune rheumatic disease with increased cancer risk)","mechanism_class":"Novel antibodies for cancer immunotherapy","modality":"monoclonal_antibody","objectID":"35343","rationale_one_line":"Novel antibodies for cancer immunotherapy in the context of scleroderma — monoclonal antibody approach spanning autoimmunity and broad oncology without a single specific supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35343","subscores":{"clinical_relevance":0.5,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":null,"title":"Novel antibodies for cancer immunotherapy"},{"biomarker_overlap":"PSMA expression","composite_score":0.5043988269794721,"cr_rationale":"PSMA mAb enters competitive space with approved lutetium-177 PSMA agent.","description_excerpt":"Unmet Need \r\nProstate-specific membrane antigen (PSMA, also known as GCPII) is a validated target for prostate cancer imaging and therapy. Macromolecular reagents, most notably monoclonal antibodies (mAbs), offer a viable alternative to small-molecule PSMA ligands for imaging and therapy. However ex","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer imaging and therapy","mechanism_class":"anti-PSMA monoclonal antibody","modality":"monoclonal_antibody","objectID":"24915","rationale_one_line":"Novel anti-PSMA monoclonal antibodies for prostate cancer imaging and therapy; prostate cancer is outside the 11 supported indication enums so mapped to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24915","subscores":{"clinical_relevance":0.5,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"PSMA","title":"New Monoclonal Antibodies Recognizing Human Prostate-specific Membrane Antigen (PSMA) for Imaging and Therapeutic Applications"},{"biomarker_overlap":"Annexin A2 as cancer target recognized by antibodies and T cells","composite_score":0.5043988269794721,"cr_rationale":"Annexin A2 antibody for pancreatic cancer addresses high-mortality indication with inadequate SoC.","description_excerpt":"C10569: Molecular Target to Diagnose & Treat Pancreatic Cancer & Methods to Identify New Targets\r\n    Value Proposition: \r\nADVANTAGES\n\n\n\n\n&#8226; Diagnostic and therapeutic target for pancreatic cancer\n\n\n\n&#8226; Molecular target to develop vaccines and antagonistic antibodies for therapy and preven","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"pancreatic cancer (Annexin A2 as diagnostic and therapeutic target)","mechanism_class":"Annexin A2 antagonistic antibody","modality":"monoclonal_antibody","objectID":"16702","rationale_one_line":"Described as 'molecular target to develop vaccines and antagonistic antibodies for therapy and prevention' of pancreatic cancer; monoclonal_antibody modality is best fit from description; pancreatic cancer is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16702","subscores":{"clinical_relevance":0.5,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"Annexin A2","title":"Annexin A2 is a Cancer Target Recognized by Antibodies and T Cells and is Involved in Cancer Development and Progression"},{"biomarker_overlap":null,"composite_score":0.5043988269794721,"cr_rationale":"VEGF antibody for CRSwNP addresses unmet need beyond current steroid SoC but indication is non-life-threatening.","description_excerpt":"UNMET NEED: A hallmark of chronic rhinosinusitis (CRS) with hyperplastic sinonasal polyposis (CRSwNP), one of the most severe forms of CRS, is the mucosal hyperplasia, resulting in chronic disease that becomes refractory to either medical or surgical management. Histological features of CRSwNP resem","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"chronic rhinosinusitis with nasal polyposis (CRSwNP) and airway inflammatory disorders","mechanism_class":"VEGF inhibitor","modality":"monoclonal_antibody","objectID":"16662","rationale_one_line":"Described as 'VEGF inhibition as a therapeutic for airway inflammatory disorders such as CRSwNP'; antibody modality confirmed by taxonomy; CRSwNP is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16662","subscores":{"clinical_relevance":0.5,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"VEGF","title":"VEGF Inhibition as a Therapeutic for Airway Inflammatory Disorders such as CRSwNP"},{"biomarker_overlap":"HIMF / FIZZ1 / RELM expression","composite_score":0.5043988269794721,"cr_rationale":"HIMF antibodies as therapeutics in lung/vascular disease have plausible but unvalidated clinical differentiation.","description_excerpt":"C04061: Hypoxia-induced Mitogenic FactorValue Proposition: \r\nJohns Hopkins University is seeking licensees for Hypoxia-Induced Mitogenic Factor (HIMF/ FIZZ1/RELM), a cell line expressing tagged HIMF, antibodies to HIMF and receptor.  HIMF provides a wide array of novel biomarkers and therapeutic tar","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"lung, vascular, cardiac and inflammatory diseases (HIMF/FIZZ1/RELM)","mechanism_class":"HIMF antibody / biomarker therapeutic","modality":"monoclonal_antibody","objectID":"16248","rationale_one_line":"HIMF/FIZZ1/RELM antibodies as biomarkers and therapeutic targets for lung, vascular, cardiac and inflammatory diseases; indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16248","subscores":{"clinical_relevance":0.5,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"HIMF","title":"Hypoxia-induced Mitogenic Factor"},{"biomarker_overlap":null,"composite_score":0.5039818946831569,"cr_rationale":"TRPA1 antagonist peptide addresses chronic pain/itch with novel mechanism vs. opioid/NSAID SoC.","description_excerpt":"Novelty:\r\nIdentification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.\r\nValue Proposition:\r\nDysregulation of ion channels is associated with various debilitating conditions, including chronic pain an","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Chronic and acute pain and itch; dysregulation of TRPA1 ion channels","mechanism_class":"TRPA1 antagonist","modality":"peptide","objectID":"53574","rationale_one_line":"Source describes a mutant peptide with strong inhibitory effect on nociceptor TRPA1 for pain and itch; taxonomy confirms Peptides modality; pain indication is not a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53574","subscores":{"clinical_relevance":0.65,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"TRPA1","title":"Cell-Permeable Protein Therapeutic for Pain and Itch"},{"biomarker_overlap":null,"composite_score":0.5039818946831569,"cr_rationale":"ACE2 peptide filament for SARS-CoV offers prevention/treatment where antiviral SoC remains limited.","description_excerpt":"Value Proposition\r\n·        Peptide-based supramolecular filament that attenuates SARS-CoV virus infectivity in vivo\r\n·        Leverages ACE2 enzyme-substrate docking activity\r\n·        Enables therapeutic protein delivery in repairable aerosols\r\nUnmet Need\r\n·        Respiratory illnesses, including","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Respiratory illnesses including COVID-19, tuberculosis, and influenza; SARS-CoV infection prevention and treatment","mechanism_class":"ACE2-based peptide supramolecular filament for coronavirus inhibition","modality":"peptide","objectID":"52987","rationale_one_line":"Source describes a peptide-based supramolecular filament that attenuates SARS-CoV infectivity via ACE2 docking; taxonomy confirms Peptides; infectious disease indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52987","subscores":{"clinical_relevance":0.65,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"ACE2","title":"Peptide for the Prevention and Treatment of Coronavirus Infection"},{"biomarker_overlap":"KRAS mutation","composite_score":0.5039818946831569,"cr_rationale":"KRAS4B peptide inhibitor targets a historically undruggable oncogene with limited direct KRAS SoC options.","description_excerpt":"Value Proposition\r\n·        KRAS oncogene function inhibitor\r\n·        24 amino acid peptide synthesized from KRAS4B structure\r\n·        Enables development of KRAS-driven cancer therapeutics\r\nUnmet Need\r\nKRAS is an oncoprotein involved in cell division regulation with gene mutations leading to cell","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"KRAS-driven cancers broadly; KRAS oncogene function inhibitor peptide","mechanism_class":"KRAS4B-derived peptide inhibitor","modality":"peptide","objectID":"52315","rationale_one_line":"Source describes a 24 amino acid peptide synthesized from KRAS4B structure as a KRAS oncogene function inhibitor; taxonomy confirms Peptides; broad KRAS-driven oncology without a specific cancer type maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52315","subscores":{"clinical_relevance":0.65,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"KRAS","title":"KRAS Inhibitor"},{"biomarker_overlap":null,"composite_score":0.49190169577967613,"cr_rationale":"Vector-specificity platform is enabling, with impact dependent on downstream therapies.","description_excerpt":"Unmet Need\r\nViral-based gene therapy holds tremendous promise for the treatment of human diseases. Using genetically engineered carriers called vectors to deliver genes into cells, gene therapy can help replace a mutated gene with a healthy copy or even introduce a new gene into the body to fight a ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Viral-based gene therapy broadly; controlling gene therapy vector specificity via alternative splicing","mechanism_class":"alternative splicing control for gene therapy vector specificity","modality":"gene_therapy","objectID":"53365","rationale_one_line":"Taxonomy tags Gene Therapies and the description addresses improving vector specificity via alternative splicing; platform gene therapy tool without a specific disease indication maps to other for indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53365","subscores":{"clinical_relevance":0.3,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Method for using alternative splicing to control specificity of gene therapy"},{"biomarker_overlap":null,"composite_score":0.49190169577967613,"cr_rationale":"CRISPR off-target detection improves safety but is not directly therapeutic.","description_excerpt":"Value Proposition:\r\n·        Utilizes components of existing workflow to better detect off-target gene editing\r\n·        Capable for use in in vivo or in vitro settings\r\n·        Maximizes impact of CRISPR-Cas9 in therapeutic development\r\nTechnology Description\r\n·        Researchers at Johns Hopkins","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"CRISPR-Cas9 gene therapy broadly; improving sensitivity of off-target detection through DNA repair modulation","mechanism_class":"CRISPR off-target detection via DNA repair modulation","modality":"gene_therapy","objectID":"52627","rationale_one_line":"Taxonomy tags Gene Therapies and Cell Therapies; source describes a method to detect CRISPR off-target editing to maximize CRISPR impact in therapeutic development; platform tool without a specific disease indication maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52627","subscores":{"clinical_relevance":0.3,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Improving the sensitivity of CRISPR off-target detection through modulation of DNA repair"},{"biomarker_overlap":null,"composite_score":0.49190169577967613,"cr_rationale":"Non-viral gene delivery platform; no single indication narrows clinical impact assessment.","description_excerpt":"Unmet Need\r\nGene therapy can be a cure-all for genetic disorders, and can be a promising therapy for diseases such as cancer, neurodegenerative diseases, neurological disorders, heart disease or diabetes. The success of gene therapy is dependent on the safety, efficacy, and specificity of the treatm","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer, neurodegenerative diseases, neurological disorders, heart disease, diabetes (broad platform)","mechanism_class":"Plasmid DNA/polycation nanoparticle gene delivery vector","modality":"gene_therapy","objectID":"36592","rationale_one_line":"Compositionally defined plasmid DNA/polycation nanoparticles as non-viral gene therapy delivery vectors for broad disease applications — platform gene therapy tool, no single supported indication applies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36592","subscores":{"clinical_relevance":0.3,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Compositionally Defined Plasmid DNA/Polycation Nanoparticles and Methods for Making the Same"},{"biomarker_overlap":null,"composite_score":0.49190169577967613,"cr_rationale":"DNA molecular switch gene regulation platform; disease-agnostic with no defined clinical endpoint.","description_excerpt":"Technical Details: The invention provides molecular switches which couple external signals to functionality and to methods of making and using the same. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"disease-agnostic gene regulation / drug delivery platform (molecular switches)","mechanism_class":"circular permutation DNA molecular switch","modality":"gene_therapy","objectID":"26315","rationale_one_line":"Molecular switches based on circular permutation of DNA for gene transcription regulation and drug delivery; gene therapy platform technology without a disease-specific indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/26315","subscores":{"clinical_relevance":0.3,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Molecular Switches and Methods for Making and Using the Same Involving the Circular Permutation of DNA"},{"biomarker_overlap":null,"composite_score":0.49190169577967613,"cr_rationale":"ZFN genome editing platform without disease-specific indication; clinical impact vs. SoC not assessable.","description_excerpt":"C11129: Site-specific and Permanent Modification of Genomes with Reduced Cytotoxicity\r\n\r\nNovelty: \r\n\r\nThis technology comprises the generation of re-engineered obligate heterodimer FokI nuclease domain variants to create ZFNs with minimal cell toxicity for targeted modifications in plant, mammalian ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"genome editing platform (plant, mammalian, and human genomes)","mechanism_class":"zinc finger nuclease (ZFN) genome editor","modality":"gene_therapy","objectID":"16840","rationale_one_line":"Described as 're-engineered obligate heterodimer FokI nuclease domain variants' for targeted genome modification; a platform gene-editing tool without a specific disease indication — maps to other/gene_therapy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16840","subscores":{"clinical_relevance":0.3,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Improved Obligate Heterodimer FokI Cleavage Domain Variants for Creating Designed Zinc Finger Nucleases with Minimal Cytotoxicity"},{"biomarker_overlap":null,"composite_score":0.49190169577967613,"cr_rationale":"Gene delivery platform with no disease-specific efficacy data; clinical impact undetermined.","description_excerpt":"Technical Details: The value of re-targeted adenoviral vectors is becoming apparent in the current age of gene therapy. However, the large size and complex organization of adenoviral vectors makes construction of re-targeted viral genomes difficult. The described invention, pFex, provides a very fle","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gene therapy delivery platform (adenoviral re-targeting)","mechanism_class":"adenoviral fiber exchange shuttle system","modality":"gene_therapy","objectID":"16329","rationale_one_line":"pFex is a flexible adenoviral vector system for re-targeted gene therapy insertion; platform/research tool with no disease-specific indication stated.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16329","subscores":{"clinical_relevance":0.3,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"pFex: An Adenoviral Fiber Exchange Shuttle System"},{"biomarker_overlap":null,"composite_score":0.49190169577967613,"cr_rationale":"Synthetic retrotransposon delivery platform lacks disease-specific data; clinical impact undetermined.","description_excerpt":"C04212: Synthetic mammalian retrotransposon gene\r\nValue Proposition: &bull; Synthetic retrotransposable element that can integrate into the genome &bull; Exhibits a higher level of expression relative to natural L1 retrotransposon gene &bull; A new method for delivering desired DNA to humans and oth","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gene therapy delivery platform (synthetic retrotransposon)","mechanism_class":"synthetic L1 retrotransposon gene delivery","modality":"gene_therapy","objectID":"16273","rationale_one_line":"Synthetic mammalian retrotransposable element as a novel gene therapy delivery vehicle; platform technology with no disease-specific indication stated.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16273","subscores":{"clinical_relevance":0.3,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Synthetic mammalian retrotransposon gene"},{"biomarker_overlap":null,"composite_score":0.49190169577967613,"cr_rationale":"Enhanced gene delivery platform has no disease-specific efficacy data; clinical relevance undetermined.","description_excerpt":"C03765: Enhanced and Effective Gene Therapy Delivery Method\r\n\r\nNovelty: \r\n\r\nThis technology is an effective gene delivery system that enhances gene transfer and expression to a solid mass of cells, particularly a solid organ, while resulting in minimal degradation and injury to endothelial cells.\r\nV","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gene therapy delivery platform (solid organ / nucleic acid delivery)","mechanism_class":"enhanced gene therapy delivery system","modality":"gene_therapy","objectID":"16190","rationale_one_line":"Gene delivery system for enhanced transfer to solid organ masses with minimal endothelial injury; platform technology, no disease-specific indication stated.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16190","subscores":{"clinical_relevance":0.3,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Enhanced and Effective Gene Therapy Delivery Method"},{"biomarker_overlap":null,"composite_score":0.49190169577967613,"cr_rationale":"Recombinant adenovirus generation system is a research/manufacturing tool with no direct clinical benefit.","description_excerpt":"Technical Details:\r\n\t\t\tRecombinant adenoviruses provide a versatile system for gene expression studies and therapeutic applications. A strategy, which simplifies the generation and production of such viruses is reported here. A recombinant adenoviral plasmid is generated with a minimum of enzymatic ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gene therapy / adenoviral vector research tool","mechanism_class":"recombinant adenoviral vector system","modality":"gene_therapy","objectID":"16135","rationale_one_line":"Simplified system for generating recombinant adenoviruses via homologous recombination; research/platform tool with no disease-specific indication stated.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16135","subscores":{"clinical_relevance":0.3,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"A Simplified System for Generating Recombinant Adenoviruses"},{"biomarker_overlap":null,"composite_score":0.4911460629132438,"cr_rationale":"Lung T-cell vaccine offers mucosal durability where approved lung-targeted vaccines are lacking.","description_excerpt":"Unmet Need\r\nRespiratory pathogens are a major contributor to global economic and public health crises. In the wake of the COVID-19 pandemic, new vaccine technologies have been developed to improve the response to emerging pathogens. However, questions remain regarding how to deal with pathogens that","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Respiratory pathogens including COVID-19 and Tuberculosis; eliciting T cell immunity in the lung","mechanism_class":"DNA vaccine for lung T-cell immunity","modality":"other","objectID":"53505","rationale_one_line":"Taxonomy tags Vaccines; vaccines are not among the 9 supported modality enums; infectious disease indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53505","subscores":{"clinical_relevance":0.65,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A DNA Vaccine for Eliciting T Cell Immunity in the Lung"},{"biomarker_overlap":null,"composite_score":0.4911460629132438,"cr_rationale":"Dual immunosuppressive/neuromodulatory molecule for MS addresses both inflammation and repair vs. current immunomodulatory-only SoC.","description_excerpt":"INVENTION NOVELTY\n\nThis molecule, through its action on a unique target that is different from current therapeutic treatments for MS, has both immunosuppressive and neuromodulatory properties that will better prevent the progression of MS and repair the neuronal damage caused by the immune cells in ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Multiple sclerosis (MS); immunosuppressive and neuromodulatory treatment to prevent MS progression and repair neuronal damage","mechanism_class":"novel immunosuppressive and neuromodulatory small molecule","modality":"small_molecule","objectID":"53259","rationale_one_line":"Taxonomy confirms Small Molecules and the invention explicitly targets MS with immunosuppressive and neuromodulatory properties; MS is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53259","subscores":{"clinical_relevance":0.65,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Therapeutic Drug for Multiple Sclerosis"},{"biomarker_overlap":null,"composite_score":0.4911460629132438,"cr_rationale":"Inhaled nintedanib may reduce systemic toxicity versus oral fibrosis SoC.","description_excerpt":"Value Proposition\r\n·        Intranasal inhaled formulation of nintedanib (NTB) allows for more targeted dosing.\r\n·        Minimizes risk of systemic adverse events in the lung.\r\n·        Enhances drug retention in the lung for local treatment via inhalation.\r\n·        Formulation allows for long-ter","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Silicosis and other fibrotic lung diseases; inhaled formulation of nintedanib for local pulmonary treatment","mechanism_class":"inhaled nintedanib (repurposed TKI)","modality":"small_molecule","objectID":"53109","rationale_one_line":"Source describes an inhaled formulation of Nintedanib (a known small molecule TKI) for fibrotic lung disease; taxonomy confirms Small Molecules and Repurposed Drugs; pulmonary fibrosis is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53109","subscores":{"clinical_relevance":0.65,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"VEGFR / PDGFR / FGFR (nintedanib)","title":"Inhaled formulation of Nintedanib for Silicosis and other Fibrotic Lung Diseases"},{"biomarker_overlap":"HER2 pathway activation; tamoxifen resistance","composite_score":0.4911460629132438,"cr_rationale":"HOXB7 inhibition targets genuine unmet need in drug-resistant breast cancer, but modality unspecified.","description_excerpt":"C11436: HOXB7 a Therapeutic Target for Drug Resistant Breast Cancer\r\nNovelty: \r\nInhibition of HOXB7 overcomes drug resistance and increases effectiveness of drugs in breast cancer patients.\r\nValue Proposition: \r\nHOXB7 has been implicated in maintaining drug resistance in breast cancer and inhibition","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"drug resistant breast cancer","mechanism_class":"HOXB7 inhibitor","modality":"other","objectID":"16043","rationale_one_line":"Source explicitly names 'drug resistant breast cancer' as the indication and HOXB7 as the target; modality maps to other because the description states only 'inhibition of HOXB7' without specifying a therapeutic modality class.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16043","subscores":{"clinical_relevance":0.65,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HOXB7","title":"HOXB7 Renders Breast Cancer Resistant to Tamoxifen through Activation of the HER2 Pathway"},{"biomarker_overlap":"PSMA expression","composite_score":0.4839818946831569,"cr_rationale":"PSMA-targeted albumin-proaerolysin prodrug for prostate cancer; selective tumor lysis beyond hormonal/taxane SoC.","description_excerpt":"UNMET NEED\r\nThe current standards of care for prostate cancer (Pca) include hormonal therapy, radiation therapy, surgery, chemotherapy, and combinational therapy. However, these treatments often have side effects that affect the quality of life of the Pca patients. Hence, there is an urgent need for","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer","mechanism_class":"albumin-proaerolysin prodrug (PSMA-targeted peptide)","modality":"peptide","objectID":"39085","rationale_one_line":"Albumin-proaerolysin peptide prodrug targeting PSMA for prostate cancer; classified under Peptides/Proteins; prostate cancer is not a supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/39085","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"PSMA","title":"Albumin-proaerolysin Prodrugs"},{"biomarker_overlap":"PD-L1, CTLA-4 inhibitory signals on tumor cells","composite_score":0.4839818946831569,"cr_rationale":"B7-DC checkpoint stimulator bypassing PD-L1/CTLA-4 inhibition; differentiated mechanism from approved checkpoint blockade.","description_excerpt":"Unmet Need\r\nUnfortunately, many human tumor cells have evolved ways of deactivating the body’s immune system by expressing inhibitory signals (e.g., PD-L1, CTLA-4) on tumor cell surfaces. As a consequence, there is a pressing need for novel immunotherapies that would allow immune cells to bypass spe","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer immunotherapy and infectious diseases (viral and bacterial infections — broad)","mechanism_class":"B7-DC variant immune checkpoint stimulator","modality":"peptide","objectID":"35508","rationale_one_line":"B7-DC variants designed to stimulate immune responses by bypassing tumor inhibitory signals (PD-L1, CTLA-4) — peptide/biologic immunotherapy spanning oncology and infectious disease; no single supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35508","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"B7-DC (PD-L2)","title":"B7-DC Variants in the Stimulation of Immune Responses"},{"biomarker_overlap":null,"composite_score":0.4839818946831569,"cr_rationale":"Carotid body targeting addresses obesity-linked hypertension and sleep apnea; current SoC is largely symptomatic.","description_excerpt":"Unmet Need\r\nOver one-third of adults in the U.S. (36.5%) have obesity. Further, obesity leads to increased cardiovascular morbidity and mortality via multiple adverse mechanisms that include increased prevalence and severity of hypertension (often resistant to treatment) and obstructive sleep apnea ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"hypertension and obstructive sleep apnea in obesity","mechanism_class":"carotid body peptide hydrogel delivery","modality":"peptide","objectID":"29111","rationale_one_line":"Supramolecular hydrogel delivering peptides to carotid bodies to treat hypertension and sleep apnea in obesity; cardiovascular/sleep indication is not in the 11 supported enums; peptide modality is stated explicitly.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/29111","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Supramolecular Hydrogel Applications to the Carotid Bodies to Treat Hypertension and Sleep Apnea in Obesity"},{"biomarker_overlap":null,"composite_score":0.4839818946831569,"cr_rationale":"Neonatal seizures have limited drug options; GABA-A modulation mechanistically justified.","description_excerpt":"Ionotropic γ-aminobutyric acid type A (GABAA) receptors are found primarily in the central nervous system (CNS) where they mediate inhibitory post-synaptic transmission by increasing CI&quot; conductance into the cell. However, GABAA receptor activation can be excitatory in neonatal neurons and dors","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurological diseases (GABA-A receptor modulation; neonatal seizures, pain)","mechanism_class":"GABA-A receptor modulator (snake toxin-derived peptide)","modality":"peptide","objectID":"24753","rationale_one_line":"Snake toxin-derived peptides as pharmacological GABA-A receptor modulators for neurological diseases; indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24753","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"GABAA","title":"Snake Toxins and their Use as Pharmacological Modulators of GABAa Receptors"},{"biomarker_overlap":"phosphatidylserine exposure on tumor surface","composite_score":0.4839818946831569,"cr_rationale":"Tumor-targeted CTL antigen delivery offers novel mechanism vs checkpoint inhibitor SoC.","description_excerpt":"Antigen-specific immunotherapy represents a promising methodology to control tumors because it can stimulate\nthe immune system to specifically target and eliminate tumor cells. To overcome the challenge of immune\ntolerance, which is common to immunotherapy, we generated a novel chimeric protein to s","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer immunotherapy (antigen-specific CTL peptide delivery to tumor cells via Annexin V)","mechanism_class":"Annexin V-chimeric antigen delivery (tumor-targeted CTL peptide coating)","modality":"peptide","objectID":"24685","rationale_one_line":"Chimeric protein delivering CTL peptide antigens to tumor cells via Annexin V to stimulate CD8+ adaptive immunity; broad oncology indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24685","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"Annexin V / phosphatidylserine","title":"Targeted delivery of antigenic CTL peptide to tumor loci by Annexin V renders tumor cells susceptible to adaptive CD8+ cell immunity"},{"biomarker_overlap":null,"composite_score":0.4839818946831569,"cr_rationale":"NHE3 peptide may supplement ORS through intestinal sodium absorption.","description_excerpt":"C11498: Effective Treatment of Acute Diarrhea Using a Novel Peptide Modification\n\nNovelty: \n\nA peptide derived from the Sodium-Hydrogen Exchanger-3 (NHE-3) protein that increases sodium absorption in the intestine, aiding rehydration and can be used as a therapeutic for acute diarrhea.\n\nValue Propos","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"acute diarrhea (sodium absorption / rehydration)","mechanism_class":"NHE3-derived peptide (sodium-hydrogen exchanger stimulator)","modality":"peptide","objectID":"16961","rationale_one_line":"Peptide derived from NHE3 protein that increases intestinal sodium absorption for acute diarrhea treatment — gastroenterology indication outside supported enum; peptide modality per taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16961","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"NHE3 (Sodium-Hydrogen Exchanger-3)","title":"Small Peptide Stimulator of NHE3, the Brush Border Epithelial Na/H Exchanger"},{"biomarker_overlap":null,"composite_score":0.4839818946831569,"cr_rationale":"Mucoadhesive sublingual peanut allergy immunotherapy improves on injection-based SoC via oral delivery.","description_excerpt":"C11103: A Novel Sublingual Film for the Treatment of Allergy\r\nValue Proposition: \r\nJHU inventors have developed a mucoadhesive film containing a quantity of allergen to be placed under the tongue for the purpose of reducing adverse reactions to allergens by immunotherapy. ADVANTAGES:- A mucoadhesive","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"peanut allergy / allergic disease (sublingual immunotherapy)","mechanism_class":"mucoadhesive sublingual allergen immunotherapy film","modality":"peptide","objectID":"16835","rationale_one_line":"Described as 'a mucoadhesive film containing a quantity of allergen...for immunotherapy' against peanut allergy; peptide/allergen modality confirmed by taxonomy; allergy is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16835","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"A Novel Sublingual Film for the Treatment of Peanut Allergy"},{"biomarker_overlap":null,"composite_score":0.4839818946831569,"cr_rationale":"Novel antithrombotic mechanism may benefit patients refractory to standard antiplatelet therapy.","description_excerpt":"C05005: Novel Class and Clinical Application of Antithrombotic Agents that Specifically Inhibit Inflammation-related Vascular Occlusion\r\n    \r\n   \r\n\r\nTechnical Details: \r\n\r\nInflammation is known to be an integral part of the vascular occlusive events that occur during heart attack and stroke, althou","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"inflammation-related vascular occlusion (cardiovascular / thrombosis)","mechanism_class":"antithrombotic peptide inhibitor","modality":"peptide","objectID":"16472","rationale_one_line":"Peptide antithrombotic agents for inflammation-driven vascular occlusion in heart attack and stroke; cardiovascular/thrombosis is outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16472","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Novel Class and Clinical Application of Antithrombotic Agents that Specifically Inhibit Inflammation-related Vascular Occlusion"},{"biomarker_overlap":"PSMA expression","composite_score":0.4839818946831569,"cr_rationale":"PSMA-targeted peptides enable precision delivery in prostate cancer beyond standard hormone therapy.","description_excerpt":"C04856: Prostate Specific Membrane (PSMA)-binding Peptides Useful for Targeted Therapy for Cancer\r\nTechnical Details: \r\nProstate-Specific Membrane Antigen (PSMA) is a glutamate carboxypeptidase II that is expressed by normal prostate epithelium and is even more highly expressed by a large proportion","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer and other PSMA-expressing tumor types","mechanism_class":"PSMA-targeted peptide","modality":"peptide","objectID":"16435","rationale_one_line":"PSMA-binding peptides for targeted therapy in prostate cancer; prostate cancer is not among the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16435","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"PSMA","title":"Prostate Specific Membrane (PSMA)-binding Peptides Useful for Targeted Therapy for Cancer"},{"biomarker_overlap":null,"composite_score":0.4839818946831569,"cr_rationale":"NSF peptide inhibitors target thrombosis with novel mechanism distinct from anticoagulant/antiplatelet SoC.","description_excerpt":"Value Proposition: This invention is a novel treatment for thrombotic disorders, such as myocardial infarction, stroke, deep venous thrombosis, pulmonary embolus, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, sepsis, and microangiopathic hemolytic anemia. This invention may also be","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"thrombotic disorders (myocardial infarction, stroke, DVT, TTP, sepsis)","mechanism_class":"NSF inhibitor (exocytosis / thrombosis pathway)","modality":"peptide","objectID":"16266","rationale_one_line":"Peptide inhibitors of N-ethylmaleimide Sensitive Factor for thrombotic disorders including MI and stroke; cardiovascular/thrombosis indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16266","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"NSF","title":"Inhibitors of N-ethylmaleimide Sensitive Factor"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Non-surgical corneal regeneration addresses transplant-dependent blindness with limited curative options.","description_excerpt":"Value Proposition\r\n·      Non-surgical, non-invasive treatment for loss of vision caused by corneal damage.\r\n·      Cost effective to manufacture\r\n·      Easy application\r\n·      Regenerates existing cornea structure to restore vision.\r\nUnmet Need\r\nThe only curative option for many cases of corneal ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Corneal blindness (corneal dystrophy, corneal neovascularization)","mechanism_class":"Polymer/dendrimer ocular delivery","modality":"other","objectID":"60678","rationale_one_line":"Non-surgical corneal regeneration using dendrimers/polymers — a delivery platform for ophthalmology; not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60678","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Non-surgical treatment for corneal blindness"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Rectal tenofovir powder may improve PrEP adherence in high-risk populations.","description_excerpt":"Unmet Need\r\nWorldwide, nearly 2 million people are infected with HIV each year (see UptoDate). In the US specifically, 36,801 people were newly diagnosed with HIV in 2019 (see CDC). Since there is no cure for HIV infection, current best practice involves prevention of infection through pre-exposure ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"HIV prevention (pre-exposure prophylaxis)","mechanism_class":"Tenofovir formulation (NtRTI)","modality":"small_molecule","objectID":"60526","rationale_one_line":"Spray-dried tenofovir sachet enema powder for HIV PrEP; small molecule formulation; HIV not in the indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60526","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Tenofovir Spray Drying Sachet Enema Powder Formulation for HIV prevention"},{"biomarker_overlap":"PSMA expression","composite_score":0.4711460629132438,"cr_rationale":"PSMA-targeted nanoparticle delivery for prostate cancer improves tumor selectivity beyond standard systemic chemotherapy SoC.","description_excerpt":"Value Proposition:\r\n·        Engineered nanoparticle system with potent urea-based PSMA inhibitor\r\n·        Drug loaded nanoparticle\r\n·        Specific and selective tumor cytotoxicity \r\nUnmet Need\r\nProstate cancer affects millions of men globally and is a leading cause of cancer death in men. The m","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Prostate cancer","mechanism_class":"PSMA-targeted nanoparticle drug delivery","modality":"other","objectID":"59907","rationale_one_line":"Urea-based PSMA inhibitor loaded in engineered nanoparticles for prostate cancer; delivery platform technology; prostate cancer not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59907","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PSMA","title":"PSMA-targeting nanoparticle for prostate cancer therapy"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Inhaled ACE2 nanoparticles differentiate from antivirals through local epithelial targeting.","description_excerpt":"Value Proposition\r\n·      Provides targeted pulmonary delivery with superior lung pharmacokinetics\r\n·      Offers mutation-resistant therapeutic action, unlike current vaccines\r\n·      Reduces risk of progression to severe lung disease in newly diagnosed patients\r\n·      Applicable to a wide range o","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"COVID-19 and respiratory infections / ARDS","mechanism_class":"Angiotensin receptor blocker (inhalable nanoparticle formulation)","modality":"small_molecule","objectID":"59847","rationale_one_line":"Inhalable angiotensin blocker encapsulated in nanomedicine for COVID-19 and respiratory infections; small molecule therapeutic; COVID-19 not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59847","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"ACE2","title":"Breathable Nanomedicine: Inhalable Angiotensin Blockers for Treating COVID-19 and Respiratory Infections"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Post-surgical nerve adhesions lack effective prevention; biomaterial solution addresses real unmet need.","description_excerpt":"Value Proposition:\r\n·       Application of composite hydrogel to mechanically irritated nerves can reduce perineural adhesions and scar formation.\r\n·       Improves patient outcomes following peripheral nerve surgery.\r\n \r\nTechnology Description\r\n·       Researchers at Johns Hopkins have developed a ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"post-surgical peripheral nerve damage / perineural adhesions","mechanism_class":"nanofiber-hydrogel composite biomaterial","modality":"other","objectID":"56049","rationale_one_line":"Nanofiber-hydrogel composite material to prevent post-surgical nerve adhesions; classified under Medical Devices and Dendrimers & Polymers — a device/biomaterial, not a classic therapeutic.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/56049","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Composite Hydrogel that Prevents Post-Surgical Nerve Damage"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Neuropathic disorders have limited disease-modifying options; EV therapeutics offer a new mechanism.","description_excerpt":"Unmet Need:\r\nHuman induced pluripotent stem cells (hiPSCs), and neurons differentiated from them, have been a powerful tool for modeling neuronal pathophysiologies and preclinical efficacy/toxicity screening of novel therapeutic compounds. However, these cells cultured in vitro typically do not full","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neuropathic disorders","mechanism_class":"extracellular vesicle-based therapeutic","modality":"other","objectID":"56043","rationale_one_line":"Extracellular vesicle delivery agents for neuropathic disorders; neurology/neuropathy indication does not map to a supported enum and the modality is a delivery platform.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/56043","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Extracellular Vesicle‐based Agents and Methods for the Treatment of Neuropathic Disorders"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Obesity pharmacotherapy landscape is growing but sustained fat-depletion via small molecule is differentiated.","description_excerpt":"Value Proposition\r\n·        Sustained release of small molecule that depletes white fat\r\n·        Local injectable administration with less intense dosing regimen\r\nUnmet Need\r\n·        Excessive white fat accumulation, commonly associated with obesity, is a significant health concern that impacts me","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"obesity / excessive white fat accumulation","mechanism_class":"white fat depletion small molecule (sustained release)","modality":"small_molecule","objectID":"55979","rationale_one_line":"Taxonomy classifies under Small Molecules; description states 'sustained release of small molecule that depletes white fat' for obesity — obesity is outside the supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55979","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Formulation and sustained release of fat reduction small molecule"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Transplant rejection prevention has calcineurin inhibitor SoC with significant toxicity; LNP immunotherapy is differentiated.","description_excerpt":"Value Proposition - Novel Therapy: Hydro(LNp), is a new therapeutic application that will improve outcomes for organ transplant recipients.  - Convenient Delivery: Hydro(LNp) is a two-phase delivery system that increases effectiveness in regulating transplant rejection. - Broad Scope: Has the potent","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"organ transplant rejection","mechanism_class":"two-phase LNP immunotherapy delivery system","modality":"other","objectID":"55093","rationale_one_line":"Delivery platform (hydrogel + LNP) for immunotherapy to prevent transplant rejection; transplantation/immunology indication is outside the supported enum set.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55093","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Immunotherapy delivery system to improve organ transplantation outcomes"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"HIV functional cure via nSMase2 is mechanistically novel vs. ART suppression SoC but still preclinical.","description_excerpt":"Unmet Need\r\nHuman immunodeficiency virus (HIV) is a retrovirus that negatively impacts the immune system, leading to immunosuppression and increased susceptibility to secondary, opportunistic infections and some cancers. It is estimated that 36.7 million people worldwide are currently living with HI","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"human immunodeficiency virus (HIV) infection","mechanism_class":"nSMase2 inhibitor (antiviral)","modality":"small_molecule","objectID":"54230","rationale_one_line":"Small molecule inhibition of nSMase2 to treat HIV infection; HIV is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54230","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SMPD3","title":"Inhibition of nSMase for the Treatment of Human Immunodeficiency Virus Infection"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"CCCA has no FDA-approved therapy; repurposed metformin offers a mechanistically grounded approach for underserved patients.","description_excerpt":"Value Proposition: - Potential first-in-class treatment for CCCA, a condition impacting a substantial proportion of Black women.  - Repurposes metformin, a well-studied and naturally available compound with an established safety profile and a low cost of manufacturing. - Oral administration as a sim","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"central centrifugal cicatricial alopecia (CCCA) / hair loss","mechanism_class":"metformin (repurposed)","modality":"small_molecule","objectID":"54193","rationale_one_line":"Repurposed metformin (small molecule) for CCCA hair loss; taxonomy classifies under Repurposed Drugs; dermatology/alopecia is outside the supported enum set.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54193","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Orally Administered Metformin to Treat Hair Loss in Central Centrifugal Cicatricial Alopecia"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Hydropersulfide precursors for cardiovascular/oncology are mechanistically novel but dual-indication dilutes clinical focus.","description_excerpt":"Unmet Need:\r\nAccording to a survey by the CDC, nearly 50% of Americans age 20 and up have some form of cardiovascular disease (see AHA). The management of cardiovascular diseases depends on the specific indication, and standard therapies include one or multiple of the following types of medications:","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cardiovascular disease and oncology","mechanism_class":"hydropersulfide precursor (alkylsulfenyl thiocarbonate)","modality":"small_molecule","objectID":"53715","rationale_one_line":"Small molecule alkylsulfenyl thiocarbonate precursors to hydropersulfides for cardiovascular and cancer applications; dual-indication and neither maps cleanly to a single supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53715","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Alkylsulfenyl Thiocarbonates as Precursors to Hydropersulfides"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"RIP kinase inhibition addresses neuroinflammation in diseases with limited neuroprotective SoC options.","description_excerpt":"Unmet Need\r\nNeurodegenerative disorders are a heterogeneous group that includes Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), dementia, and Huntington’s disease. These disorders result from progressive degeneration of the structure,","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, ALS, multiple sclerosis, dementia, and Huntington's disease","mechanism_class":"RIP kinase inhibitor","modality":"small_molecule","objectID":"53561","rationale_one_line":"Title states Inhibition of rip kinases and taxonomy confirms Small Molecules; indication spans multiple neurodegenerative diseases outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53561","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"RIPK1","title":"Inhibition of rip kinases for treating neurodegenerative disorders"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"GCPII inhibitor reduces glutamate excitotoxicity where no disease-modifying small-molecule SoC exists.","description_excerpt":"Unmet Need\r\nGlutamate is the primary excitatory neurotransmitter in the human brain [1]. Excessive glutamate signaling can disrupt calcium homeostasis, leading to mitochondrial dysfunction, the overproduction of reactive oxygen species, and neuron loss via necrotic or apoptotic pathways [2]. This ph","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Neurological diseases associated with excitotoxicity and excessive glutamate signaling","mechanism_class":"GCPII inhibitor","modality":"small_molecule","objectID":"53510","rationale_one_line":"Title identifies GCPII Inhibitors as small molecules for neurology; taxonomy confirms Small Molecules; excitotoxicity/neurology indication is not a specific supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53510","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GCPII","title":"DOPA and Caffeic Acid Analogs as Novel GCPII Inhibitors"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Oxidative stress modulator for trigeminal neuralgia addresses refractory pain where carbamazepine SoC has limited efficacy.","description_excerpt":"Unmet Need\r\nTrigeminal neuralgia is a condition that affects the fifth cranial nerve, caused either via trigeminal nerve compression or secondary to another medical condition (i.e., multiple sclerosis, facial injury, tumors, etc.). Trigeminal neuralgia results in severe orofacial pain that is except","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Trigeminal neuralgia; severe orofacial pain caused by trigeminal nerve compression or secondary to other conditions","mechanism_class":"oxidative stress modulator","modality":"small_molecule","objectID":"52855","rationale_one_line":"Taxonomy confirms Small Molecules; title describes modulation of oxidative stress as a therapeutic pathway for trigeminal neuralgia; pain/neuralgia indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52855","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Modulation of Oxidative Stress as a Therapeutic Pathway in Trigeminal Neuralgia"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Flt3L-albumin fusion boosts dendritic cell priming; meaningful immune activation beyond checkpoint inhibitors.","description_excerpt":"Unmet Need: Active immunotherapy, such as anti-PD-1/PD-L1 and anti-CTLA-4 checkpoint blockage, involves the administration of molecules to mobilize host immune cells to recognize and kill tumors. Proper presentation of tumor antigens through antigen presenting cells is a prerequisite to elicit a pot","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Oncology / cancer immunotherapy (anti-tumor immunity enhancement)","mechanism_class":"Albumin-Flt3L fusion protein / dendritic cell activator","modality":"other","objectID":"50609","rationale_one_line":"Albumin-Flt3L fusion protein enhances anti-tumor immunity and antigen-specific T-cell cytotoxicity; a biologic fusion protein classified under Biologics; general oncology does not map to a specific enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50609","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"FLT3L","title":"Albumin-Flt3L Fusion Protein to Enhance Anti-Tumor Immunity and Antigen-specific T-cell Cytotoxicity"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"IP6K inhibition faces crowded diabetes SoC including GLP-1 and SGLT2 agents.","description_excerpt":"Unmet Need \r\nGlobally, in 2021, there were approximately 537 million cases of diabetes which resulted in about 6.7 million deaths and $966 billion of healthcare expenditure (IDF). About 95% of diabetes cases are type 2 diabetes (T2D), which is characterized by either impaired insulin production or i","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"Type 2 diabetes (T2D)","mechanism_class":"IP6K inhibitor","modality":"small_molecule","objectID":"50060","rationale_one_line":"Non-acid IP6K inhibitors for Type 2 Diabetes; explicitly classified under 'Type 2 Diabetes' and 'Small Molecules' in the taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50060","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"IP6K","title":"Non-acid IP6K Inhibitors"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Broad HNO-release claims dilute impact across heart failure and oncology.","description_excerpt":"Unmet Need:\r\nAn estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths (see WHO). Nitroglycerin has been used as a vasodilator to treat heart conditions for over 130 years. It wasn&#39;t until 2003 that scientists realized the beneficial effect","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cardiovascular diseases and oncology (controlled HNO release)","mechanism_class":"HNO donor (intramolecular cyclization-elimination)","modality":"small_molecule","objectID":"48836","rationale_one_line":"Controlled HNO release through intramolecular cyclization-elimination for cardiovascular and oncology applications; classified under Small Molecules; neither cardiovascular nor general oncology map cleanly to a single supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48836","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Controlled HNO Release through Intramolecular Cyclization-Elimination"},{"biomarker_overlap":"Tumor hypoxia","composite_score":0.4711460629132438,"cr_rationale":"Neutrophil suppression preconditioning enables oncolytic bacterial therapy for GBM where no curative SoC exists.","description_excerpt":"Unmet Need\r\nHypoxia is a prominent feature of solid tumors and can function as fertile environment for oncolytic anaerobic bacteria such as Clostridium novyi-NT (C. novyi-NT) where it can induce tumor destruction in mice and patients. However, two major obstacles have limited its use, namely the hos","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Solid tumors / glioblastoma (oncolytic bacterial therapy preconditioning)","mechanism_class":"neutrophil suppression preconditioning for oncolytic bacteria","modality":"other","objectID":"47956","rationale_one_line":"Neutrophil suppression preconditioning to increase efficacy of Clostridium novyi-NT oncolytic bacterial therapy in solid tumors/glioblastoma; modality is biological/cellular but not a standard enum; brain cancer not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/47956","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Neutrophil Suppression as Preconditioning to Increase Efficacies and Safety of Oncolytic Bacterial Therapies"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"RNA Pol I inhibition offers distinct cancer mechanism, with unproven differentiation.","description_excerpt":"This invention describes a set of novel small molecules that inhibit RNA polymerase I. RNA polymerase I (Pol I) governs the transcription of ribosomal RNAs, which are needed for building and function of the ribosomes. These ribosynthetic activities are greatly increased in cancer cells, and Pol I tr","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer (RNA polymerase I inhibition)","mechanism_class":"RNA polymerase I inhibitor","modality":"small_molecule","objectID":"47101","rationale_one_line":"Pyridoquinazoline small molecule RNA Polymerase I inhibitors for cancer; classified under Small Molecules / Oncology; general oncology without a specific supported enum indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/47101","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"POLR1A","title":"Pyridoquinazolinesmall molecule RNA Polymerase I inhibitors"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"MSC Trojan horse targets GBM, a disease lacking curative SoC.","description_excerpt":"Human Adipose-derived Mesenchymal Stem Cells can be engineered to synthesize and release anti-tumor proteins and therefore can be used as “Trojan Horses”.  The inventors have created a novel technology which encompasses a solution containing biodegradable, polymeric nanoparticles that is combined wi","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Brain cancer / glioma / neurological diseases (mesenchymal stem cell Trojan horse)","mechanism_class":"nanoparticle-modified adipose mesenchymal stem cell delivery (Trojan Horse)","modality":"other","objectID":"46071","rationale_one_line":"Nanoparticle modification of adipose-derived mesenchymal stem cells to release anti-tumor proteins for brain cancer/glioma; classified under Cell Therapies / Biologics; brain cancer not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/46071","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Nanoparticle Modification of Human Adipose-derived Mesenchymal Stem Cells for Brain Cancer and Other Neurological Diseases"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Sustained growth-factor delivery addresses limited peripheral nerve regenerative options.","description_excerpt":"Unmet Need\r\nGlobal incidence rates for peripheral nerve injury (PNI) are not well aggregated. However, US data collected shows that 20 million Americans suffer from peripheral nerve injury caused by trauma and medical disorders. [16] When a tension-free early repair is possible, microsurgical direct","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Peripheral nerve injury (nanoparticle sustained delivery of pro-regenerative growth factors)","mechanism_class":"nanoparticle sustained-release growth factor delivery","modality":"other","objectID":"46035","rationale_one_line":"Nanoparticle compositions for sustained delivery of pro-regenerative growth factors for nerve repair; classified under Therapeutic Delivery Platforms / Wound Healing; indication not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/46035","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Nanoparticle Compositions for Sustained Delivery of Pro-regenerative Growth Factors for Nerve Repair, Preparation Processes of the Same, and Treatment Methods Using the Same"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Epigenetic synthetic lethality is novel, but differentiation remains unclear.","description_excerpt":"Invention Novelty\r\nThis invention is a novel paradigm for the induction of synthetic lethality through epigenetic modulations. This can induce functionality and efficacy of therapeutics against cancer cells that may have resistance to each therapeutic alone. \r\nValue Proposition\r\nThe complex and adap","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer (synthetic lethality induction via epigenetic therapy)","mechanism_class":"epigenetic synthetic lethality inducer","modality":"small_molecule","objectID":"45717","rationale_one_line":"Induction of synthetic lethality through epigenetic modulations (ISLET) for cancer treatment; classified under Small Molecules / Targets; general oncology without specific supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45717","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Induction of synthetic lethality with epigenetic therapy (ISLET)"},{"biomarker_overlap":"Novel lncRNA overexpressed in group 3 medulloblastoma","composite_score":0.4711460629132438,"cr_rationale":"lncRNA targeting addresses high-mortality group 3 medulloblastoma without targeted SoC.","description_excerpt":"Unmet Need / Invention Novelty: Current strategies to provide personalized treatment based on molecular profiles for patients suffering from MB lack efficiency and are accompanied by severe side effects and high mortality rates. There is an unmet need to understand the molecular mechanisms of group ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Medulloblastoma (group 3 MB)","mechanism_class":"long non-coding RNA (lncRNA) therapeutic target","modality":"nucleic_acid","objectID":"45432","rationale_one_line":"Novel long-coding RNA as marker and therapeutic target for medulloblastomas; classified under Diagnostics / Therapeutic Modalities; medulloblastoma not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45432","subscores":{"clinical_relevance":0.6,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel long-coding RNA as a marker and therapeutic target for medulloblastomas"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Novel HIV protein adds mechanism, but effective ART already exists.","description_excerpt":"Unmet Need: HIV infection remains a significant global health burden despite availability of current antiviral treatments. With increasing drug resistance against available therapeutics, there is an urgent need for additional strategies to treat HIV.\r\n \r\nTechnical Details: Researchers at Johns Hopki","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"HIV infection / HIV/AIDS","mechanism_class":"novel HIV antiviral protein","modality":"other","objectID":"45267","rationale_one_line":"Novel HIV antiviral proteins for therapeutic methods against HIV; classified under Targets / Biomarkers; HIV/AIDS is an infectious disease not in the 11 indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45267","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel HIV Antiviral Proteins and Their Uses in Therapeutic Methods"},{"biomarker_overlap":"miR-603","composite_score":0.4711460629132438,"cr_rationale":"miR-603 liposomes target GBM stem-cell resistance absent from current SoC.","description_excerpt":"Unmet Need: Glioblastoma (GBM) is the most common malignant brain tumor in adults, affecting 17K patients in the US annually. GBM stem cells underlie GBM recurrence, leading to treatment resistance and poor patient outcomes. Standard treatments remove the primary tumor cells but leave space for GBM ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Glioblastoma (GBM) / GBM stem cells","mechanism_class":"miRNA delivery (miR-603) via targeted liposomes","modality":"nucleic_acid","objectID":"45264","rationale_one_line":"Targeted liposomes encapsulating miR-603 complexes to target GBM stem cells; nucleic acid modality; glioblastoma not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45264","subscores":{"clinical_relevance":0.6,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Targeted Liposomes Encapsulating miR-603 Complexes"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"M4N may overcome TMZ resistance in GBM with limited SoC.","description_excerpt":"Unmet Need\r\nGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incr","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Glioblastoma multiforme (GBM)","mechanism_class":"M4N + temozolomide combination (demethylation agent + alkylating agent)","modality":"small_molecule","objectID":"45197","rationale_one_line":"M4N and temozolomide combination therapy for glioblastoma multiforme; classified under Small Molecules; glioblastoma not in the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45197","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Mutant GAPDH glycolytic targeting is mechanistically distinct from cytotoxic SoC in solid tumors.","description_excerpt":"Unmet Need: One of the hallmarks of cancer cells is metabolic reprogramming for faster metabolism and cell growth. For example, increased glycolysis has long been known to be part of cancer cells’ biochemical adaptation. One of the key enzymes of glycolysis is glyceraldehyde-3-phosphate dehydrogenas","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"solid malignancies (cancer)","mechanism_class":"mutant GAPDH glycolysis inhibitor","modality":"other","objectID":"45050","rationale_one_line":"Targets GAPDH (glycolysis enzyme) in solid malignancies; classified under Biologics/Proteins, not a supported modality enum; broad oncology does not map to a supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45050","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GAPDH","title":"Mutant GAPDH: A Novel Anticancer Therapeutic for Solid Malignancies"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"PTPN22 inhibition to boost TIL activity is mechanistically distinct from checkpoint inhibitor SoC.","description_excerpt":"Unmet Need\r\nTumor-infiltrating lymphocytes (TILs) such as B-cells, T-cells, and natural killers are gaining traction in anti-tumor immune responses. TILs involve the use of special immune cells called T-cells, otherwise known as lymphocytes, which protect the body from viral infections, fight cancer","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (tumor immunotherapy)","mechanism_class":"PTPN22 inhibition / TIL immunotherapy","modality":"other","objectID":"44926","rationale_one_line":"Targets PTPN22 to enhance tumor-infiltrating lymphocyte activity; broad oncology immunotherapy with an animal model classification; no supported indication enum applies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44926","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PTPN22","title":"Targeting PTPN22 in Cancer Therapy"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Sustained-release epinephrine gel for endoscopic hemostasis; addresses recurrent bleeding limitation of injection SoC.","description_excerpt":"Unmet Need:\r\nGI bleeding can result from different pathologies, and the current treatment methods have not evolved to address the persistent clinical need for improved bleeding treatments. Current modalities to control GI bleeding have limited efficacy/application, are temporary with high recurrence","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gastrointestinal bleeding","mechanism_class":"sustained-release epinephrine gel","modality":"small_molecule","objectID":"44652","rationale_one_line":"Sustained-release epinephrine gels for GI endoscopy bleeding control; epinephrine is a small molecule but indication (GI bleeding) does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44652","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"adrenergic receptor","title":"Sustained Release Epinephrine Gels for use in Gastrointestinal Endoscopy"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Multi-epitope ETEC vaccine; diarrheal disease causes high global mortality with no licensed preventive vaccine.","description_excerpt":"Unmet Need: Enterotoxigenic Escherichia coli (ETEC) is the leading cause of diarrheal diseases worldwide but to date no effective vaccine exists due to the heterogeneity in ETEC strains. There is a need for a vaccine that elicits a broad yet productive immune response against multiple ETEC antigens ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"ETEC diarrheal disease (infectious disease)","mechanism_class":"multi-epitope fusion antigen vaccine","modality":"other","objectID":"39495","rationale_one_line":"Multi-epitope fusion antigen vaccine for Enterotoxigenic E. coli; infectious disease vaccine, indication does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/39495","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Multi-epitope Fusion Antigen Vaccine for ETEC"},{"biomarker_overlap":"PSMA expression","composite_score":0.4711460629132438,"cr_rationale":"PSMA-expressing engineered cells for prostate cancer; targeted approach vs. androgen deprivation SoC with clear target.","description_excerpt":"Unmet Need\r\nProstate cancer is the second leading cause of cancer related death in American men and it is estimated that approximately 164,690 new cases will be diagnosed in 2018. Various treatment strategies, including surgery, radiation and chemotherapy, exist for prostate cancer but their success","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer","mechanism_class":"PSMA-expressing engineered cell line","modality":"other","objectID":"39159","rationale_one_line":"Engineered cells expressing PSMA for prostate cancer therapy; classified under Cell Therapies; prostate cancer is not a supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/39159","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PSMA","title":"ENGINEERED CELLS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) OR A MODIFIED FORM THEREOF AND RELATED METHODS"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"CAF-targeting engineered fibroblasts for breast/colorectal cancer; tumor microenvironment approach vs. cytotoxic SoC.","description_excerpt":"Unmet Need / Invention Novelty: Carcinoma associated fibroblasts (CAFs) are associated with the development of high-grade malignancies of poor prognoses, as they facilitate cancer invasion and hinder anti-cancer drug delivery. In order to improve the long-term survival rate of pre-metastatic cancer ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"breast cancer and colorectal cancer (carcinoma progression)","mechanism_class":"genetically engineered fibroblast cell therapy (CAF targeting)","modality":"other","objectID":"39012","rationale_one_line":"Genetically engineered fibroblasts targeting carcinoma-associated fibroblasts in 'Oncology > Breast Cancer' and colorectal cancer; primary listed indication is breast cancer; cell therapy modality maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/39012","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Cell Therapy for the Treatment and Prevention of Carcinoma and Tumor Progression"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"DNA cancer vaccine for melanoma; immunotherapy approach competitive with checkpoint inhibitors.","description_excerpt":"Unmet Need\r\nTherapeutic cancer vaccines aim to activate the antitumor T cell response. These vaccines are designed to prime naïve antitumor T cells, by activating antigen presenting cells, particularly dendritic cells (DCs). DNA-based cancer vaccines are a particularly promising approach, partially ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"melanoma","indication_free_text":"Melanoma (skin cancer)","mechanism_class":"DNA cancer vaccine / dendritic cell activator","modality":"other","objectID":"38545","rationale_one_line":"DNA-based cancer vaccine designed to activate dendritic cells and prime antitumor T cells against melanoma — categorized under Oncology > Melanoma; modality is vaccine/immunotherapy, mapped to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/38545","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Compositions and Methods for Treating Melanoma--Further Modifications"},{"biomarker_overlap":"PSMA expression on prostate cancer cells","composite_score":0.4711460629132438,"cr_rationale":"PSMA-targeted phototheranostic for prostate cancer; PDT offers localized treatment vs systemic hormonal SoC.","description_excerpt":"Unmet Need\r\nProstate cancer is the leading cancer in the U.S. population and the second leading cause of cancer death in men. A promising precision cancer treatment known as photodynamic therapy (PDT) offers a way to selectively target prostate cancer cells for destruction. Prostate PDT uses a ligan","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Prostate cancer","mechanism_class":"PSMA-targeted phototheranostic (photodynamic therapy) agent","modality":"other","objectID":"36530","rationale_one_line":"Long-circulating PSMA-targeted porphyrin-based phototheranostic agent for prostate cancer PDT — theranostic/photodynamic modality; prostate cancer is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36530","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PSMA","title":"Long-Circulating PSMA-Targeted Phototheranostic Agent"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Patient-specific VT ablation target prediction; computational guidance may reduce failed ablations vs current approach.","description_excerpt":"Unmet Need\r\nVentricular tachycardia (VT) is a heart rhythm disorder that affects hundreds of thousands of Americans every year. VT is defined as an irregular accelerated heart rate due to abnormal electrical signaling in the heart’s lower chambers. Implantable Cardioverter Defibrillators (ICDs) can ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Ventricular tachycardia (VT) in patients with myocardial infarction or fibrosis","mechanism_class":"Patient-specific cardiac modeling for catheter ablation target prediction","modality":"other","objectID":"36503","rationale_one_line":"Patient-specific heart modeling to predict optimal catheter ablation targets for ventricular tachycardia — a computational/diagnostic tool, not a drug therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36503","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Using Patient-Specific Modeling of the Heart for Prediction of Optimal Targets for Catheter Ablation of Ventricular Tachycardia in Patients with Myocardial Infarction or Fibrosis and ICDs"},{"biomarker_overlap":"Kidney repair biomarkers to assess organ viability post-brain death","composite_score":0.4711460629132438,"cr_rationale":"Kidney repair biomarker panel reduces transplant organ discard; addresses real clinical waste problem.","description_excerpt":"Unmet Need:\r\nThe prevalence of end-stage renal disease (ESRD) is predicted to rise sharply over the next few decades due to an aging population and an increased incidence of diabetes and hypertension. ESRD patients that receive a kidney transplant have improved outcomes compared to patients that rem","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"End-stage renal disease (ESRD) / kidney transplantation","mechanism_class":"Repair biomarker panel for kidney discard reduction post-brain death","modality":"other","objectID":"36393","rationale_one_line":"Biomarker-based tool to reduce discard of kidneys for transplantation after brain death — a diagnostic/organ preservation tool, not a therapeutic drug; renal disease is outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36393","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Reduce Discard of Kidneys for Transplantation after Brain Death using Repair Biomarkers"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Non-immunosuppressive FK506 analog for chronic wounds; avoids systemic immunosuppression of current wound treatments.","description_excerpt":"Unmet Need\r\nChronic, nonhealing wounds are estimated to affect approximately 2% of the general population, and the cost of caring for these wounds exceeds $50 billion per year. These costs are expected to rise due to the increasing prevalence of diabetes and other diseases that hinder wound healing.","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Chronic non-healing wounds","mechanism_class":"Non-immunosuppressive FK506 analog (wound healing)","modality":"small_molecule","objectID":"35368","rationale_one_line":"Non-immunosuppressive FK506 analogs for treating chronic non-healing wounds — small molecule; wound healing is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35368","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"FKBP12 / mTOR pathway","title":"Non-immunosuppressive FK506 analogs and use thereof"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"PDE9 inhibitor for post-menopausal T2D/obesity; novel mechanism vs metformin/GLP-1 agonist SoC.","description_excerpt":"Unmet Need\r\nObesity is a serious health problem both globally and in the United States. Obesity is associated with numerous comorbidities including type-2 diabetes, cardiovascular disease, and certain types of cancers. In particular, obesity is commonly seen in the post-menopausal population as 74% ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"Post-menopausal obesity and associated disease including type-2 diabetes","mechanism_class":"PDE9 inhibitor","modality":"small_molecule","objectID":"35355","rationale_one_line":"PDE9 inhibitors for treatment of post-menopausal obesity and associated comorbidities including 'type-2 diabetes' — small molecule; type2_diabetes is the closest supported enum given the explicit diabetes association.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35355","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PDE9","title":"Treatment of Post-menopausal Obesity and Associated Disease by PDE9 Inhibitors"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Self-assembling CPT amphiphiles may improve tumor delivery vs conventional topoisomerase inhibitor dosing.","description_excerpt":"Unmet need: DNA topoisomerases have become a widely exploited chemotherapeutic drug target for the treatment of advanced cancer. Multiple classes of topoisomerase inhibitors have been marketed including camptothecin (CPT) derivatives. However, while these analogues are less toxic than CPT, they are ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"advanced cancer (broad oncology)","mechanism_class":"topoisomerase inhibitor amphiphile","modality":"small_molecule","objectID":"34441","rationale_one_line":"Self-assembling camptothecin (CPT) derivative amphiphiles targeting topoisomerase; broad cancer indication does not map to any specific supported enum so mapped to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/34441","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TOP1","title":"Self-assembling CPT-drug Amphiphiles for Cancer Treatment"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"TDP-43 target validation in ALS addresses a disease with no disease-modifying SoC approved.","description_excerpt":"Unmet Need\r\nAmyotrophic lateral sclerosis (ALS) is a rare but debilitating disease characterized by the death of motor neurons that eventually leads to difficulty moving, speaking, swallowing, and breathing. The fundamental cause of ALS is unknown and as a result treatment options are primarily rest","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"amyotrophic lateral sclerosis (ALS)","mechanism_class":"TDP-43 splicing repression target validation","modality":"other","objectID":"30419","rationale_one_line":"Target validation of TDP-43 splicing repression function in motor neurons for ALS; ALS is not in the 11 supported indications; this is a target discovery/validation asset without a defined therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/30419","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TDP-43 (TARDBP)","title":"Target Validation of Splicing Repression, a Major Function of TDP-43 in the Motor Neuron"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Synergistic checkpoint target could overcome anti-PD-1 resistance; broad but meaningful unmet need.","description_excerpt":"Unmet Need\r\nImmune checkpoint therapy has revolutionized how we think about and treat cancers; however, despite remarkable success, immuno-monotherapy has only provided a robust response in ~20-30% of tumors treated. Researchers are now exploring other treatment paradigms including cell, gene, and v","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"immuno-oncology / anti-tumor immunity (broad cancer)","mechanism_class":"PD-1 synergistic immune checkpoint target","modality":"other","objectID":"30374","rationale_one_line":"Novel target that synergizes with anti-PD-1 therapy to promote anti-tumor immunity; broad immuno-oncology indication without a specific cancer type matching the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/30374","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A Novel Target that Synergies with Anti-PD-1 Therapy to Promote Anti-tumor Immunity"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Therapeutic angiogenesis for PAD targets limb ischemia where revascularization options are often unavailable.","description_excerpt":"Unmet Need\r\nIn the United States alone, almost 8.5 million people suffer from peripheral artery disease (PAD). The market for PAD and Peripheral Vascular Disease (PVD) is expected to reach $378.53 million with a CAGR of 7.06% by 2024. Therapeutic angiogenesis are therapies aimed at growing new vesse","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"peripheral artery disease (PAD) and wound healing via therapeutic angiogenesis","mechanism_class":"stem cell-based therapeutic angiogenesis","modality":"other","objectID":"28872","rationale_one_line":"Stem cell approach for therapeutic angiogenesis targeting PAD and wound healing; cardiovascular/wound indication is not in the supported enums; cell therapy maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28872","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Cancer in Angiogenesis"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"nSMase2 inhibition for Alzheimer's addresses disease with no disease-modifying approved therapy.","description_excerpt":"Unmet Need\r\nAlzheimer’s disease (AD) is the most common form of dementia, affecting approximately 5.7 million people in the United States in 2018. Yet, no cure exists for AD, and AD therapeutics presently on the market fail to treat the disease’s underlying causes. Recent studies in mice reveal that","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"Alzheimer's disease and oncologic diseases (neurodegenerative and oncology)","mechanism_class":"nSMase2 inhibitor","modality":"small_molecule","objectID":"28851","rationale_one_line":"DPTIP small molecule inhibitor of neutral sphingomyelinase 2 (nSMase2) for Alzheimer's disease and oncologic diseases; neither Alzheimer's nor general oncology maps to the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28851","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"nSMase2 (SMPD3)","title":"Discovery of 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP) a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"MicroRNA gene therapy for HCC; systemic options for advanced HCC remain limited beyond sorafenib/IO.","description_excerpt":"Unmet need\r\nOver 500,000 people are diagnosed with liver cancer worldwide each year. According the American Cancer Society, liver cancer resists most chemotherapy drugs and the most effective agents shrink less than 1 in 5 tumors and generally for only a short time. Hepatocellular carcinoma (HCC) is","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"hepatocellular carcinoma (HCC) / liver cancer","mechanism_class":"microRNA gene therapy","modality":"nucleic_acid","objectID":"28107","rationale_one_line":"MicroRNA delivery as gene therapy for liver cancer; nucleic_acid modality; liver cancer is not in the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28107","subscores":{"clinical_relevance":0.6,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"MicroRNA Delivery as a Novel Therapeutic Strategy for Liver Cancer"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Improved isoniazid derivatives for TB; resistance-overcoming potential is clinically meaningful.","description_excerpt":"Unmet Need\r\nIn 2015, there were approximately 10.4 million new cases of tuberculosis (TB). More than 95% of cases and deaths due to TB are found in developing countries with India, Indonesia, China, Pakistan and South Africa accounting for 60% of global TB cases. TB is an airborne disease that can b","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"tuberculosis (TB)","mechanism_class":"isoniazid derivative antibacterial","modality":"small_molecule","objectID":"28101","rationale_one_line":"Improved isoniazid derivatives for tuberculosis; infectious disease indication is not in the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28101","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Further Improved Derivatives of Isoniazid with Enhanced Activity"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"HCV E1E2 vaccine targets broadly neutralizing response; prior HCV vaccines failed, defining genuine unmet need.","description_excerpt":"Unmet Need\r\n185 million people worldwide are infected with Hepatitis C (HCV). It is a major cause of liver failure and hepatocellular carcinoma. Recent development of potent, oral, interferon-free therapies have improved treatment of HCV significantly, but treatment alone is unlikely to eradicate th","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"Hepatitis C virus (HCV) infection","mechanism_class":"broadly neutralizing antibody vaccine (E1E2 antigen)","modality":"other","objectID":"28018","rationale_one_line":"HCV E1E2 gene-based vaccine stimulating broadly neutralizing antibodies; infectious disease and vaccine modality are both outside the 11 supported indication enums and 9 modality enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28018","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HCV E1E2","title":"Hepatitis C virus E1E2 genes stimulating development of broadly neutralizing antibodies"},{"biomarker_overlap":"KRAS mutation status and novel EGFR sensitivity mechanism","composite_score":0.4711460629132438,"cr_rationale":"Anti-EGFR sensitivity biomarker for CRC enables patient selection, improving outcomes over unselected EGFR therapy.","description_excerpt":"Unmet Need:\r\nColorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are monoclonal antibodies, which prevent epidermal growth factor receptor (EGFR) activation. Several stud","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"colorectal_cancer","indication_free_text":"colorectal cancer (late-stage, anti-EGFR therapy sensitivity)","mechanism_class":"anti-EGFR therapy sensitivity biomarker","modality":"other","objectID":"27657","rationale_one_line":"Identification of novel mechanism of sensitivity to anti-EGFR therapy in colorectal cancer; CRC is explicitly named and is a supported enum; modality is a biomarker/target discovery rather than a therapeutic class.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/27657","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"EGFR, KRAS","title":"Identification of novel mechanism of sensitivity to anti-EGFR therapy"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Heterotopic ossification prevention has no approved pharmacotherapy; high clinical burden post-trauma or surgery.","description_excerpt":"Unmet Need\r\n \r\nHeterotopic ossification (HO) is the process of bone formation outside of the skeleton in areas such as soft tissue surrounding the joint. When this occurs, patients experience a high increase in pain and limited range of motion in their joint. HO can be caused by trauma to the hip or","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"heterotopic ossification (HO) — pathological bone formation","mechanism_class":"HO prevention target","modality":"other","objectID":"27439","rationale_one_line":"Therapeutic treatment or prevention of heterotopic ossification; musculoskeletal/traumatic injury indication is not in the 11 supported enums; modality is target validation.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/27439","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Therapeutic Treatment or Prevention of Heterotopic Ossification"},{"biomarker_overlap":"BBS10 gene mutations as diagnostic biomarker","composite_score":0.4711460629132438,"cr_rationale":"BBS10 gene identification for Bardet-Biedl Syndrome enables diagnosis and future gene therapy in rare disease.","description_excerpt":"Unmet Need\r\nCurrently nine BBS(1-9) genes have been discovered and they account for only 40-50% of all mutations that result in BBS. This technology comprises of BBS10, a novel BBS gene whose mutational involvement in the disease makes it an attractive diagnostic and therapeutic target. Other advant","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"Bardet-Biedl Syndrome (BBS) — rare genetic disease","mechanism_class":"BBS10 gene diagnostic and therapeutic target","modality":"other","objectID":"26733","rationale_one_line":"Identification of BBS10 as the most common gene for Bardet-Biedl Syndrome; rare genetic disease indication is not in the 11 supported enums; modality is target/diagnostic.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/26733","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"BBS10","title":"Identification of the Most Common Gene for Bardet-Biedl Syndrome"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Artemisinin ozonide antiviral for CMV in immunocompromised patients addresses limited treatment options.","description_excerpt":"INVENTION NOVELTY: This technology involves the use of a derivative of artemisinin as a new therapy for Cytomegalovirus (CMV) infection.\r\n\r\n - VALUE PROPOSITION: CMV infection is recognized as a cause of morbidity and mortality, especially in immunocompromised individuals. CMV is also the most commo","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cytomegalovirus (CMV) infection in immunocompromised patients","mechanism_class":"artemisinin ozonide antiviral","modality":"small_molecule","objectID":"26018","rationale_one_line":"Ozonide derivative of artemisinin inhibiting CMV replication in vitro and in vivo; infectious disease/viral indication is not in the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/26018","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Ozonides forms of artemisinins inhibit cytomegalovirus (CMV) replication in vitro and in vivo"},{"biomarker_overlap":"intrahepatic triacylglycerol accumulation, insulin resistance","composite_score":0.4711460629132438,"cr_rationale":"NAFLD/NASH lipid therapy addressed disease lacking approved drugs at filing.","description_excerpt":"Non-alcoholic fatty liver disease (NAFLD), a major cause of liver dysfunction, is characterized by intrahepatic triacylglycerol (TAG) overaccumulation resulting from excess dietary lipids and de novo fatty acid synthesis. NAFLD is closely linked to insulin resistance and uncontrolled gluconeogenesis","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"nash","indication_free_text":"non-alcoholic fatty liver disease (NAFLD) closely linked to insulin resistance and obesity","mechanism_class":"protein therapeutic for hepatic lipid metabolism","modality":"other","objectID":"25310","rationale_one_line":"Protein therapeutics for NAFLD targeting intrahepatic triacylglycerol overaccumulation; NAFLD/NASH maps to the nash enum; modality is protein biologic but classified as other since it is disease-context protein rather than a mAb/peptide.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/25310","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Protein Therapeutics for Non-alcoholic Fatty Liver Disease (NAFLD)"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Rhomboid protease inhibitor antibiotic targets novel mechanism for drug-resistant bacterial and parasitic infections.","description_excerpt":"This invention describes a method for creating novel, inhibitors of desired bacterial rhomboid proteases (RhP), and applies this method to produce potent antibiotics.  The value proposition is very high providing a means of identifying and creating novel, specific bacterial Rhp inhibitors (antibioti","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"bacterial infections, malaria, and parasitic infections","mechanism_class":"bacterial rhomboid protease inhibitor antibiotic","modality":"small_molecule","objectID":"25123","rationale_one_line":"Inhibitors of bacterial rhomboid proteases as novel class of antibiotics; infectious disease/antibiotic indication is not in the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/25123","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"bacterial rhomboid proteases (RhP)","title":"Inhibitors of Bacterial Rhomboid Proteases, a New Class of Antibiotics"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Oral insulin addresses major adherence gap vs subcutaneous injection SoC.","description_excerpt":"Unmet Need:\r\nRepeated injections of insulin is the standard of care for treating Type 1 diabetes, and essential for control and management of Type 2 diabetes. Drawbacks of this treatment include poor patient compliance, discomfort, and an impaired lifestyle, and hypoglycemia. Oral administration of ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"Type 1 and Type 2 diabetes (insulin delivery)","mechanism_class":"oral insulin nanoparticle delivery","modality":"other","objectID":"24923","rationale_one_line":"Insulin-loaded nanoparticle platform for oral delivery to manage diabetes; mapped to type2_diabetes as the closest supported enum (description covers T1D/T2D); modality is a delivery platform, not a canonical therapeutic modality enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24923","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Insulin-Loaded Nanoparticle"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Novel fatty acid biologic for NASH where SoC is only recently established.","description_excerpt":"Unmet Need\r\nObesity is a leading preventable cause of death worldwide, and it is associated with a number of comorbidities, including Non-alcoholic Fatty Liver Disease (NAFLD).  Fatty liver is the accumulation of triglycerides and other fats in the liver cells.  The amount of fatty acid in the liver","dev_stage":"unknown","exclusivity_status":"unknown","indication":"nash","indication_free_text":"Non-alcoholic Fatty Liver Disease (NAFLD) / fatty liver disease","mechanism_class":"fatty acid metabolism regulator (protein/biologic)","modality":"other","objectID":"24901","rationale_one_line":"Biologic protein targeting fatty acid accumulation in the liver for NAFLD/NASH treatment; mapped to nash as the closest supported enum; modality is a protein biologic not fitting canonical enums cleanly.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24901","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Fatty Liver Disease Treatment"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Local antibiotic delivery improves on systemic SoC with poor implant-site penetration.","description_excerpt":"This invention describes biodegradable nanofiber-film composite that forms a conformal coating on medical devices for local, sustained release of multiple antibiotics following implantation. This composite coating comprises of one or more sets of biodegradable polymer fibers embedded in a biodegrada","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prevention of implant-associated infections (local antibiotic delivery)","mechanism_class":"biodegradable nanofiber-film composite antibiotic coating","modality":"other","objectID":"24868","rationale_one_line":"Medical device coating for local sustained antibiotic release post-implantation; drug delivery/device platform without a disease-specific therapeutic modality enum match.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24868","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"COMPOSITE POLYMER COATINGS ON MEDICAL IMPLANTS, AND THEIR USE FOR CODELIVERY OF MULTIPLE ANTIMICROBIAL AGENTS"},{"biomarker_overlap":"ATP7B mutation; copper accumulation","composite_score":0.4711460629132438,"cr_rationale":"Wilson's disease SoC is poorly tolerated; novel mechanism offers meaningful differentiation.","description_excerpt":"Wilson disease is a hepato-neurologic disorder caused by mutations in the gene ATP7B and accumulation of copper in tissues, predominantly in the liver.  The disease is lethal, unless treated. Current life-long treatment involves copper chelation or copper replacement using Zn. Both procedures allevi","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Wilson's disease (hepato-neurologic disorder from ATP7B mutation / copper accumulation)","mechanism_class":"liver nuclear receptor modulator","modality":"small_molecule","objectID":"24759","rationale_one_line":"Small molecule targeting liver nuclear receptors for Wilson's disease; rare genetic disease outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24759","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"liver nuclear receptors","title":"Targeting liver nuclear receptors as a treatment for Wilsons disease"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Selective autophagy inhibition improves on non-specific chloroquine derivatives in cancer.","description_excerpt":"There is an unmet need for selective and specific autophagy inhibitors in cancer research and cancer drug development. Many cancer types rely on autophagy, whereby the cell degrades unnecessary or damaged cellular components, to maintain homeostasis of the cell, particularly in the hypoxic environme","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (autophagy inhibition in tumor cells)","mechanism_class":"autophagy inhibitor","modality":"small_molecule","objectID":"24737","rationale_one_line":"Selective autophagy inhibitor small molecules targeting cancer cells relying on autophagy for homeostasis; broad oncology indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24737","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Inhibition of Autophagy in Cancer Lines"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Oxygen delivery overcomes ischemic barrier in chronic wounds lacking effective SoC.","description_excerpt":"Unmet Need\r\nTherapeutic gas delivery remains one of the greatest challenges in tissue engineering. Consequently many technologies and approaches have been developed but all lack\r\neffective ways to deliver sufficient therapeutic gas, such as oxygen, to targeted regions within deeper tissue. This inve","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"wound healing and tissue regeneration (therapeutic gas delivery)","mechanism_class":"therapeutic gas delivery microtank (oxygen)","modality":"other","objectID":"24728","rationale_one_line":"Medical device microtank system for therapeutic gas (oxygen) delivery to deeper tissue for regeneration; device platform without a canonical therapeutic modality enum match.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24728","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Therapeutic Gas Delivery Microtanks for Tissue Regeneration"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"No approved anti-scarring barrier at nerve/vessel repair; addresses real surgical gap.","description_excerpt":"This invention describes a novel semi-permeable nanofiber construct in the form of a wrap or sheath that can prevent inflammatory scarring at primary nerve or vessel repair site. The wrap/sheath consists of a nanofiber mesh with thickness ranging from 50 to 500 m and pore size of less than 10 m, and","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"inflammatory scarring at nerve or vessel repair site","mechanism_class":"nanofiber wrap/sheath anti-scarring barrier","modality":"other","objectID":"24689","rationale_one_line":"Semi-permeable nanofiber wrap to prevent inflammatory scarring at nerve/vessel repair; medical device without a supported indication or therapeutic modality enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24689","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Nanofiber wraps and sheaths to minimize inflammation and scarring"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Joint lubrication biomaterial for osteoarthritis with no approved disease-modifying SoC.","description_excerpt":"We introduce a transformational biomaterial approach to engineering lubrication at the tissue surface that can be applied in a single application.  Articular cartilage explants were modified with a synthetic peptide-polymer system designed to non-covalently bind HA to the tissue surface and work syn","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"articular cartilage lubrication / joint surface engineering","mechanism_class":"synthetic peptide-polymer hyaluronic acid binding system","modality":"other","objectID":"24688","rationale_one_line":"Biomaterial approach for engineering cartilage surface lubrication via HA-binding peptide-polymer; medical device/biomaterial without a supported indication or therapeutic modality enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24688","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Hyaluronic Acid Binding Polymer System Transforms Tissue and Biomaterial Surfaces"},{"biomarker_overlap":"estrogen receptor status","composite_score":0.4711460629132438,"cr_rationale":"Sulforaphane synergism adds chemoprotection beyond approved aromatase inhibitor SoC.","description_excerpt":"Estrogens control the growth and development of the majority of breast cancers, the most prevalent malignancies of women in the developed world. Exemestane, a synthetic steroid commonly used clinically to prevent, delay progression of, and treat breast cancer, was designed to inhibit estrogen biosyn","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"breast cancer (chemoprotective / treatment with exemestane and sulforaphane synergism)","mechanism_class":"aromatase inhibitor / chemoprotective agent (exemestane + sulforaphane synergism)","modality":"small_molecule","objectID":"24686","rationale_one_line":"Exemestane (aromatase inhibitor) with sulforaphane synergism for broad-spectrum chemoprotection in estrogen-driven breast cancer; directly maps to breast_cancer indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24686","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"aromatase (CYP19A1)","title":"Broad Spectrum Chemoprotective Activities of Exemstane Against Cancer and Other Chronic Diseases: Synergism with Sulforaphane"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"DNA repair inhibition addresses prostate cancer drug resistance with no approved agent.","description_excerpt":"Unmet Need: Targeted cancer therapies against DNA repair enzymes have successfully been implemented in cancer treatments but now suffer from the development of drug resistance. There is a need for additional DNA repair enzyme targets to overcome current resistance issues.\r\n \r\nTechnical Details: John","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer (DNA repair enzyme inhibition to overcome drug resistance)","mechanism_class":"DNA polymerase beta inhibitor","modality":"small_molecule","objectID":"24684","rationale_one_line":"Small molecule inhibitor of DNA polymerase beta as a novel cancer therapy for prostate cancer drug resistance; prostate cancer outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24684","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"POLB","title":"Inhibition of DNA Polymerase beta as a novel cancer therapy"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Bacterial nectar feed for vector control addresses malaria/dengue transmission with novel mechanism.","description_excerpt":"Unmet Need: Treatment and preventative measures against vector-borne diseases remain underdeveloped. With increasing resistance against drugs and insecticides, and a general lack of vaccines, there is an urgent need for disease transmission blocking strategies. \r\n \r\nTechnical Details: Johns Hopkins ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"vector-borne diseases including dengue fever and malaria; disease transmission blocking","mechanism_class":"insecticidal biological agent (Chromobacterium-based)","modality":"other","objectID":"24334","rationale_one_line":"Strategy uses a bacterial organism (Chromobacterium) as an insecticidal nectar feed to block mosquito transmission; this is a disease-control tool, not a therapeutic modality — indication and modality map to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24334","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Insecticidal Nectar Feed to Block Transmission of Mosquito-borne Diseases"},{"biomarker_overlap":"PSMA expression","composite_score":0.4711460629132438,"cr_rationale":"PSMA-targeted PDT offers focal therapy option beyond prostatectomy/radiation for prostate cancer.","description_excerpt":"Invention novelty: This invention is a novel drug composition that can target prostate tumors in vivo for use in photodynamic therapy (PDT).\r\nValue Proposition:\r\nCurrently, prostate cancer treatment often requires invasive surgery or treatment with drugs that may cause adverse side-effects. This cur","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer","mechanism_class":"PSMA-targeted photosensitizer for photodynamic therapy","modality":"small_molecule","objectID":"24283","rationale_one_line":"Drug composition targets 'prostate tumors in vivo for use in photodynamic therapy' via PSMA targeting; small molecule photosensitizer for prostate cancer, which is outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24283","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"FOLH1 (PSMA)","title":"Prostate-specific Membrane Antigen-targeted Photosensitizers for Photodynamic Therapy"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"NDGA+sorafenib combination for HCC may improve on sorafenib monotherapy with limited SoC options.","description_excerpt":"INVENTION NOVELTY\r\n\r\nJHU investigators have combined the NDGA derivatives M4N and sorafenib to create a pharmaceutical composition that inhibits cancer cell growth. This novel drug combination has increased cytotoxic activity and inhibits growth of HCC human cancer cells in a dose-dependent manner.\r","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"hepatocellular carcinoma (HCC) / liver cancer","mechanism_class":"NDGA derivative + sorafenib combination","modality":"small_molecule","objectID":"24254","rationale_one_line":"Combination of NDGA derivative M4N and sorafenib 'inhibits growth of HCC human cancer cells'; small molecule combination for hepatocellular carcinoma, outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24254","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Compositions Comprising NDGA Derivatives and Sorafenib and their Use in the Treatment of Cancer"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"DNA repair gene siRNA radiation sensitizer may improve prostate cancer local control beyond standard RT.","description_excerpt":"Invention novelty: A new mechanism to selectively sensitize the prostate to radiation therapy by knocking down DNA repair gene transcripts.\r\n\r\n - Value Proposition: Current dose-escalated radiation therapy for localized prostate cancer treatment has increased the risk of injury of surrounding non-ca","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer; radiation sensitization via DNA repair gene knockdown","mechanism_class":"siRNA / gene knockdown radiation sensitizer","modality":"nucleic_acid","objectID":"24231","rationale_one_line":"Mechanism is 'knocking down DNA repair gene transcripts' to selectively sensitize prostate to radiation; nucleic acid (siRNA) modality for prostate cancer, outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24231","subscores":{"clinical_relevance":0.6,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"DNA repair genes (unspecified)","title":"Radiation Sensitization Agents for Prostate Cancer"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Pol-beta inhibitor sensitizes melanoma/GBM to TMZ; meaningful improvement on chemotherapy resistance.","description_excerpt":"INVENTION NOVELTY\r\nJohns Hopkins researchers have developed multiple unique inhibitors to DNA polymerase beta, a potential anti-cancer therapeutic target. \r\n \r\nVALUE PROPOSITION\r\nThe DNA damaging agent temozolomide (TMZ) is used to treat melanoma and glioblastoma. TMZ damages cancer cell DNA by intr","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"melanoma","indication_free_text":"melanoma and glioblastoma; DNA polymerase beta inhibition as anti-cancer strategy","mechanism_class":"DNA polymerase beta inhibitor","modality":"small_molecule","objectID":"23852","rationale_one_line":"Inhibitors to DNA polymerase beta enhance TMZ efficacy; description explicitly names melanoma and glioblastoma as targets — melanoma is an enumerated indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/23852","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"POLB (DNA polymerase beta)","title":"DNA Polymerase Beta Inhibitors"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Novel low-dose HCMV inhibitor addresses resistant CMV infection in immunocompromised patients.","description_excerpt":"UNMET NEED: Infection with human cytomegalovirus (HCMV) continues to be a major threat for pregnant women and immunocompromised hosts. Although anti-HCMV therapies are available, development of new agents are desired because of the limited drugs approved for HCMV, the side effects associated with th","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"human cytomegalovirus (HCMV) infection","mechanism_class":"HCMV replication inhibitor","modality":"small_molecule","objectID":"23800","rationale_one_line":"Novel low-dose inhibitor of human cytomegalovirus (HCMV) replication; small molecule antiviral for an infectious disease outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/23800","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Low Dose Human Cytomegalovirus Inhibitor"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"ACVR2B/Fc fusion blocks myostatin for muscle wasting; unmet need but no direct SoC comparison data.","description_excerpt":"Invention Novelty: This technology identifies the use of soluble receptor (ACVR2B/Fc) to block the activities of members of the TGF-beta superfamily of signaling molecules.\r\n \r\nValue Proposition:\r\nMyostatin is a member of the TGF-&beta; family; it suppresses muscle growth and its absence stimulates ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"musculoskeletal disease; muscle wasting; myostatin inhibition","mechanism_class":"soluble receptor decoy (ACVR2B/Fc fusion)","modality":"other","objectID":"23370","rationale_one_line":"Soluble ACVR2B/Fc blocks TGF-beta superfamily members including myostatin to stimulate muscle growth; biologic fusion protein for musculoskeletal disease, not matching any enumerated indication — modality is a fusion protein closest to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/23370","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"ACVR2B (activin type IIB receptor); myostatin (MSTN)","title":"Soluble Form of Activin Type IIB Receptor (ACVR2B/Fc)"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Arsenic-based Hh/Smo inhibitor for AML addresses resistance pathway in hematologic malignancy.","description_excerpt":"INVENTION NOVELTY\r\nJohns Hopkins researchers have developed a novel Hedgehog signaling pathway inhibitor that can be used in the treatment of various types of leukemia.\r\n \r\nVALUE PROPOSITION\r\nThe Hedgehog (Hh) pathway has been found to be important in a number of cancers. Various Hh inhibitors, spec","dev_stage":"unknown","exclusivity_status":"unknown","indication":"aml","indication_free_text":"hematopoietic malignancies including leukemia; proliferative disorders","mechanism_class":"Hedgehog pathway / Smo inhibitor (arsenic-based)","modality":"small_molecule","objectID":"23282","rationale_one_line":"Arsenic compounds for 'Hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies'; Hh/Smo inhibitor small molecule targeting leukemia — AML is the closest enumerated indication for hematopoietic malignancies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/23282","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SMO (Smoothened)","title":"Arsenic compounds for Hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Preconditioned BMSC therapy for enteric nerve injury addresses GI neurodegeneration with no approved SoC.","description_excerpt":"UNMET NEED\r\nInjury or neurodegenerative disorders of the enteric nervous system (ENS) cause gastrointestinal dysfunctions for which there is no effective therapy, therefore new and effective treatments are urgently needed. Researchers from Johns Hopkins and Hospital of Tongji Medical College develop","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"enteric nervous system injury and neurodegenerative disorders; gastrointestinal dysfunction","mechanism_class":"preconditioned bone marrow-derived stromal cell (BMSC) therapy","modality":"other","objectID":"22362","rationale_one_line":"Preconditioned BMSCs promote 'de novo nerve regeneration' for enteric nerve injury; a cell therapy for GI/neurological disease outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/22362","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Preconditioned BMSC Promote de novo Nerve Regeneration: Potential application in therapy of enteric nerve injury/disorders and vascularized composite allotransplantation (VCA)"},{"biomarker_overlap":"YAP activity in Tregs","composite_score":0.4711460629132438,"cr_rationale":"YAP inhibition combined with immunomodulation addresses Treg-mediated resistance in solid tumors.","description_excerpt":"TITLE:              INHIBITION OF YAP FOR BREAKING TUMOR IMMUNE TOLERANCE\r\n \r\nCASE NUMBER:       C13353\r\n \r\nUNMET NEED\r\nRegulatory T cells (Tregs) play critical roles in maintaining self-tolerance and homeostasis  by suppressing the activation and function of other immune cells. At the same time,  t","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (broad); tumor immune tolerance via YAP inhibition in regulatory T cells","mechanism_class":"YAP inhibitor combined with immunomodulation","modality":"other","objectID":"21767","rationale_one_line":"Inhibition of YAP activity 'in Combination with Immunomodulation' to alter Treg-mediated immune regulation for cancer; target-based approach without a specific enumerated indication — modality maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/21767","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"YAP1","title":"Targeting YAP Activity in Combination with Immunomodulation to Alter Regulatory T Cell-mediated Immune Regulation in order to Treat Cancer"},{"biomarker_overlap":"AIM gene expression panel; DNA methylation","composite_score":0.4711460629132438,"cr_rationale":"Low-dose 5-azacitidine immune reprogramming in epithelial cancers extends azacitidine beyond hematology.","description_excerpt":"Improved Treatment Prognosis For Cancers\r\nJHU REF: C12842\r\n \r\nInvention Novelty:\r\nThis technology offers a prognostic panel derived from the gene expression of several different cancers, which was validated in multiple primary human samples. The panel, termed &quot;AIM&quot;, differentiates patients","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"common human epithelial cancers; epigenetic immunomodulation","mechanism_class":"DNMT inhibitor (low dose 5-azacitidine) for immune regulation","modality":"small_molecule","objectID":"20843","rationale_one_line":"Low-dose 5-azacitidine for 'immune regulation' in 'common human epithelial cancers'; small molecule DNMT inhibitor for broad epithelial oncology — no single enumerated indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/20843","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"DNMT (DNA methyltransferase)","title":"Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Epigenetic priming to sensitize tumors to PARP inhibitors addresses PARP-resistance gap across multiple cancers.","description_excerpt":"Combinatorial Drug Therapy for Cancers\r\nJHU REF: [C12345]\r\n \r\nInvention novelty: a combinatorial drug therapy for leukemia, ovarian, breast and lung cancers by targeting both epigenetic and DNA repair pathways.\r\n \r\nValue Proposition\r\nConventional forms of cancer drug therapy are limited in their res","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"leukemia, ovarian, breast and lung cancers","mechanism_class":"DNMT inhibitor + HDAC inhibitor + PARP inhibitor combination","modality":"small_molecule","objectID":"20428","rationale_one_line":"Combinatorial epigenetic (DNA demethylating + HDAC inhibitor) therapy to sensitize multiple cancers to PARP inhibitors; spans leukemia, ovarian, breast, and lung so maps to other; small_molecule modality per taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/20428","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"DNMT, HDAC, PARP","title":"Reprograming the Cancer Cells with Epigenetic Therapy (DNA Demethylating Agents and Histone Deacetylase Inhibitors) Sensitizes Multiple Cancers to PARP Inhibitors"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Artemisinin dimers offer mechanistically distinct CMV activity vs ganciclovir-resistant cases with limited alternatives.","description_excerpt":"UNMET NEED: Infection with cytomegalovirus (CMV) is common in humans and is usually asymptomatic; yet, in immunocompromised hosts, such as transplant recipients and patients with AIDS, CMV infection is associated with significant morbidity and mortality. Cytomegalovirus infection also is the most co","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cytomegalovirus (CMV) infection","mechanism_class":"artemisinin dimer antimicrobial","modality":"small_molecule","objectID":"18742","rationale_one_line":"Artemisinin dimers as small molecule anti-CMV agents for immunocompromised patients; CMV is an infectious disease outside the supported enum, maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/18742","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Artemisinin dimers as potent anti-cytomegalovirus (CMV) agents"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Cardiac glycoside analogs for HCMV; ganciclovir resistance in transplant settings represents unmet clinical need.","description_excerpt":"Novelty: Novel group of cardiac glycosides shown to have effective anti-HCMV properties for HCMV infection treatment.\r\n \r\nValue Proposition: HCMV infection is a serious problem in organ transplant patients and congenitally-infected babies. The currently available systemic therapies for HCMV targetin","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"human cytomegalovirus (HCMV) infection","mechanism_class":"cardiac glycoside analog antiviral","modality":"small_molecule","objectID":"17246","rationale_one_line":"Novel cardiac glycoside analogs with anti-HCMV activity for transplant and congenital HCMV infections; CMV is an infectious disease outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17246","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Cardiac Glycoside Analogs as Anti-Human Cytomegalovirus (HCMV) Agents"},{"biomarker_overlap":"three protein biomarkers highly expressed in pancreatic cancer vs. normal pancreatic cells","composite_score":0.4711460629132438,"cr_rationale":"PDAC biomarker panel addresses early detection, but is diagnostic, not therapeutic.","description_excerpt":"C12251: Diagnostic Protein Biomarkers For Pancreatic Cancer\r\n\r\nNovelty: \r\n\r\nThis technology comprises the identification of three protein biomarkers, highly expressed in pancreatic cancer compared to normal pancreatic cells.\r\nValue Proposition: \r\nPancreatic ductal adenocarcinoma is the fourth leadin","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"pancreatic ductal adenocarcinoma (pancreatic cancer)","mechanism_class":"protein biomarker panel (diagnostic)","modality":"other","objectID":"17207","rationale_one_line":"Three diagnostic protein biomarkers and therapeutic targets for pancreatic ductal adenocarcinoma — primarily diagnostic; pancreatic cancer outside enum; no defined drug modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17207","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Discovery of Diagnostic Biomarkers and Therapeutic Targets for Pancreatic Cancer"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Wnt pathway modulation for HCMV offers new mechanism vs ganciclovir; resistance setting has limited options.","description_excerpt":"Novelty: A novel therapeutic strategy for HCMV infection by modulation of the Wnt signaling pathway.\r\n \r\nValue Proposition: HMCV infection is a serious threat for pregnant women and the immunocompromised, such as HIV/AIDS patients or solid organ transplant recipients. Currently, the main HCMV treatm","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"human cytomegalovirus (HCMV) infection","mechanism_class":"Wnt signaling pathway modulator (antiviral)","modality":"small_molecule","objectID":"17204","rationale_one_line":"Novel therapeutic strategy for HCMV by modulating the Wnt signaling pathway; infectious disease outside supported enum, small_molecule per taxonomy classification.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17204","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"Wnt signaling pathway","title":"Novel Therapeutic Strategy for Human Cytomegalovirus (HCMV) Infection"},{"biomarker_overlap":"GAPDH nitrosylation","composite_score":0.4711460629132438,"cr_rationale":"GAPDH nitrosylation inhibition for cocaine addiction; no approved pharmacotherapy for cocaine use disorder exists.","description_excerpt":"C12097: Novel Treatment for Cocaine Drug Abuse\r\nNovelty: \r\nA novel therapeutic strategy for cocaine abuse using known compounds.\r\nValue Proposition: \r\nCocaine is a powerful addictive stimulant that causes psychological dependence and brain damage. Currently there are no FDA-approved drug for cocaine","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cocaine drug abuse / addiction","mechanism_class":"GAPDH nitrosylation inhibitor","modality":"small_molecule","objectID":"17172","rationale_one_line":"Known compounds repurposed to prevent GAPDH nitrosylation as a therapeutic strategy for cocaine abuse — addiction/psychiatry indication outside supported enum; small_molecule per taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17172","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GAPDH","title":"Treatment of Drug Abuse by Preventing GAPDH Nitrosylation"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Epigenetic priming for immune checkpoint sensitization; addresses primary resistance to checkpoint inhibitors.","description_excerpt":"In addition to the conventional forms of cancer therapy (chemotherapy, surgery, radiation), newer forms of therapy, including epigenetic modulation with DNA demethylating agents and HDAC inhibitors and therapies targeted at the immune system, are being investigated. We have discovered that epigeneti","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"advanced cancer (epigenetic modulation combined with immunotherapy)","mechanism_class":"DNMT inhibitor + HDAC inhibitor + immune checkpoint combination","modality":"small_molecule","objectID":"17112","rationale_one_line":"Epigenetic modulation (DNA demethylating agents + HDAC inhibitors) alters tumor gene expression to sensitize tumors to immune therapy — broad oncology, maps to other; small_molecule per primary modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17112","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"DNMT, HDAC","title":"Novel Combination Therapy for Advanced Cancer"},{"biomarker_overlap":"circulating free fatty acid levels","composite_score":0.4711460629132438,"cr_rationale":"Myonectin reduces circulating FFAs; novel mechanism vs metformin/GLP-1 SoC for type-2 diabetes and obesity.","description_excerpt":"Novelty: \n\n\r\n \n\n\r\nThis technology identifies a novel myonectin protein, which links skeletal muscle to metabolic regulation. Myonectin was found to lower circulating free fatty acid levels by promoting lipid uptake.\n\n\r\nValue Proposition: \n\n\r\nType-2 diabetes, obesity, and metabolic syndrome are disea","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"type-2 diabetes and obesity (myonectin protein therapeutic)","mechanism_class":"myokine / secreted protein (lipid metabolism regulator)","modality":"other","objectID":"17075","rationale_one_line":"Novel myonectin protein linking skeletal muscle to metabolic regulation lowers circulating free fatty acids — type-2 diabetes and obesity match the supported type2_diabetes enum; protein therapeutic modality closest to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17075","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"Myonectin","title":"Novel Protein Therapeutic for Diabetes and Obesity"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Selective chymase inhibitor for atherosclerosis targets a mechanism not addressed by statin or antihypertensive SoC.","description_excerpt":"C11636: Novel Chymase Inhibitors for Treatment of Atherosclerosis\r\n\r\nNovelty: \r\n\r\nThis technology comprises of a series of compounds based on a novel scaffold allowing for selective inhibition of chymase, an enzyme implicated in the development of atheroscleriosis.\r\nValue Proposition: \r\nActivation o","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"atherosclerosis / cardiovascular disease","mechanism_class":"chymase serine protease inhibitor","modality":"small_molecule","objectID":"17007","rationale_one_line":"Selective chymase inhibitors for atherosclerosis via blockade of a serine protease implicated in plaque development — cardiovascular indication outside supported enum; small_molecule per taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17007","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"chymase","title":"High Affinity Chymase Inhibitors"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Combination immune-physical intervention to reverse tumor immunosuppression; addresses primary checkpoint resistance.","description_excerpt":"Novelty: \r\nThis invention is a novel means of augmenting immune-based cancer therapies by using a physical intervention to counter a tumor's natural immunosuppressive effect.\r\nValue Proposition: \r\nThis therapeutic strategy combines two accepted approaches to cancer management - immune-based and phys","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (augmenting immunotherapy via physical intervention)","mechanism_class":"combination immune + physical anti-tumor adjuvant","modality":"other","objectID":"16991","rationale_one_line":"Combines immune-based and physical interventions to counter tumor immunosuppression — broad cancer indication outside single supported enum; hybrid device+immunotherapy modality maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16991","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"C11601: Novel Adjuvant Based Approach to Enhance Cancer Immunotherapy"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"SGK-1 inhibition for autoimmune diseases; mechanistically distinct from current DMARDs/biologics, limited SoC overlap.","description_excerpt":"C11550: Novel Target for Treatment of Autoimmune Diseases\r\n\r\nNovelty: \r\n\r\nInhibition of this novel target has the potential to treat autoimmune diseases, as well as enhancing immunity against pathogen infections and tumor formation.\r\nValue Proposition: \r\nCurrently, most immunosuppressive therapies n","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"autoimmune diseases / immunity against pathogens and tumors","mechanism_class":"SGK-1 inhibitor (immunomodulator)","modality":"other","objectID":"16977","rationale_one_line":"SGK-1 inhibition described as a novel means to treat autoimmune diseases and enhance anti-pathogen/anti-tumor immunity — autoimmune broad indication not matching specific enum; modality is target-based immunomodulation, maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16977","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"SGK-1","title":"Inhibition of SGK-1 as a Novel Means to Treat Autoimmune Disease and Enhance Anti-pathogen and Anti-tumor Immunity"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Recombinant BChE countermeasure addresses life-threatening nerve agent exposure with no effective SoC.","description_excerpt":"C11380: Novel Biological Countermeasure Against Toxic Nerve Agents\r\n\r\nNovelty: \r\n\r\nThe technology comprises a novel recombinant butyrlcholinesterase (BChE) protein that is long lived and has the same properties as those of plasma derived natural BChE protein.\r\nValue Proposition: \r\nCurrently, the sho","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"toxic nerve agent exposure (countermeasure)","mechanism_class":"recombinant bioscavenger (BChE)","modality":"other","objectID":"16915","rationale_one_line":"Description describes 'a novel recombinant butyrlcholinesterase (BChE) protein' as a biological countermeasure against nerve agents; not a disease therapeutic — maps to other/other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16915","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"BChE","title":"Engineering post-translational processing for native-like BChE production in CHO cells"},{"biomarker_overlap":"diagnostic biomarkers for cognitive impairment (MS)","composite_score":0.4711460629132438,"cr_rationale":"First-in-class CNS immunomodulator for MS cognitive impairment; unmet need with no approved SoC.","description_excerpt":"Novelty:\r\nThis technology is a first of its kind, potential therapeutic in alleviating cognitive impairment (CI) as a result of Multiple Sclerosis (MS) and related central nervous system (CNS) autoimmune diseases.\r\n\r\nValue Proposition:\r\nCI is a debilitating outcome of many CNS disorders, including M","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cognitive impairment from Multiple Sclerosis (MS) and related CNS autoimmune diseases","mechanism_class":"CNS immunomodulator","modality":"small_molecule","objectID":"16905","rationale_one_line":"Described as 'a first of its kind, potential therapeutic in alleviating cognitive impairment (CI) as a result of Multiple Sclerosis'; small molecule category confirmed by taxonomy; MS is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16905","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"C11355: Therapeutic Alleviating Cognitive Impairment from Multiple Sclerosis (MS)"},{"biomarker_overlap":"GAPDH as biomarker for cell death in neurodegeneration","composite_score":0.4711460629132438,"cr_rationale":"GAPDH-Siah inhibitor targets neurodegeneration cell death; multiple unmet-need indications but preclinical only.","description_excerpt":"Value Proposition - Targeted therapy:  Small molecule compound that inhibits the GAPDH-Siah cell cascade to prevent cell death in degenerative diseases  - Broad Application: Effective across stress-mediated conditions, including Alzheimer’s, Parkinson’s, stroke, heart disease, and psychiatric disord","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurodegenerative and stress-mediated diseases including Alzheimer's, Parkinson's, stroke, heart disease, and schizophrenia","mechanism_class":"GAPDH-Siah cell death cascade inhibitor","modality":"small_molecule","objectID":"16836","rationale_one_line":"'Small molecule compound that inhibits the GAPDH-Siah cell cascade to prevent cell death in degenerative diseases'; Alzheimer's and other neurological indications fall outside the supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16836","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GAPDH","title":"Novel Compounds targeting GAPDH-Siah Cell Death Cascade"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Microenvironment-informed combo kinase inhibitor for HCC addresses sorafenib resistance, a clear SoC gap.","description_excerpt":"Unmet Need\r\nSorafenib, a kinase inhibitor, has been the gold-standard treatment for most individuals with hepatocellular carcinoma (HCC); however, studies suggest survival after treatment remains less than 15% (Raoul et al. 2019). Additionally, side effects, including hand-foot skin reactions and di","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"hepatocellular carcinoma (HCC)","mechanism_class":"microenvironment-informed combinatorial kinase inhibitor therapy","modality":"small_molecule","objectID":"16786","rationale_one_line":"Described as 'microenvironment-informed combinatorial therapy for hepatocellular carcinoma' addressing limitations of sorafenib; HCC is outside the supported indication enum; small molecule category inferred from kinase inhibitor context.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16786","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Microenvironment-informed combinatorial therapy for hepatocellular carcinoma"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"MetAP inhibitor targets TB, a high-burden disease with drug-resistant strains exceeding current SoC.","description_excerpt":"C10796: Novel Antimycobacterial Targets\r\n Value Proposition: &bull; Promising target for the development of new antibiotics. &bull; Compounds that inhibit the growth of mycobacteria in culture. &bull; Plasmids containing MetAP genes can be used to generate protein for anti-tuberculosis drug screenin","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"tuberculosis (antimycobacterial targets for drug development)","mechanism_class":"methionine aminopeptidase (MetAP) inhibitor","modality":"small_molecule","objectID":"16766","rationale_one_line":"Described as identifying 'methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targets'; small molecule inhibitor modality; tuberculosis is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16766","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"MetAP","title":"Methionine Aminopeptidases from Mycobacterium Tuberculosis as Novel Antimycobacterial Targets:  I. Cloning, Over-expression, and Purification of Methionine Aminopeptidases from Mycobacterium Tuberculosis.  II. Discovery of Inhibitors of M. Tuberculos"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"nAChRa7 modulator for UC/CD targets novel pathway; meaningful differentiation from anti-TNF/biologic SoC.","description_excerpt":"C10382: Breakthrough Therapeutic for Inflammatory Bowel Diseases (IBD)\r\nNovelty: \r\nThis technology identifies a nicotinic acetylcholine receptor isoform (nAChR7) that has a prevalent role in affecting Inflammatory Bowel Disease (IBD), as well as several agonist/antagonists to nAChR7, that are highly","dev_stage":"unknown","exclusivity_status":"unknown","indication":"ulcerative_colitis","indication_free_text":"ulcerative colitis (UC) and Crohn's disease (CD) — inflammatory bowel disease","mechanism_class":"nAChRa7 agonist/antagonist","modality":"small_molecule","objectID":"16649","rationale_one_line":"Explicitly states 'highly effective drugs in therapy of Ulcerative Colitis (UC) and Crohn's Disease (CD)' via nAChRa7 modulation; ulcerative_colitis is the primary supported indication; small molecule modality confirmed.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16649","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"nAChRa7","title":"PNU-120596 and 3-(2,4-dimethoxybenzylidene) Anabaseine (GTS-21) (both nAchRa7 agonists) and Methyllycaconitine (anAchRa7 antagonist), are Highly Effective Drugs in Therapy of Ulcerative Colitis (UC) and Crohn's Disease (CD)"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Decoy LTbetaR for GVHD and autoimmunity addresses transplant-related unmet need beyond calcineurin inhibitor SoC.","description_excerpt":"Technical Details:\r\n\t\t\tDecoy lymphotoxin beta receptor (LT? has potent immune inhibitory activities, and thus represents a promising biologic for the treatment of inflammation, autoimmune diseases and graft-versus-host disease (GVHD). As this reagent interrupts multiple molecular interactions, inclu","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"transplant rejection / graft-versus-host disease (GVHD) and autoimmune diseases","mechanism_class":"decoy lymphotoxin beta receptor (LTbetaR) immune inhibitor","modality":"other","objectID":"16498","rationale_one_line":"Described as 'decoy lymphotoxin beta receptor (LTbetaR)...for the treatment of inflammation, autoimmune diseases and graft-versus-host disease'; biologic decoy receptor modality maps to 'other'; GVHD/transplantation is outside the supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16498","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HVEM / LTbetaR","title":"Inhibition of Transplantation Rejection By Suppressing HVEM"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Neurodegeneration lacks disease-modifying SoC; neuroprotective agents address major unmet need.","description_excerpt":"Invention novelty: A series of compounds from the limonoid family that can be used in protecting neurons from different types of toxicity.  \r\n \r\nUnmet Need: Neurodegenerative diseases are characterized by extensive deterioration of neurons or glia. Because these cells are not easily regenerated, the","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurodegenerative diseases","mechanism_class":"neuroprotective agent (limonoid)","modality":"small_molecule","objectID":"16481","rationale_one_line":"Limonoid-family small molecules for neuroprotection in neurodegeneration; neurology indication is outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16481","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Limonoid Compounds as Neuroprotective Agents"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Restoring endocardial thromboresistance addresses recurrent thrombosis with limited SoC options.","description_excerpt":"C04927: Augmentation of Endocardial Thromboresistance\r\n   \r\n\r\nTechnical Details: \r\n\r\nA critical function of the endocardium is to maintain local thromboresistance by providing an anticoagulant surface. Thrombomodulin, is expressed on the surface of the endocardium endothelial cells and is the key co","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"endocardial thromboresistance / cardiovascular thrombosis","mechanism_class":"cell therapy / biologic (thrombomodulin expression)","modality":"other","objectID":"16454","rationale_one_line":"Cell/biologic therapy to restore thrombomodulin-mediated anticoagulant activity in endocardium; cardiovascular indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16454","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"thrombomodulin","title":"Augmentation of Endocardial Thromboresistance"},{"biomarker_overlap":"HIMF / FIZZ1 / RELM expression","composite_score":0.4711460629132438,"cr_rationale":"HIMF targeting in pulmonary hypertension addresses condition with limited and inadequate SoC.","description_excerpt":"C04858: HIMF and Related Proteins in Pulmonary, Cardiac and Inflammatory Disorders\r\n \r\nTechnical Details: \r\nHypoxia-Induced Mitogenic Factor (HIMF; also known as FIZZ1/RELM) a member of the resistin protein family, is a secreted protein that was found to be highly up regulated in the lungs as a resu","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"pulmonary hypertension, cardiac and inflammatory disorders","mechanism_class":"HIMF / FIZZ1 / RELM pathway modulator","modality":"other","objectID":"16436","rationale_one_line":"HIMF is a secreted protein biomarker and therapeutic target for hypoxia-induced pulmonary hypertension and cardiac/inflammatory disorders; indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16436","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HIMF","title":"HIMF and related proteins in pulmonary, cardiac and inflammatory disorders"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"NO bioactivity restoration in CHF targets residual mortality burden beyond standard ACE/beta-blocker regimens.","description_excerpt":"Technical Details: \r\nIn the US, CHF is the number one cause of hospitalization in people over age 65, and it affected approximately 5 million people in 2004. This translates into a potential cost of $29 billion for the healthcare system. In the US over half a million new cases are diagnosed with, an","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"congestive heart failure","mechanism_class":"reactive oxygen species enzyme inhibitor / NO bioactivity","modality":"small_molecule","objectID":"16388","rationale_one_line":"Small molecule inhibiting reactive oxygen-generating enzyme with nitric oxide bioactivity for congestive heart failure; cardiovascular indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16388","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Reactive Oxygen Generating Enzyme Inhibitor with Nitric Oxide Bioactivity and Uses Thereof"},{"biomarker_overlap":"STAT3 expression","composite_score":0.4711460629132438,"cr_rationale":"STAT3 inhibition in hematologic malignancies addresses resistance to standard chemotherapy regimens.","description_excerpt":"C04665: Targeting of Stat-3 Signaling in the Hematopoietic System Evokes Multicomponent Therapeutic Antitumor Immunity\r\n    \r\n   \r\n\r\nTechnical Details: \r\n\r\nThe immune system can act as an extrinsic suppressor of tumors. Therefore, tumor progression depends in part on mechanisms that down modulate in","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"hematological malignancies / oncology (Stat-3 targeting)","mechanism_class":"STAT3 inhibitor (gene therapy / immunotherapy combination)","modality":"other","objectID":"16386","rationale_one_line":"Targeting Stat-3 in the hematopoietic system to evoke anti-tumor immunity; spans gene therapy, immunotherapy, and small molecule approaches — broad oncology outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16386","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"STAT3","title":"Targeting of Stat-3 Signaling in the Hematopoietic System Evokes Multicomponent Therapeutic Antitumor Immunity"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"Siglec-8 agonism depletes eosinophils with potential superiority over broad corticosteroid SoC.","description_excerpt":"C04430: Novel Carbohydrate Based Therapeutic for Allergic, Asthmatic, and Other Inflammatory Disorders\r\n\r\nNovelty: \r\n\r\nA Sialic acid immunoglobulin-like lectin-8 (Siglec-8) carbohydrate based ligand has been identified which provides a platform for development of effective therapies for inflammation","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"allergic, asthmatic, and other inflammatory disorders","mechanism_class":"Siglec-8 carbohydrate ligand / eosinophil suppressor","modality":"small_molecule","objectID":"16336","rationale_one_line":"Sialic acid Siglec-8 carbohydrate-based ligand for allergic/asthmatic/inflammatory conditions driven by eosinophils, basophils and mast cells; indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16336","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"Siglec-8","title":"Identification of a Specific Ligand for Siglec-8"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"VP22-enhanced DNA vaccine potency may improve cervical cancer prevention beyond current HPV vaccines.","description_excerpt":"C03895: Enhancement of DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an Antigen\r\n \r\nTechnical Details: \r\nWe have previously employed an spreading strategy using herpes simplex virus type 1 (HSV-1) VP22 protein to enhance DNA vaccine potency because DNA vaccines lack the intrins","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cervical cancer / HPV","mechanism_class":"DNA vaccine (VP22 linkage for antigen spreading)","modality":"other","objectID":"16218","rationale_one_line":"DNA vaccine potency enhancement via Marek's Disease Virus VP22 antigen spreading for cervical cancer; vaccine modality and cervical cancer indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16218","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Enhancement of DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an Antigen"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"HSP70-linked suicidal DNA vaccine enhances immune response against HPV in cervical cancer prevention.","description_excerpt":"C03797: Enhancement of Suicidal DNA Vaccine Potency by Linkage Mycobacterium Tuberculosis Heat Shock Protein 70 to an Antigen\r\n    \r\n   \r\n\r\nTechnical Details: \r\n\r\nNaked DNA vaccines represent an attractive approach for generating antigen-specific immunity because of their stability and simplicity of","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cervical cancer / HPV","mechanism_class":"DNA vaccine (HSP70 linkage for immunopotentiation)","modality":"other","objectID":"16197","rationale_one_line":"Suicidal DNA vaccine linking M. tuberculosis HSP70 to antigen for enhanced immunity in cervical cancer; vaccine modality and cervical cancer indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16197","subscores":{"clinical_relevance":0.6,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Enhancement of Suicidal DNA Vaccine Potency by Linkage Mycobacterium Tuberculosis Heat Shock Protein 70 to an Antigen"},{"biomarker_overlap":null,"composite_score":0.4711460629132438,"cr_rationale":"HIV-1 integrase inhibitors are clinically validated class; early compounds show meaningful antiviral potency.","description_excerpt":"Technical Details: \r\nThis invention is related to isolation of two highly potent, non-toxic inhibitors against human immunodeficiency virus type 1 (HIV-1) integrase and viral replication. Two water soluble compounds, M522 and M532, have been discovered by isolating them from Salvia miltiorrhiza root","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"HIV-1 infection","mechanism_class":"HIV-1 integrase inhibitor","modality":"small_molecule","objectID":"16072","rationale_one_line":"Water-soluble compounds M522 and M532 are 'highly potent, non-toxic inhibitors against human immunodeficiency virus type 1 (HIV-1) integrase'; infectious disease outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16072","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HIV-1 integrase","title":"Antiviral Compositions and Methods of Use"},{"biomarker_overlap":"MDM2 expression; p53 status","composite_score":0.4681460629132438,"cr_rationale":"MDM2-p53 inhibition reactivates tumor suppression in breast cancer unresponsive to hormonal therapy.","description_excerpt":"Technical Details:  A class of anti-cancer agents such as chalcones has shown promising therapeutic efficacy for the management of human cancers. Recent studies have shown that anticancer agents such as chalcones induce apoptosis in variety of cell types, including breast cancers. Biochemical experi","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"breast cancer (MDM2-mediated cancers)","mechanism_class":"MDM2-p53 interaction inhibitor (chalcone/boronic chalcone)","modality":"small_molecule","objectID":"16321","rationale_one_line":"Boronic chalcones disrupt 'the MDM2/p53 interaction' and induce apoptosis in breast cancers among other cell types; breast cancer is explicitly named.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16321","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.49},"target":"MDM2","title":"Additional Boronic-Chalcones as Therapeutics for MDM2-mediated Cancers"},{"biomarker_overlap":null,"composite_score":0.4643988269794721,"cr_rationale":"Broad antibody engineering platform; no defined indication or differentiated clinical endpoint vs SoC.","description_excerpt":"Antibodies have exquisite specificity for their antigen.  Thus antibodies have great therapeutic potential in terms of selectively targeting receptors to either promote or inhibit receptor activity.  Likewise, antibodies can target infected or tumor cells by recognizing their antigen on the cell of ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"oncology / immunotherapy (cancer, broad)","mechanism_class":"antibody engineering platform","modality":"monoclonal_antibody","objectID":"20826","rationale_one_line":"Classified under Antibodies and Biologics in Oncology; describes novel methods to enhance antibody-based immune responses but names no specific indication, target, or biomarker — mapped to other/mAb.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/20826","subscores":{"clinical_relevance":0.4,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":null,"title":"NOVEL METHODS TO ENHANCE IMMUNE RESPONSES TO IMMUNOTHERAPY"},{"biomarker_overlap":"O-GlcNAc protein modification","composite_score":0.4643988269794721,"cr_rationale":"O-GlcNAc mAb primarily a research tool; clinical differentiation from insulin/GLP-1 SoC for diabetes unclear.","description_excerpt":"Technical Details:\r\n\t\t\tO-linked N-acetylglucosamine (O-GlcNAc) is a newly described but ubiquitous dynamic modification of key regulatory proteins in side virtually all multi-cellular eukaryotic cells. Recently, this sugar modification has been shown to be as abundant as protein phosphorylation, oft","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"diabetes, cancer, neurology (O-GlcNAc modification research tool and therapeutic)","mechanism_class":"O-GlcNAc monoclonal antibody (CTD110.6)","modality":"monoclonal_antibody","objectID":"18720","rationale_one_line":"CTD110.6 mAb targets O-GlcNAc modification across diabetes, cancer, and neurology; diabetes is the highest-confidence supported indication match given the metabolic disease classification.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/18720","subscores":{"clinical_relevance":0.4,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"O-GlcNAc (O-linked N-acetylglucosamine)","title":"CTD110.6 monoclonal antibody"},{"biomarker_overlap":null,"composite_score":0.463981894683157,"cr_rationale":"Dual oncolytic/anti-angiogenic peptide offers combined mechanism but broad oncology positioning limits differentiation.","description_excerpt":"Value Proposition - High cancer cell specificity by cell surface characteristics. - High water solubility. - Combination of oncolytic and anti-angiogenic properties.\r\nUnmet Need\r\nThere currently are no peptides reported to have both oncolytic and anti-angiogenic activities. Additionally, drug develo","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer broadly; oncolytic and anti-angiogenic activity targeting cancer cells","mechanism_class":"oncolytic and anti-angiogenic peptide","modality":"peptide","objectID":"53507","rationale_one_line":"Source describes soluble peptides that induce immunogenic cancer cell death with combined oncolytic and anti-angiogenic properties; taxonomy confirms Peptides; broad oncology maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53507","subscores":{"clinical_relevance":0.55,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Soluble peptides that induce immunogenic cancer cell death"},{"biomarker_overlap":null,"composite_score":0.463981894683157,"cr_rationale":"Microbiome AMP offers IBS pain mechanism beyond symptomatic SoC.","description_excerpt":"Value Proposition:\r\n·        A synthetic antimicrobial peptide (AMP) that may be a potent therapeutic for irritable bowel syndrome (IBS) pain.\r\n·        This AMP limits the growth of harmful bacteria, while not interfering with beneficial ones.\r\n·        This AMP can be delivered directly to the col","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Irritable bowel syndrome (IBS) pain; antimicrobial peptide targeting gut bacteria delivered to the colon","mechanism_class":"antimicrobial peptide (AMP) for gut microbiome modulation","modality":"peptide","objectID":"53003","rationale_one_line":"Source describes a synthetic antimicrobial peptide (AMP) that may be a potent therapeutic for irritable bowel syndrome (IBS) pain; taxonomy confirms Peptides; IBS is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53003","subscores":{"clinical_relevance":0.55,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Method of Treatment of Irritable Bowel Syndrome (KSL-W)"},{"biomarker_overlap":null,"composite_score":0.4511460629132439,"cr_rationale":"Itraconazole analog offers dual activity but faces approved targeted-agent competition.","description_excerpt":"Value Proposition\r\n·      Itraconazole is in clinical trials for cancer treatment as it is known to have antiangiogenic activity and anti-Hedgehog pathway activity, but its use has been limited by its potent inhibition of the drug metabolizing enzyme CYP3A4\r\n·      The designed analog for itraconazo","dev_stage":"phase_1","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer (anti-angiogenic) and macular degeneration","mechanism_class":"Hedgehog pathway inhibitor / anti-angiogenic (itraconazole analog)","modality":"small_molecule","objectID":"59224","rationale_one_line":"Itraconazole analog with antiangiogenic and anti-Hedgehog activity; 'in clinical trials for cancer treatment' noted in description; small molecule; no specific supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59224","subscores":{"clinical_relevance":0.55,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Anti-Fungal Drug Analogs to Treat Cancer by Preventing Angiogenesis and Hedgehog Pathway Activity"},{"biomarker_overlap":null,"composite_score":0.4511460629132439,"cr_rationale":"Broad neuroprotective small molecule across multiple diseases; lacks disease-specific differentiation vs. symptomatic SoC.","description_excerpt":"Unmet Need\r\nAn estimated 930K people in the US are living with a neurodegenerative disease (Alzheimer’s and Parkinson’s are most common). However, current standard of care treatments mostly addresses symptoms of these diseases. To date no disease modifying or neuroprotective treatments are approved ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, ALS, HIV-associated neurocognitive disorders, and multiple sclerosis","mechanism_class":"neuroprotective small molecule","modality":"small_molecule","objectID":"53436","rationale_one_line":"Taxonomy confirms Small Molecules for neurodegenerative disease treatment; indication spans multiple neurological diseases outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53436","subscores":{"clinical_relevance":0.55,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Methods to Treat Neurodegenerative Diseases"},{"biomarker_overlap":null,"composite_score":0.4511460629132439,"cr_rationale":"Hypothalamic neurogenesis via tanycytes is mechanistically novel but clinical unmet need is not well-defined.","description_excerpt":"Value Proposition\r\n·        Identifies targets for modulation of tanycyte-derived neurogenesis.\r\n·        Demonstrates efficacy of small molecule induction of tanycyte-derived neurogenesis.\r\n·        Combines viral constructs and small molecules to generate specific subtypes of tanycyte-derived neur","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Hypothalamic disorders; homeostatic regulatory dysfunction requiring tanycyte-derived neurogenesis","mechanism_class":"tanycyte neurogenesis induction via small molecule and viral constructs","modality":"other","objectID":"53419","rationale_one_line":"Source combines viral constructs and small molecules for hypothalamic tanycyte neurogenesis; mixed platform does not fit one modality enum cleanly; hypothalamic indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53419","subscores":{"clinical_relevance":0.55,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Controlling homeostatic regulatory circuitry in hypothalamus"},{"biomarker_overlap":null,"composite_score":0.4511460629132439,"cr_rationale":"Novel mitochondrial receptor modulator for hypertension; crowded SoC space reduces differentiation potential.","description_excerpt":"Unmet Need\r\nAccording to WHO, over one billion people worldwide are living with elevated blood pressure which may lead to a range of adverse health conditions that cause ~1,100 deaths per day. Many current high blood pressure therapies focus on angiotensin receptor blocking drugs. Unfortunately, adv","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Hypertension and associated cardiovascular conditions; targeting a novel mitochondrial anti-inflammatory receptor","mechanism_class":"mitochondrial anti-inflammatory receptor modulator","modality":"small_molecule","objectID":"53258","rationale_one_line":"Taxonomy confirms Small Molecules; title references selective targeting of a mitochondrial protective receptor for hypertension; cardiovascular indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53258","subscores":{"clinical_relevance":0.55,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Selective Targeting of a Novel Protective Anti-inflammatory Receptor in Human Mitochondria and its Role in Preserving Mitochondrial Functions"},{"biomarker_overlap":null,"composite_score":0.4511460629132439,"cr_rationale":"Novel glycolipid inhibitor for atherosclerosis enters crowded statin/PCSK9 SoC space with unproven differentiation.","description_excerpt":"INVENTION NOVELTY\r\nA novel glycolipid inhibitor anti-atherosclerosis drug compound able to enhance\r\ngastro-intestinal absorption and residence time to reduce and ameliorate\r\neffects of arteriosclerosis \r\nVALUE PROPOSITION\r\nDespite great success of statins (cholesterol reducing agents), little is kno","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Atherosclerosis and cardiovascular disease; glycolipid inhibitor to reduce arteriosclerosis effects","mechanism_class":"glycolipid inhibitor for atherosclerosis","modality":"small_molecule","objectID":"52386","rationale_one_line":"Source describes a novel glycolipid inhibitor anti-atherosclerosis drug compound; taxonomy confirms Small Molecules; cardiovascular/atherosclerosis indication is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52386","subscores":{"clinical_relevance":0.55,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Glycolipid Inhibitor for the Treatment of Atherosclerosis"},{"biomarker_overlap":null,"composite_score":0.44933937906413357,"cr_rationale":"Bispecific antibody construction platform; engineering tool for broad oncology without specific SoC differentiation.","description_excerpt":"Unmet Need: In the United States, 40% of males and 38% of females will develop cancer in their lifetimes. Additionally, as of 2015, the annual direct medical costs of cancer stood at $80.2 billion. Targeted therapies, such as monoclonal antibody drugs, show great promise in cancer treatment, but the","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer (broad — targeted cancer therapy)","mechanism_class":"Single-chain knobs-in-holes bispecific antibody","modality":"bispecific","objectID":"34760","rationale_one_line":"Single-chain knobs-in-holes bispecific antibody construction platform for targeted cancer therapy — bispecific antibody modality; broad oncology without a single supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/34760","subscores":{"clinical_relevance":0.5,"ira_exposure":0.85,"modality_pos":0.331131263547112,"whitespace":0.5},"target":null,"title":"Single-chain Knobs-in-holes Bispecific Antibody Construction"},{"biomarker_overlap":null,"composite_score":0.44398189468315696,"cr_rationale":"Collagen IV peptides compete with established anti-VEGF therapy despite dual mechanism.","description_excerpt":"Novelty:\r\nmodified peptides from collagen IV derived parent peptide Pentastatin-1\r\nValue Proposition:\r\nThe invention describes the synthesis of novel anti-angiogenic by substituting particular amino acids of the peptide Pentastatin-1 derived from collagen IV. Other advantages include:\r\n• Ability to ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Oncology (anti-angiogenic, broad solid tumors)","mechanism_class":"Anti-angiogenic collagen-derived mimetic peptide","modality":"peptide","objectID":"59751","rationale_one_line":"Modified Pentastatin-1 peptides from collagen IV with anti-angiogenic and pro-apoptotic activity; peptide modality; no specific supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59751","subscores":{"clinical_relevance":0.5,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Novel Anti-Angiogenic Collagen Derived Mimetic Peptides"},{"biomarker_overlap":null,"composite_score":0.44398189468315696,"cr_rationale":"Sustained retinal delivery addresses real compliance burden in chronic retinal disease treatment.","description_excerpt":"Value Proposition\r\n·      Reducing the number of daily eye drop doses required for therapeutic effect in the posterior chamber\r\n·      Limited systemic absorption of medication delivered via topical eyedrops \r\n \r\nUnmet Need\r\n·      The mainstay of medication delivery to the eye remains topical eye-d","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"ophthalmic drug delivery to the posterior chamber / retina","mechanism_class":"sustained retinal drug delivery platform","modality":"peptide","objectID":"56872","rationale_one_line":"Taxonomy classifies under Peptides and Therapeutic Delivery Platforms; indication is ophthalmology (retinal drug delivery), which falls outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/56872","subscores":{"clinical_relevance":0.5,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Sustained, retinal-specific drug release via topical administration"},{"biomarker_overlap":null,"composite_score":0.44398189468315696,"cr_rationale":"BBB permeabilization enables CNS drug delivery but is a platform tool, not a standalone therapeutic.","description_excerpt":"Unmet Need\r\nThe blood-brain barrier (BBB) is responsible for regulating the brain microenvironment by tightly controlling the entry of molecules and cells into the brain. This restricted access has presented challenges in the delivery of therapeutic agents to the brain. As a result, only a few centr","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"central nervous system disorders (blood-brain barrier drug delivery)","mechanism_class":"BBB permeabilization peptide","modality":"peptide","objectID":"56001","rationale_one_line":"Melittin is a peptide; the technology reversibly opens the blood-brain barrier to enable CNS drug delivery — a delivery platform for CNS disorders outside the supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/56001","subscores":{"clinical_relevance":0.5,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Method for Reversible Blood-brain Barrier Opening Using Melittin and Melittin Variants"},{"biomarker_overlap":null,"composite_score":0.44398189468315696,"cr_rationale":"Novel p75NTR mechanism vs robust heart failure SoC; preclinical differentiation unclear.","description_excerpt":"Unmet Need / Invention Novelty: Hemodynamic stress during heart disease results in adverse remodeling and loss of function of the myocardial  tissue. One mechanism that underlies this pathology is activation of the p75 neurotrophin receptors (p75NTR) in the heart. There is an unmet need for a therap","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"acute and chronic cardiac disease / heart failure","mechanism_class":"p75NTR antagonist","modality":"peptide","objectID":"24946","rationale_one_line":"Peptide and small molecule antagonists of p75 neurotrophin receptor targeting cardiac adverse remodeling; heart failure is outside the 11 supported indication enums so mapped to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24946","subscores":{"clinical_relevance":0.5,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"p75NTR","title":"P75 Neurotrophin Receptor Antagonist for the Treatment of Acute and Chronic Cardiac Disease"},{"biomarker_overlap":null,"composite_score":0.44398189468315696,"cr_rationale":"Antigen-specific T-cell activation platform addresses immunotherapy gaps but lacks indication focus.","description_excerpt":"Unmet Need: Use of T-cells in the eradication of diseases has been limited by the inability to produce or enhance activation of desired T-cell populations to an antigen of interest, ultimately leading to disease progression. \r\n\r\nTechnical Details: Johns Hopkins researchers have developed novel fusio","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"antigen-specific immune modulation; T-cell activation against diseases including cancer","mechanism_class":"peptide-MHC fusion construct","modality":"peptide","objectID":"24355","rationale_one_line":"Technology described as 'novel fusion constructs that produce and/or enhance T-cell activation' using peptide-MHC anchors for immune modulation; maps to peptide modality with no single indication specified.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24355","subscores":{"clinical_relevance":0.5,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"MHC","title":"Programmed Self-assembly of a Peptide-MHC Dynamic Anchor for Antigen-specific Immune Modulation"},{"biomarker_overlap":null,"composite_score":0.44398189468315696,"cr_rationale":"Autoantigen peptide cancer vaccine offers novel immunotherapy angle but broad oncology framing limits SoC comparison.","description_excerpt":"Autoimmunity-based Peptides as Cancer Vaccines\n\nJHU REF: C12807\n\n \n\nInvention novelty: This technology uses autoantigen-derived peptides as novel immunotherapy to prevent and treat cancer. \n\n \n\nValue Proposition:\n\nToday, millions of people are living with cancer or have had cancer. Despite significa","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (broad); autoimmunity-based peptide cancer vaccines","mechanism_class":"autoantigen-derived peptide cancer vaccine","modality":"peptide","objectID":"22629","rationale_one_line":"Autoantigen-derived peptides as 'novel immunotherapy to prevent and treat cancer'; peptide vaccine modality for broad oncology — no single enumerated indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/22629","subscores":{"clinical_relevance":0.5,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Autoimmunity-based Peptides as Cancer Vaccines"},{"biomarker_overlap":null,"composite_score":0.44398189468315696,"cr_rationale":"Collagen mimetic peptides enable targeted delivery across cancer and wound healing; platform with conditional benefit.","description_excerpt":"C11749: Novel Collagen Targeting for Imaging and Therapeutic Applications\r\n\r\nNovelty: \r\n\r\nThis technology employs collagen mimetic peptides to target denatured collagen in vivo for imaging and treatment of cancer and other diseases affecting the collagen matrix.\r\nValue Proposition: \r\nThere are curre","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer, cardiovascular, wound healing (collagen targeting)","mechanism_class":"collagen mimetic peptide targeting denatured collagen","modality":"peptide","objectID":"17040","rationale_one_line":"Collagen mimetic peptides targeting denatured collagen for imaging and therapy across cancer, cardiovascular, and wound healing — multi-indication platform; peptide modality per taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17040","subscores":{"clinical_relevance":0.5,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"denatured collagen","title":"Targeting Collagen Strands for Imaging and Therapy"},{"biomarker_overlap":null,"composite_score":0.44398189468315696,"cr_rationale":"DECApeptide tumor-targeting conjugate for colon/esophageal cancer; selective delivery over systemic SoC chemotherapy.","description_excerpt":"C10039: Specific Delivery of a Tumor-ablating Agent by a DECApeptide to Colon and Esophageal Cancer Cell Lines as a Therapeutic TreatmentValue Proposition: \r\nThe effectiveness of immunotherapeutic antibodies is limited by their relatively large size.  This attribute results in the antibody attachmen","dev_stage":"unknown","exclusivity_status":"unknown","indication":"colorectal_cancer","indication_free_text":"colon and esophageal cancer (DECApeptide-targeted tumor-ablating agent)","mechanism_class":"tumor-targeting DECApeptide conjugate","modality":"peptide","objectID":"16575","rationale_one_line":"Described as 'specific delivery of a tumor-ablating agent by a DECApeptide to colon and esophageal cancer cell lines'; colorectal_cancer is the supported indication among the two mentioned; peptide modality confirmed by taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16575","subscores":{"clinical_relevance":0.5,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Specific Delivery of a Tumor-ablating Agent by a DECApeptide to Colon and Esophageal Cancer Cell Lines as a Therapeutic Treatment"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Improved graft mechanics may reduce failure, offering durability benefit over prostheses.","description_excerpt":"Technical Problem\r\nCurrent synthetic small-diameter tissue engineered vascular grafts face challenges such as thrombogenicity, decreased elasticity, aneurysmal failure, calcification, and intimal hyperplasia, limiting their clinical effectiveness for pediatric congenital cardiovascular defects, coro","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Congenital cardiovascular defects, coronary artery disease, peripheral artery disease","mechanism_class":null,"modality":"other","objectID":"59943","rationale_one_line":"Implantable vascular graft with improved mechanical properties — a medical device/tissue substrate, not a classic therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59943","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Long Term Storage and Improved Mechanical Properties of Implantable Vascular Grafts"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Conditional protein delivery for pain lacks clinical differentiation from established SoC.","description_excerpt":"Value Proposition\r\n·        Effective &amp; Targeted: Harnesses endogenous pain signaling via receptor tyrosine kinases to conditionally deliver effector proteins to the plasma membrane, enabling suppression of chronic pain under pathological conditions\r\n·        Broadly Applicable: Enables modular,","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Chronic pain","mechanism_class":"Receptor tyrosine kinase-mediated conditional protein delivery","modality":"other","objectID":"57640","rationale_one_line":"Conditional delivery of effector proteins to plasma/endosomal membranes via RTK signaling for chronic pain suppression — a delivery mechanism platform; pain not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/57640","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A method to conditionally deliver effector proteins to plasma and endosomal membranes to treat chronic pain"},{"biomarker_overlap":"svRNA species as diagnostic and therapeutic biomarkers","composite_score":0.43114606291324387,"cr_rationale":"Antiviral svRNA approach for SARS-CoV-2 offers mechanistic novelty but antivirals exist as SoC.","description_excerpt":"Value Proposition - Novel Biomarkers for Diagnosis &amp; Prognosis - Insights into viral immune evasion mechanism  - Identify key host pathways targeted by svRNAs  - Novel Therapeutic Targets - Identified pathways enable the development of immune-modulating therapies. \r\n \r\nUnmet Need - Studies have ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"SARS-CoV-2 and related virus infection","mechanism_class":"viral small RNA theragnostic","modality":"nucleic_acid","objectID":"57075","rationale_one_line":"Short viral RNAs (svRNAs) are nucleic acid entities; indication is COVID-19/infectious disease, which maps to 'other' outside the supported enum set.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/57075","subscores":{"clinical_relevance":0.5,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Short viral RNAs (svRNAs) with theragnostic potential in infection with SARS-CoV-2 and related viruses"},{"biomarker_overlap":"elevated translation rate","composite_score":0.43114606291324387,"cr_rationale":"Targeting translation in high-rate cancers is mechanistically differentiated but lacks specificity data.","description_excerpt":"Value Proposition: - Targeted cancer therapeutic and combination therapy to prevent resistance - Target cancer cell’s vulnerable translation processes - Target aggressive cancers with poor prognoses at present\r\n \r\nTechnology Description\r\nThe disclosed technology addresses the major challenge of iden","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancers with high translation rates","mechanism_class":"translation process inhibitor","modality":"other","objectID":"56529","rationale_one_line":"Broad oncology platform targeting 'cancer cell's vulnerable translation processes'; no specific indication within the supported enum and no named modality class in the description.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/56529","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Targeted Antineoplastic Therapeutic for Cancers with High Translation Rates"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Exosome vaccine platform for COVID/emerging pathogens; differentiated delivery but vaccines already broadly available.","description_excerpt":"Unmet Need\r\nNext-generation vaccines are needed to address the emergence of new pathogens, the limitations of current vaccine technologies, and the need for more effective and durable immunity against complex diseases like cancer, HIV, and emerging viruses. Traditional vaccines require long producti","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"COVID-19 and emerging pathogens (vaccine platform)","mechanism_class":"exosome-based vaccine platform","modality":"other","objectID":"55011","rationale_one_line":"Exosome vaccine platform for COVID-19 and next-generation vaccines; classified under Vaccines — infectious disease / vaccine platform outside the supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55011","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Covid 19 Exosome Vaccine Platform"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Dynamic hydrogel for vascular/tissue regeneration is a platform biomaterial with broad but unspecified clinical impact.","description_excerpt":"Unmet Need\r\nOrgan/tissue regeneration remains a major area of research with few viable clinical products. A major barrier is the development of biologically accurate tissue constructs, with vascularization being a primary component. Classic static hydrogels have non-reversible crosslinks such that n","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"organ/tissue regeneration, vascular disease, wound healing","mechanism_class":"dynamic hydrogel biomaterial","modality":"other","objectID":"53890","rationale_one_line":"Dynamic hydrogel tissue substrate for organ/vascular regeneration; classified under Tissue Substrates and Medical Devices — a biomaterial, not a classic therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53890","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Dynamic Hydrogels"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Broad glucose-metabolism inhibition lacks clear differentiation from current oncology SoC.","description_excerpt":"Value Proposition:\r\n·      Drug reduces tumor burden by interrupting cancer cells’ reliance on glucose metabolism.\r\n·      Tolerated by healthy, normal cells.\r\n·      Potential for combination therapy with other modalities (chemotherapy, radiation, immunotherapy, etc.)\r\nUnmet Need\r\n·      Cancer is ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer broadly; interrupting cancer cells reliance on glucose metabolism","mechanism_class":"glucose metabolism inhibitor","modality":"small_molecule","objectID":"53541","rationale_one_line":"Description states drug reduces tumor burden by interrupting cancer cells reliance on glucose metabolism; broad oncology without specific cancer type maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53541","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Antitumor drug interrupting glucose metabolism as a therapeutic strategy for cancer"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"T-cell COVID vaccine adds durability, but mRNA vaccines already address acute disease.","description_excerpt":"Unmet Need\r\n·        In response to the global COVID-19 pandemic, a variety of vaccines have been rapidly developed to prevent serious illness or death from infection by SARS-CoV-2. The gold standard are mRNA vaccines which deliver mRNA to make copies of the SARS-CoV-2 spike protein, which ultimatel","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"SARS-CoV-2 / COVID-19 (T-cell vaccine)","mechanism_class":"T-cell vaccine","modality":"other","objectID":"50582","rationale_one_line":"T-cell vaccine against SARS-CoV-2; classified under Vaccines; vaccine modality and infectious disease indication are outside the 9+11 enums, both map to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50582","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"T-cell Vaccine for SARS Virus"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Broad-spectrum antivirals have high need but azide-biomolecule mechanism lacks clinical validation vs established antivirals.","description_excerpt":"Unmet Need: Viral infections in humans, animals, plants and insects lead to many societal burdens including disease and agricultural loss. Most anti-viral treatment strategies to date are limited in scope to the virus of interest and often result in drug resistance, incomplete efficacy, and/or toxic","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Viral infections (broad-spectrum antiviral)","mechanism_class":"broad-spectrum antiviral / azide-modified biomolecule","modality":"small_molecule","objectID":"48716","rationale_one_line":"Broad-spectrum antiviral azide-modified biomolecules targeting viral infections; classified under Small Molecules / Therapeutic Delivery Platforms; infectious disease not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48716","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Broad Spectrum anti-viral azide-modified biomolecules"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Clavulanate biosynthesis improves manufacturing, not direct therapeutic impact.","description_excerpt":"Clavulanic acid is a potent b-lactamase inhibitor used to combat resistance to penicillin and cephalosporin antibiotics. There is a demand for high-yielding fermentation strains for industrial production of this valuable product. Clavulanic acid biosynthesis is initiated by the condensation of L-arg","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Bacterial infections / antibiotic resistance (clavulanic acid biosynthesis / beta-lactamase inhibition)","mechanism_class":"beta-lactamase inhibitor (clavulanic acid)","modality":"small_molecule","objectID":"47779","rationale_one_line":"Clavulanic acid biosynthesis engineering to combat penicillin/cephalosporin resistance; a manufacturing/fermentation tool for antibiotic production; infectious disease not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/47779","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Same as above"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Localized immunosuppressive delivery at transplant site could reduce systemic toxicity vs systemic SoC immunosuppression.","description_excerpt":"Value Proposition\r\n·        Localized Drug Delivery: Enables targeted delivery of immunosuppressive drugs directly to transplant sites or affected organs, minimizing systemic exposure.\r\n·        Minimize Systemic Toxicity: Local delivery enables lower drug doses and minimizes systemic drug-associate","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Organ transplantation / immunosuppression (localized drug delivery)","mechanism_class":"injectable peptide hydrogel delivery platform","modality":"other","objectID":"47435","rationale_one_line":"Injectable peptide hydrogel for localized controlled delivery of immunosuppressive drugs to transplant sites; a delivery platform classified under Therapeutic Delivery Platforms; transplant/immunosuppression not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/47435","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Injectable Peptide Hydrogel for Local and Controlled Delivery of Immunosuppressive Drugs"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Proteasome inhibitors (bortezomib/carfilzomib) are established SoC; novel analogs offer incremental differentiation.","description_excerpt":"Unmet Need / Invention Novelty: Currently available anti-cancer proteasome inhibitors are highly effective against liquid tumors, however, resistance develops. Furthermore, available proteasome inhibitors are not effective against solid tumors. There is an unmet need to develop anti-cancer proteasom","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"liquid and solid tumors","mechanism_class":"proteasome inhibitor","modality":"small_molecule","objectID":"45053","rationale_one_line":"Description states 'Novel small molecule proteasome inhibitors' targeting both liquid and solid tumors; broad oncology, not a supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45053","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"proteasome","title":"Novel small molecule proteasome inhibitors for the treatment of liquid and solid tumors"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Bis-benzylidine piperidone proteasome inhibitors; incremental vs. approved bortezomib/carfilzomib/ixazomib class.","description_excerpt":"Unmet Need\r\nA hallmark of many human cancers is the proteasomal degradation of tumor suppressor proteins, leading to apoptosis arrest and sustained cell proliferation. Yet, to date, the therapeutic use of proteasome inhibitors is impeded by the grave side effects and emergence of disease resistance.","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (hematologic and solid tumors)","mechanism_class":"proteasome inhibitor","modality":"small_molecule","objectID":"44906","rationale_one_line":"Bis-benzylidine piperidone small molecule proteasome inhibitors with anticancer activity; broad oncology does not map to a supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44906","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"proteasome","title":"Novel Bis-benzylidine Piperidone-based Proteasome Inhibitors with Anticancer Activity"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Novel proteasome inhibitor series; meaningful class precedent limits differentiation without clinical data.","description_excerpt":"Unmet Need\r\nCancer cells differ critically from normal cells, e.g., higher metabolic rates. Proteasomes play a pivotal role in managing excessive metabolism and maintaining protein homeostasis, as the continued over-accumulation of mis-folded proteins is toxic to cells.\r\n\r\nSeveral proteasome inhibit","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"hematologic malignancies and solid tumors","mechanism_class":"proteasome inhibitor","modality":"small_molecule","objectID":"44793","rationale_one_line":"Small molecule proteasome inhibitors with antitumor properties for hematologic and solid malignancies; broad oncology does not map to a supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44793","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"proteasome","title":"Candidate Small Molecule Proteasome Inhibitors with Antitumor Properties"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Sonolucent burr hole for transcranial ultrasound therapy; enables FUS procedures limited by current skull access.","description_excerpt":"Unmet Need: Brain imaging techniques are commonly used to visualize the distribution of tissues and fluids within the skull. These techniques are classically used to either (1) diagnose abnormalities in the structure of the brain (traumatic brain injury, stroke, tumors, abnormal fluid buildup, etc.)","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"brain conditions (traumatic brain injury, stroke, tumors, fluid buildup)","mechanism_class":"transcranial ultrasound device","modality":"other","objectID":"43389","rationale_one_line":"Sonolucent burr hole and acoustic lens for transcranial ultrasound; medical device/imaging technology, not a therapeutic modality with a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/43389","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Sonolucent Burr Hole and Implantable Acoustic Lens Permitting and Enhancing Transcranial Ultrasound"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"MRI-guided brachytherapy needle improves dose precision vs. standard brachytherapy; procedural incremental gain.","description_excerpt":"Unmet Need\r\nEffective radiation treatment of tumors combines maximal radiation dose delivery to planned locations while mitigating radiation impacts on surrounding normal tissues. A delivery of radiation absorption materials (biocompatible gels) to create pockets of radiation dissipation has proven ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"oncology (cervical cancer, prostate cancer — radiation brachytherapy)","mechanism_class":"MRI-guided brachytherapy needle","modality":"other","objectID":"43248","rationale_one_line":"MRI-guided active injection needle for radiation oncology brachytherapy; medical device for radiation delivery, not a biologic or small molecule therapeutic.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/43248","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"MRI-Guided Active Injection Needle for Radiation-Oncology Brachytherapy"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Sulforaphane antiviral for COVID-19; nutritional Nrf2 activator with modest differentiation vs. antiviral SoC.","description_excerpt":"Unmet Need: COVID-19 is a worldwide problem, and infection rates continue to -increase as new variants arise .  Additionally, Long COVID has emerged as a growing problem of great concern.  Very few options for treatment are available for general use. Therefore, more therapies and prophylactics are u","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"COVID-19 / coronavirus infection","mechanism_class":"sulforaphane (Nrf2 activator / antiviral nutritional compound)","modality":"small_molecule","objectID":"43247","rationale_one_line":"Sulforaphane (nutritional small molecule) to inhibit coronaviruses including SARS-CoV-2; infectious disease indication does not map to a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/43247","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Use of Sulforaphane to inhibit Coronaviruses such as SARS-CoV-2 and to treat coronavirus diseases such as COVID19"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Inhaled DNA lung-cancer vaccine offers novel route, but limited clinical evidence.","description_excerpt":"Unmet Need\r\nWith lung diseases, namely influenza and lung cancer, on the rise, pulmonary vaccination is a promising approach to elicit strong immunity to inhaled pathogens and lung cancer compared to systemic immunization strategies. In particular, inhaled DNA vaccination, a rapidly developing field","dev_stage":"unknown","exclusivity_status":"unknown","indication":"nsclc","indication_free_text":"lung cancer (and influenza, tuberculosis — pulmonary vaccination)","mechanism_class":"pulmonary dendritic cell-mediated DNA vaccination","modality":"other","objectID":"40553","rationale_one_line":"Inhaled DNA vaccination platform with explicit category 'Oncology > Lung Cancer'; lung cancer maps to nsclc as the closest supported indication; modality is a vaccine/delivery platform.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/40553","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Method to Enhance Pulmonary Dendritic Cell-mediated DNA Vaccination"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Stem cell nanofiber stent sleeve for vascular ischemia; novel paracrine approach vs. standard revascularization SoC.","description_excerpt":"Invention novelty:\r\nStem cells are harnessed to create a stent-based “paracrine factor factory” using a novel biodegradable nanofiber sleeve which protects the cells from washout and immune attack, and provides a sheltered in vivo on-stent milieu for the cells to continuously produce and deliver hea","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"vascular injury / ischemia (intravascular growth factor delivery)","mechanism_class":"stem cell-seeded nanofiber stent sleeve (paracrine factor delivery)","modality":"other","objectID":"39330","rationale_one_line":"Cell-impregnated nanofiber stent sleeve for intravascular growth factor production; medical device/cell therapy platform for vascular injury, not a supported indication or modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/39330","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Cell Impregnated Nanofiber Stent Sleeve (\"CINSS\") for Intravascular Growth Factor Production"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Sustained-release polymer prodrug for HIV; convenience improvement over daily oral antiretroviral SoC.","description_excerpt":"Unmet Need:\r\nHuman immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) are amongst the most serious and challenging health problems in the world. There are nearly 37 million people worldwide living with HIV/AIDS and approximately 1 million AIDS-related deaths have o","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"HIV infection and AIDS","mechanism_class":"Polymer prodrug sustained-release antiviral delivery","modality":"other","objectID":"38489","rationale_one_line":"Polymer prodrug delivery platform for sustained release of antivirals to treat or prevent HIV — a therapeutic delivery platform for an infectious disease outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/38489","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Polymer of Prodrug Methods for Sustained Release of Antivirals for Treatment or Prevention of HIV"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Demethylating/polyamine inhibitor combo for solid tumors; synergy plausible but pan-oncology dilutes impact.","description_excerpt":"Unmet Need\r\nThe present invention could be used for treatment of any solid tumor, including ovarian, breast, melanoma, lung, colon, pancreas, liver, esophageal, stomach, epithelial, sarcoma, cervical, and uterine. This encompasses a huge market size and compelling unmet need. The effectiveness of th","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Solid tumors (ovarian, breast, melanoma, lung, colon, pancreas, liver, esophageal, stomach, epithelial, sarcoma, cervical, uterine)","mechanism_class":"DNA demethylating agent + polyamine biosynthesis inhibitor combination","modality":"small_molecule","objectID":"38384","rationale_one_line":"Combination of DNA demethylating agents and inhibitors of polyamine biosynthesis to enhance antitumor response across broad solid tumor indications — pan-oncology, no single supported enum applies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/38384","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Combination Treatment Using DNA Demethylating Agents and Inhibitors of Polyamine Biosynthesis to Enhance Antitumor Response"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Biomimetic aAPC cell therapy platform; broad immunotherapy application without focused clinical differentiation.","description_excerpt":"Unmet Need\r\nOver the past decade, a myriad of immune cell therapies based on the infusion of allogeneic immune cells into patients have been tested and progressed in clinical applications. Despite continual advances, immune cell therapy via antigen presenting cells is relatively expensive and time c","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Autoimmunity and immuno-oncology (broad cell therapy platform)","mechanism_class":"Cationic biodegradable polymer biomimetic artificial antigen-presenting cell","modality":"other","objectID":"36526","rationale_one_line":"Cationic biodegradable polymer compositions of biomimetic artificial antigen-presenting cells for immune cell therapy — a cell therapy/biomaterial platform spanning autoimmunity and immuno-oncology.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36526","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Cationic Biodegradable Polymer Compositions of Biomimetic Particles including Artificial Antigen Presenting Cells"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"HIF-1 gene therapy spanning hypoxia/cardiovascular/cancer; broad target diffuses clinical impact vs specific SoC.","description_excerpt":"The purified and characterization of hypoxia-inducible factor 1 (HIF-1) is described. HIF-1 is composed of subunits HIF-1 and HIF-1 . Purified HIF-1 polypeptide, its amino acid sequence and polynucleotide sequence are provided. A HIF-1 variant that dimerizes to HIF-1 producing a nonfunctional HIF-1 ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Hypoxia-related conditions, cardiovascular disease, cancer","mechanism_class":"HIF-1 gene therapy / dominant-negative HIF-1 variant","modality":"other","objectID":"36454","rationale_one_line":"Gene therapy using purified HIF-1 polypeptide and a dominant-negative HIF-1 variant for hypoxia-related conditions and cardiovascular disease — spans multiple indications outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36454","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HIF-1 (HIF1A)","title":"Gene Therapy for Hypoxia Related Conditions and HIF1a mouse monoclonal antibody"},{"biomarker_overlap":"PSMA expression on prostate cancer cells","composite_score":0.43114606291324387,"cr_rationale":"PSMA dendrimer theranostic for prostate cancer; imaging plus therapy combination vs separate diagnostic/treatment SoC.","description_excerpt":"Unmet Need\r\nAccording to The American Cancer Society, approximately 1 in 9 men will be diagnosed with prostate cancer in their lifetime, with 174,650 new cases diagnosed yearly in the US.  As prostate cancer is the second leading cause of cancer death in American men, early detection is important fo","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Prostate cancer","mechanism_class":"PSMA-targeted PAMAM dendrimer for imaging and therapeutic delivery","modality":"other","objectID":"35358","rationale_one_line":"PSMA-targeted PAMAM dendrimers for prostate cancer imaging, contrast, and therapeutic agent delivery — a theranostic/delivery platform; prostate cancer is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35358","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PSMA","title":"PSMA-Targeted PAMAM Dendrimers for Specific Delivery of Imaging, Contrast and Therapeutic Agents"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"PGE2 target validation for OA offers structural modification potential; no approved DMARD exists for OA.","description_excerpt":"Unmet Need\r\nMore than 50 million US adults are affected by arthritis, a joint disorder that can result in persistent pain. There is no cure for arthritis, and in the end stages of the disease, joint replacement is often needed. Current approaches to treat arthritis aim to control pain via the use of","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"arthritis / osteoarthritis (joint pain and skeletal disease)","mechanism_class":"prostaglandin E2 signaling modulator","modality":"other","objectID":"30477","rationale_one_line":"Target validation for prostaglandin E2 in sensory nerve and bone formation for osteoarthritis; osteoarthritis is not in the supported indications; modality is a target/mechanism rather than a specific therapeutic class.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/30477","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PTGER","title":"Prostaglandin E2 Mediates Sensory Nerve for Bone Formation and Pain of Skeletal Diseases"},{"biomarker_overlap":"PSMA expression (prostate cancer and ccRCC biomarker)","composite_score":0.43114606291324387,"cr_rationale":"Reducing off-target organ toxicity in PSMA-targeted radiotherapy meaningfully improves therapeutic index.","description_excerpt":"Unmet Need\r\nProstate cancer is the second leading cause of cancer related death in American men and it is estimated that approximately 164,690 new cases will be diagnosed in 2018. Elevated prostate-specific membrane antigen (PSMA) serves as a biomarker for prostate cancer and as well as primary clea","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer and clear cell renal carcinoma (PSMA-positive tumors)","mechanism_class":"PSMA binding agent / radiopharmaceutical blocker","modality":"small_molecule","objectID":"30469","rationale_one_line":"Competitive PSMA binding agents to reduce off-target organ uptake during PSMA-targeted radiotherapy; prostate cancer is not in the 11 supported indications so mapped to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/30469","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PSMA (FOLH1)","title":"Competitive PSMA Binding Agents for Reduction of Non-target Organ Uptake of Radiolabeled PSMA Inhibitors for PSMA Positive Tumor Imaging and Radiopharmaceutical Therapy"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Repurposed beta-blocker for RP; no approved pharmacotherapy exists, though effect size unclear.","description_excerpt":"Unmet Need\r\nRetinitis pigmentosa (RP) is a genetic disorder with a prevalence of 1 in 4000 people worldwide. RP can be the result of a number of mutations that all result in severe rod photoreceptor degeneration and death, causing excess oxygen in the outer retina and subsequent oxidative damage to ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"retinitis pigmentosa (RP) and macular degeneration (ophthalmology)","mechanism_class":"repurposed beta-blocker for retinal degeneration","modality":"small_molecule","objectID":"28104","rationale_one_line":"Metipranolol (repurposed beta-blocker) for retinitis pigmentosa; ophthalmic indication not in the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28104","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"ADRB (beta-adrenergic receptor)","title":"Metipranolol for Treatment of Retinitis Pigmentosa"},{"biomarker_overlap":"BRAF V600E mutation, TERT promoter mutation","composite_score":0.43114606291324387,"cr_rationale":"BRAF/TERT pathway discovery in melanoma; target validation without defined therapeutic agent limits score.","description_excerpt":"Unmet Need\r\nThe oncogenic duet of BRAF V600E and TERT promoter mutations occurs in approximately 7-8% of papillary thyroid cancer (PTC) cases and 20-50% of melanoma cases. These percentages also correspond to the proportion of cases with the poorest clinical and pathological outcomes. When mutations","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"melanoma","indication_free_text":"melanoma and papillary thyroid cancer (BRAF V600E / TERT promoter mutations)","mechanism_class":"BRAF V600E / TERT promoter pathway target","modality":"other","objectID":"28021","rationale_one_line":"Molecular mechanism study of mutant TERT activation by BRAF V600E/MAP kinase pathway; melanoma is explicitly named and is a supported enum; modality is target discovery rather than a defined therapeutic class.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28021","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"BRAF, TERT","title":"A Molecular Mechanism for the Activation of Mutant TERT by the BRAF V600E/MAP Kinase Pathway"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Drug repurposing for RP addresses unmet need with no approved treatment; efficacy evidence pending.","description_excerpt":"Unmet Need\r\nRetinitis pigmentosa (RP) is a genetic disorder that can result from more than 60 mutations that cause severe rod photoreceptor degeneration and death. It is estimated to affect 1 in 4000 people worldwide, with approximately 100,000 cases in the United States. Symptoms begin in childhood","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"retinitis pigmentosa (RP) (ophthalmology)","mechanism_class":"repurposed approved drug for retinal degeneration","modality":"small_molecule","objectID":"28019","rationale_one_line":"Repurposing of approved drugs for retinitis pigmentosa; ophthalmic indication not in the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28019","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Repurposing of approved drugs as a treatment for Retinitis pigmentosa"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Enhanced intravesical delivery for NMIBC could improve BCG/chemotherapy efficacy in recurrent disease.","description_excerpt":"Unmet Need: Bladder cancer is a global disease, with 540,000 incident cases and 188,000 deaths in 2015 worldwide.   In the United States 81,190 patients will be diagnosed in 2018 and 17,240 will die from their disease.(1) The first-line treatment of non-muscle-invasive bladder cancer (NMIBC) is the ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"non-muscle-invasive bladder cancer (NMIBC)","mechanism_class":"intravesical drug delivery enhancement","modality":"small_molecule","objectID":"27583","rationale_one_line":"Methods for enhanced drug delivery to the bladder for bladder cancer treatment; bladder cancer is not in the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/27583","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Methods to achieve enhanced drug delivery to the bladder"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Enthesopathy target identification addresses chronic tendon/joint disease with limited effective therapies.","description_excerpt":"Unmet Need\r\nOver half of sports injuries involve tendons and entheses (the sites of attachment between ligament and bone). Enthesopathy, a disorder involving the attachment of tendon or ligament, represents one-fourth of tendon diseases and is a difficult disorder to treat. Tendon disorders, which i","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"enthesopathy and tendon disorders (musculoskeletal / rheumatology)","mechanism_class":"enthesopathy therapeutic target","modality":"other","objectID":"26830","rationale_one_line":"Target-based treatment of enthesopathy; musculoskeletal/rheumatology indication is not rheumatoid arthritis specifically and does not map to the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/26830","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Therapeutic Treating or Preventing Enthesopathy"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Neural regeneration target for stroke/depression; early discovery stage limits clinical impact assessment.","description_excerpt":"Unmet need\r\nCurrent anti-depressants in the market have various limitations including lack of broad-spectrum drugs, unexpected side effects, toxicity and low efficacy for certain patients. New generation of anti-depressants based on most recent biomedical discoveries concerning depression are urgent","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"depression, stroke, and neural regeneration (neurology / psychiatry)","mechanism_class":"neural regeneration target for anti-depressants and stroke","modality":"other","objectID":"26828","rationale_one_line":"Novel therapeutic target for neural regeneration, stroke, and anti-depressants; neurology/psychiatry indications are not in the 11 supported enums; modality is target discovery.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/26828","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Therapeutic Target for Neural Regeneration, Stroke and Anti-depressants"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"LSD1 inhibitor for cancer/neurodegeneration is mechanistically plausible but diffuse across indications.","description_excerpt":"Unmet Need: Epigenetic regulation of gene expression is one mechanism that can be dysregulated in the development of diseases such as cancer and has specifically been implicated in the the development of therapeutic resistance mechanisms in cancer and tumor metastasis. There remains a significant ne","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer and neurodegenerative disease (epigenetic regulation)","mechanism_class":"LSD1 histone demethylase inhibitor","modality":"small_molecule","objectID":"26403","rationale_one_line":"Selective LSD1 histone demethylase inhibitor small molecule for cancer and neurological indications; broad/multiple indication coverage does not map cleanly to a single supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/26403","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"LSD1 (KDM1A)","title":"A Selective Inhibitor of Histone Demethylase LSD1"},{"biomarker_overlap":"mutations in cellular motility pathways","composite_score":0.43114606291324387,"cr_rationale":"Motility hyperactivation-induced cell death is mechanistically novel; patient selection biomarker undefined.","description_excerpt":"Invention Novelty:\r\nThis technology is based on the discovery that hyper-activation of cellular motility networks can sensitize cancer cells to stressor to induce cell death. This is a novel method for the induction of cell death in cancers with mutations in motility pathways.\r\n \r\nValue Proposition:","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer with mutations in motility pathways (broad oncology)","mechanism_class":"motility network hyperactivation-induced cell death","modality":"other","objectID":"25512","rationale_one_line":"Novel method inducing cell death by hyperactivating motility networks in cancers with motility pathway mutations; broad oncology without a specific supported indication; modality is a mechanism concept rather than a defined class.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/25512","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Inducing Cell Death by Hyperactivation of Motility Networks"},{"biomarker_overlap":"GULP1 expression in urine","composite_score":0.43114606291324387,"cr_rationale":"Urine biomarker improves on invasive cystoscopy surveillance for bladder cancer.","description_excerpt":"Invention Novelty:\r\nThe technology identifies a novel biomarker to detect the presence of bladder cancer via a urine test. The technology could be coupled with existing urine-based cancer tests to improve sensitivity as a diagnostic or to test drug efficacy. \r\n \r\nValue Proposition:\r\nBladder cancer (","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"bladder cancer / urothelial carcinoma (biomarker detection via urine test)","mechanism_class":"tumor suppressor gene biomarker (GULP1)","modality":"other","objectID":"24806","rationale_one_line":"GULP1 as a urine-based diagnostic/prognostic biomarker for bladder cancer; primarily diagnostic target; bladder cancer outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24806","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GULP1","title":"Engulfment Gene GULP1 as a Functional Tumor Suppressor in Urothelial Carcinoma"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Intranasal GCPII inhibitor enhances CNS delivery; preclinical stage limits SoC comparison.","description_excerpt":"Inventors have developed a novel method to enhance the penetrance of multiple GCPII inhibitors which were developed by the inventor and Dr. Pomper at JHU. This method demonstrated improved brain penetrance in rodents. The penetrance of a specific GCPII inhibitor showed significant brain penetrance i","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurological diseases (enhanced intranasal brain delivery of GCPII inhibitors)","mechanism_class":"GCPII inhibitor (intranasal CNS delivery)","modality":"small_molecule","objectID":"24780","rationale_one_line":"Intranasal delivery method enhancing brain penetration of GCPII inhibitors; demonstrated in rodents and non-human primates (preclinical); neurological indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24780","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GCPII","title":"Intranasal Administration of Glutamate Carboxypeptidase (GCP-II) Inhibitors for Enhanced Brain Delivery"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Warburg-effect metabolic target in cancer; preclinical with no direct SoC comparator.","description_excerpt":"Unmet Need: Greatly enhanced glucose metabolism – known as the Warburg effect – is a metabolic alteration that characterizes almost all types of cancer. Over 50 years of attempts to develop therapies that target the Warburg effect have failed, largely because of safety issues connected to interferin","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"oncology (targeting Warburg effect / hexosamine biosynthetic pathway in cancer)","mechanism_class":"AGX/UAP inhibitor (hexosamine biosynthetic pathway)","modality":"small_molecule","objectID":"24769","rationale_one_line":"Small molecule AGX/UAP inhibitors targeting the Warburg effect via hexosamine biosynthetic pathway flux; broad oncology indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24769","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Use of AGX/UAP Inhibitors to Inhibit Flux through the Hexosamine Biosynthetic Pathway (HBP)"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"MRI-guided BBB disruption enables CNS drug delivery; clinically enabling but device-only.","description_excerpt":"Unmet Need: The blood-brain barrier (BBB) is a major hurdle to therapeutic agents reaching the brain. Osmolar agents can be used to create openings in the BBB, but this technique is clinically limited because of wide variability in the size and location of the resulting openings. JHU inventors have ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurological diseases (MRI-guided blood-brain barrier disruption for drug delivery)","mechanism_class":"MRI-guided BBB disruption system","modality":"other","objectID":"24711","rationale_one_line":"MRI-guided system for controlled blood-brain barrier opening to improve CNS drug delivery; medical device/procedure platform without a specific therapeutic modality enum match.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24711","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"MRI-guided Blood Brain Barrier Disruption System for Drug Delivery"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Wireless wound monitoring fills surveillance gap; pressure ulcer prevention lacks device SoC.","description_excerpt":"INVENTION NOVELTY\n\nThe Mercury Patch is the first low-cost, wireless wound care product that provides both a monitoring and therapeutic function to help prevent pressure ulcer development within a hospital setting. \n\nVALUE PROPOSITION\n\nExisting pressure monitoring devices focus on expensive mattress","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"pressure ulcer prevention (wireless wound monitoring device)","mechanism_class":"wireless biocompatible pressure monitoring and therapeutic device","modality":"other","objectID":"24383","rationale_one_line":"Wireless low-cost wound monitoring and therapeutic device for pressure ulcer prevention; medical device without a supported therapeutic indication or modality enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24383","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel biocompatible wireless monitoring device for the prevention of pressure ulcers"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"VPA-derived AMPK activators compete with established metformin/GLP-1 SoC; modest differentiation.","description_excerpt":"Technology Description - Researchers at Johns Hopkins have identified that valproic acid (VPA) and its metabolites may be useful for the treatment of obesity and related metabolic diseases (e.g., type 2 diabetes, fatty liver disease). - VPA and its cytochrome P450- and beta-oxidation-dependent metab","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"obesity and related metabolic diseases including type 2 diabetes and fatty liver disease","mechanism_class":"AMPK activator","modality":"small_molecule","objectID":"24330","rationale_one_line":"Valproic acid (VPA) and metabolites activate AMPK for 'treatment of obesity and related metabolic diseases (e.g., type 2 diabetes, fatty liver disease)'; small molecule AMPK activator targeting type 2 diabetes.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24330","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"AMPK","title":"​Therapeutics for the treatment of obesity-associated diseases"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"TLR3 agonist dsRNA for wound healing targets indication with few approved regenerative agents.","description_excerpt":"Invention novelty: This invention is a method to increase skin regeneration and wound healing. It relies on activation of the innate immune response involving Toll-like receptor 3 (TLR3).\r\n \r\nValue Proposition: Current approaches to wound healing and skin regeneration are limited in that they do not","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"wound healing and skin regeneration; follicular neogenesis","mechanism_class":"dsRNA analogue / TLR3 agonist","modality":"nucleic_acid","objectID":"22494","rationale_one_line":"dsRNA analogues activate TLR3 innate immune response to 'increase skin regeneration and wound healing'; nucleic acid (dsRNA) modality for dermatology/wound healing, outside the 11 enumerated indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/22494","subscores":{"clinical_relevance":0.5,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TLR3","title":"dsRNA Analogues to Promote Skin Regeneration"},{"biomarker_overlap":"DNA methylation changes; tumor suppressor gene promoter hypermethylation","composite_score":0.43114606291324387,"cr_rationale":"DNMT inhibitor for solid tumors extends epigenetic immunotherapy concept but lacks indication specificity.","description_excerpt":"UNMET NEED\r\nCancers are now recognized as being driven by widespread changes in the epigenome including changes in DNA methylation and chromatin packaging. Changes in DNA methylation include global loss of methylation and focal gain of methylation at promoter regions of tumor suppressor genes leadin","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"solid tumors; epigenome-targeting cancer therapy","mechanism_class":"DNMT inhibitor / epigenetic therapy","modality":"small_molecule","objectID":"22174","rationale_one_line":"Small molecule compositions targeting epigenetic DNA methylation changes in 'solid tumors'; DNMT inhibitor for broad oncology — no single enumerated solid-tumor indication specified.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/22174","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"DNMT (DNA methyltransferase)","title":"Compositions and Methods for Treating Solid Tumors"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"H3T3 phosphorylation inhibition targets mitosis in cancer; differentiation from existing mitotic inhibitors unclear.","description_excerpt":"C13222\r\n \r\nUNMET NEED\r\nCancer is incredibly difficult to treat, due to the confluence of factors that cause and perpetuate the disease and the difficulty of targeting cancer cells without affecting normal cells. As such, the academic and industry space is perpetually engaged in researching new targe","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer; rapidly dividing cells (H3T3 phosphorylation reduction)","mechanism_class":"H3T3 phosphorylation inhibitor","modality":"other","objectID":"21506","rationale_one_line":"Novel method to reduce H3T3 phosphorylation in rapidly dividing cells for cancer treatment; mechanism class described but modality form unclear from truncated description — maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/21506","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"H3T3 (histone H3 threonine 3)","title":"C13222 - A Novel Method to Reduce H3T3 Phosphorylation in Rapidly Dividing Cells"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"tDCS for early Parkinson's motor symptoms offers non-pharmacological option complementing levodopa SoC.","description_excerpt":"Non-Invasive Treatment to Improve Motor Function for Parkinson&rsquo;s Disease\r\nJHU REF: C13031\r\n \r\nInvention Novelty: A minimally invasive method and device for symptom management and treatment of early stage Parkinson's disease (PD) using transcranial direct current stimulation (tDCS). \r\n \r\nValue ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Parkinson's disease; motor symptom management","mechanism_class":"transcranial direct current stimulation (tDCS) device","modality":"other","objectID":"21163","rationale_one_line":"Minimally invasive tDCS method and device for 'symptom management and treatment of early stage Parkinson's disease'; a neurostimulation device — modality maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/21163","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Non-invasive brain stimulation method for improvement of motor symptoms in Parkinsons Disease"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Novel TB target identification; clinical utility depends on downstream drug development, not direct therapeutic.","description_excerpt":"Susceptibility Target for TB TherapyJHU REF: C10895\r\nInvention novelty: This invention has identified a new target and a new way to kill the Mycobacterium tuberculosis pathogen.\r\n \r\nValue Proposition: Currently the mechanism by which M. tuberculosis maintains 3-3 cross-linkages in the peptidoglycan ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"tuberculosis (Mycobacterium tuberculosis)","mechanism_class":"peptidoglycan cross-link target identification","modality":"other","objectID":"18737","rationale_one_line":"Identifies a new susceptibility target in M. tuberculosis peptidoglycan layer; primarily a target-discovery tool for TB — infectious disease outside enum, no defined therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/18737","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Molecular Target of Mycobacterium Tuberculosis for Development of Drug and Vaccine"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Butyrate HDAC inhibitor with anti-cancer and neuroprotective activity; comparable to existing HDAC inhibitor class.","description_excerpt":"C04704: Short Chain Fatty Acid (SCFA) - Carbohydrate Bifunctional Hybrid Molecules with Novel Anti-cancer Properties\r\n Value Proposition: \r\nButyrate, a natural short chain fatty acid (SCFA), is well-established to have anti-cancer properties via its ability to induce cell cycle arrest and apoptosis ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (anti-cancer) / Parkinson's disease","mechanism_class":"SCFA-carbohydrate bifunctional hybrid (butyrate analog, HDAC inhibitor)","modality":"small_molecule","objectID":"18725","rationale_one_line":"Butyrate-based SCFA-carbohydrate bifunctional hybrids with anti-cancer properties via cell cycle arrest/apoptosis; oncology spans multiple tumor types and also Parkinson's — maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/18725","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HDAC","title":"Short Chain Fatty Acid (SCFA) - Carbohydrate Bifunctional Hybrid Molecules with Novel Anti-cancer Properties"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"TAP behavioral intervention improves dementia patient function; comparable to existing occupational therapy SoC.","description_excerpt":"C12825: Tailored Activity Program (TAP) for Improved Lifestyle with Dementia\r\n\r\nNovelty: \r\n\r\nAn individualized home-based intervention program to reduce behavioral challenges, improve engagement for dementia patients and to improve quality of life of both the patient and the caregiver.\r\nValue Propos","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"dementia / Alzheimer's disease (behavioral intervention program)","mechanism_class":"individualized behavioral intervention program","modality":"other","objectID":"17298","rationale_one_line":"Tailored Activity Program (TAP) is a home-based behavioral intervention for dementia patients — a care/behavioral program, not a drug modality; dementia outside enum, modality is other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17298","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Tailored Activity Program for People with Dementia"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Stem-cell patch is incremental over current wound-care SoC.","description_excerpt":"C12353: Stem Cell Developed Patches for Accelerated Angiogenesis\r\n\r\nNovelty: \r\n\r\nThis technology describes compositions and methods of use of certain patches, with infused stem cells and/or derived growth factors, used for accelerated healing of tissue injuries.\r\nValue Proposition: \r\nExisting therap","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"wound healing / tissue injury repair","mechanism_class":"stem cell-seeded nanofiber patch (angiogenesis stimulation)","modality":"other","objectID":"17230","rationale_one_line":"Stem cell-infused nanofiber patches for accelerated angiogenesis in tissue injury healing — a medical device / stem cell scaffold for wound healing, not in supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17230","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Methods to Accelerate Healing of Injured Tissues via Stem Cells in Nanofiber Patches"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Family Spirit home-visiting program improves maternal-child outcomes in underserved populations; evidence-based.","description_excerpt":"C12042: Family Spirit Program: Family Strengthening for Native American Communities\r\n\r\nNovelty: \r\n\r\nThe invention is a method designed in the form of home visiting intervention program to support young Native American Indian women during pregnancy and 3 years post-partum.\r\nValue Proposition: \r\nThe F","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"maternal and child health / behavioral health (Native American communities)","mechanism_class":"home visiting behavioral intervention program","modality":"other","objectID":"17147","rationale_one_line":"Family Spirit Program is a home-visiting intervention for Native American mothers and children — a public health / behavioral program, not a drug modality; no disease indication in supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17147","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Family Spirit Program: Family Strengthening for Native American Communities"},{"biomarker_overlap":"molecular signature linked to aggressive and invasive epithelial cancer subpopulations","composite_score":0.43114606291324387,"cr_rationale":"Metastasis biomarker signature improves prognostic stratification; incremental over existing pathology-based staging.","description_excerpt":"C11851: Assay and molecular signature to identify invasive cancer cell population in tumors\r\nNovelty: \r\nThis invention is an assay for evaluating the metastatic potential of epithelial cancers, and a molecular signature linked to aggressive and invasive cancer subpopulations.\r\nValue Proposition: \r\nI","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"epithelial cancers (invasive cancer subpopulation stratification)","mechanism_class":"molecular signature / metastasis biomarker assay","modality":"other","objectID":"17074","rationale_one_line":"Assay and molecular signature for evaluating metastatic potential in epithelial cancers — primarily diagnostic/prognostic; epithelial cancer is not a specific supported indication enum entry.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17074","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Molecular Signatures of Invasive Cancer Subpopulations"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Polymer artificial cells for melanoma immune stimulation; adjuvant role alongside checkpoint inhibitor SoC unclear.","description_excerpt":"Invention novelty: This invention is polymer based artificial cells that can be functionalized to induce an immune response or act as stem cells.\r\n \r\nValue Proposition\r\nAntibiotics are the most commonly used treatment for infectious diseases. Unfortunately, overuse and misuse of these compounds is f","dev_stage":"unknown","exclusivity_status":"unknown","indication":"melanoma","indication_free_text":"melanoma / infectious disease (polymer artificial cells for immune response or stem cell function)","mechanism_class":"polymer-based artificial cell (immune stimulation / stem cell mimic)","modality":"other","objectID":"17057","rationale_one_line":"Polymer-based artificial cells classified under Oncology > Melanoma in taxonomy; functionalizable for immune response — melanoma is a supported indication enum value, modality is a cell-therapy-adjacent platform mapped to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17057","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Same as above"},{"biomarker_overlap":"receptor-specific antibody in pregnant mothers as autism risk marker","composite_score":0.43114606291324387,"cr_rationale":"Angiotensin receptor as autism target is novel; no pharmacological SoC for ASD core symptoms exists.","description_excerpt":"C11584: Diagnosis and of Autism based on Specific Receptor Site\r\n\r\nNovelty: \r\n\r\nThis invention is a new method to test pregnant mothers for an increased risk of having autistic children.  The identification of this receptor-specific antibody suggests that specific inhibitors, antibodies, or other ag","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"autism spectrum disorder","mechanism_class":"angiotensin receptor diagnostic + therapeutic target","modality":"other","objectID":"16983","rationale_one_line":"Identifies angiotensin receptor as diagnostic and therapeutic target for autism — autism/psychiatry indication outside supported enum; modality is a target-identification platform maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16983","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"angiotensin receptor","title":"Angiotensin Receptor as a Therapeutic Target for Autism Disorder"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Hydroxyurea repurposed for autism; modest evidence base, no approved pharmacotherapy SoC to displace.","description_excerpt":"C11387: Hydroxyurea for the Treatment of Autism\r\n\r\nNovelty: \r\n\r\nThis technology employs hydroxyurea (HU), a common treatment for sickle cell disease, to reduce core symptoms, like social responsiveness, in patients of all ages with autism.\r\nValue Proposition: \r\nCurrently, the only available drugs fo","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"autism spectrum disorder","mechanism_class":"ribonucleotide reductase inhibitor (repurposed)","modality":"small_molecule","objectID":"16920","rationale_one_line":"Description states 'employs hydroxyurea (HU)...to reduce core symptoms...in patients of all ages with autism'; small molecule modality confirmed; autism is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16920","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Hydroxyurea in Autism"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Neuroprotective small molecule for glaucoma; limited SoC comparison at preclinical screen stage.","description_excerpt":"Glaucoma is a major cause of visual loss and blindness in elderly Americans and throughout the world. One approach to treatment of glaucoma, and other optic nerve diseases as well as other neurodegenerations, is to develop neuroprotective agents that promote the survival of neurons. Through a high c","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"glaucoma and optic nerve disease / neurodegeneration","mechanism_class":"neuroprotective agent","modality":"small_molecule","objectID":"16909","rationale_one_line":"Description identifies a small molecule from a 'high content screen of libraries of small molecule compounds' for glaucoma and neurodegeneration; glaucoma is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16909","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Neurprotective Drug for Glaucoma Treatment"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Iron oxide nanoparticle hyperthermia platform for cancer; delivery innovation without clear SoC superiority data.","description_excerpt":"C11199: Targeted radiation- and chemo-enhancing heat therapy for cancer\r\n\r\nNovelty: \r\n\r\nThe proposed technology is a device and platform for treating local and metastatic cancer using multifunctionalized iron oxide nanoparticles in conjunction with radiation and chemotherapeutic agents.\r\nValue Propo","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"local and metastatic cancer (radiation- and chemo-enhancing hyperthermia)","mechanism_class":"iron oxide nanoparticle hyperthermia platform","modality":"other","objectID":"16862","rationale_one_line":"Described as 'a device and platform for treating local and metastatic cancer using multifunctionalized iron oxide nanoparticles'; this is a device/delivery platform — modality and indication both map to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16862","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A Process for Making Iron Oxide Nanoparticle Preparations for Cancer Hyperthermia"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Neurite-stimulating small molecules for glaucoma/neurodegeneration; unmet need but preclinical stage only.","description_excerpt":"Glaucoma is a major cause of visual loss and blindness in elderly Americans and throughout the world. One approach to treatment of glaucoma, and other optic nerve diseases as well as other neurodegenerations, is to develop “neuroprotective” agents that promote the survival of neurons. We have synthe","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"glaucoma, optic nerve disease, and neurodegeneration","mechanism_class":"neuroprotective / neurite-stimulating agent","modality":"small_molecule","objectID":"16792","rationale_one_line":"Description focuses on novel compounds for 'treatment of glaucoma, optic nerve disease, and other forms of neurodegeneration'; small molecule modality; glaucoma is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16792","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel molecules exhibiting neuroprotective and neurite stimulating activity for treatment of glaucoma, optic nerve disease, and other forms of neurodegeneration"},{"biomarker_overlap":"plasma sterol levels outside typical range as patient stratification biomarker","composite_score":0.43114606291324387,"cr_rationale":"Cholesterol modulator for ASD sterol-dysregulation subpopulation; niche unmet need but limited patient fraction.","description_excerpt":"C10705: Autism Spectrum Disorder: A Treatment Approach\r\nValue Proposition: \r\nWhile there is no known single cause for autism, Inventors have determined that a population of patients with ASD that is not associated with Smith-Lemli-Opitz Syndrome has plasma sterol levels that are outside the typical ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"autism spectrum disorder (ASD) — cholesterol/sterol dysregulation subpopulation","mechanism_class":"sterol/cholesterol modulator","modality":"small_molecule","objectID":"16740","rationale_one_line":"Described as cholesterol treatment for 'a population of patients with ASD' with abnormal plasma sterol levels; small molecule modality confirmed; autism is outside the supported indication enum; preliminary studies suggest preclinical stage.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16740","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Cholesterol Treatment of Autism Spectrum Disorder"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Repurposed FDA-approved drug for glaucoma/neurodegeneration; faster path but limited SoC differentiation data.","description_excerpt":"C10454: Known Drug found to have applicability in the area of glaucoma, optic nerve diseases, and other neurodegenerationsValue Proposition: \r\nKey Features\n•\tProvides treatment for glaucoma, other optic nerve diseases, and potentially any disease with neuronal dysfunction or loss.\n•\tExploits an FDA ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"glaucoma, optic nerve diseases, and neurodegeneration","mechanism_class":"neuroprotective agent (repurposed FDA-approved drug)","modality":"small_molecule","objectID":"16671","rationale_one_line":"Described as 'known drug found to have applicability in the area of glaucoma, optic nerve diseases' exploiting an FDA-approved small molecule; glaucoma is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16671","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A Neuroprotective Agent with Applicability to Glaucoma, Optic Nerve Diseases, and other Neurodegenerations"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Anti-meningitis agent addresses high-mortality infection; current SoC exists but resistance gaps are real.","description_excerpt":"C10349: Prevention and Treatment of Bacterial and Fungal Meningitis\r\nValue Proposition: Johns Hopkins University is currently seeking licensees for a method of preventing meningitis caused by bacterial or fungal infection. Meningitis is a serious and often deadly inflammation of the central nervous ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"bacterial and fungal meningitis","mechanism_class":"anti-meningitis agent","modality":"small_molecule","objectID":"16642","rationale_one_line":"Described as 'a method of preventing meningitis caused by bacterial or fungal infection'; small molecule modality confirmed by taxonomy; meningitis is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16642","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"C10349: Prevention and Treatment of Bacterial and Fungal Meningitis"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Helios Treg modulator is a broad multi-indication platform; clinical differentiation vs. SoC not defined.","description_excerpt":"C10323: Modulation of Regulatory T cell (Treg) Function\r\n    Value Proposition: \r\n•\tUp-regulate immune response\n•\tDown-regulate immune response\n•\tTreatment of cancer, infection, autoimmunity, and inflammation\r\n\r\nTechnical Details: \r\n\r\nRegulatory T cells (Treg) are a subset of the CD4 T cell populati","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer, infection, autoimmunity, and inflammation (regulatory T cell modulation)","mechanism_class":"Helios transcription factor modulator (Treg function)","modality":"other","objectID":"16636","rationale_one_line":"Described as manipulation of 'transcription factor Helios to enhance or down-modulate regulatory T cell function' for cancer, infection, autoimmunity, and inflammation; multi-indication target technology maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16636","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"IKZF2 (Helios)","title":"Manipulation of the Transcription Factor Helios to Enhance or Down-modulate Regulatory T Cell Function"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Combinational anti-HIV agent for co-infections; HAART SoC exists, marginal benefit over current regimens unclear.","description_excerpt":"Technical Details: \r\nWHO report has stated that there are 39.5 million people currently HIV positive worldwide. Of these, 4.3 million have been infected in the year 2006 alone. AIDS death reached 2.9 million this year which is the highest ever reported in any year. There are 40,000 new AIDS cases a ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"HIV/AIDS, HIV/HSV, and HIV/HPV co-infections","mechanism_class":"anti-HIV combinatorial agent","modality":"small_molecule","objectID":"16507","rationale_one_line":"Described as 'a combinational paradigm combating HIV, HIV/HSV or HIV/HPV infections'; small molecule modality confirmed by taxonomy; HIV/AIDS is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16507","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Development of a Combinational Paradigm Combating HIV, HIV/HSV or HIV/HPV Infections in Humans"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Artemisinin derivatives for toxoplasmosis; limited SoC alternatives for immunocompromised patients create real need.","description_excerpt":"C05086: Use of Novel Derivatives of Artemisinin To Inhibit Toxoplasma Gondii \r\nTechnical Details: \r\nToxoplasmosis, caused by the protozoan Toxoplasma gondii, is a medically important infection that is distributed worldwide. Current treatments for the prevention and treatment of toxoplasmosis are of ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"toxoplasmosis (Toxoplasma gondii infection)","mechanism_class":"artemisinin derivative antiparasitic","modality":"small_molecule","objectID":"16499","rationale_one_line":"Described as 'novel derivatives of artemisinin to inhibit Toxoplasma gondii'; small molecule modality confirmed; toxoplasmosis is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16499","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Use of Novel Derivatives of Artemisinin To Inhibit Toxoplasma Gondii"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"MBD2 first-in-class epigenetic inhibitor for broad cancer; novel target but no defined SoC differentiation yet.","description_excerpt":"C05053: Small Molecules Epigenetic Inhibitors for Cancer Prevention and Treatment.\r\nValue Proposition: &bull; Compounds represent first in class small molecule agents for inhibition of MBD2 activity. &bull; Reversible inhibition. &bull; Truly epigenetic agents, unlike other epigenetic drugs which ap","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer prevention and treatment (MBD2 epigenetic inhibitors); also sickle cell disease","mechanism_class":"MBD2 epigenetic inhibitor","modality":"small_molecule","objectID":"16488","rationale_one_line":"Described as 'first in class small molecule agents for inhibition of MBD2 activity' for cancer prevention and treatment; small molecule modality confirmed; broad cancer indication outside specific supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16488","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"MBD2","title":"C05053: Small Molecules Epigenetic Inhibitors for Cancer Prevention and Treatment."},{"biomarker_overlap":"IP6K2 expression","composite_score":0.43114606291324387,"cr_rationale":"HSP90 inhibitors show activity in refractory cancers where few options remain.","description_excerpt":"C05044: Developing Anti-cancer Drugs by Blockade of IP6-HSP90 BindingValue Proposition: \r\nA cellular enzyme known as inositol pyrophosphate 6 kinase 2 (IP6K2) has an important role in programmed cell death (apoptosis). JHU scientists discovered an interaction between IP6K2 and a protein known as Hea","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer / oncology (apoptosis / programmed cell death)","mechanism_class":"HSP90 inhibitor / IP6K2 blocker","modality":"small_molecule","objectID":"16482","rationale_one_line":"Description targets 'IP6K2 and a protein known as Heat Shock Protein-90 (HSP90)' via small-molecule blockade for anti-cancer activity; no specific PhaseFolio indication matched.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16482","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HSP90","title":"Developing Anti-cancer Drugs by Blockade of IP6-HSP90 Binding"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Anti-angiogenic strategies complement existing VEGF therapies but offer incremental benefit.","description_excerpt":"Technical Details:\r\n\t\t\tMicroRNAs (miRNAs) are 18-24 nucleotide RNA molecules that regulate the stability or translational efficiency of target mRNAs. miRNAs are frequently dysregulated in cancer cells and can act as oncogenes and tumor-suppressors. The proto-oncogene c-MYC encodes a transcription fa","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer / oncology (angiogenesis)","mechanism_class":"miRNA anti-angiogenic therapy","modality":"nucleic_acid","objectID":"16478","rationale_one_line":"MicroRNAs targeting c-MYC-regulated angiogenesis in cancer; classified as nucleic_acid per 'miRNAs are 18-24 nucleotide RNA molecules'; broad oncology does not map to a specific supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16478","subscores":{"clinical_relevance":0.5,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"c-MYC","title":"MicroRNAs As Targets for Anti-Angiogenic Therapies"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"Liquid embolic device improves procedural options for cerebral aneurysm embolization.","description_excerpt":"Value Proposition:\r\n·      Technology is a liquid embolic agent\r\n·      Provides a solution to adhesion and lack of control of embolic agent release during therapeutic embolization\r\n·      Has applications in procedures including aneurysm clippings and drug delivery\r\n \r\nUnmet Need\r\nTherapeutic embol","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cerebral aneurysm / therapeutic embolization","mechanism_class":"liquid embolic agent (polymer/dendrimer)","modality":"other","objectID":"16471","rationale_one_line":"EmboGel/EmboClear is a liquid embolic delivery device for endovascular occlusion; classified as device/platform, not a classic therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16471","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"EmboGel / EmboClear Therapeutic Solution"},{"biomarker_overlap":null,"composite_score":0.43114606291324387,"cr_rationale":"A2a modulation in T cell tolerance is mechanistically distinct but competes with approved checkpoint inhibitors.","description_excerpt":"C04897: Inducing and Inhibiting T Cell Tolerance with A2a Receptor Agonists and AntagonistsValue Proposition: \r\n\n&#8226; Therapeutic target for developing tolerance-inducing agents and tolerance-inhibiting agents for the treatment of autoimmune disease and cancer\n\n\n&#8226; Methods of treating an inf","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"autoimmune disease and cancer (T cell tolerance modulation)","mechanism_class":"A2a receptor agonist/antagonist","modality":"small_molecule","objectID":"16448","rationale_one_line":"A2a receptor small-molecule modulators for T cell tolerance in autoimmune disease and cancer; crosses multiple areas, no single PhaseFolio-supported indication dominant.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16448","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"ADORA2A","title":"Inducing and Inhibiting T Cell Tolerance with A2a Receptor Agonists and Antagonists"},{"biomarker_overlap":"STAT3 expression","composite_score":0.43114606291324387,"cr_rationale":"STAT3 cancer vaccine approach is immunologically rational but efficacy vs. checkpoint inhibitors unclear.","description_excerpt":"Technical Details:\r\n\t\t\tThe present invention relates to methods for treating and/or preventing cancer. In particular the present invention relates to ex vivo immunotherapeutic methods. The methods comprise decreasing Stat3 (signal transducer and activator of transcription3) expression and/or functio","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (ex vivo immunotherapy / cancer vaccine)","mechanism_class":"STAT3 antagonist cancer vaccine (ex vivo immunotherapy)","modality":"other","objectID":"16292","rationale_one_line":"Ex vivo immunotherapeutic method decreasing Stat3 in tumor cells for anti-cancer vaccination; broad oncology, no specific PhaseFolio-supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16292","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"STAT3","title":"Stat3 Antagonists and Their Uses as Vaccines Against Cancer"},{"biomarker_overlap":"SOCS1 promoter methylation","composite_score":0.43114606291324387,"cr_rationale":"SOCS1 methylation identifies JAK inhibitor sensitivity, enabling precision use of approved ruxolitinib-class drugs.","description_excerpt":"C03870: Identification and treatment of cancers with epigenetic silencing of SOCS/CIS genes.Value Proposition: \r\n\n&#8226; Methods for early detection, progression, and recurrence of hematological malignancies\n\n\n&#8226; Predictive biomarker useful for determining sensitivity to JAK inhibitors \n\n&#822","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"hematological malignancies (multiple myeloma, AML-adjacent)","mechanism_class":"SOCS1 promoter methylation / JAK inhibitor sensitization","modality":"other","objectID":"16214","rationale_one_line":"SOCS1 epigenetic silencing identifies JAK/STAT pathway activation in 'hematological malignancies'; covers multiple myeloma and related cancers — AML not the primary focus, mapped to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16214","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"JAK/STAT pathway","title":"SOCS1 Promoter Methylation Identifies a Target for JAK/STAT Activation"},{"biomarker_overlap":"BARX2 mutation","composite_score":0.43114606291324387,"cr_rationale":"BARX2 as ovarian cancer diagnostic/therapeutic target addresses an indication with inadequate early-detection SoC.","description_excerpt":"Technical Details:\r\n\t\t\tSurprisingly, it has been found that the Barx2 gene is mutated in ovarian cancer. The invention provides methods of diagnosis, prognosis and treatment of cancer related to the Barx2 gene.\r\n\t\t\tLooking for Partners:\r\n\t\t\tThis technology could be commercialized as diagnostic and p","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"ovarian cancer","mechanism_class":"BARX2 tumor suppressor / diagnostic target","modality":"other","objectID":"16158","rationale_one_line":"Barx2 gene mutations identified in ovarian cancer as diagnostic/therapeutic target; ovarian cancer outside supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16158","subscores":{"clinical_relevance":0.5,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"BARX2","title":"Human BARX2 Genes"},{"biomarker_overlap":"Cancer stem cell (CSC) surface markers","composite_score":0.42439882697947207,"cr_rationale":"Cancer stem cell detection assay; diagnostic/research tool with no direct therapeutic clinical impact.","description_excerpt":"Unmet Need\r\nWhile cancer therapeutics have drastically improved patient outcomes in numerous indications, novel methods to prevent cancer metastasis and recurrence are needed. Cancer stem cells (CSCs) are a unique subpopulation of a tumor that are more oncogenic and slow-growing than other cancer ce","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer stem cells — bladder cancer and broad oncology","mechanism_class":"Cancer stem cell assay / antibody-based carcinoma stem cell detection","modality":"monoclonal_antibody","objectID":"36490","rationale_one_line":"Rapid assay for carcinoma stem cells using antibody-based detection — primarily a diagnostic/research tool; bladder cancer is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36490","subscores":{"clinical_relevance":0.3,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":null,"title":"Rapid Assay for Carcinoma Stem Cells"},{"biomarker_overlap":"stage-specific antigen on immature human marrow cells (MY-10 antigen / CD34)","composite_score":0.42439882697947207,"cr_rationale":"CD34 isolation antibody enables transplant workflow improvement but does not alter clinical outcomes directly.","description_excerpt":"Human Stem Cells and Monoclonal Antibodies (MY-10)\r\n\t\t\tCase Number C02182\r\n\t\t\tABSTRACT\r\n\t\t\tMonoclonal antibodies that recognize a stage-specific antigen on immature human marrow cells. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"bone marrow transplantation; isolation of human marrow/blood cells","mechanism_class":"stem cell isolation antibody","modality":"monoclonal_antibody","objectID":"31266","rationale_one_line":"Monoclonal antibodies recognizing a stage-specific antigen on immature marrow cells for bone marrow transplantation; transplantation/cell isolation is not a therapeutic disease indication in the supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/31266","subscores":{"clinical_relevance":0.3,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"CD34","title":"Human Stem Cells and Monoclonal Antibodies (MY-10)"},{"biomarker_overlap":null,"composite_score":0.41114606291324385,"cr_rationale":"Molybdenum supplementation for IBS is a convenience/low-risk add-on; no evidence it outperforms SoC.","description_excerpt":"Unmet Need\r\nIrritable Bowel Syndrome is a chronic and incurable gastrointestinal disorder that affects 3-20% of Americans depending on certain sociocultural and comorbid factors. A poorly understood condition, current treatments consist of antispasmodics, antidiarrheals, and dietary restrictions. Un","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Irritable Bowel Syndrome (IBS); chronic gastrointestinal disorder","mechanism_class":"molybdenum supplementation","modality":"small_molecule","objectID":"53562","rationale_one_line":"Title and taxonomy confirm small molecule (molybdenum) for IBS; IBS is distinct from Crohn's and UC and is not among the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53562","subscores":{"clinical_relevance":0.45,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Treatment of Irritable Bowel Syndrome with Molybdenum"},{"biomarker_overlap":null,"composite_score":0.40398189468315693,"cr_rationale":"Peptide hydrogel for vascular anastomosis; surgical adjunct with limited comparative clinical outcome data.","description_excerpt":"Unmet Need\r\nThe formation of vascular anastomosis, the joining of two blood vessels, is a fairly common procedure utilized by many surgeons. All vascular bypass operations and solid organ transplants require anastomoses.  However, as the vessels being anastomosed become smaller or less firm, surgeon","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Vascular anastomosis / wound healing (surgical procedure support)","mechanism_class":"Multiphase transitioning peptide hydrogel for vascular anastomosis","modality":"peptide","objectID":"36500","rationale_one_line":"Multiphase transitioning peptide hydrogel to facilitate vascular anastomosis in bypass and transplant surgery — a biomaterial/medical device for a surgical procedure outside supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36500","subscores":{"clinical_relevance":0.4,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Multiphase Transitioning Peptride Hydrogel for Use in Vascular Anastamosis"},{"biomarker_overlap":null,"composite_score":0.40398189468315693,"cr_rationale":"Broad neurological peptide platform; no specific SoC comparison possible.","description_excerpt":"The ability to convert transient stimuli from the extracellular environment into long-term changes in neuronal function is central to an animal’s capacity to adapt and learn from its environment. This is mediated through sensory organs, which transduce physical and chemical stimuli into precise patt","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurological diseases (brain activity peptide therapeutics for neuronal function)","mechanism_class":"brain activity peptide (neuronal signal transduction modulator)","modality":"peptide","objectID":"24615","rationale_one_line":"Peptide therapeutics targeting neuronal long-term function changes mediated by extracellular stimuli; neurological indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24615","subscores":{"clinical_relevance":0.4,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Brain Activity Peptides (therapeutics)"},{"biomarker_overlap":"cholesterol modification of hedgehog protein","composite_score":0.40398189468315693,"cr_rationale":"Sterol-modified hedgehog peptides target broad cardiovascular/signaling axis without specific SoC comparison.","description_excerpt":"The present invention sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described. In one aspect of the invention, the method provides a me","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"hedgehog signaling; cholesterol biosynthesis and transport; cardiovascular applications","mechanism_class":"sterol-modified hedgehog polypeptide","modality":"peptide","objectID":"24196","rationale_one_line":"Sterol-modified hedgehog polypeptides for affecting cholesterol biosynthesis/transport; peptide modality with cardiovascular and hedgehog signaling focus — no single enumerated indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24196","subscores":{"clinical_relevance":0.4,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":"SHH (Hedgehog)","title":"Multiple Roles of Cholesterol in Hedgehog Protein Biogenesis and Signaling"},{"biomarker_overlap":null,"composite_score":0.40398189468315693,"cr_rationale":"Anti-angiogenic peptides are me-too without differentiation from approved anti-VEGF agents.","description_excerpt":"C04835: Novel Peptide Inhibitors of Angiogenesis\r\n\r\nNovelty: \r\n\r\nIdentification of 156 novel peptide fragments with putative anti-angiogenic properties.\r\nValue Proposition: \r\nAnti-angiogenic inhibitors are proving to be a very effective way of targeting a variety of cancers with metastatic potential","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancers with metastatic potential (anti-angiogenesis)","mechanism_class":"anti-angiogenic peptide inhibitor","modality":"peptide","objectID":"16426","rationale_one_line":"156 novel peptide fragments with 'anti-angiogenic properties' targeting a variety of cancers; no specific PhaseFolio-supported indication stated.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16426","subscores":{"clinical_relevance":0.4,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Identification of Novel Putative Endogeneous Angiogenic Protein Inhibitors"},{"biomarker_overlap":null,"composite_score":0.39439882697947204,"cr_rationale":"Autoantibody-based immunotherapy for breast cancer offers differentiated mechanism vs. chemotherapy/targeted SoC.","description_excerpt":"TITLE:          Autoantibodies as Anti-cancer Therapeutic Agents\r\nCASE NUMBER:    C13604\r\n \r\nUNMET NEED\r\n      It has been speculated that autoimmunity and cancer were linked but the missing step was how to turn that concept into a robust method for identifying which specific auto antibodies would b","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"breast cancer; autoantibodies as anti-cancer therapeutic agents","mechanism_class":"autoantibody-based cancer immunotherapy","modality":"monoclonal_antibody","objectID":"21899","rationale_one_line":"Autoantibodies identified as 'Anti-cancer Therapeutic Agents' with explicit breast cancer classification; monoclonal antibody immunotherapy for an enumerated indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/21899","subscores":{"clinical_relevance":0.6,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0},"target":null,"title":"Autoantibodies as Anti-cancer Therapeutic Agents"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Sutureless biodegradable connectors could reduce anastomotic complications but lack clinical evidence vs suture SoC.","description_excerpt":"Value Proposition\r\n·      Eliminates the need for time-consuming microsurgical sutures for tubular organ repair, reducing operative time and anesthesia exposure.\r\n·      Minimizes additional tissue trauma caused by suturing, improving functional recovery and reducing complications.\r\n·      Uses biod","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Tubular organ repair, wound healing","mechanism_class":null,"modality":"other","objectID":"61088","rationale_one_line":"Sutureless adhesive connectors using biodegradable materials are a medical device for tissue repair — not a classic therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/61088","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Sutureless Adhesive Connectors for Tissue Repair"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Sustained ocular delivery improves dosing, but existing antibiotic SoC remains adequate.","description_excerpt":"Unmet Need\r\n·        Ocular infections are quite common, with millions of cases occurring each year. Without proper treatment, infections can lead to serious complications (e.g., blindness).\r\n·        The current standard of care requires patients to self-administer eye drops at least 3 times daily ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Ocular infections","mechanism_class":"Ion-paired crystal drug delivery formulation","modality":"other","objectID":"60528","rationale_one_line":"Ion-paired crystal formulation for sustained ophthalmic drug delivery — a delivery platform; ocular infection not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60528","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Ion-paired Crystal Formulations for the Treatment and Prevention of Ocular Infection"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Microcrystal sustained-release platform for neuroprotection is a formulation improvement without demonstrated superiority over existing formulations.","description_excerpt":"Value Proposition\r\n·        High concentration, low volume, solvent-free microcrystal preparation of neuroprotective compounds.\r\n·        Facilitates direct delivery and sustained release of neuroprotective compounds to areas where low volumes are required (e.g., eye, inner ear, brain).\r\n·        Fo","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Neuroprotection (eye, inner ear, brain) — platform application","mechanism_class":"Microcrystal sustained-release formulation","modality":"other","objectID":"60527","rationale_one_line":"Water-based microcrystal formulation for sustained delivery of neuroprotective compounds — a delivery platform with no single supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60527","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Water-based Microcrystal Formulations for Sustained Release"},{"biomarker_overlap":"CD201, CD141","composite_score":0.39114606291324383,"cr_rationale":"Stem-cell selection is a manufacturing tool without proven outcome advantage.","description_excerpt":"Unmet Need\r\nBone defects are common and devastating conditions that are addressed in over 2.2 million surgeries yearly. Additionally, the biomedical burden of soft tissue defects is likewise enormous, estimated to be addressed in 5.2 million surgeries yearly. Autologous stem cell therapies hold grea","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Bone defects and soft tissue defects (regenerative medicine)","mechanism_class":"Stem cell surface marker partitioning (CD201/CD141)","modality":"other","objectID":"59856","rationale_one_line":"Partitioning of mesenchymal stem cells by CD201/CD141 expression for regenerative therapy — a stem cell selection/processing technology; bone/tissue defects not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59856","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Partitioning of Human Mesenchymal Stem Cells based on Expression of CD201 or CD141"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Broad mRNA/immunotherapy delivery platform; clinical advantage depends on payload not the platform.","description_excerpt":"Value Proposition:\r\n·        Creates a programmable immunostimulatory niche.\r\n·        Allows for tailor-made immune responses to vaccines and antigens.\r\n·        Flexible drug delivery platform enables mRNA therapeutics for infectious diseases and cancers.\r\n·        Applicable to existing mRNA vacc","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"infectious diseases and cancers (mRNA vaccines and immunotherapy)","mechanism_class":"mRNA LNP nanofiber-hydrogel immunostimulatory platform","modality":"other","objectID":"56057","rationale_one_line":"Broad delivery platform for mRNA vaccines and cancer immunotherapy; taxonomy places it under Therapeutic Delivery Platforms + Vaccines with no single supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/56057","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A mRNA Lipid Nanoparticle Incorporated Nanofiber-hydrogel Composite to Generate a Local Immunostimulatory Niche for Immunotherapy"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Intranasal testosterone prodrug is a delivery modification; CNS androgen delivery is niche and unvalidated.","description_excerpt":"Unmet Need\r\nProstate cancer (PC) is the most common non-cutaneous malignancy in men with over 1.4 million new cases diagnosed globally in 2020 (see Wang 2022). Although disease confined to the prostate is highly curable, many men will be diagnosed with metastatic prostate cancer which is not curable","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer / CNS androgen delivery","mechanism_class":"testosterone prodrug (intranasal CNS delivery)","modality":"small_molecule","objectID":"55806","rationale_one_line":"Taxonomy classifies under Small Molecules; the technology is an intranasal testosterone prodrug delivery system for CNS — prostate cancer context but primarily a delivery modality outside supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55806","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Intranasal Delivery of Testosterone Prodrugs to the CNS"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Polymeric neurotoxin delivery platform has therapeutic potential but aesthetic application dilutes clinical score.","description_excerpt":"Value Proposition\r\n·      Protein delivery system with tunable, sustained release profile, high payload capacity, and bioactivity retention\r\n·      Neurotoxin release profile of at least 120 days\r\n·      Scalable and translational manufacturing process\r\nUnmet Need\r\n·      Neurotoxins are widely use","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurotoxin (neuromodulator) sustained release — aesthetic and therapeutic applications","mechanism_class":"polymeric nanoparticle sustained-release platform","modality":"other","objectID":"55465","rationale_one_line":"Polymeric nanoparticle delivery platform for neurotoxins/neuromodulators; no disease-specific indication and platform classification makes modality 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55465","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Polymeric Nanoparticle Compositions for Encapsulation and Sustained Release of Neuromodulators"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Nanoparticle immunotherapy platform is versatile but lacks specific indication focus limiting clinical relevance assessment.","description_excerpt":"Value Proposition - Versatile immunotherapy platform with the ability to specifically target antigen presenting cells (APCs) ) following systemic delivery and without requiring targeting ligands to improve treatment efficacy.  - Flexibility to modulate the immune system through activation or inducin","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Autoimmune and inflammatory diseases broadly; immune modulation via nanoparticle-based genetic vaccination platform","mechanism_class":"immune-modulating nanoparticle vaccination platform","modality":"other","objectID":"53106","rationale_one_line":"Source describes a versatile nanoparticle immunotherapy and vaccination platform targeting antigen-presenting cells; delivery platform without a specific supported indication maps to other for both fields.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53106","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Immune-modulating nanoparticles as a versatile genetic vaccination platform"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Modified mRNA platform with broad application; clinical impact is platform-level and indication-agnostic.","description_excerpt":"Value Proposition\n\n\n\tmRNA use for therapeutic purposes has proven useful in treating a wide array of diseases. \n\tMajor challenges of mRNA therapies include immunogenicity, poor expression, and low stability.\n\tThis therapy contains modifications improving mRNA stability, efficiency, and immunogenicit","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Broad disease applications; mRNA modifications improving stability, efficiency, and immunogenicity for therapeutic translation","mechanism_class":"modified mRNA platform","modality":"nucleic_acid","objectID":"53078","rationale_one_line":"Source describes mRNA modifications applicable to a wide array of diseases; taxonomy confirms Gene Therapies and Vaccines; nucleic_acid is the best modality fit; no specific indication maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53078","subscores":{"clinical_relevance":0.4,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Compositions and Methods of Increasing RNA Translation"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"OA has only symptomatic SoC; glycosylation modulation offers marginal differentiation over existing agents.","description_excerpt":"Unmet Need:\r\nOsteoarthritis (OA) is the most common form of arthritis, affecting an estimated 32.5 million adults in the United States, with an increasing incidence as the population ages (see CDC) . OA is associated with considerable morbidity as a consequence of joint damage, resulting in pain, lo","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Osteoarthritis (OA) / musculoskeletal system","mechanism_class":"hexosamine analog / glycosylation modulator","modality":"small_molecule","objectID":"51729","rationale_one_line":"Description targets osteoarthritis via 'Hexosamine Analogs' classified under Small Molecules; OA is not among the 11 supported indication enums so maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/51729","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Hexosamine Analogs for Regenerative Medicine and Diseases Associated with the Musculoskeletal System"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Glioma siRNA delivery benefit depends on unproven payload efficacy.","description_excerpt":"C12218: Efficient Delivery Vehicle for Controlled Gene Knockdown\n\n\r\nNovelty: \n\n\r\nThis technology comprises the use of bioreducible polymer based nanoparticle system that can release siRNA cargo to the cytoplasm of cells to knockdown target gene expression in tissues.\n\n\r\nValue Proposition: \n\n\r\nGene t","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Brain cancer / glioma / neurological diseases (siRNA gene knockdown delivery)","mechanism_class":"siRNA delivery via bioreducible polymer nanoparticle","modality":"nucleic_acid","objectID":"50799","rationale_one_line":"Bioreducible poly(beta-amino ester) nanoparticle system delivers siRNA for gene knockdown; primarily a delivery platform for glioma/brain cancer; modality is nucleic_acid (siRNA); brain cancer not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/50799","subscores":{"clinical_relevance":0.4,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Bioreducible Poly(beta-amino ester)s for siRNA Delivery"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"ssDNA nanotube benefit depends on payload, not platform alone.","description_excerpt":"Unmet Need\r\nA large number of cancers, including glioblastoma (GBM), lack effective treatment due to inaccessibility of the primary tumor to pharmaceutical interventions. GBM is highly malignant, leading to 5-year survival rates below 10%. The inability to treat GBM tumors effectively is largely due","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Brain tumors / glioblastoma (ssDNA nanotube delivery)","mechanism_class":"ssDNA nanotube targeted delivery","modality":"nucleic_acid","objectID":"48133","rationale_one_line":"ssDNA nanotubes selectively targeting brain tumors and other cancers; a nucleic-acid-based delivery platform; brain cancer / glioblastoma not in enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48133","subscores":{"clinical_relevance":0.4,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"ssDNA Nanotubes Targeting Brain Tumors and Other Cancers Selectively"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Dialysate device improves AKI logistics without changing established CVVHD outcomes.","description_excerpt":"Unmet Need\r\nAcute kidney injury is common among critically ill patients, and has an associated mortality rate of 30% to 70% [1]. Continuous veno-venous hemodialysis (CVVHD) is a treatment for acute kidney injury that uses diffusive clearance to remove toxins and solutes from the patient’s circulatio","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Acute kidney injury / continuous veno-venous hemodialysis (dialysate production device)","mechanism_class":null,"modality":"other","objectID":"46015","rationale_one_line":"Device and method to produce dialysate for acute kidney injury treatment; a medical device / manufacturing tool; indication and modality both map to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/46015","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Device and Method to produce Dialysate"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Sorafenib controlled-release formulation is a convenience improvement over existing dosing of an approved drug.","description_excerpt":"Unmet NeedCancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. Despite technological advancements, the challenge remains to create anti-cancer drugs, or antineoplastics, that are safe, effective, and deliverable to the correct tissue at the right time. Today, targ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer (controlled long-term drug delivery of sorafenib)","mechanism_class":"crystallized multikinase inhibitor (sorafenib) controlled-release formulation","modality":"other","objectID":"45863","rationale_one_line":"Crystallization of sorafenib for controlled long-term drug delivery following single injection for cancer treatment; a delivery platform; general oncology without specific supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45863","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Crystallization of the Multi-receptor Tyrosine Kinase Inhibitor Sorafenib for Controlled Long-term Drug Delivery following a Single Injection"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Broad multi-CNS/COVID cocktail with no focused mechanistic claim; undecidable differentiation vs. SoC.","description_excerpt":"Unmet Need / Invention Novelty: There is an unmet clinical need to identify therapeutic interventions for perinatal and adult CNS insults and diseases for which there are currently no effective therapeutics. These include those resulting from perinatal opioid exposure, hydrocephalus, cerebral palsy,","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"perinatal and adult CNS insults and diseases, COVID-19","mechanism_class":null,"modality":"other","objectID":"45052","rationale_one_line":"Drug cocktail for CNS conditions (perinatal opioid exposure, hydrocephalus, cerebral palsy, brain trauma) and COVID-19; no single supported indication or modality enum applies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45052","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel drug cocktail for treatment of perinatal and adult CNS insults and diseases and COVID-19"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"ERCP-based hepatic delivery platform; clinical value depends on therapeutic payload, not the delivery method.","description_excerpt":"Unmet Need\r\nThe liver is a critical organ that performs more than 500 physiological functions in the human body including maintenance of metabolic homeostasis, digestion of drugs &amp; hormones, and secretion of essential proteins. Unfortunately, the liver is susceptible to a wide variety of disease","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"liver diseases (viral infection, inherited disorders, metabolic disease)","mechanism_class":"biliary hydrodynamic injection delivery","modality":"other","objectID":"44970","rationale_one_line":"Procedure/device for macromolecule delivery to the liver via ERCP; primarily a delivery method/medical device, not a therapeutic modality with a supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44970","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Optimized Biliary Hydrodynamic Injection via Endoscopic Retrograde Cholangiopancreatography for Macromolecule Delivery into the Liver"},{"biomarker_overlap":"novel biomarker for breast cancer outcome and nucleolin/CDK inhibitor sensitivity","composite_score":0.39114606291324383,"cr_rationale":"Nucleolin/CDK sensitization biomarker; adds treatment-selection value but is not a standalone therapeutic.","description_excerpt":"Unmet Need: Despite widespread research efforts, breast cancer remains the second leading cause of cancer deaths in women. There is an urgent need to identify novel biomarkers and treatment strategies against aggressive forms of breast cancer to improve prognosis and therapy.\r\n \r\nTechnical Details: ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"breast cancer (detection and treatment sensitization)","mechanism_class":"nucleolin/CDK inhibitor sensitization biomarker","modality":"other","objectID":"44791","rationale_one_line":"Novel biomarker for breast cancer detection and sensitization to nucleolin and CDK inhibitors; primary category is Oncology > Breast Cancer; technology is a target/biomarker, mapped modality to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44791","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"nucleolin","title":"Novel Biomarker for Breast Cancer Detection Outcome and Treatment Sensitization to Nucleolin and CDK Inhibitors"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Intraocular microcrystalline delivery platform; clinical impact depends entirely on therapeutic payload selected.","description_excerpt":"Unmet Need / Invention Novelty: Intravitreal injection is the gold standard for achieving drug delivery to the posterior segment of the eye. However, achieving effective delivery is challenging and the injections need to be performed frequently which hinders patient compliance. There therefore exist","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"posterior segment eye diseases (intraocular drug delivery)","mechanism_class":"sustained intraocular microcrystalline drug delivery","modality":"other","objectID":"44247","rationale_one_line":"Formulation for sustained intraocular delivery of drugs in microcrystalline form; ophthalmology delivery platform without a specific disease-modifying target or supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44247","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Methods and compositions for sustained intraocular delivery of drugs in microcrystalline form"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Suprachoroidal delivery platform for posterior segment; route advantage is real but payload-dependent.","description_excerpt":"Unmet Need / Invention Novelty: Traditional routes of administrating drugs to the eye are limited by lack of efficiency, frequent side effects, and poor patient tolerance of repeated injections into the eye. Injections into the suprachoroidal space (SCS) is an attractive strategy to overcome these l","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"posterior segment eye diseases (suprachoroidal drug delivery)","mechanism_class":"controlled-release suprachoroidal drug delivery","modality":"other","objectID":"43809","rationale_one_line":"Suprachoroidal space injection compositions for targeted ocular drug delivery; ophthalmology delivery platform, no specific molecular target or supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/43809","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Compositions and methods for controlled release suprachoroidal drug delivery"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Fluid-eluting orthopedic implant; device innovation with marginal differentiation vs. established implant SoC.","description_excerpt":"Unmet Need: \r\n \r\nThe current designs of weightbearing orthopaedic implants are limited due to the variabilities in the material and structural properties of the bones in which they are implanted.  In addition, many orthopaedic conditions -- and the implantation of foreign materials into the body -- ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"orthopedic conditions requiring weight-bearing implants","mechanism_class":"fluid-eluting orthopedic implant","modality":"other","objectID":"40354","rationale_one_line":"Individualized fluid-eluting orthopedic implants; medical device for orthopedic conditions, not a drug modality or supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/40354","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Individualized Fluid-Eluting Orthopedic Implants"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Inhalable dendrimer delivery platform for lung diseases; route is rational but payload-agnostic clinical value.","description_excerpt":"Unmet Need\r\nThe current global market for respiratory drugs is expected to increase from $30.9 billion in 2016 to $41.3 billion in 2023. While many aerosol therapeutics are used to treat lung diseases such as chronic obstructive pulmonary disease, asthma, and cystic fibrosis, administration of drugs","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"lung diseases (COPD, asthma, cystic fibrosis — pulmonary delivery)","mechanism_class":"inhalable supramolecular therapeutic delivery","modality":"other","objectID":"40064","rationale_one_line":"Dendrimer/polymer inhalable supramolecular delivery platform for lung diseases; respiratory delivery platform, no specific molecular therapeutic or supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/40064","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Inhalable Supramolecular Therapeutics to Treat Lung Diseases"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Self-assembling prodrug immune booster platform; broad cancer claim with no specific SoC comparison point.","description_excerpt":"Unmet Need\r\nThe market size for cancer immunotherapy was worth $58.1 billion in 2018, and with a CAGR of 14.5%, it is likely to reach up to $126.9 billion by 2026. Cancer immunotherapy is an extremely interesting and attractive means of extending the lifespan of patients with certain cancers. Howeve","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (immunotherapy, advanced-stage)","mechanism_class":"self-assembling prodrug immune booster","modality":"other","objectID":"40063","rationale_one_line":"Self-assembling prodrug delivery platform as immune booster for cancer immunotherapy; broad oncology immunotherapy platform does not map to a supported indication or modality enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/40063","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Self-Assembling Prodrugs as Immune Boosters for Cancer Immunotherapy"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Bioactive bone graft substitute for spinal fusion; incremental vs existing graft materials.","description_excerpt":"Unmet Need\r\nSpinal fusion is the welding together of adjacent vertebrae. Each year, more than 400,000 Americans undergo spinal fusion to treat conditions like neck and back pain, spinal instability, radiculopathy, and myelopathy. These surgeries require many items, such as spinal rods, screws, and c","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Spinal fusion / bony fusion (musculoskeletal)","mechanism_class":"Biomimetic mussel-inspired bone graft substitute","modality":"other","objectID":"38488","rationale_one_line":"Bioactive bone graft substitute material for spinal fusion — a tissue substrate/medical device for a musculoskeletal surgical procedure, not a drug-like therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/38488","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Biomimetic, Mussel-inspired, Bioactive Bone Graft Substitute Materials for Bony Fusion"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"DNA vaccine enhancement platform; immunogenicity improvement without specific clinical endpoint data.","description_excerpt":"Unmet Need: DNA vaccine technology is a desirable antiviral and cancer immunotherapeutic strategy for its simple design and cost-effective implementation. However, current DNA vaccine programs are hindered by poor immunogenicity. \r\n\r\nTechnical Details: Johns Hopkins researchers have designed a novel","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer immunotherapy and antiviral (broad oncology)","mechanism_class":"CD4+ T-cell activating fusion construct for DNA vaccine enhancement","modality":"other","objectID":"37978","rationale_one_line":"Fusion construct to enhance DNA vaccine immunogenicity via CD4+ T-cell activation — a platform immunotherapy technology for broad oncology/antiviral applications; modality is vaccine/platform, mapped to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/37978","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"CD4+ T-cell Activating Agent to Enhance DNA Vaccine Efficacy"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Polymer coating for antimicrobial delivery; incremental improvement over standard wound care.","description_excerpt":"Technology Description\r\nResearchers at Johns Hopkins have developed a polymer film coating for bandages and/or medical devices. treating or preventing infections. The coating can be used to delivery drugs for the treatment or prevention of infections, as the material can be synthesized to include se","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Bacterial infections / wound infections","mechanism_class":"Polymer film coating for antimicrobial drug delivery","modality":"other","objectID":"36588","rationale_one_line":"Composite polymer coatings for bandages/medical devices to deliver drugs preventing bacterial infections — a therapeutic delivery platform/medical device for infectious disease outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36588","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Composite polymer coatings for treating wounds"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Adhesive nanoparticle delivery platform; tumor uptake enhancement without specified therapeutic payload.","description_excerpt":"Unmet Need\r\nEffective drug delivery to solid tumors remains challenging. Outcome failure rates can reach 90% for current therapeutic approaches for solid tumors. The use of nanoparticles for the delivery of therapeutic agents can enhance the safety, pharmacokinetic profile, and bioavailability of ad","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Solid tumors (general cancer)","mechanism_class":"Adhesive/adsorption-switching nanoparticle for tumor uptake enhancement","modality":"other","objectID":"36587","rationale_one_line":"Nanoparticle platform with adhesive/adsorption switch to increase tumor uptake and delay tumor clearance — a delivery platform technology for broad solid tumor oncology, not fitting a single supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36587","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Adhesive/adsorption switch on nanoparticles to increase tumor uptake and delay tumor clearance"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"TSC2 phosphorylation platform for mTOR signaling; mechanism tool without specific clinical outcome advantage.","description_excerpt":"Unmet Need\r\nThe mechanistic target of rapamycin complex-1 (mTORC1) coordinates cellular processes and regulates recycling pathways in order to control cell growth and metabolic homeostasis. Additionally, in immune cells when the T-cell receptor is activated, the mTORC1 signaling pathway is also enga","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"T cell activation / immune cell signaling (broad therapeutic indications)","mechanism_class":"TSC2 phosphorylation / gene engineering to regulate mTOR signaling","modality":"other","objectID":"35364","rationale_one_line":"Targeting TSC2 S1365 by gene engineering or phosphorylation to regulate mTOR signaling for broad therapeutic indications — a target/mechanism platform without a specific supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35364","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TSC2 / mTORC1","title":"Targeting TSC2 S1366 (mouse, rat) S1365 (human) by gene engineering or phosphorylation to Regulate mTOR Signaling Cascades for Therapeutic Indications"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Force-dependent drug release platform; biophysical delivery concept without clinical differentiation data.","description_excerpt":"Unmet Need\r\nEach year, 650,000 people receive chemotherapy in an outpatient oncology clinic in the US. This technology is a development of force-dependent drug release system for the enhancement of selective killing and minimization of adverse effects to cancer treatments. Current chemotherapies suf","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Solid tumors (broad oncology chemotherapy)","mechanism_class":"Force-dependent drug release system for selective cancer cell killing","modality":"other","objectID":"35350","rationale_one_line":"Force-dependent drug release protein system to enhance selective killing of cancer cells during chemotherapy — a delivery/biophysical platform for broad oncology without a single supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35350","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Force-dependent drug release system for enhanced cancer treatment"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Phase-dependent neuromodulation device; CNS device without specific comparative clinical outcome data.","description_excerpt":"Unmet Need                 \r\nNeuromodulation is a technology that involves the spatiotemporal alteration of brain activity with electrical, magnetic, or chemical stimulation. Neuromodulation devices can be implantable or non-implantable and target specific areas of the body in order to restore prope","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Neurological disorders (neuromodulation — broad CNS disease)","mechanism_class":"Phase-dependent brain neuromodulation system","modality":"other","objectID":"35285","rationale_one_line":"System and method for phase-dependent brain neuromodulation — a neurostimulation medical device for neurological disorders, not a drug therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35285","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"System and Method for Phase Dependent Brain Neuromodulation"},{"biomarker_overlap":"p53 mutation status; p21WAF1/CIP1/SDI1; 14-3-3 sigma expression in CRC","composite_score":0.39114606291324383,"cr_rationale":"14-3-3/p53 G2 arrest mechanism in CRC; target discovery tool rather than therapeutic with SoC comparison.","description_excerpt":"Technical Details:\r\n\t\t\tExposure of colorectal cancer (CRC) cells to ionizing radiation results in a cell-cycle arrest in G1 and G2. The G1 arrest is due to p53-mediated induction of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/SDI1, but the basis for the G2 arrest is unknown. Through a quantit","dev_stage":"unknown","exclusivity_status":"unknown","indication":"colorectal_cancer","indication_free_text":"Colorectal cancer (CRC)","mechanism_class":"14-3-3 mediated p53-induced G2 cell cycle arrest","modality":"other","objectID":"35025","rationale_one_line":"14-3-3 mediates p53-induced G2 arrest in CRC cells — a target/biomarker discovery for colorectal cancer; modality is target/research tool, mapped to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35025","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"14-3-3 / TP53 / p21","title":"14-3-3 Mediates a p53-Induced G2 Arrest"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Delivery platform for existing ARBs in diabetic wounds; modest improvement over wound SoC.","description_excerpt":"Unmet Need: Dysregulation in the renin-angiotensin system (RAS) has been increasingly implicated in abnormal diabetic wound healing. The effect of angiotensin receptor blockers in a wounded subject can be harmful during the early stages of wound healing; however, use of angiotensin receptor blockers","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"diabetic wound healing","mechanism_class":"angiotensin receptor blocker hydrogel delivery","modality":"other","objectID":"34531","rationale_one_line":"Supramolecular hydrogel delivery platform for angiotensin receptor blockers targeting 'diabetic wound healing'; modality is a delivery platform not a classic therapeutic class, mapped to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/34531","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"AGTR1","title":"Supramolecular Hydrogels Containing Angiotensin Receptor Blockers for Targeted Treatment of Diabetic Wounds"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Multi-indication H2S donor platform; undifferentiated across diseases with no primary endpoint advantage shown.","description_excerpt":"Unmet Need\r\nHydrogen sulfide (H2S) has long been studied as an endogenous signaling molecule responsible for a variety of bodily functions including inhibition of inflammation, inhibition of oxidative stress and regulation of calcium and pH levels in brain cells (anti-Parkinson’s Disease). In additi","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"inflammation, oxidative stress, Parkinson's disease, liver and ovarian cancer","mechanism_class":"hydropersulfide donor / H2S signaling modulator","modality":"small_molecule","objectID":"30481","rationale_one_line":"S-substituted thioisothiourea small molecules as hydropersulfide donors; multi-indication description spans Parkinson's, cancer, and inflammation — none mapping cleanly to a single supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/30481","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"S-Substituted Thioisothioureas as New Physiologically Useful Hydropersulfide Donors"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Delivery platform for siRNA in cancer; clinical impact depends entirely on undefined therapeutic payload.","description_excerpt":"Unmet Need\r\nIn theory, RNA interference (RNAi) can be used to decrease expression of any gene driving a disease or pathology, but has seen limited clinical usage as gene therapy due to technical issues, i.e., small interfering RNA (siRNA) cannot enter cells efficiently due to their weight and charge","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"oncology (broad cancer) — siRNA gene therapy delivery","mechanism_class":"cationic nanopolymer siRNA delivery","modality":"nucleic_acid","objectID":"28988","rationale_one_line":"Biodegradable dextran cationic nanopolymer carrier for siRNA delivery in cancer; modality is nucleic_acid (siRNA); broad oncology does not map to a specific supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28988","subscores":{"clinical_relevance":0.4,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A Novel Method to Efficiently Synthesize a Biodegradable Dextran to Use as an Efficient Cationic Nanopolymer Carrier for siRNA Delivery"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Lacrimal delivery device improves convenience for dry eye/glaucoma; existing topical SoC is adequate.","description_excerpt":"Unmet Need\r\nThere has been a growing development of novel drug delivery implants and tear drainage occlusion devices designed for delivery in the canalicular space. These implants are delivered through the punctal os, or the entrance to the lacrimal canicular space. These current strategies require ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"dry eye syndrome and glaucoma (ophthalmology)","mechanism_class":"lacrimal canalicular drug delivery device","modality":"other","objectID":"28802","rationale_one_line":"Lacrimal canalicular delivery system for ophthalmic drug delivery in dry eye and glaucoma; device/delivery platform for ophthalmology, not in supported indication or modality enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28802","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"LACRIMAL CANALICULAR DELIVERY SYSTEM"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Cellulose hydrogel offers corneal wound delivery/device improvement over existing care.","description_excerpt":"Unmet Need\r\nCorneal lacerations are a common type of eye injury. These can occur in varying degrees of severity, and in many cases the wound is non-self-sealing. This type of injury requires significant intervention including sutures and, in some cases, many layers of grafts. During the course of tr","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"corneal laceration wound healing (ophthalmology)","mechanism_class":"cellulose hydrogel wound healing membrane","modality":"other","objectID":"26834","rationale_one_line":"Biocompatible cellulose hydrogel membrane for corneal wound healing; medical device/biomaterial for ophthalmology is outside supported indication and modality enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/26834","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Wound Healing Compositions Comprising Biocompatible Cellulose Hydrogel Membranes and Methods of Use Thereof"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Delivery platform only; no disease-specific SoC comparison possible.","description_excerpt":"Targeted, noninvasive neuromodulation of the brain of an otherwise awake subject could revolutionize both basic and clinical neuroscience. Towards this goal, the JHU scientists have developed nanoparticles that allow noninvasive uncaging of a neuromodulatory drug upon the application of focused ultr","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"targeted noninvasive neuromodulation of the brain","mechanism_class":"ultrasound-gated nanoparticle drug uncaging","modality":"other","objectID":"25111","rationale_one_line":"Delivery platform technology — biodegradable nanoparticles for focused-ultrasound-triggered neuromodulatory drug release; no specific disease indication or therapeutic modality enum applies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/25111","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Particulate Drug Delivery System to Enable Targeted Ultrasound-gated Release of Neuromodulatory Agents"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Inhalable delivery platform for NSCLC chemo; no clinical differentiation over approved SoC.","description_excerpt":"Unmet Need:\r\nLocalized delivery of chemotherapeutics to the lung via inhalation provides a straightforward method of directly targeting lung cancers. However, due to the presence of multiple delivery barriers, the effectiveness of the        approach has been limited. Here, we disclose an invention ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"nsclc","indication_free_text":"lung cancer (inhalable chemotherapeutic delivery)","mechanism_class":"inhalable ferritin nanocage drug delivery","modality":"other","objectID":"24907","rationale_one_line":"PEGylated ferritin nanocage platform for inhalable delivery of chemotherapeutics to lung cancers; mapped to nsclc as the supported lung cancer enum; modality is a delivery platform.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24907","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"PEGylated Human Heavy Chain Ferritin Nanocages and Their Uses for Therapeutic and Diagnostic Delivery"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Biomimetic delivery platform; no disease-specific SoC comparison.","description_excerpt":"Unmet Need: \r\nAlthough biomimetic polymeric particles have been used for drug delivery, these particles have not been able to mimic the natural cell in terms of size, shape, mechanical properties, and surface features. This invention is a biomimetic particle platform that can be used to simulate nat","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"drug delivery platform (biomimetic particle simulating natural cells)","mechanism_class":"biomimetic cell-mimicking drug delivery particle","modality":"other","objectID":"24866","rationale_one_line":"Platform technology — biomimetic particles mimicking natural cells for drug delivery; no disease-specific indication or therapeutic modality enum applies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24866","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Biomimetic particle platform for enhanced drug delivery"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"CNS delivery platform; clinical impact depends entirely on cargo.","description_excerpt":"Unmet Need / Invention Novelty: Drug delivery to the brain is hindered by the brain’s wide perivascular space and protein-dense extracellular matrix, which limits diffusion of drugs from site of administration into the brain parenchyma. Methods are needed to improve the penetration of drugs into the","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"drug delivery to the brain parenchyma (overcoming perivascular space barriers)","mechanism_class":"brain-penetrating nanoparticle delivery enhancement","modality":"other","objectID":"24839","rationale_one_line":"Platform technology to improve nanoparticle penetration into brain parenchyma; delivery platform with no specific disease indication or therapeutic modality enum match.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24839","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Method to Improve Brain Penetration of Nanoparticles"},{"biomarker_overlap":"PSMA expression","composite_score":0.39114606291324383,"cr_rationale":"Raman nanoplex incremental vs approved PSMA imaging agents for prostate cancer.","description_excerpt":"Unmet Need:\r\nNon-invasive assessment of tumor burden and cancer-selective treatment in prostate cancer. This approach is will allow visualization in real-time of the distribution and action of therapeutic agents in vivo by transducing the presence of PSMA at the tissue level to characteristic Raman ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer (PSMA-targeted imaging and therapy)","mechanism_class":"PSMA-targeted Raman spectroscopy nanoplex","modality":"small_molecule","objectID":"24830","rationale_one_line":"PSMA-targeted plasmon-enhanced Raman nanoplex for prostate cancer imaging and therapy; prostate cancer is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24830","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PSMA","title":"PSMATargeted Plasmon-enhanced Raman Spectroscopy Reporters for Molecular Imaging and Therapy of Prostate Cancer"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Generic stimulus-triggered delivery platform; no disease indication for SoC comparison.","description_excerpt":"UNMET NEED\n\nMany diseases in the human body are best treated using drug delivery in which a triggered release of extracellular therapeutics or a triggered shape change of intracellular therapeutics mediates the delivery of drugs. However, these therapeutics should only be released under specific cir","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"triggered drug release platform for extracellular and intracellular therapeutics","mechanism_class":"shape-memory particle triggered drug release","modality":"other","objectID":"24815","rationale_one_line":"Shape memory particles as a platform for stimulus-triggered drug delivery; no disease-specific indication stated and modality is a delivery platform.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24815","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Shape Memory Particles for Biomedical Uses"},{"biomarker_overlap":"PSMA expression","composite_score":0.39114606291324383,"cr_rationale":"PSMA theranostic space has approved agents; triazole conjugate is incremental.","description_excerpt":"Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein expressed on the surface of prostate tumors, particularly in castrate-resistant, advanced and metastatic disease.  PSMA is also expressed in neovascular endothelium of most solid tumors, such as lung, colon, pancreatic,","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer and solid tumors (PSMA-targeted diagnostic imaging and therapy)","mechanism_class":"PSMA-targeted radiolabeled triazole conjugated urea","modality":"small_molecule","objectID":"24732","rationale_one_line":"Radiolabeled PSMA-targeted small molecule (YC-88) for imaging and therapy of prostate cancer and neovascular solid tumors; prostate cancer outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24732","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PSMA","title":"Radiolabeled Triazole Conjugated Ureas \n(YC-88)"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Local brain drug delivery hydrogel platform; clinical value depends on specific cargo.","description_excerpt":"We have developed a novel type of therapeutic agent-containing liquids that comprise self-assembling peptide nanofibers and  physically encapsulated and chemically bound medicinal compounds, capable of transforming into a gel form upon contact with body fluids. The resulting gel can gradually releas","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"brain-related diseases (local drug delivery via nanofiber hydrogel)","mechanism_class":"self-assembling peptide nanofiber hydrogel drug delivery","modality":"other","objectID":"24722","rationale_one_line":"Peptide nanofiber hydrogels for local controlled drug release in brain-related diseases; delivery platform technology without a specific supported indication or therapeutic modality enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24722","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Therapeutic Nanofiber Hydrogels for Local Treatment of Brain-related Diseases"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Nanogel delivery platform for insoluble drugs; no disease-specific SoC comparison.","description_excerpt":"The present invention involves a biocompatible nanogel composition for the delivery of hydrophobic substances that are not readily soluble in organic solvents.  These nanogels have been designed to contain hydrophobic cores which encapsulate the insoluble molecules, and a hydrophilic shell which all","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"hydrophobic drug delivery (nanogel carriers for insoluble compounds)","mechanism_class":"hydrophobic-core nanogel drug carrier","modality":"other","objectID":"24629","rationale_one_line":"Biocompatible smart nanogels as delivery carriers for hydrophobic drugs; platform technology with no disease-specific indication or therapeutic modality enum match.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24629","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Biocompatible \"smart\" nanogels as carriers for hydrophobic drugs"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Migraine has multiple approved SoC; fospropofol delivery is incremental reformulation.","description_excerpt":"INVENTION NOVELTY\n\nThis invention provides for novel formulations and delivery methods of the propofol prodrug, fospropofol, allowing for its use in additional indications beyond anesthesia, including migraine, analgesia, and emesis treatment. \n\n\r\nVALUE PROPOSITION\n\nPropofol and its water soluble pr","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"migraine, analgesia, and emesis (fospropofol prodrug delivery beyond anesthesia)","mechanism_class":"GABA-A modulator / anesthetic prodrug (fospropofol buccal/intranasal delivery)","modality":"small_molecule","objectID":"24375","rationale_one_line":"Novel buccal and intranasal formulations of fospropofol for migraine, analgesia, and emesis; neurological/pain indication outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24375","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"GABAA","title":"Buccal and Intranasal Delivery of Fospropofol"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Extracellular vesicle delivery platform for cancer biologics; no disease-specific SoC.","description_excerpt":"UNMET NEED\n\nBiologic therapeutics, specifically antibodies, have demonstrated tremendous potential for treatment of a wide range of cancer types. Antibodies are designed to possess a strong affinity for a particular target, a very desirable characteristic for a drug. However, antibodies must be admi","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (biologic antibody delivery via engineered extracellular vesicles)","mechanism_class":"anucleate cellular vesicle biologics delivery platform","modality":"other","objectID":"24372","rationale_one_line":"Engineered anucleate cellular and extracellular vesicles as a novel platform for repeated biologics/antibody delivery in cancer; delivery platform without a specific supported indication or therapeutic modality enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24372","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Engineered Anucleate Cellular and Extracellular Vesicles as a Novel Biologics Delivery Platform"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Myosin II activators span too many indications; no clear SoC-beating clinical differentiation evident.","description_excerpt":"Novelty:\r\nA panel of myosin II activators developed to treat disease and useful for tissue engineering in regenerative medicine.\r\nValue Proposition:\r\nChanges in cellular mechanics due to impaired activity of myosin II, a motor protein essential for cell division, motility, and rigidity, is associate","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"myopathies, heart disease, pancreatic cancer, and other diseases involving impaired myosin II activity; regenerative medicine","mechanism_class":"myosin II activator","modality":"small_molecule","objectID":"24313","rationale_one_line":"Panel of small-molecule myosin II activators for broad disease applications including myopathies and cancer; no single enumerated indication dominates — maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24313","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"MYH (myosin II)","title":"Activators of Myosin II for Modulating Cell Mechanics"},{"biomarker_overlap":"giant obscurin expression level and distribution in tumor tissue","composite_score":0.39114606291324383,"cr_rationale":"Obscurin biomarker for breast cancer metastasis prognosis; no direct therapeutic improvement over SoC.","description_excerpt":"Provided herein are methods and kits for evaluating potential for invasiveness, metastasis, or recurrence of an epithelial cell cancer. In the methods the expression profile of giant obscurins is detected in a tissue sample of tumor cells or suspected tumor cells and assessed for giant obscuring exp","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"breast cancer; epithelial cell cancer invasiveness, metastasis, and recurrence","mechanism_class":"tumor suppressor protein (giant obscurins)","modality":"other","objectID":"24273","rationale_one_line":"Methods and kits evaluate invasiveness/metastasis of epithelial cancers using giant obscurin expression; classified under breast cancer with therapeutic and prognostic potential — primarily a biomarker/protein tool mapping to 'other' modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24273","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"OBSCN (giant obscurins)","title":"Giant Obscurins: Novel Tumor and Metastasis Suppressors in Breast Cancer with Prognostic and Therapeutic Potentials"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Drug-amphiphile nanocarrier platform improves delivery but lacks disease-specific clinical differentiation data.","description_excerpt":"UNMET NEED\r\nMany anticancer drug delivery systems suffer from lack of target specificity and drug-loading limitations. Additionally, many drug delivery systems require the use of a nanocarrier, which have certain disadvantages including limitations on the amount of loaded drug and batch to batch var","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (broad oncology); anticancer chemotherapeutic delivery","mechanism_class":"self-assembling drug-amphiphile nanocarrier","modality":"other","objectID":"24265","rationale_one_line":"Self-assembled drug-amphiphile delivery platform for anticancer chemotherapeutics; primarily a delivery platform technology across broad oncology — no specific enumerated indication, modality maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24265","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Self-Assembling Drug-Amphiphiles for the Delivery of Anticancer Chemotherapeutics"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Smooth muscle cell differentiation protocol is early-stage tool; clinical translation to vascular repair is distant.","description_excerpt":"This invention relates, e.g., to a method for differentiating mammalian (e.g., human) pluripotent stem cells (PSCs) into smooth muscle-like cells (SMLCs) in vitro, comprising a) plating a single-cell suspension of PSCs that are smaller than 50 μm at a seeding concentration of about 5×104 cells/cm2-a","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"smooth muscle cell-based regenerative medicine; vascular tissue engineering","mechanism_class":"pluripotent stem cell differentiation protocol","modality":"other","objectID":"24229","rationale_one_line":"Method for differentiating human pluripotent stem cells into smooth muscle-like cells for cord-like structure support in vitro; a regenerative medicine / research tool, not a conventional therapeutic.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24229","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Smooth-muscle-like-cells (SMLCs) Derived from Human Embryonic Stem Cells (hESCs) Support Cord-like Structure in vitro"},{"biomarker_overlap":"BRAF V600E mutation; TERT C228T promoter mutation","composite_score":0.39114606291324383,"cr_rationale":"BRAF+TERT co-mutation biomarker improves thyroid cancer risk stratification but is prognostic, not therapeutic.","description_excerpt":"BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer with Highest Recurrence\r\nJHU REF: C12971\r\n \r\nInvention Novelty: \r\nThis invention discloses the coexistence of BRAF V600E and TERT C228T mutations as novel molecular marker that defines the most","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"papillary thyroid cancer; aggressive thyroid cancer with BRAF V600E and TERT promoter co-mutations","mechanism_class":"co-mutation biomarker panel (BRAF V600E + TERT C228T)","modality":"other","objectID":"22516","rationale_one_line":"Coexistence of BRAF V600E and TERT C228T as a molecular marker for aggressive papillary thyroid cancer; primarily a diagnostic/prognostic biomarker tool — modality maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/22516","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"BRAF, TERT","title":"BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer with Highest Recurrence"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Anisotropic lipid bilayer particle platform improves antigen presentation but lacks disease-specific clinical data.","description_excerpt":"Invention novelty: This invention is ellipsoidal biomimetic particle with supported lipid bilayer (SLB) that mimic the most critical features of cell-cell interactions including paracrine release of soluble mediators, dynamic radius of curvature, and fluidity of surface receptors for clustering.\r\n \r","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer and infectious diseases; drug/antigen delivery platform","mechanism_class":"anisotropic biodegradable particle with supported lipid bilayer","modality":"other","objectID":"21794","rationale_one_line":"Ellipsoidal biomimetic particles with supported lipid bilayer for dynamic surface protein presentation; a delivery platform technology spanning oncology and infectious diseases — modality maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/21794","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Anisotropic biodegradable particles with supported lipid bilayers for spatially dynamic surface protein presentation"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"SCFA hybrids with broad multi-indication claims and no defined molecular target; marginal differentiation.","description_excerpt":"Value Proposition: This invention solves two problems inherent with the use of Short Chain Fatty Acid (SCFA)-monosaccharide hybrid molecules to modulate cellular activity. The first problem is the toxicity of former versions of these compounds. The current invention uses structure activity relations","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer or viral infection","mechanism_class":"SCFA-monosaccharide hybrid modulator","modality":"small_molecule","objectID":"18728","rationale_one_line":"Short chain fatty acid hybrid compounds for cancer or viral infection via cellular activity modulation; broad multi-indication without a named molecular target, maps to other/small_molecule.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/18728","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Short Chain Fatty Acid (SCFA) Hybrid Compounds as Carbohydrate-based Therapeutics for Cancer or Viral Infection"},{"biomarker_overlap":"amyloid precursor protein (APP) in cerebrospinal fluid","composite_score":0.39114606291324383,"cr_rationale":"APP MRM assay improves Alzheimer's biomarker measurement; incremental over existing CSF amyloid/tau diagnostics.","description_excerpt":"C12148: Method for Measuring Amyloid Precursor Proteins for Alzheimer&rsquo;s Disease\r\nNovelty: \r\nThis invention develops a method to measure the concentrations of various forms of Amyloid Precursor Proteins (APP) in cerebrospinal fluid (CSF).\r\nValue Proposition: \r\nAlzheimer's disease (AD) is the mo","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Alzheimer's disease (amyloid precursor protein measurement in CSF)","mechanism_class":"MRM assay for APP measurement","modality":"other","objectID":"17180","rationale_one_line":"MRM assay measuring APP concentrations in CSF for Alzheimer's disease diagnosis — primarily a diagnostic/research tool; Alzheimer's outside supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17180","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"Amyloid Precursor Protein (APP)","title":"MRM Assay Measurement of Amyloid Precursor Protein in Healthy and Alzheimers Disease Cerebrospinal Fluids"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Dietary compounds to reduce alcohol toxicity; marginal vs supportive care SoC for alcohol-associated harm.","description_excerpt":"C11719: Drug to Prevent Alcohol Toxicity\r\n\r\nNovelty: \r\n\r\nThe technology involves the use of dietary chemicals to reduce the unpleasant symptoms associated with alcohol consumption and reduce the risk of serious diseases.\r\nValue Proposition: \r\nAlcohol toxicity from the consumption of a large amount o","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"alcohol toxicity prevention / metabolic disease","mechanism_class":"dietary chemical / nutritional compound (alcohol metabolism modulator)","modality":"small_molecule","objectID":"17035","rationale_one_line":"Dietary chemicals to reduce alcohol toxicity symptoms and associated metabolic disease risk — alcohol toxicity is not a supported indication enum entry; small_molecule via nutritional compound taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17035","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Prevention of Alcohol Toxicity"},{"biomarker_overlap":"oncogenic mutations in amino acid sequence of novel cancer gene","composite_score":0.39114606291324383,"cr_rationale":"Oncogenic mutation target discovery tool; early-stage platform without defined therapeutic or endpoint vs SoC.","description_excerpt":"C11563: A Novel Target for Anti-cancer Drug Development\r\nNovelty: \r\nThis technology identifies novel oncogenic mutations in a gene that contribute to cancer development suggesting new opportunities for therapeutic management using inhibitors of this gene.\r\nValue Proposition: \r\nThe researchers have i","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (oncogenic mutations in novel gene)","mechanism_class":"oncogenic mutation target identification","modality":"other","objectID":"16980","rationale_one_line":"Identifies novel oncogenic mutations in an unnamed gene as a target for anti-cancer drug development — broad oncology target discovery without named indication in supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16980","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A Novel Target for Anti-cancer Drug Development"},{"biomarker_overlap":"Tardbp as biomarker for obesity, diabetes, ALS, and dementia","composite_score":0.39114606291324383,"cr_rationale":"TDP-43 knockout model is preclinical target ID for diabetes/obesity; no therapeutic modality defined.","description_excerpt":"C11168: A Gene Linked to Obesity, and Alters Body Fat Metabolism\r\n    Value Proposition: \r\n\n&#8226; Identifies novel therapeutic target to control obesity and diabetes.\n\n\n\n&#8226; Helps to understand incurable diseases: frontal temporal dementia and amyotrophic lateral sclerosis.\n\r\n\r\nTechnical Detai","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"obesity and diabetes; also ALS and frontotemporal dementia","mechanism_class":"TDP-43 (Tardbp) knockout model / therapeutic target","modality":"other","objectID":"16848","rationale_one_line":"Description identifies 'novel therapeutic target to control obesity and diabetes' via conditional Tardbp knockout; type2_diabetes is the best-fit supported indication among the multiple areas mentioned; preclinical animal model stage confirmed.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16848","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TARDBP","title":"Germline and Conditional Deletion of Tardbp"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Transcription inhibitor combination for broad cancer; me-too synergy claim without differentiated clinical endpoint.","description_excerpt":"Value Proposition: Tetra-O-methyl nordihydroguaiaretic acid (M4N, EM1421, Terameprocol), a novel transcription inhibitor, is an effective anticancer agent with excellent safety profile (Smolewski, P. Idrugs 11, 204-214, 2008). In the current study, we report an enhancement of anticancer activities o","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (broad — transcription inhibitor combination anticancer)","mechanism_class":"transcription inhibitor combination","modality":"small_molecule","objectID":"16807","rationale_one_line":"Describes 'enhancement of anticancer activities of M4N' (a transcription inhibitor) in combination with UCN-01; small molecule modality confirmed; broad cancer indication does not map cleanly to a single supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16807","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Rapid Induction of Human Cancer Cell Death by Synergistic Treatment of Tetra-O-Methyl Nordihydroguaiaretic Acid (M4N, Terameprocol) with 7-Hydroxystaurosporine (UCN-01)"},{"biomarker_overlap":"histone acetyltransferase activity as biomarker for cancer","composite_score":0.39114606291324383,"cr_rationale":"Broad HAT inhibition lacks clear differentiation from epigenetic oncology SoC.","description_excerpt":"C10974: Anti-Cancer Therapeutic Biomarker\r\n\r\nNovelty: \r\n\r\nThis technology includes a novel histone acetyltransferase (HAT) inhibitor as a therapeutic and biomarker for a vast scope of cancers.\r\nValue Proposition: \r\nAcetylation and deacetylation of histone protein lysine residues are a major mechanis","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"broad cancer (HAT inhibitor as anticancer therapeutic and biomarker)","mechanism_class":"HAT inhibitor","modality":"small_molecule","objectID":"16804","rationale_one_line":"Described as 'a novel histone acetyltransferase (HAT) inhibitor as a therapeutic and biomarker for a vast scope of cancers'; small molecule modality confirmed; broad-cancer indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16804","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Use of Histone Acetyltransferase Inhibitors as Novel Anti-cancer Therapies"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Mitochondrial angiotensin agonist for wound healing; preclinical with no head-to-head SoC comparison.","description_excerpt":"C10816: Wound Healing Therapeutic Based on Protective Anti-inflammatory Receptor\r\n Value Proposition: \r\nJHU scientists have recently determined that mitochondria contain functional Angiotensin (AT) receptors which are anti-inflammatory and potential targets for agents that protect and preserve mitoc","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"wound healing (mitochondrial angiotensin receptor-mediated anti-inflammatory therapy)","mechanism_class":"mitochondrial angiotensin receptor agonist","modality":"small_molecule","objectID":"16769","rationale_one_line":"Described as 'therapeutic based on protective anti-inflammatory receptor' targeting mitochondrial angiotensin receptors for wound healing; small molecule confirmed by taxonomy; wound healing is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16769","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"AT receptor (angiotensin receptor)","title":"Presence of a Novel Protective Anti-inflammatory Receptor in Human Mitochondria and Its Role in Preserving Mitochondrial Functions"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"ABCG2 urate transport modulation for gout; research tool without differentiated therapeutic profile vs. SoC.","description_excerpt":"C10666: Treatment of Hyperuricemia and Gout\r\n   \r\n\r\nTechnical Details: \r\n\r\nAbout 3 million people in U.S. are suffering from insufficiently treated gout.  Incidence has more than tripled in the past 20 years, as the disease is correlated with being overweight, drinking too much alcohol, or having di","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"hyperuricemia and gout (ABCG2-mediated urate transport modulation)","mechanism_class":"ABCG2 urate transporter modulator","modality":"other","objectID":"16726","rationale_one_line":"Described as 'modulation of ABCG2-mediated urate transport to treat hyperuricemia and gout'; primarily a target/research tool without a confirmed therapeutic modality; gout is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16726","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"ABCG2","title":"Modulation of ABCG2-mediated Urate Transport to Treat Hyperuricemia and Gout"},{"biomarker_overlap":"FOXF1/FOXF2 epigenetic silencing as biomarker for breast cancer","composite_score":0.39114606291324383,"cr_rationale":"FOXF tumor suppressor reactivation target for breast cancer; research tool without defined therapeutic modality.","description_excerpt":"C10643: Expression plasmids for HA-tagged FOXFl and HA-tagged FOXF2\r\nValue Proposition: \r\nTechnical Details: \r\nJHU scientists have developed HA-tagged FOXFl and HA-tagged FOXF2 expression plasmids. Full-length cDNAs for FOXF genes were isolated by using RT-PCR of RNA from normal mammary organoids an","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"breast cancer (FOXF genes epigenetically silenced)","mechanism_class":"FOXF tumor suppressor reactivation target","modality":"other","objectID":"16719","rationale_one_line":"Described as 'FOXF genes are novel negative regulators of DNA replication and are epigenetically silenced in breast cancer'; breast_cancer is a supported indication; modality is a research tool/target vector — maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16719","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"FOXF1/FOXF2","title":"Forkhead box-F (FOXF) Genes are Novel Negative Regulators of DNA Replication and are Epigenetically Silenced in Breast Cancer"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"M4N is early broad oncology without clear SoC differentiation data.","description_excerpt":"Technical Details: \r\n\t\t\tM4N is an anti-cancer drug candidate, which is currently under the first phase of clinical trials. Although M4N can reduce tumor cell growth; it fails to induce quick tumor cell death. JHU scientists showed that the combination treatment of M4N with either two specific kinase","dev_stage":"phase_1","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (M4N transcription inhibitor combination with kinase inhibitors)","mechanism_class":"transcription inhibitor + PKCdelta/PI3K inhibitor combination","modality":"small_molecule","objectID":"16624","rationale_one_line":"Described as 'M4N is an anti-cancer drug candidate, which is currently under the first phase of clinical trials'; phase_1 stage confirmed; small molecule modality confirmed; broad cancer indication outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16624","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Rapid Induction of Cancer Cell Death by Synergistic Treatment of Tetra-O-methyl Nordihydroguaiaretic Acid (M4N) with either Rottlerin or Ly294002"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"TGF-beta inhibitor for muscle wasting is preclinical in vitro; no clear SoC comparison established.","description_excerpt":"Technical Details: \r\nMuscle mass is normally regulated by the activities of members of the transforming growth factor-B (TGF-B) superfamily, which act to limit muscle growth. Scientists at JHU have now found a protein that is capable of binding certain members of the TGF-B family and inhibiting thei","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"muscle wasting / musculoskeletal disease (TGF-beta family inhibitor)","mechanism_class":"TGF-beta family binding protein (muscle mass regulator)","modality":"other","objectID":"16514","rationale_one_line":"Described as 'a protein that is capable of binding certain members of the TGF-B family and inhibiting their activities in vitro' to increase muscle mass; protein/biologic modality maps to 'other'; musculoskeletal indication is outside the supported enum; in vitro confirms preclinical.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16514","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TGF-beta family","title":"C05182: Novel Protein Increases Muscle Mass"},{"biomarker_overlap":null,"composite_score":0.39114606291324383,"cr_rationale":"Surgical robot improves procedural precision but is platform/delivery with no standalone clinical endpoint.","description_excerpt":"C04870: Multi-Imager Compatible Surgical Robot\r\n\r\nNovelty: \r\n\r\nAn apparatus that allows for safe and precise interventions in cooperation with preferred imaging techniques.\r\nValue Proposition: \r\nRobotic systems have the potential to expand the field of radiology by augmenting physician manipulations","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"image-guided interventions / brachytherapy (oncology)","mechanism_class":"surgical robot / brachytherapy seed injector","modality":"other","objectID":"16439","rationale_one_line":"Multi-imager compatible surgical robot for image-guided procedures; medical device, not a therapeutic modality — maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16439","subscores":{"clinical_relevance":0.4,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Multi-Imager Compatible Robot for Image-Guided Interventions and Fully Automated Brachytherapy Seed Injector"},{"biomarker_overlap":"NADPH-dependent alkenal/one oxidoreductase expression","composite_score":0.39114606291324383,"cr_rationale":"Mechanistic bioactivation study without established clinical endpoint superiority over existing alkylators.","description_excerpt":"C04330: Use of NADPH-dependent alkenal/one oxidoreductase in the Bioactivation of Irofulven and Related Compounds that Preferentially Kill Cancer Cells\r\n   \r\n\r\nTechnical Details: \r\n\r\nIrofulven (6-hydroxymethylacylfulvene, HMAF) is a novel anticancer chemotherapeutic that is under extensive clinical ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (alkylating agent bioactivation)","mechanism_class":"NADPH-oxidoreductase-activated alkylating agent","modality":"small_molecule","objectID":"16308","rationale_one_line":"Irofulven bioactivation via NADPH-dependent oxidoreductase preferentially kills cancer cells; mechanism study for broad oncology, no specific supported indication named.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16308","subscores":{"clinical_relevance":0.4,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PTGR1","title":"Use of NADPH-dependent alkenal/one oxidoreductase in the Bioactivation of Irofulven and Related Compounds that Preferentially Kill Cancer Cells"},{"biomarker_overlap":null,"composite_score":0.3843988269794721,"cr_rationale":"Research-tool monoclonal antibodies for diagnostics; no direct therapeutic benefit demonstrated.","description_excerpt":"C04888: A. phagocytophilum Monoclonal ab hybridomas\r\n   \r\n\r\nTechnical Details: \r\n\r\nResearchers at JHU have created hybridomas producing monoclonal antibodies reactive with the obligate intracellular bacterium Anaplasma phagocytophilium 44kDa antigens (Msp2), AnkA and unidentified labile antigens.\r\n\r","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Anaplasma phagocytophilum infection (diagnostic / research tool)","mechanism_class":"research-grade monoclonal antibodies","modality":"monoclonal_antibody","objectID":"16444","rationale_one_line":"Hybridoma-derived monoclonal antibodies against A. phagocytophilum for immunohistochemistry and diagnostics; infectious disease outside supported enums and primary use is as research tool.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16444","subscores":{"clinical_relevance":0.2,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"Msp2 (Anaplasma phagocytophilum 44kDa antigen)","title":"A. phagocytophilum Monoclonal ab hybridomas"},{"biomarker_overlap":null,"composite_score":0.3843988269794721,"cr_rationale":"Ganglioside antibodies are primarily research/diagnostic tools without established therapeutic use.","description_excerpt":"C04184: Eight Anti-ganglioside Monoclonal Antibodies\r\n   \r\n\r\nTechnical Details: \r\n\r\nMonoclonal antibodies to major brain cell surface antigens involved in axon-myelin stability, nerve regeneration, and control of nerve cell signaling.\r\n\r\n\r\nLooking for Partners: \r\n\r\nDiagnostic analysis, neuropathic l","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurological disorders (axon-myelin stability, nerve regeneration)","mechanism_class":"anti-ganglioside monoclonal antibody","modality":"monoclonal_antibody","objectID":"16267","rationale_one_line":"Monoclonal antibodies against brain gangliosides involved in 'axon-myelin stability, nerve regeneration'; primarily diagnostic/research tool for neurology, outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16267","subscores":{"clinical_relevance":0.2,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"gangliosides (brain cell surface antigens)","title":"Eight Anti-ganglioside Monoclonal Antibodies"},{"biomarker_overlap":null,"composite_score":0.3811460629132439,"cr_rationale":"CSC-targeting small molecule for drug-resistant recurrent NSCLC addresses a high-unmet-need relapsed population.","description_excerpt":"Value Proposition:\r\n·         Combination treatment strategy enhances existing chemotherapy treatment regimens to improve long-term survival.\r\n·         Integration of small molecules with conventional chemotherapy regimens establishes new treatment options for drug-resistant and recurrent lung canc","dev_stage":"unknown","exclusivity_status":"unknown","indication":"nsclc","indication_free_text":"Drug-resistant and recurrent lung cancer (adenocarcinoma); cancer stem cells as target in lung cancer","mechanism_class":"CSC-targeting small molecule in combination with chemotherapy","modality":"small_molecule","objectID":"52853","rationale_one_line":"Taxonomy explicitly tags Oncology > Lung Cancer and Adenocarcinoma; description states new treatment options for drug-resistant and recurrent lung cancer using small molecules targeting cancer stem cells.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52853","subscores":{"clinical_relevance":0.75,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0},"target":null,"title":"Combination Small Molecule-Chemotherapy for Targeting of Cancer Stem Cells in Drug-resistant Lung Cancer"},{"biomarker_overlap":null,"composite_score":0.3711460629132438,"cr_rationale":"Dual co-stimulation nucleic acid platform across multiple indications; delivery innovation without indication-specific clinical advantage demonstrated.","description_excerpt":"Value Proposition:\r\n·      Dual specific targeting for improved full T-cell and amplification.\r\n·      Interchangeable protein components can be customized for cancer, infectious disease, and autoimmune disorder therapies.\r\n·      Deliverable by nanoparticles into cells in vivo, in vitro, and ex viv","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer, infectious disease, autoimmune disorders (immunotherapy platform)","mechanism_class":"Single-construct dual immune activation signal co-expression","modality":"nucleic_acid","objectID":"60639","rationale_one_line":"Single-construct nucleic acid system deliverable by nanoparticles for dual T-cell co-stimulation; no single specific indication; modality is nucleic_acid per Gene Therapies classification.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60639","subscores":{"clinical_relevance":0.35,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Single-construct Co-expression of Immune Activation Signals for Immunotherapy"},{"biomarker_overlap":null,"composite_score":0.3711460629132438,"cr_rationale":"Combination delivery platform for solid tumors lacks specific differentiation vs existing nanoparticle combination strategies.","description_excerpt":"Unmet Need\r\nCancer is the second leading cause of death in the United States, with an estimated 1.8 million cases having been diagnosed and 606,520 people having succumbed to the disease in 2020. The most common cancer diagnosis overall and for women is breast cancer, and the most common cancer diag","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Solid tumors (general)","mechanism_class":"Combination drug delivery platform","modality":"other","objectID":"60580","rationale_one_line":"Non-intuitive combination of drug delivery carriers for synergistic tumor growth delay — a delivery platform technology, not a specific therapeutic agent.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60580","subscores":{"clinical_relevance":0.35,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumors"},{"biomarker_overlap":null,"composite_score":0.3711460629132438,"cr_rationale":"Endosomal escape is a delivery tool without indication-specific outcome evidence.","description_excerpt":"Unmet Need\r\n There are significant roadblocks to the routine delivery of macromolecules such as proteins, peptides, imaging agents, polysaccharides and more to the cytosol of mammalian cells. While most macromolecules are easily directed to existing cellular uptake mechanisms, they are often trapped","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Intracellular macromolecule delivery (broad applications)","mechanism_class":"Endosomal escape delivery platform","modality":"other","objectID":"60436","rationale_one_line":"Title is a placeholder ('Out for review...'); description describes cytosolic macromolecule delivery technology — a delivery platform with no specific indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60436","subscores":{"clinical_relevance":0.35,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Out for review, Need to check with Tulane whether we can post it or not."},{"biomarker_overlap":null,"composite_score":0.3711460629132438,"cr_rationale":"Hair nanoparticle delivery improves topical administration but lacks strong therapeutic differentiation.","description_excerpt":"Invention novelty: This invention is a nanoparticle for topical drug delivery targeting hair growth conditions. The particle may be an effective drug delivery tool for conditions such as hirsutism (excess hair) or alopecia (hair loss).\r\nValue Proposition\r\nThis technology can be used as a treatment ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Hair growth conditions (hirsutism, alopecia)","mechanism_class":"Topical nanoparticle drug delivery","modality":"other","objectID":"59725","rationale_one_line":"Nanoparticle platform for topical delivery targeting hair growth conditions — a delivery platform; alopecia/hirsutism not in indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59725","subscores":{"clinical_relevance":0.35,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Nanoparticles for Topical Drug Delivery and Treatment of Hair Growth Conditions"},{"biomarker_overlap":null,"composite_score":0.3711460629132438,"cr_rationale":"Piezoelectric scaffold improves implant mechanics without addressing unmet therapeutic gaps.","description_excerpt":"Value Proposition\r\n·       This technology demonstrates superior mechanical properties and has a simpler manufacturing process as compared to other mechanically adaptive materials.\r\n·       Unlike other existing materials, this technology enhances its own mechanical properties with cyclic loading, t","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Orthopedic devices / implantable materials","mechanism_class":null,"modality":"other","objectID":"57937","rationale_one_line":"Liquid-infused porous piezoelectric scaffolds with self-reinforcing mechanical properties — an engineering material/device, not a therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/57937","subscores":{"clinical_relevance":0.35,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Liquid-infused Porous Piezoelectric Scaffolds with their Applications"},{"biomarker_overlap":null,"composite_score":0.3711460629132438,"cr_rationale":"Organ-targeted IM LNPs improve delivery but are not therapeutically differentiated.","description_excerpt":"Value Proposition: - Organ-targeted drug or mRNA delivery to focus therapy on specific tissues.  - Accessible intramuscular administration, offering broadly applicable, out-of-the-box drug delivery system for a range of therapeutics. - Achieves organ-specific delivery without antibodies or targeting","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Organ-targeted drug or mRNA delivery (broad platform)","mechanism_class":"Organ-targeted lipid nanoparticle (LNP) delivery platform","modality":"other","objectID":"57575","rationale_one_line":"LNP formulations achieving systemic organ-specific delivery via intramuscular administration — a delivery platform without a specific therapeutic indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/57575","subscores":{"clinical_relevance":0.35,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Lipid Nanoparticle Formulations Capable of Migrating to Systemic Organs Following Intramuscular Administration"},{"biomarker_overlap":null,"composite_score":0.3711460629132438,"cr_rationale":"CAR-T manufacturing platform improves production but does not directly improve patient clinical outcomes vs. SoC.","description_excerpt":"Value Proposition:\r\n·        This platform improves current methods for expansion of CD4+ T-cells, which could be used in adoptive transfer therapies.\r\n·        Improves modulation, activation, and expansion of T cells over current methods used for CAR T-cell therapy\r\nTechnology Description\r\n·      ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Adoptive T-cell and CAR-T cell therapy; expansion and modulation of CD4+ T cells for immuno-oncology","mechanism_class":"nanoparticle-based T-cell expansion platform","modality":"other","objectID":"53504","rationale_one_line":"Platform improves CAR-T cell manufacturing via nanoparticles; it is a manufacturing/delivery tool not a therapeutic modality in the supported enum; broad immuno-oncology without specific cancer type maps to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53504","subscores":{"clinical_relevance":0.35,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Nanoparticles for Delivery of Immunoregulatory Materials to T Cells"},{"biomarker_overlap":"biomarkers for CIP diagnosis and prognosis","composite_score":0.3711460629132438,"cr_rationale":"CIP diagnostic biomarker identifies irAE risk but does not itself treat the complication.","description_excerpt":"Unmet Need\n\nCheckpoint inhibitor pneumonitis (CIP) can develop as a complication of cancer immunotherapy and is the leading cause of treatment-related death. CIP incidence will continue to rise as immunotherapy treatments become more widespread. However, there are no reliable biomarkers for CIP diag","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Checkpoint inhibitor pneumonitis (CIP); complication of cancer immunotherapy","mechanism_class":"diagnostic biomarker and treatment target identification for CIP","modality":"other","objectID":"53090","rationale_one_line":"Taxonomy confirms Diagnostic Biomarkers and Targets; this is a diagnostic and target discovery technology for checkpoint inhibitor pneumonitis, not a therapeutic; both fields map to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53090","subscores":{"clinical_relevance":0.35,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Diagnostic and Treatment Target for Checkpoint Inhibitor Pneumonitis"},{"biomarker_overlap":null,"composite_score":0.3711460629132438,"cr_rationale":"EV delivery platform lacks demonstrated efficacy advantage versus B-cell SoC.","description_excerpt":"Value Proposition\r\n·      Purified EVs with preferential targeting for B cells in both ex-vivo and in-vivo applications.\r\n·      EVs have half-life between 30-40 minutes, longer than many comparable extracellular vesicles.\r\n·      EVs purified from cell culture medium to increase throughput, speed, ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"B cell diseases; extracellular vesicles for targeted delivery and treatment of B cell-mediated conditions","mechanism_class":"culture-derived extracellular vesicle (EV) delivery platform for B cells","modality":"other","objectID":"52984","rationale_one_line":"Source describes culture-derived EVs with preferential targeting for B cells as a delivery platform; EVs are not among the 9 supported modality enums; B cell diseases are outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52984","subscores":{"clinical_relevance":0.35,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Culture-derived EVs for targeted delivery and treatment of B cell diseases"},{"biomarker_overlap":null,"composite_score":0.3639818946831569,"cr_rationale":"Non-metallic CEST MRI contrast agent; imaging platform with no direct therapeutic or outcome advantage shown.","description_excerpt":"C12189: Novel Self-Assembling Peptide Hydrogels for MRI\r\nNovelty: \r\nSelf-assembling peptide hydrogels that can function as non-metallic MRI contrast agents.\r\nValue Proposition: \r\nCurrently used metallic or non-metallic MRI contrast agents have some limitations for in vivo imaging such as toxicity or","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"MRI imaging contrast agent (non-metallic)","mechanism_class":"self-assembling peptide hydrogel CEST MRI contrast agent","modality":"peptide","objectID":"17193","rationale_one_line":"Self-assembling peptide hydrogels as non-metallic CEST MRI contrast agents — imaging platform technology, no specific disease; peptide modality from taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17193","subscores":{"clinical_relevance":0.3,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0.5},"target":null,"title":"Novel Peptide Hydrogels Generating Chemical Exchange Saturation Transfer MRI Contrast and Uses Thereof"},{"biomarker_overlap":null,"composite_score":0.3611460629132438,"cr_rationale":"AML/MDS prodrug offers immunotherapy mechanism beyond high-relapse hypomethylating SoC.","description_excerpt":"Unmet Need\r\nApproximately 1.24 million hematological cancer cases occur each year, accounting for approximately 6% of all cancer cases (Bristol Myers Squibb). Currently, standard treatment strategies include chemotherapy, radiation therapy, and stem cell transplants. However, there exist several maj","dev_stage":"unknown","exclusivity_status":"unknown","indication":"aml","indication_free_text":"hematological malignancies including AML/MDS","mechanism_class":"prodrug for immunological and oncological therapy","modality":"small_molecule","objectID":"53969","rationale_one_line":"Taxonomy classifies under Hematologic Malignancies and Small Molecules; AML is the best-fit supported enum for the hematological cancer context described.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53969","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0},"target":null,"title":"Prodrug for Immunological and Oncological Therapy"},{"biomarker_overlap":null,"composite_score":0.3611460629132438,"cr_rationale":"NSCLC lung metastasis inhibitor addressing 30-70% post-surgical recurrence rate with no approved SoC.","description_excerpt":"Unmet Need\r\nCancer recurrence, even following complete surgical resection, remains a large unmet clinical problem. In non-small cell lung cancer (NSCLC) patients, recurrence following surgery remains 30-70%, and the five-year survival rate remains 23% with over 140,000 deaths occurring each year. Re","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"nsclc","indication_free_text":"Non-small cell lung cancer (NSCLC) — post-surgical recurrence and metastasis","mechanism_class":"Cancer metastasis modifier / lung metastasis inhibitor","modality":"small_molecule","objectID":"36709","rationale_one_line":"Small molecule modifiers to inhibit cancer lung metastases in NSCLC, where 'recurrence following surgery remains 30-70%' — explicit NSCLC indication, small molecule classification from taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36709","subscores":{"clinical_relevance":0.7,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0},"target":null,"title":"Modifiers Inhibit Cancer Lung Metastases"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Computational antibody design platform with no direct therapeutic action; marginal clinical impact vs SoC.","description_excerpt":"Unmet Need\r\nMonoclonal antibody therapies have become an extremely popular and effective treatment route for cancer, rheumatoid arthritis, and infectious diseases. At present, there are over 100 FDA approved monoclonal antibody therapies with many more in late stage clinical trials (see Nature). One","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer, rheumatoid arthritis, infectious diseases (platform tool for antibody sequence design)","mechanism_class":"Generative language model for antibody design","modality":"other","objectID":"61211","rationale_one_line":"IgLM is an AI/ML algorithm for antibody sequence generation — a computational platform tool, not a therapeutic asset; maps to other/other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/61211","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Generative Language Model for Antibody Sequence Design (IgLM)"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Self-assembling peptide hydrogel delivery platform with broad applications and no specific clinical differentiation demonstrated.","description_excerpt":"The compositions and methods disclosed herein pertain to the manufacture and use of hydrogels. The disclosed compositions and methods pertain to hydrogels capable of induction by a variety of methodologies, such as by pH, salt and/or mixing. Such hydrogels are capable of self- or co-assembly and whi","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Drug delivery platform (broad applications)","mechanism_class":"Self-assembling peptide hydrogel","modality":"other","objectID":"60513","rationale_one_line":"Co-assembling peptide hydrogels for entrapment and delivery of bioactive agents — a delivery platform with no specific disease indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60513","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Co-assembling Peptide Hydrogels"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"3D surgical modeling aids planning without directly improving transplant therapeutic efficacy.","description_excerpt":"Value Proposition\r\n·      Real-Time Operation Adjustments: The system provides live 3D positioning updates of the donor and recipient anatomies, allowing for instant feedback for surgeons. \r\n·      Mastication Simulation: The technology spontaneously identifies ideal positioning of the donor face to","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Facial transplantation surgery / craniomaxillofacial trauma","mechanism_class":null,"modality":"other","objectID":"60331","rationale_one_line":"3D live surgical modeling system for facial transplant — a medical device/software tool, not a therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60331","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"3D Live Modeling of Facial Transplantation Surgery to Maximize Patient Outcomes"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Stem-cell viscosity preconditioning lacks demonstrated in vivo clinical benefit.","description_excerpt":"Value Proposition\r\n·      Preserve bone-forming potential (osteogenic phenotype) in soft tissue environments\r\n·      Reduces immune rejection by promoting an immunosuppressive macrophage response\r\n·      Enables preconditioning of stem cells for enhanced engraftment success\r\n·      Applicable to a w","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Bone and tissue regeneration, transplantation","mechanism_class":"Fluid viscosity-based stem cell preconditioning","modality":"other","objectID":"59848","rationale_one_line":"Stem cell growth enhancement platform using fluid viscosity for tissue regeneration — a cell culture/processing technology; not a specific therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59848","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"System for Enhancing Stem Cell Growth & Development Using Fluid Viscosity to Support Tissue Regeneration and Engraftment"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Polymeric peptide delivery lacks efficacy differentiation from other depot technologies.","description_excerpt":"Value Proposition\r\n·      Stability: polymeric nanoparticle encapsulation increases and sustains peptide residence time, for increased accumulation in tissue vasculature and maximize treatment effects\r\n·      Safety: use of nanoparticles reduces toxicity by confining peptide delivery to site of admi","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Vascular disease / broad therapeutic applications (peptide delivery platform)","mechanism_class":"Polymeric nanoparticle peptide delivery","modality":"other","objectID":"58974","rationale_one_line":"Polymeric particles for sustained delivery of multimodal peptide therapeutics — a delivery platform without a specific disease indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/58974","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Polymeric particles for sustained delivery of multimodal peptide therapeutics"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Cationic delivery platform lacks proven advantage over existing LNP systems.","description_excerpt":"Value Proposition\r\n·        Delivery Efficacy: Demonstrates more effective gene delivery to cancer associated fibroblasts (CAFs) or human primary fibroblasts than industry gold-standards such as Lipofectamine 2000 and polyethylenimine (PEI).\r\n·        Cargo Compatibility: Enables encapsulation and d","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cancer-associated fibroblasts / gene delivery (broad)","mechanism_class":"Cationic polymer gene/drug delivery","modality":"other","objectID":"58825","rationale_one_line":"Multicomponent degradable cationic polymers for DNA/RNA/drug delivery — a delivery platform technology with no specific therapeutic indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/58825","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Multicomponent Degradable Cationic Polymers for Drug and Gene Delivery"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"PDMS surface modification is a manufacturing tool; no direct therapeutic clinical advantage.","description_excerpt":"Value Proposition\r\n·       Increased efficacy: This method effectively eliminates PDMS&#39;s drug adsorption property while preserving its beneficial characteristics, making this discovery potentially transformative for any drug efficacy and toxicity studies utilizing microfluidic devices.\r\n·       ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"drug pharmacokinetics in microfluidic medical devices","mechanism_class":"PDMS surface modification","modality":"other","objectID":"57021","rationale_one_line":"This is a manufacturing/device platform tool — modification of PDMS polymer to reduce drug adsorption in microfluidic devices; no disease indication or therapeutic modality applies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/57021","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Enhancing Drug Pharmacokinetics in Medical Devices by Modification to a Silicone Polymer (Polydimethylsiloxane/ PDMS) to Reduce Drug Absorption"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Manufacturing process for LNP synthesis; no direct therapeutic clinical impact demonstrated.","description_excerpt":"Value Proposition:\r\n·        Technology creates particles optimally size for use as vehicles for cell transfection.\r\n·        The reagents and processes for particle creation are kinetically controlled and reproducible.\r\n·        Cationic particles created using these methods can carry larger payloa","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"nucleic acid transfection / gene and cell therapy manufacturing","mechanism_class":"kinetically controlled cationic particle synthesis","modality":"other","objectID":"56053","rationale_one_line":"Manufacturing/process technology for producing nucleic acid transfection vehicles; no disease-specific indication and no single therapeutic modality applies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/56053","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Kinetically controlled methods to prepare concentrated shelf-stable nucleic acid transfection vehicles"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"LNP formulation screening platform; clinical relevance depends entirely on therapeutic payload.","description_excerpt":"Value Proposition:\r\n·        Library screen of lipid nanoparticles to develop compositions for efficient transfection and tissue-specific delivery.\r\n·        Selected high efficiency lipid nanoparticles for delivering plasmid DNA, siRNA, and mRNA. \r\nTechnology Description\r\n·        Researchers at Jo","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"plasmid DNA delivery to the liver","mechanism_class":"lipid nanoparticle delivery platform","modality":"other","objectID":"56048","rationale_one_line":"Lipid nanoparticle screening and formulation platform for gene delivery; no disease-specific indication in the description — purely a Therapeutic Delivery Platform.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/56048","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Compositions of Lipid Nanoparticles for Plasmid DNA Delivery to the Liver and Methods for Preparing the Same"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Vaccine manufacturing tool improving antigen surface expression; no direct patient-facing clinical advantage.","description_excerpt":"Value Proposition\r\n·      Improved antigenicity due to increased cell surface expression of viral proteins\r\n·      Boosts vaccine efficacy\r\n·      Potential for integration into various vaccine platforms, including viral-mediated, mRNA-mediated, and DNA-mediated vaccines\r\n \r\nUnmet Need\r\n·      The d","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"vaccine development platform (viral, mRNA, DNA vaccines)","mechanism_class":"membrane protein surface expression enhancer","modality":"other","objectID":"55321","rationale_one_line":"Platform technology to improve cell-surface antigen expression for vaccines; classified under Proteins + Vaccines — a vaccine manufacturing tool without a specific disease indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55321","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Method for Surface Expression of Membrane Proteins that have a Cytoplasmic C-terminal Tail"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Exosome yield enhancement is a manufacturing platform tool with no standalone clinical relevance.","description_excerpt":"This invention solves the problem of how to increase the yield of exosomes, as well as how to create genetically modified exosomes.\r\nUnmet Need\r\nEach year in the US, ~1.7 million new patients are diagnosed with cancer and of those, 600,000 will die (see CDC 2022). The treatment of many cancers relie","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer drug delivery (exosome-based)","mechanism_class":"exosome production enhancement platform","modality":"other","objectID":"55178","rationale_one_line":"Manufacturing platform to enhance exosome yield for drug delivery; classified under Therapeutic Delivery Platforms — no specific indication beyond broad cancer context.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/55178","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"C17074 Genetic enhancement of exosome production"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Delivery platform technology with no specific indication; clinical impact is indirect and contingent on payload.","description_excerpt":"Value Proposition:\r\n·        Scalable, efficient, and tunable nanoparticle creation technique that can deliver a variety of payloads\r\n·        Polymer-lipid nanoparticles are biodegradable and are being tested for immunogenicity\r\n·        Can be used for in vivo gene therapy delivery as well as in v","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Gene therapy delivery and in vitro cell transfection; broad oncology and gene therapy applications","mechanism_class":"kinetic nanoparticle nucleic acid delivery platform","modality":"other","objectID":"53503","rationale_one_line":"This is a delivery platform technology (scalable, efficient, and tunable nanoparticle creation technique) without a specific therapeutic indication; delivery platform maps to other for both fields.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53503","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Compositions of Kinetic Nanoparticles containing Nucleic  Acids, Polycations, and Lipids with Defined Sizes, and Methods of Producing the Same"},{"biomarker_overlap":"DNA methylation patterns; gene copy number","composite_score":0.3511460629132438,"cr_rationale":"Diagnostic biomarker assay aids detection but does not directly treat prostate cancer.","description_excerpt":"Value Proposition:\r\n·        Detection of methylation patterns that are linked to prostate cancer development in an individual.\r\n·        Enable development of a personalized treatment plan for individuals with aggressive prostate cancer.\r\n·        Simultaneous determination of gene methylation and ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Prostate cancer; detection of methylation patterns linked to prostate cancer development","mechanism_class":"DNA methylation biomarker assay","modality":"other","objectID":"53431","rationale_one_line":"This is a diagnostic biomarker technology for prostate cancer detection; not a therapeutic modality in the supported enum; prostate cancer is outside the 11 supported indications.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53431","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"DNA Methylation Markers for Prostate Cancer Detection"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Hydrogel CRISPR delivery platform is a research tool; no direct indication-specific clinical impact.","description_excerpt":"Value Proposition\r\n·        Mechanical tuning of stiffness and viscoelasticity results in higher editing efficiency and requires less transfection reagents compared to traditional plasmid-based CRISPR-Cas9 methods. \r\n·        Enhanced cell-substrate interactions between the cells and gels leads to g","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"CRISPR-Cas9 gene editing; enhancing delivery and editing efficiency via mechanically tuned hydrogels","mechanism_class":"mechanically tuned hydrogel platform for CRISPR-Cas9 delivery","modality":"other","objectID":"53208","rationale_one_line":"This is a research and manufacturing tool (a hydrogel platform to improve CRISPR-Cas9 editing efficiency) not a disease-specific therapeutic; maps to other for both fields.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53208","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A method to enhance delivery and editing efficiencies of CRISPR-Cas9"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Platform device with no defined therapeutic indication; clinical impact vs SoC undecidable.","description_excerpt":"Value Proposition:\r\n·        Unidirectional crawler without necessity of wiring, external power supply, or patterned surface.\r\n·        3D-printed, cheap and easy to mass produce.\r\n·        Direction and speed can be controlled by strategic gel design.\r\n·        Minimally invasive and could be used ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Medical device for diagnosing, imaging, or delivering therapeutics (minimally invasive)","mechanism_class":null,"modality":"other","objectID":"51427","rationale_one_line":"Gel Crawlers are 3D-printed soft-robotic medical devices; classified under Medical Devices / Therapeutic Modalities; no therapeutic indication or drug modality applies.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/51427","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Gel Crawlers"},{"biomarker_overlap":"DNA methylation markers distinguishing benign from malignant breast cancer","composite_score":0.3511460629132438,"cr_rationale":"Methylation diagnostic for breast cancer; established imaging and biopsy SoC limits added clinical impact.","description_excerpt":"Unmet Need\r\nBreast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in low and middle income countries (LMICs), and is expected to increase in incidence due to longer life expectancies, decreased burden of infectious diseases, and changes in reproductive risk fact","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"breast cancer (benign vs. malignant diagnosis and risk prediction)","mechanism_class":"methylation biomarker diagnostic","modality":"other","objectID":"45051","rationale_one_line":"Title and categories explicitly cite 'Breast Cancer'; technology is a methylation-based diagnostic/biomarker tool, not a therapeutic modality, so modality maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/45051","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Methylation Markers that Provide Molecular Diagnosis by Distinguishing Between Benign from Malignant Breast Cancer and Predict Risk"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Shelf-stable pDNA/PEI manufacturing particle; no direct patient-facing clinical impact.","description_excerpt":"Unmet Need\r\nGene therapy has become increasingly popular for treating genetic and acquired diseases, with nearly 1000 ongoing clinical trials globally. These therapies are typically delivered via viral vectors, which are produced in vector production cell lines following transient transfection using","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gene therapy manufacturing (plasmid DNA/PEI particle production)","mechanism_class":"viral vector production nanoparticle","modality":"other","objectID":"44860","rationale_one_line":"Shelf-stable pDNA/PEI particles for virus production in gene therapy manufacturing; a manufacturing/platform tool, not a disease-targeted therapeutic.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44860","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Composition of Shelf-stable Plasmid DNA/PEI Particles with Defined Sizes for Virus Production and Method for Preparation of the Same"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"pDNA/polycation particle preparation method; manufacturing tool with no direct therapeutic differentiation.","description_excerpt":"Unmet Need\r\nGene therapy has become increasingly popular for treating genetic and acquired diseases, with nearly 1000 ongoing clinical trials globally. These therapies are typically delivered via viral vectors, which are produced in vector production cell lines following transient transfection using","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gene therapy manufacturing (plasmid DNA/polycation particle preparation)","mechanism_class":"nucleic acid delivery nanoparticle preparation","modality":"other","objectID":"44859","rationale_one_line":"Methods for shelf-stable pDNA/polycation particles for cell transfection in gene therapy manufacturing; platform/manufacturing tool without a disease-specific indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44859","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Methods for Preparation of Shelf-stable Plasmid DNA/Polycation Particles with Defined Sizes for Cell Transfection"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Disease-agnostic polyelectrolyte nanoparticle platform; clinical relevance undetermined without a specific payload.","description_excerpt":"Value Proposition\r\n·      Controllable and scalable nanoparticle preparation with narrow and uniform size distribution\r\n·      Production of condensed and compact polyelectrolyte nanoparticles with improved polymer chain entanglement\r\n·      Allows for efficient protein encapsulation while retaining","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"therapeutic delivery platform (polyelectrolyte nanoparticle formulation)","mechanism_class":"polyelectrolyte nanoparticle formulation","modality":"other","objectID":"44853","rationale_one_line":"Platform technology for nanoparticle preparation enabling protein encapsulation; disease-agnostic delivery platform, not a supported indication or modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44853","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel polyelectrolyte nanoparticle formulation method"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"pDNA/lipid particle gene therapy delivery platform; disease-agnostic with no specific clinical differentiation.","description_excerpt":"Unmet Need\r\nGene therapy has the potential to provide effective treatment options for a variety of monogenic human diseases [1].Viral-mediated gene therapy has seen some clinical success, including the recent FDA approval of therapeutics for retinal dystrophy and spinal muscular atrophy [2]. However","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gene therapy (monogenic human diseases, broad)","mechanism_class":"plasmid DNA/lipid particle delivery","modality":"other","objectID":"44467","rationale_one_line":"Methods for pDNA/lipid particles for in vitro and in vivo transfection; disease-agnostic gene therapy delivery platform, no supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/44467","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Methods for Preparation of Plasmid DNA/Lipid Particles with Defined Size for in vitro and in vivo Transfection"},{"biomarker_overlap":"alpha-synuclein, amyloid-beta, tau protein aggregation","composite_score":0.3511460629132438,"cr_rationale":"Human neuron drug screening platform; research infrastructure tool with no direct patient clinical impact.","description_excerpt":"Unmet Need\r\nThe WHO has predicted that neurological disorders (NDs) will become the second leading cause of death in 20 years after cardiovascular diseases. Various proteins have been identified to aggregate and accumulate in the brain depending on the indication: amyloid-beta or tau in Alzheimer’s ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurological disorders (Alzheimer's, Parkinson's disease, and others)","mechanism_class":"human neuron drug screening platform","modality":"other","objectID":"43246","rationale_one_line":"Platform for drug screening in human neurons for neurological disorders including Parkinson's and Alzheimer's; research tool/platform, not a direct therapeutic.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/43246","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Platform for drug screening in human neurons"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Retinoic acid/dsRNA combination for skin aging; cosmetic indication with no disease-modifying SoC benchmark.","description_excerpt":"Unmet Need\r\nGlobally, the anti-aging cosmetic treatment market is projected to grow to $57.5B dollars in 2020. Currently, one of the leading the leading topical ingredients in anti-aging creams for wrinkle reduction is retinoids, which are derivatives of vitamin A. Retinoic acid, the active metaboli","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"skin aging / sun damage (cosmetic and dermatological)","mechanism_class":"retinoic acid and dsRNA combination","modality":"other","objectID":"42080","rationale_one_line":"Combination retinoic acid and dsRNA for skin rejuvenation/anti-aging; cosmetic/dermatology indication and mixed modality do not map to supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/42080","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Use of Combination Retinoic Acid and dsRNA Products for Skin Rejuvenation"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Research screening platform for DMD; no direct therapeutic impact vs SoC.","description_excerpt":"Unmet Need\r\nThe development of new drugs is a capital and time intensive process. For this reason, the development of orphan drugs for those diseases that affect a small subset of the population. One of such diseases, Duchenne’s muscular dystrophy (DMD) affects 1 in 5000 boys worldwide and has no kn","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Duchenne's muscular dystrophy (DMD)","mechanism_class":"iPSC-based drug screening platform","modality":"other","objectID":"39010","rationale_one_line":"Human iPSC-based platform for drug testing in DMD — a research tool/screening platform, not a therapeutic modality; indication is a rare neuromuscular disease outside the 11 supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/39010","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Human IPSC-Based Drug Testing Platform for Duchenne Muscular Dystrophy"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Implantable lens capsule device; procedural refinement with no clear clinical outcome advantage.","description_excerpt":"Unmet Need\r\nCataract surgery is the most common intraocular surgery, with more than 3.5 million occurring each year in the U.S. Various circumstances compromise the ability to safely insert an intraocular lens (IOL) implant following cataract extraction such as zonular insufficiency or posterior cap","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cataract surgery / intraocular lens placement (ophthalmology)","mechanism_class":"Implantable lens capsule device","modality":"other","objectID":"38484","rationale_one_line":"Implantable lens capsule for intraocular lens insertion following cataract extraction — a medical device for an ophthalmic procedure, not a therapeutic drug modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/38484","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Implantable lens capsule for intraocular lens insertion."},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Broad-platform nucleic acid nanoparticle; no specific indication limits clinical relevance scoring.","description_excerpt":"Unmet Need\r\nGene therapy has the potential to offer a one-time cure for severe, debilitating diseases that were previously untreatable or required chronic therapy. While a few viral-based gene therapies have recently received FDA approval, safety concerns around viral-based gene therapies continue t","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Severe debilitating genetic disorders, cancer, neurodegenerative diseases (broad platform)","mechanism_class":"Non-viral nucleic acid-containing nanoparticle delivery","modality":"nucleic_acid","objectID":"36580","rationale_one_line":"Non-viral nucleic acid nanoparticle compositions for in vivo gene delivery across broad disease indications — nucleic acid delivery platform without a single supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36580","subscores":{"clinical_relevance":0.3,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Compositions of nucleic acid-containing nanoparticles for in vivo delivery"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Spinal deformity surgical device; procedural device with no therapeutic differentiation over existing instrumentation.","description_excerpt":"Unmet Need\r\nSpinal deformity occurs frequently and may affect up to 68% of the elderly population. Left untreated, these deformities may develop into spondylolisthesis, a spinal misalignment caused by a stress fracture in the vertebra and displacement of the vertebra from its original location. Spon","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Spinal deformity / spondylolisthesis (musculoskeletal)","mechanism_class":"Vertebral body manipulation surgical device","modality":"other","objectID":"36348","rationale_one_line":"Vertebral body manipulation device for correcting spinal deformity — a medical device for a musculoskeletal surgical procedure, not a therapeutic drug modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/36348","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Vertebral Body Manipulation Device and Methods"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Cellulose hydrogel platform; broad-use materials platform without specific clinical differentiation.","description_excerpt":"Unmet Need\r\nHydrogels are water-insoluble polymers with the ability to swell without dissolution and to retain a large portion of solution within their structure. They have many uses, including contact lenses, wound dressings, tissue regenerative applications, orthopedic applications, drug delivery ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Drug delivery, wound dressings, tissue regeneration, orthopedic applications (broad platform)","mechanism_class":"Cellulose-based hydrogel delivery platform","modality":"other","objectID":"35509","rationale_one_line":"Cellulose-based hydrogels as a broad-use delivery platform for drug delivery, wound dressings, and tissue regeneration — a materials platform without a specific therapeutic indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35509","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Cellulose-Based Hydrogels and Methods of Making Thereof"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Vascular network platform for tissue regeneration is early-stage with no disease-specific clinical endpoint defined.","description_excerpt":"Unmet Need\r\nTissue regeneration is a large part of a huge market for redeveloping tissues that have been damaged or have lost functionality. The success of tissue regenerative therapies is dependent on functional and multicellular vasculature within the redeveloping tissue. The problem with human en","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"tissue regeneration / vascular network formation","mechanism_class":"pluripotent stem cell vascular network platform","modality":"other","objectID":"28844","rationale_one_line":"Self-organized vascular networks from human pluripotent stem cells in synthetic matrix for tissue regeneration; regenerative medicine platform without a specific disease indication in the supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28844","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Self-organized Vascular Networks from Human Pluripotent Stem Cells in a Synthetic Matrix"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Disease-agnostic protein delivery nanoparticle; no specific clinical impact determinable without payload context.","description_excerpt":"Value Proposition\r\n·      Biodegradable nanoparticle composition with core-shell structure\r\n·      Controllable nanoparticle size with low polydispersity index\r\n·      Wide range for protein loading level\r\n·      Nanoparticles capable of sustained released over period of 2 weeks to 3 months\r\nUnmet N","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"protein therapeutics delivery (broad platform, disease-agnostic)","mechanism_class":"polymeric nanoparticle sustained-release delivery platform","modality":"other","objectID":"28020","rationale_one_line":"Biodegradable core-shell polymeric nanoparticles for encapsulation and sustained release of protein therapeutics; platform technology without a disease-specific indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/28020","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Polymeric Nanoparticle Compositions for Encapsulation and Sustained Release of Protein Therapeutics and Methods for Scalable Production of the Same"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Disease-agnostic vesicular delivery platform; clinical relevance entirely contingent on future payload.","description_excerpt":"Unmet Need\r\nCreating artificial vesicular systems that can mimic natural cells continues to be a challenge in the fields of synthetic biology as well as gene and drug delivery. This class of artificial systems serve as a powerful platform for both studying biology in a minimal, controlled system and","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"synthetic biology / gene and drug delivery platform (disease-agnostic vesicular system)","mechanism_class":"artificial vesicle delivery platform","modality":"other","objectID":"26844","rationale_one_line":"Vesicular platform for biocompatible encapsulation and cellular delivery; synthetic biology delivery platform without a disease-specific indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/26844","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Vesicular Platform for Biocompatible encapsulation and cellular delivery"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Fungal biosensor is a diagnostic tool; clinical value is detection, not treatment, limiting therapeutic score.","description_excerpt":"Unmet Need\r\nIncreasingly, invasive mold infections have been recognized in people who are immune compromised by genetic conditions, aging, other infections (e.g. HIV) and modern medicine (e.g. transplantation). Moreover, increasing evidence points to the role of these organisms as causes of environm","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"invasive mold and fungal infections (immunocompromised patients)","mechanism_class":"mold/fungal biosensor diagnostic","modality":"other","objectID":"25179","rationale_one_line":"Mold and fungal biosensor for diagnostic detection in immunocompromised patients; primarily a diagnostic tool for fungal infections, not a therapeutic in any supported modality enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/25179","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Mold and Fungal Biosensor"},{"biomarker_overlap":"Angiotensin type 1 receptor Autoantibody (AT1RaAb)","composite_score":0.3511460629132438,"cr_rationale":"Prognostic biomarker only; does not directly treat chronic wound healing.","description_excerpt":"Unmet Need:\r\nChronic wounds are among the most common, painful, debilitating and costly conditions in diabetics and in older adults, and are an important portal for bacterial infections that often lead to amputations, sepsis and mortality. In diabetic and aging skin, chronic inflammation commonly ac","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"chronic wound healing in diabetics and older adults","mechanism_class":"AT1R autoantibody prognostic biomarker","modality":"other","objectID":"24862","rationale_one_line":"AT1RaAb as a prognostic biomarker for wound healing and drug response; primarily a diagnostic/biomarker target without a matched therapeutic modality enum; wound healing is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24862","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"AT1R","title":"The use of Angiotensin type 1 receptor Autoantibody (AT1RaAb) as a prognostic biomarker for wound healing and for measuring response to drug treatment."},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Primarily a research tool for diabetic vascular complications; limited direct therapeutic role.","description_excerpt":"In diabetics, hyperglycemia results in deficient endothelial progenitors and cells, leading to cardiovascular complications. We aim to engineer three-dimensional (3D) vascular networks in synthetic hydrogels from type-1 diabetes (T1D) patient-derived human induced pluripotent stem cells (hiPSCs), th","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"Type 1 diabetes (vascular complications from hyperglycemia)","mechanism_class":"hiPSC-derived 3D vascular network tissue engineering","modality":"other","objectID":"24819","rationale_one_line":"3D vascular network assembly from diabetic patient-derived iPSCs for diabetes vascular complications; mapped to type2_diabetes as the closest supported diabetes enum; modality is cell/stem cell therapy platform.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24819","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Three-dimensional Vascular Network Assembly from Diabetic Patient-derived Induced Pluripotent Stem Cells"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Glycosylation manufacturing tool has no direct therapeutic impact vs. SoC.","description_excerpt":"Unmet Need: Glycosylation has a major impact on recombinant glycoproteins with important implications for increasing therapeutic use of these compounds. Various approaches are being developed to afford scientists and engineers more control over the type, location, and amount of sugar added to the pr","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"manufacturing tool for recombinant glycoprotein production; not disease-specific","mechanism_class":"glycosylation reagent","modality":"other","objectID":"24309","rationale_one_line":"Hexosamine reagents for controlling sugar addition to recombinant glycoproteins are a manufacturing/research tool; no therapeutic indication — both indication and modality map to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24309","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Novel Hexosamine Reagents for Improved Quality Recombinant Glycoprotein Production"},{"biomarker_overlap":"aristolochic acid mutational signature; urothelial carcinoma biomarkers","composite_score":0.3511460629132438,"cr_rationale":"Aristolochic acid mutation biomarker aids detection but does not improve treatment outcomes directly.","description_excerpt":"Invention novelty: a comprehensive panel of biomarkers for aristolochic acid, an environmental carcinogen for urothelial carcinoma, the most common form of bladder cancer\r\n \r\nValue Proposition\r\nEarly detection is usually critical for the successful treatment of cancer, therefore there is a constant ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"urothelial carcinoma / bladder cancer; aristolochic acid-associated cancer biomarkers","mechanism_class":"mutational signature biomarker panel","modality":"other","objectID":"24297","rationale_one_line":"Biomarker panel for early detection of aristolochic acid-associated urothelial carcinoma; primary classification is Diagnostics/Biomarkers, not a therapeutic — maps to modality 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24297","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Mutational Signature of Aristolochic Acid Exposure"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Carbapenem synthesis tool improves manufacturing efficiency but does not directly improve clinical outcomes.","description_excerpt":"Value Proposition:\r\n• Regio- and stereospecific introduction of the (8R)-hydroxyl group late in a chemoenzymatic production process\r\n• Simpler, more chemically robust starting materials can be used from the outset allowing more vigorous reaction conditions in subsequent steps\r\n• Simpler, cheaper, an","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"bacterial infections; carbapenem antibiotic synthesis","mechanism_class":"chemoenzymatic synthesis tool for carbapenem beta-lactam antibiotics","modality":"other","objectID":"24105","rationale_one_line":"Enzymes and methods for improved synthesis of carbapenem beta-lactam antibiotics; a manufacturing/synthesis tool for anti-infectives — not a direct therapeutic, modality maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24105","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Enzymes and Methods for Improved Syntheses of Carbapenem Beta-Lactam Antibiotics"},{"biomarker_overlap":"vascular permeability (dextran-based MRI signal)","composite_score":0.3511460629132438,"cr_rationale":"Dextran MRI vascular permeability imaging is a diagnostic/monitoring method without therapeutic benefit.","description_excerpt":"Novel Strategy to Assess Vascular Permeability for Nanoparticle Therapy\r\nJHU REF: C12886\r\n \r\nInvention Novelty: Use of dextran to assess target tissue vascular permeability and clearance of nanoparticles of various sizes for clinical diagnosis and assessment of appropriate nanoparticle treatment of ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer and other diseases; assessment of tissue vascular permeability for nanoparticle therapy","mechanism_class":"MRI-based vascular permeability assessment using dextran","modality":"other","objectID":"23328","rationale_one_line":"Use of non-labeled dextran detected by MRI to assess tissue vascular permeability for nanoparticle treatment of cancer; a diagnostic/imaging method — modality maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/23328","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Method of Assessing Tissue Vascular Permeability Using Non-labeled Dextran Detected by MRI"},{"biomarker_overlap":"TERT promoter mutations","composite_score":0.3511460629132438,"cr_rationale":"TERT promoter mutation diagnostic for thyroid cancer aids detection but does not change treatment SoC.","description_excerpt":"Novel Thyroid Cancer Diagnostic and Prognostic Biomarker\r\nJHU REF: C12422\r\n \r\nInvention novelty: This technology detects somatic mutations that occur at high frequency in papillary, follicular and anaplastic thyroid cancers.\r\n \r\nValue Proposition:\r\nPapillary and follicular thyroid carcinomas account","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"thyroid cancer (papillary, follicular, anaplastic)","mechanism_class":"TERT promoter mutation diagnostic biomarker","modality":"other","objectID":"22515","rationale_one_line":"Detects TERT promoter mutations for diagnosis of papillary, follicular, and anaplastic thyroid cancers; a diagnostic biomarker technology — modality maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/22515","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TERT","title":"TERT Promoter Mutations in Thyroid Cancer"},{"biomarker_overlap":"RASAL1 genetic mutations and epigenetic alterations","composite_score":0.3511460629132438,"cr_rationale":"RASAL1 tumor suppressor as thyroid cancer marker is primarily a research/diagnostic target, not therapeutic.","description_excerpt":"Novel Molecular Diagnostics for Thyroid Cancer\r\nJHU REF: C12597\r\n \r\nInvention novelty: This invention has identified a novel tumor suppressor gene, RASAL1 in thyroid cancers. Genetic mutations and epigenetic alterations of the RASAL1 gene can be used for the diagnosis of thyroid cancers.\r\n \r\nValue P","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"thyroid cancer (papillary and follicular)","mechanism_class":"RASAL1 tumor suppressor gene diagnostic/therapeutic target","modality":"other","objectID":"21015","rationale_one_line":"RASAL1 identified as 'Major Tumor Suppressor Gene in Thyroid Cancer'; primarily a diagnostic molecular target — modality maps to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/21015","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"RASAL1","title":"RASAL1 is a Major Tumor Suppressor Gene in Thyroid Cancer"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"MRI nano-carrier imaging platform; no therapeutic endpoint or differentiation from existing imaging SoC.","description_excerpt":"Nanoparticle Diagnostic and Therapeutic Imaging\r\nJHU REF: [C12327]\r\n \r\nInvention novelty: Improved method for magnetic resonance imaging of diagnostic and therapeutic nano-carriers.\r\n \r\nValue Proposition\r\nThere is an urgent need to develop simple and safe approaches to image nano-carriers in vivo ov","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"oncology / nano-carrier imaging and therapy","mechanism_class":"MRI nano-carrier surface conjugation","modality":"other","objectID":"20367","rationale_one_line":"Medical imaging / delivery platform for MRI tracking of nano-carriers — device/platform technology with no specific therapeutic indication or molecule, maps to other/other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/20367","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A Surface Conjugation Approach to Formulate Nano-carriers for Magnetic Resonance Imaging (MRI) Tracking"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"3D microwell encapsulation is a manufacturing platform; no direct clinical endpoint or SoC comparison.","description_excerpt":"C11150: Three Dimensional Microwell ArrayValue Proposition: \r\nParallel encapsulation of living cargo in an array format while enabling interaction with the surrounding in all three dimensions. Increased surface to volume ratios allow preventing cell death related to hypoxia and in general to lack of","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"bioartificial organ / cell encapsulation platform","mechanism_class":"3D microwell array cell encapsulation","modality":"other","objectID":"18747","rationale_one_line":"Three-dimensional microwell array for parallel encapsulation of living cargo — a manufacturing/research platform with no specific disease indication or therapeutic modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/18747","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Three Dimensional Microwell Array"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Self-assembling microdevice delivery platform; no disease-specific endpoint or superiority claim vs SoC.","description_excerpt":"C10325: Self-Assembling Microdevices with Broad Applications in Drug Delivery, Minimally Invasive Surgery and Medical ImagingValue Proposition: \r\n\n\n&#8226; Current human engineered automata utilize external mechanisms for actuation and motion that are derived from complex pneumatic, hydraulic, or el","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"drug delivery / minimally invasive surgery / medical imaging platform","mechanism_class":"thermal/chemical triggered self-assembling microdevice","modality":"other","objectID":"18730","rationale_one_line":"Self-assembling microdevices for drug delivery and surgery — an industrial/device platform with no specific disease indication or therapeutic molecule.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/18730","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Thermal and Chemically Triggered Assembly of Untethered 3D Structures"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Untethered micro-device drug delivery platform; no disease indication or clinical superiority claim vs SoC.","description_excerpt":"C12387: Mechanical-Chemical Controlled-Release Microtools for Targeted Drug Delivery\r\nNovelty: \r\nNovel mechanical-chemical drug-loaded micro-devices capable of anchoring to diseased tissue followed by sustained drug release.\r\nValue Proposition: \r\nThere is an unmet need for improved drug delivery sys","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"drug delivery platform (diseased tissue targeting)","mechanism_class":"mechanical-chemical controlled-release microtool","modality":"other","objectID":"17242","rationale_one_line":"Untethered micro-devices for anchoring to diseased tissue and sustained drug release — a drug delivery device platform with no specific disease indication or therapeutic molecule.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17242","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Untethered Actuators for Controlled Release of Drugs"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Motion-insensitive MRI endoscopy method; technical imaging improvement with no direct therapeutic indication.","description_excerpt":"C12175: Motion Insensitive MRI Endoscopy\r\n\r\nNovelty: \r\n\r\nThis technology enables MRI endoscopy to capture clear images despite any patient/endoscope movement.\r\nValue Proposition: \r\nPatient movement during traditional MRI can dramatically decrease the quality of the resulting images.  MRI endoscopy a","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"MRI endoscopy (motion-insensitive imaging method)","mechanism_class":"projection-based motion-insensitive MRI endoscopy","modality":"other","objectID":"17188","rationale_one_line":"Motion-insensitive MRI endoscopy method — a medical imaging device technology with no therapeutic indication or drug modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17188","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Motion-insensitive, Projection-based MRI Endoscopy Method"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Microfiber fabrication method is a manufacturing technology with no disease-specific clinical endpoint.","description_excerpt":"C11956: Improved Stretched Microfiber Production\r\n\r\nNovelty: \r\n\r\nThis technology is a new method for producing stretched microfibers with smaller, more consistent diameters.\r\nValue Proposition: \r\nWhile there are numerous known applications for microfibers, current fabrication methods lack a signific","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"microfiber therapeutic delivery platform","mechanism_class":"electromechanically stretched microfiber fabrication","modality":"other","objectID":"17114","rationale_one_line":"New method for producing stretched microfibers for delivery platforms — a manufacturing/materials technology with no disease indication or drug modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17114","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Electro-mechanically Stretched Micro Fibers and Methods of Use"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Magnetic micro-biopsy device improves GI sampling statistics; diagnostic device with no therapeutic endpoint.","description_excerpt":"C11650: Relatively Non-Invasive Biopsy Sampling Device of Tissue\r\n\r\nNovelty: \r\n\r\nThe micro-tools uses a tetherless design which is relatively non-invasive, non-toxic, and collects using a magnetic probe, which allows for a large number of samples to be extracted by covering more surface area for ran","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gastrointestinal tissue biopsy sampling","mechanism_class":"tetherless magnetic biopsy microdevice","modality":"other","objectID":"17011","rationale_one_line":"Tetherless magnetic micro-tools for statistical GI tissue sampling — a medical device for biopsy, not a therapeutic modality; no disease indication in supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/17011","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Statistical Gastrointestinal Tissue Sampling with Tetherless Microdevices"},{"biomarker_overlap":"DAXX/ATRX mutations as prognostic indicators","composite_score":0.3511460629132438,"cr_rationale":"Prognostic biomarker for pancreatic NET; diagnostic/research tool with marginal direct therapeutic impact.","description_excerpt":"C11331: Methods and Biomarkers for the detection of Pancreatic Neuroendrocrine TumorsValue Proposition: \r\n\n&#8226; Mutations useful to accurately diagnose a patient with pancreatic neuroendocrine tumor \n\n&#8226; Novel prognostic indicators that predict clinical outcome \n\n&#8226; Genetic mutations id","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"pancreatic neuroendocrine tumors","mechanism_class":"prognostic biomarker target","modality":"other","objectID":"16902","rationale_one_line":"Described as 'mutations useful to accurately diagnose a patient with pancreatic neuroendocrine tumor' and prognostic biomarker; primarily a diagnostic/target technology, indication is pancreatic NET which falls outside the supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16902","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"DAXX/ATRX","title":"DAXX/A TRX genes provide prognostic information in cancers"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"RF shielding method is a device engineering improvement; no direct clinical endpoint advantage stated.","description_excerpt":"C10911: Targeted radiation- and chemo-enhancing heat therapy for cancer\r\n\r\nNovelty: \r\n\r\nThe proposed technology is a device and platform for treating local and metastatic cancer using multifunctionalized iron oxide nanoparticles in conjunction with radiation and chemotherapeutic agents.\r\nValue Propo","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"local and metastatic cancer (RF shielding for nanoparticle hyperthermia device)","mechanism_class":"RF electromagnetic shielding method for cancer hyperthermia","modality":"other","objectID":"16785","rationale_one_line":"Described as 'shielding methods to reduce power deposition in tissue exposed to radio-frequency electromagnetic fields'; this is a device/engineering method — modality is 'other'; broad oncology indication is outside the supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16785","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Shielding Methods to Reduce Power Deposition in Tissue Exposed to Radio-frequency Electromagnetic Fields"},{"biomarker_overlap":"glyco-ligand liver function correlation","composite_score":0.3511460629132438,"cr_rationale":"Radiolabeled imaging agent for liver fibrosis; diagnostic tool with marginal therapeutic SoC comparison.","description_excerpt":"Value Proposition\r\n·        Non-invasive imaging agent correlates with liver function and can detect low levels of liver-fibrosis.\r\n·        Imaging agent has higher sensitivity than traditional liver function tests.\r\n·        Glyco-ligand can potentially be used to target other drugs to the liver. ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"nash","indication_free_text":"liver fibrosis and liver function assessment (hepatology)","mechanism_class":"radiolabeled glyco-ligand imaging agent","modality":"other","objectID":"16775","rationale_one_line":"Described as a 'non-invasive imaging agent correlates with liver function and can detect low levels of liver-fibrosis'; liver fibrosis maps most closely to 'nash' among supported indications; modality is a diagnostic imaging agent, hence 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16775","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Radiolabeled glyco-ligands for non-invasive measurement of liver function"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Biologically compatible polymer adhesive is a biomaterial platform; no disease-specific SoC comparison possible.","description_excerpt":"C10737: Biological AdhesiveValue Proposition: \r\nJohns Hopkins researchers have developed a composition comprising a biologically compatible polymer functionalized by at least two different reactive moieties to provide a biological adhesive.\r\n\r\nTechnical Details: \r\n\r\nA useful biomaterial mimics a nat","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"biological adhesive / tissue engineering platform","mechanism_class":"biologically compatible polymer adhesive","modality":"other","objectID":"16746","rationale_one_line":"Described as 'a composition comprising a biologically compatible polymer functionalized by at least two different reactive moieties to provide a biological adhesive'; this is a biomaterial/device platform — both indication and modality map to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16746","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Biological Adhesive"},{"biomarker_overlap":"CYP2E1 epitope as biomarker for DILI and hepatitis C","composite_score":0.3511460629132438,"cr_rationale":"CYP2E1 immunoassay for DILI and hepatitis C diagnosis; diagnostic value only, no therapeutic SoC comparison.","description_excerpt":"TITLE:          New Diagnostic Test for Drug Induced Liver Injury and Chronic Hepatitis C\r\nCASE NUMBER:    C10654\r\n \r\nUNMET NEED\r\n      Idiosyncratic drug-induced acute liver failure (Id-ALF) is the third most common cause of acute liver failure in the United States and is the leading cause for drug","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"drug-induced liver injury (DILI) and chronic hepatitis C","mechanism_class":"CYP2E1 epitope diagnostic / immunological assay","modality":"other","objectID":"16724","rationale_one_line":"Described as 'a new diagnostic test for drug induced liver injury and chronic hepatitis C' using CYP2E1 epitope recognition; primarily a diagnostic with some therapeutic context — indication and modality both outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16724","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"CYP2E1","title":"Recognition of Critical CYP2E1 Epitopes"},{"biomarker_overlap":"ovarian cancer methylome — early detection, therapy response, and risk prediction biomarkers","composite_score":0.3511460629132438,"cr_rationale":"Methylation biomarker panel for ovarian cancer detection; diagnostic value, no head-to-head therapeutic SoC impact.","description_excerpt":"C10640: Methylation Based Biomarkers for Ovarian Cancer\r\n    Value Proposition: \r\nADVANTAGES:\n\n\n\n\n&#8226; Biomarkers for early detection/diagnosis of ovarian cancer\n\n\n\n&#8226; Predictive biomarkers for risk of developing ovarian cancer\n\n\n\n&#8226; Biomarkers for the prediction of therapy response\n\n\n\n","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"ovarian cancer (methylation-based biomarkers)","mechanism_class":"methylation biomarker panel","modality":"other","objectID":"16718","rationale_one_line":"Described as 'biomarkers for early detection/diagnosis of ovarian cancer' based on the methylome; primarily a diagnostic/biomarker technology; ovarian cancer is outside the supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16718","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Ovarian Cancer Methylome and Its Potential as Biomarker"},{"biomarker_overlap":"Mrgpr receptor expression as marker for chloroquine-induced itch","composite_score":0.3511460629132438,"cr_rationale":"Mrgpr receptor target ID for chloroquine itch; basic research tool with no direct therapeutic comparison.","description_excerpt":"C10519: Methods and Compositions for Treating Itch\r\n Value Proposition: \r\nInventors have identified a cell receptor family known as Mrgprs that is exclusively expressed in a small subset of neurons. In vitro and animal studies suggest that the Mrg receptor family directly mediates chloroquine (CQ) i","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"chloroquine-induced itch / pruritus (Mrg receptor-mediated)","mechanism_class":"Mrgpr receptor modulator","modality":"other","objectID":"16683","rationale_one_line":"Described as identifying 'Mrg receptor family directly mediates chloroquine (CQ) induced itch'; primarily a target-identification research tool for itch/pruritus — indication outside supported enums, modality is 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16683","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"MrgprA3 (Mrgpr family)","title":"Chloroquine-induced Itch is Mediated by Mrgs"},{"biomarker_overlap":null,"composite_score":0.3511460629132438,"cr_rationale":"Chondroitin sulfate hydrogel/adhesive is a biomaterial platform without disease-specific SoC comparison.","description_excerpt":"C05068: Chondroitin Sulfate-based Two-component Adhesive and Hydrogel\r\n    Value Proposition: \r\nIn part, the present disclosure provides for a composition comprising at least one monomelic unit of a biologically compatible polymer functionalized with an imide to provide a tissue adhesive, a hydrogel","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"wound healing / tissue engineering (chondroitin sulfate adhesive and hydrogel)","mechanism_class":"chondroitin sulfate polymer tissue adhesive / hydrogel","modality":"other","objectID":"16490","rationale_one_line":"Described as 'a composition comprising at least one monomeric unit of a biologically compatible polymer...to provide a tissue adhesive, a hydrogel or both'; biomaterial/device platform — both indication and modality map to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16490","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Chondroitin Sulfate-based Two-component Adhesive and Hydrogel"},{"biomarker_overlap":"mutated protein tyrosine phosphatases","composite_score":0.3511460629132438,"cr_rationale":"Phosphatome mutational mapping is a diagnostic research tool without direct therapeutic application.","description_excerpt":"Technical Details:\r\n\t\t\tJHU researchers have performed a comprehensive mutational analysis of the protein tyrosine phosphatases super gene family in colorectal tumors and other cancers. It was discovered that the mutated tyrosine phosphatases are tumor suppressor genes, regulating pathways that may b","dev_stage":"unknown","exclusivity_status":"unknown","indication":"colorectal_cancer","indication_free_text":"colorectal cancer","mechanism_class":"tyrosine phosphatase tumor suppressor target","modality":"other","objectID":"16337","rationale_one_line":"Mutational analysis of tyrosine phosphatome in 'colorectal tumors' identifies tumor suppressor targets; modality is research tool / diagnostic rather than a defined therapeutic.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16337","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"PTP (protein tyrosine phosphatase family)","title":"Mutational analysis of the tyrosine phosphatome in colorectal cancers"},{"biomarker_overlap":"claudin 1, 3, 4, 7 differential expression","composite_score":0.3511460629132438,"cr_rationale":"Claudin biomarker panel is primarily diagnostic; therapeutic targeting of claudins is early-stage.","description_excerpt":"C03995: Claudins As Markers for Early Detection, Diagnosis, Prognosis and as Targets of Therapy For Breast Cancer\r\n \r\nTechnical Details: \r\nWe have recently identified Claudins 1, 3, 4, and 7 as differentially expressed in breast cancer relative to normal breast tissue. Further studies have shown Cla","dev_stage":"unknown","exclusivity_status":"unknown","indication":"breast_cancer","indication_free_text":"breast cancer","mechanism_class":"claudin-targeted therapy / diagnostic biomarker","modality":"other","objectID":"16233","rationale_one_line":"Claudins 1, 3, 4, 7 differentially expressed in 'breast cancer relative to normal breast tissue' as diagnostic/prognostic biomarkers and therapeutic targets.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16233","subscores":{"clinical_relevance":0.3,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"claudins (CLDN1, CLDN3, CLDN4, CLDN7)","title":"Claudins As markers For Early Detection, Diagnosis, Prognosis and as Targets of Therapy For breast Cancer"},{"biomarker_overlap":null,"composite_score":0.3339818946831569,"cr_rationale":"Mitophagy peptides face dominant GLP-1 obesity and diabetes SoC.","description_excerpt":"Value Proposition:\r\n·      Drug treats mitochondrial dysfunction by promoting mitochondrial fission and mitophagy.\r\n·      Decreases fat levels and represses glucose production in the liver to effectively treat diabetes, obesity, and non-alcoholic fatty liver disease.\r\n·      Possesses antitumor act","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"Diabetes, obesity, and non-alcoholic fatty liver disease (metabolic diseases)","mechanism_class":"mitochondrial fission/mitophagy activator peptide","modality":"peptide","objectID":"48358","rationale_one_line":"Novel peptides treating metabolic diseases including diabetes and obesity via mitochondrial fission/mitophagy; classified under Peptides; type2_diabetes is the closest supported enum given 'Type 2 Diabetes' explicit taxonomy path and primary indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48358","subscores":{"clinical_relevance":0.6,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0},"target":null,"title":"Novel peptides for treating and preventing metabolic diseases"},{"biomarker_overlap":"iodide-handling gene induction as response biomarker","composite_score":0.3211460629132438,"cr_rationale":"Dual PI3K/MAP kinase inhibitor sensitizes radioiodine therapy in undifferentiated thyroid cancer with poor SoC.","description_excerpt":"Novelty: \r\nApplication of radioiodine therapy for the treatment of undifferentiated thyroid cancer and melanoma facilitated by induction of iodide-handling genes via dual suppression of PI3K/Akt and MAP kinase pathways\r\nValue Proposition: \r\nThyroid cancer is typically treated by radioiodine therapy,","dev_stage":"unknown","exclusivity_status":"unknown","indication":"melanoma","indication_free_text":"undifferentiated thyroid cancer and melanoma (radioiodine therapy sensitization)","mechanism_class":"PI3K/Akt + MAP kinase dual pathway inhibitor (radioiodine sensitizer)","modality":"small_molecule","objectID":"16625","rationale_one_line":"Described as 'combination therapy for thyroid cancer and melanoma' via dual PI3K/Akt and MAP kinase suppression to enable radioiodine therapy; melanoma is the supported indication among the two mentioned; small molecule confirmed by taxonomy.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16625","subscores":{"clinical_relevance":0.6,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0},"target":null,"title":"C10292: Combination Therapy for Thyroid Cancer and Melanoma"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Research/manufacturing tool for transgene locus characterization; no direct therapeutic disease indication.","description_excerpt":"Value Proposition:\r\n·        High-throughput screening of loci for exogenous gene insertion \r\n·        Quantifies expression level of exogenous genes in cell type of interest\r\n \r\nUnmet Need\r\n·        Exogenous or synthetic genes that are inserted into the genome serve various purposes, depending on ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Gene therapy / transgene insertion (research tool)","mechanism_class":null,"modality":"other","objectID":"60531","rationale_one_line":"High-throughput method for characterizing suitable genomic loci for transgene expression — a research/manufacturing tool with no specific disease indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60531","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A method for characterizing suitable sites for expressing transgenes"},{"biomarker_overlap":"TERT promoter mutation","composite_score":0.31114606291324387,"cr_rationale":"TERT promoter mutation biomarker is a diagnostic/prognostic tool with no direct therapeutic disease-modifying function.","description_excerpt":"Invention novelty: This invention has discovered high frequency mutations in the telomerase reverse transcriptase (TERT) promoter of certain cancers.\r\n \r\nValue Proposition:\r\nEarly detection is usually critical for the successful treatment of cancer, therefore there is a constant market need to devel","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Human cancer (broad; TERT promoter mutations as diagnostic/prognostic biomarker)","mechanism_class":null,"modality":"other","objectID":"57457","rationale_one_line":"TERT promoter mutation biomarker for cancer diagnosis/prognosis — primarily a diagnostic tool; no therapeutic modality; broad oncology not in specific indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/57457","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TERT","title":"Compositions and Biomarkers for Human Cancer and Methods of Use"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Manufacturing/purification platform for antibody production; no direct patient-facing clinical benefit.","description_excerpt":"Unmet Need\r\nCell and cell-derived therapies, including protein and antibodies, are being developed as a new and promising class of medicine.  These kinds of therapeutics require a nuanced and precise manufacturing process, including bioreactors and filtration systems that can reliably obtain large q","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Antibody and protein manufacturing; membrane filtration systems for continuous protein harvesting","mechanism_class":"peptide-based antifouling membrane filtration","modality":"other","objectID":"53367","rationale_one_line":"This is a manufacturing/purification platform for protein and antibody production, not a therapeutic; both indication and modality map to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53367","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Peptide-Based Antifouling Membrane Filtration Systems for Continuous Protein Harvesting"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Stimulus-responsive polymer for mAb purification is a manufacturing tool with no patient-level clinical relevance.","description_excerpt":"Value Proposition - Results in &gt;97% precipitation yield, &gt;88% elution yield of mAbs - Simplified molecular design compared to elastin-like polypeptide (ELP)-based materials - Does not need additional salt to achieve mAb precipitation and recovery\r\nTechnology Description\r\nResearchers at Johns H","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Monoclonal antibody manufacturing and purification; peptide-based platform for mAb precipitation and recovery","mechanism_class":"stimulus-responsive polymer for mAb purification","modality":"other","objectID":"53159","rationale_one_line":"This is a manufacturing platform for antibody purification achieving over 97% precipitation yield, not a therapeutic; maps to other for both indication and modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53159","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Polymers for Binding-Triggered Antibody Precipitation and Purification"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Biomacromolecule purification system is a manufacturing tool with no direct clinical impact on patients.","description_excerpt":"Market hold: no patent application filed for this invention.\r\nUnmet Need\r\n·        It is estimated that between ~50-80% of costs in antibody production are spent in purification (Mustafaoglu et al. 2016), which is typically performed by affinity chromatography. Although this method has adequate bind","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Antibody and biomacromolecule purification; supramolecular high-affinity protein-binding system","mechanism_class":"supramolecular protein-binding purification system","modality":"other","objectID":"53158","rationale_one_line":"Source explicitly frames this as a purification and manufacturing tool for biomacromolecules with no patent filed (Market hold); maps to other for both fields.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53158","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A Novel Supramolecular High Affinity Protein-Binding System for Purification of Biomacromolecules"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Nanoparticle characterization tool; no direct therapeutic impact on patients.","description_excerpt":"Polymeric and lipid nanoparticles (NPs) are an effective and safe method for therapeutic delivery. At each of the various steps in nanoparticle development and manufacturing (i.e., research and design, quality assurance), assessing the features of these vehicles is essential. Some features (i.e., pa","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Nucleic acid nanoparticle characterization (research / manufacturing tool)","mechanism_class":null,"modality":"other","objectID":"48534","rationale_one_line":"Methods for payload and size characterization of nucleic acid nanoparticles; a research/manufacturing quality-assurance tool classified under Therapeutic Delivery Platforms; no therapeutic indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/48534","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Methods for Payload and Size Characterization of Nucleic Acid Nanoparticles"},{"biomarker_overlap":"ZnT8 expression","composite_score":0.31114606291324387,"cr_rationale":"ZnT8 assay is a research tool without direct patient benefit.","description_excerpt":"Unmet Need: Prevalence of Type 2 Diabetes (T2D) continues to rapidly increase worldwide, contributing significant economic and global health burdens. There is an urgent need for the development of novel therapeutic strategies to treat T2D.\r\nTechnical Details: Johns Hopkins researchers have identifie","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"Type 2 Diabetes","mechanism_class":"ZnT8 modulator screening assay","modality":"other","objectID":"43870","rationale_one_line":"Assay to screen for ZnT8 modulators explicitly to treat T2D; technology is a research assay/target discovery tool, modality mapped to other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/43870","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"ZnT8","title":"Assay to Screen for ZnT8 Modulators to treat T2D and Other Diseases"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Malaria vaccine manufacturing tool; process efficiency improvement with no direct clinical endpoint impact.","description_excerpt":"Unmet Need\r\nMalaria is one of the world’s most common mosquito-borne illnesses, with an estimated 219 million cases and 435,000 deaths in 2017. An estimated $12 billion is lost every year in Africa due to malaria. Although vaccines have been developed to eradicate malaria, vaccine production is hind","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Malaria vaccine production (manufacturing tool)","mechanism_class":"Automated mosquito salivary gland extraction for malaria vaccine","modality":"other","objectID":"35510","rationale_one_line":"Rapid automated extraction of mosquito salivary glands to improve malaria vaccine production efficiency — a manufacturing/process tool, not a therapeutic; malaria is outside the 11 supported indication enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/35510","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Rapid Automated Extraction of Mosquito Salivary Glands For Improved Malaria Vaccine Production"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Fluorinated DREADD ligands are research/imaging tools with no direct therapeutic clinical impact.","description_excerpt":"Unmet Need\r\nChemogenetics is defined as a method by which proteins are made to interact with small molecules, typically neurological molecules, as they have never been interacted with before. There is a powerful and versatile approach for remote and momentary manipulation of cellular activity called","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"chemogenetics / neurological manipulation via DREADD technology","mechanism_class":"DREADD ligand / chemogenetic actuator","modality":"small_molecule","objectID":"30471","rationale_one_line":"Fluorinated DREADD ligands for PET imaging and chemogenetic cellular manipulation; primarily a research tool/neuroimaging agent without a specific therapeutic disease indication in the supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/30471","subscores":{"clinical_relevance":0.2,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"DREADD (designer receptor)","title":"New fluorinated DREADD actuators and ligands suitable for PET imaging"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Digital safety app for intimate partner violence is a behavioral intervention, not a clinical therapeutic.","description_excerpt":"Technology Overview\r\nThis technology is a personalized safety decision application for access through smart phones targeting college women. The safety decision-making process (e.g., knowing the advantages and disadvantages of the relationship, having enough information to make a safety decision, hel","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"intimate partner violence prevention in college women (public health / safety app)","mechanism_class":"digital safety decision application","modality":"other","objectID":"26280","rationale_one_line":"Personalized smartphone safety application for intimate partner violence prevention; digital health/behavioral intervention is not a therapeutic modality in any supported enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/26280","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Developing an Interactive, Personalized Safety Decision Smart Phone Application to Prevent and Respond to Intimate Partner Violence in College Women"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Cortical neuron culture is a screening tool without direct therapeutic impact.","description_excerpt":"Unmet Need:  Translating neuroprotective treatments from discovery in cell and animal models to the clinic has proven challenging. To reduce the gap between basic studies of neurotoxicity and neuroprotection and clinically relevant therapies, JHU scientists developed a human cortical neuron culture ","dev_stage":"preclinical","exclusivity_status":"unknown","indication":"other","indication_free_text":"neurotoxicity / neuroprotection (stroke and neurological disease)","mechanism_class":"human cortical neuron culture system for neuroprotection screening","modality":"other","objectID":"25115","rationale_one_line":"Human cortical neuron culture method from stem cells for neuroprotection research; research tool/cell culture platform for neurological indications not in the supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/25115","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Method of culturing excitatory and inhibitory neuronal networks."},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Research tool for 3D microtissue conditioning; no therapeutic application vs SoC.","description_excerpt":"We have recently demonstrated an approach that enables mechanical stimulation of microtissues via magnetic actuation of magnetic microspheres bonded to one of the cantilevers in each device (ALL THREE ZHAO REFS).  This has notably allowed measurement of the mechanical stiffness of such constructs, a","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"3D microtissue mechanical conditioning (tissue engineering research tool)","mechanism_class":"magnetic actuation microfabricated mechanical conditioning device","modality":"other","objectID":"24727","rationale_one_line":"Microfabricated device for mechanical stimulation of 3D microtissues via magnetic actuation; research/device tool with no therapeutic indication or modality enum match.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24727","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"A Microfabricated Multiple Actuation Device for Mechanical Conditioning of 3D Microtissues"},{"biomarker_overlap":"mutant hDISC1 expression","composite_score":0.31114606291324387,"cr_rationale":"Transgenic DISC1 mouse model is a research tool with no direct patient clinical impact.","description_excerpt":"Invention Novelty: \r\nThe disclosed technologies are two tangible materials that are improved homozygous mouse strains with inducible expression of mutant human Disrupted-In-Schizophrenia-1 (hDISC1) using Tet-off system under the control of CAMKII. \r\n \r\nValue Proposition:\r\nThe disclosed materials are","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"schizophrenia; psychiatric disorders (DISC1 mouse model)","mechanism_class":"transgenic animal model (Tet-off inducible DISC1)","modality":"other","objectID":"24243","rationale_one_line":"Homozygous mouse strains with inducible mutant hDISC1 are research tools / animal models for schizophrenia; not a therapeutic modality — both indication and modality map to 'other'.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24243","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"DISC1","title":"Homozygous Mutant DISC1 Mice, Lines 1001 and 1302"},{"biomarker_overlap":"biomarkers for antipsychotic-induced weight gain","composite_score":0.31114606291324387,"cr_rationale":"Antipsychotic weight-gain assay is a development tool without direct patient impact.","description_excerpt":"Novelty: This invention is a method for screening for orexigenic (weight inducing) antipsychotic drugs.\r\n\r\nValue Proposition: Atypical antipsychotic drugs (AAPDs) have revolutionized the treatment of schizophrenia and other psychoses, however, certain AAPDs cause weight gain. Weight gain is a side e","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"schizophrenia and psychosis (screening for weight-gain side effects of antipsychotics)","mechanism_class":"screening assay for orexigenic antipsychotic drug effects","modality":"other","objectID":"16483","rationale_one_line":"Described as 'a method for screening for orexigenic (weight inducing) antipsychotic drugs'; this is a screening/diagnostic tool for drug side effects in schizophrenia — maps to other/other; schizophrenia is outside supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16483","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Method for Identifying Weight Gain Inducing Effects of Antipsychotic Drugs"},{"biomarker_overlap":"BAX gene status","composite_score":0.31114606291324387,"cr_rationale":"Isogenic BAX cell lines are a research tool; no therapeutic application demonstrated.","description_excerpt":"C04218: Isogenic Cell Lines with or without Intact BAX Genes\r\n   \r\n\r\nTechnical Details: \r\n\r\nTo assess the role of BAX in drug-induced apoptosis in human colorectal cancer cells, we generated cells that lack functional BAX genes. Such cells were partially resistant to the apoptotic effects of the che","dev_stage":"unknown","exclusivity_status":"unknown","indication":"colorectal_cancer","indication_free_text":"colorectal cancer","mechanism_class":"BAX apoptosis pathway research tool","modality":"other","objectID":"16276","rationale_one_line":"Isogenic cell lines lacking BAX to study drug-induced apoptosis in 'human colorectal cancer cells'; colorectal cancer is explicitly stated, but this is primarily a research tool.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16276","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"BAX","title":"Isogenic Cell Lines with or without Intact BAX Genes"},{"biomarker_overlap":"p53 status","composite_score":0.31114606291324387,"cr_rationale":"p53-activating compound screening cell line is a research tool with no direct therapeutic benefit.","description_excerpt":"C03857: Cell line to identify inhibitors of p53\r\n \r\nTechnical Details: \r\nAn exciting, new invention from the laboratory of Dr. Scott Kern at The Johns Hopkins University School of Medicine for the identification of p53 activating compounds that would be of interest to In Vitro Technologies. The stat","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (p53 pathway)","mechanism_class":"p53 activating compound screening tool","modality":"other","objectID":"16211","rationale_one_line":"Cell line for identifying p53-activating compounds across human tumors; research tool for broad oncology, no specific PhaseFolio-supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16211","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"TP53","title":"Identification of P53-activating Compounds for Cancer Research and Therapy"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Metastasis suppressor somatic cell hybrid is a basic research tool; no translational therapeutic application.","description_excerpt":"Technical Details:\r\n\t\t\tSomatic cell hybrids created from highly metastatic rat prostatic cancer cells and human chromosome 11 were created using micro cell-mediated chromosome transfer. The introduction of human chromosome 11 into the highly metastatic rat prostate cancer cells suppressed the metast","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"prostate cancer (metastasis suppression)","mechanism_class":"chromosome-mediated metastasis suppressor","modality":"other","objectID":"16203","rationale_one_line":"Somatic cell hybrid R-3327-AT6.1 demonstrates chromosome 11 suppression of metastasis in rat prostate cancer; research tool, prostate cancer outside supported enums.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16203","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"R-3327-AT6.1"},{"biomarker_overlap":"securin expression; chromosomal instability","composite_score":0.31114606291324387,"cr_rationale":"Securin-null cell lines enable aneuploidy drug screening but have no standalone clinical impact.","description_excerpt":"C03816: Securin is Required for Chromosomal Stability in Human CellsValue Proposition: \r\nADVANTAGES \n\n&#8226; hSecurin-/- cells exhibit chromosomal instability\n\n\n&#8226; hSecurin-/- cells are defective in their ability to execute anaphase\n\n\n\n&#8226; hSecurin-/- cells have gross aneuploidy\n\n\n\n&#8226;","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (chromosomal instability / aneuploidy screening)","mechanism_class":"securin / chromosomal stability target","modality":"other","objectID":"16199","rationale_one_line":"hSecurin-null cells exhibit chromosomal instability enabling screening for anti-aneuploidy agents; research tool for broad oncology, no specific supported indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16199","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"securin (PTTG1)","title":"Securin is Required for Chromosomal Stability in Human Cells"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Scriptaid HDAC inhibitor used to boost plasmid expression; research tool without therapeutic indication.","description_excerpt":"C03611: Facilitation of the Expression in Eukaryotic Cells of Exogenous Genes by an Exogenous Compound\r\n   \r\n\r\nTechnical Details: \r\n\r\nScriptaid is a histone deacetylase inhibitor that provides a simple means of increasing the efficiency of plasmid-based reporter and expression constructs. When added","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"gene expression research tool (HDAC inhibitor for plasmid expression)","mechanism_class":"HDAC inhibitor (gene expression enhancer)","modality":"small_molecule","objectID":"16168","rationale_one_line":"Scriptaid is a histone deacetylase inhibitor that enhances plasmid-based gene expression in mammalian cells; primarily a research tool with no specific therapeutic indication stated.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16168","subscores":{"clinical_relevance":0.2,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":"HDAC","title":"Facilitation of the Expression in Eukaryotic Cells of Exogenous Genes by an Exogenous Compound"},{"biomarker_overlap":null,"composite_score":0.31114606291324387,"cr_rationale":"Research-tool platform with no disease indication; zero clinical impact vs SoC.","description_excerpt":"C01426: Engineering Intracellular Sialylation PathwaysValue Proposition: \r\nManipulating carbohydrate processing pathways in insect and other eukaryotic cells so that the cells produce complex sialylated glycoproteins is useful for enhancing the value of heterologous expression systems and increasing","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"heterologous expression systems and engineering of complex sialylated glycoproteins in insect and eukaryotic cells","mechanism_class":"glycoprotein sialylation engineering","modality":"other","objectID":"16064","rationale_one_line":"This is a manufacturing/research-tool platform — 'manipulating carbohydrate processing pathways in insect and other eukaryotic cells' — with no disease indication or therapeutic modality; maps cleanly to other/other.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16064","subscores":{"clinical_relevance":0.2,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Engineering Intracellular Sialylation Pathways"},{"biomarker_overlap":null,"composite_score":0.29398189468315694,"cr_rationale":"Ternary nanoparticle sustained-release peptide for T2D; GLP-1 SoC is well-established; route improvement is incremental.","description_excerpt":"Unmet Need\r\nType 2 diabetes (T2D) contributes to 90% of all cases of diabetes and represents a critical global public health problem. T2D specifically affects glucose metabolism and those with the disease either do not produce enough insulin or do not respond properly to insulin signaling to maintai","dev_stage":"unknown","exclusivity_status":"unknown","indication":"type2_diabetes","indication_free_text":"Type 2 Diabetes","mechanism_class":"ternary nanoparticle sustained-release peptide delivery","modality":"peptide","objectID":"39011","rationale_one_line":"Size-controlled ternary nanoparticles for sustained release of peptide therapeutics explicitly to treat T2D; categories confirm Peptides and T2D context.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/39011","subscores":{"clinical_relevance":0.5,"ira_exposure":0.3,"modality_pos":0.3132729822771898,"whitespace":0},"target":null,"title":"Production of Size-Controlled Ternary Nanoparticles for Sustained Release of Peptide Therapeutics"},{"biomarker_overlap":null,"composite_score":0.29114606291324385,"cr_rationale":"DNA origami control is a research tool without therapeutic indication.","description_excerpt":"Unmet Need\r\nMolecular assemblies inside cells often undergo structural reconfiguration in response to stimuli to alter their function. Adaptive reconfiguration of cytoskeletal networks, for example, enables cellular shape change, movement, and cargo transport and plays a key role in driving complex ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Biological sensing, transport, and self-assembly (research tool)","mechanism_class":"DNA oligonucleotide for DNA origami reconfiguration","modality":"nucleic_acid","objectID":"60523","rationale_one_line":"DNA oligonucleotide method for controlling DNA origami structure reconfiguration — primarily a research/sensing tool; no therapeutic indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60523","subscores":{"clinical_relevance":0.15,"ira_exposure":0.4,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Method to Use a DNA Oligonucleotide to Bind and Unbind Functional DNA Origami Structures for Applications in Biological Sensing, Transport and Self-assembly"},{"biomarker_overlap":null,"composite_score":0.28114606291324384,"cr_rationale":"Wnt/Hedgehog modulators in CRC; partial SoC overlap with approved Hedgehog inhibitors.","description_excerpt":"Unmet Need:\r\nWnt and Hedgehog are important signaling pathways involved in cellular proliferation and differentiation.  Both pathways have been shown to play roles in the development, growth and migration of different types of cancer, including colorectal, prostate, lung, breast, and brain cancer.  ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"colorectal_cancer","indication_free_text":"colorectal, prostate, lung, breast, and brain cancer (Wnt and Hedgehog pathway modulators)","mechanism_class":"Wnt / Hedgehog pathway modulator","modality":"small_molecule","objectID":"24624","rationale_one_line":"Small molecule modulators of Wnt and Hedgehog signaling pathways across multiple cancer types including colorectal; mapped to colorectal_cancer as the first listed supported indication enum.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24624","subscores":{"clinical_relevance":0.5,"ira_exposure":0.2,"modality_pos":0.2704868763774794,"whitespace":0},"target":null,"title":"C04341 & C04342 - Small molecule modulators of Wnt and Hedgehog pathways"},{"biomarker_overlap":null,"composite_score":0.27114606291324383,"cr_rationale":"Silicon crosslinker is a materials tool without therapeutic disease application.","description_excerpt":"Value Proposition:\r\n·       Includes: increasing polymer network toughness through a novel chemical modification.\r\n·       Enables stronger, durable 3D-printed materials.\r\n·       Adaptable to modern 3D printing platforms for improved production from existing machinery.\r\nUnmet Need:\r\nPolymer network","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Materials science / 3D printing (engineering application)","mechanism_class":null,"modality":"other","objectID":"57576","rationale_one_line":"Silicon-doped crosslinkers to toughen polymer networks for 3D printing — a materials engineering technology with no therapeutic indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/57576","subscores":{"clinical_relevance":0.1,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Network Toughening by Silicon-doped Crosslinkers"},{"biomarker_overlap":null,"composite_score":0.27114606291324383,"cr_rationale":"Organophosphate MOF catalysis is synthetic chemistry with no therapeutic clinical application.","description_excerpt":"Unmet Need\r\nThere is a continuously growing need for new and better asymmetric catalysts, as is evidenced by the fact that the 2021 Nobel Prize in Chemistry went to two scientists for development of asymmetric organocatalysis (see Nobel Prize). Currently, most synthetic catalysis is carried out via ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"asymmetric catalysis / synthetic chemistry (organophosphate metal-organic frameworks)","mechanism_class":"organo-phosphate MOF asymmetric catalyst","modality":"other","objectID":"54919","rationale_one_line":"This is a synthetic chemistry / catalysis technology (metal-organic frameworks); not a therapeutic asset — maps to 'other' for both indication and modality.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/54919","subscores":{"clinical_relevance":0.1,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Organo-phosphate Modified Metal Organic Frameworks and Applications"},{"biomarker_overlap":null,"composite_score":0.27114606291324383,"cr_rationale":"Industrial polymer chemistry tool; no therapeutic indication or clinical impact.","description_excerpt":"Unmet Need\r\nAlthough vinyl alcohol-methyl methacrylate (VA-MMA) copolymers have intriguing functionally-rich structure that could impact a polymer’s properties, they are synthetically inaccessible from vinyl acetate (VAc), the traditional precursor to polyvinyl alcohol (PVA). VAc is poorly compatibl","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Polymer chemistry / materials science (vinyl alcohol-methyl methacrylate copolymers)","mechanism_class":"Organoborane polymerization strategy","modality":"other","objectID":"38590","rationale_one_line":"Industrial materials chemistry for synthesizing VA-MMA copolymers via organoborane strategy — a manufacturing/chemistry tool with no specific therapeutic indication.","rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/38590","subscores":{"clinical_relevance":0.1,"ira_exposure":0.5,"modality_pos":0.2704868763774794,"whitespace":0.5},"target":null,"title":"Organoborane Strategy for Polymers Bearing Lactone, Ester, and Alcohol Functionality"}],"tail_summary":{"count":492,"score_max":0.5111460629132438,"score_min":0.27114606291324383},"top":[{"biomarker_overlap":"HLA matching; tumor neoantigen profile (somatic mutations)","composite_score":0.7700000000000001,"cr_rationale":"Allogeneic neoantigen T cell therapy addresses checkpoint-refractory tumors with no SoC.","description_excerpt":"The present invention describes methods of preparing a cell composition for treating cancer in a human being by obtaining lymphocytes from a partially or fully HLA-matched healthy donor, activating and expanding T cells reactive to tumor neoantigens (i.e. new epitopes resulting from somatic mutation","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cancer (personalized allogeneic T cell therapy targeting tumor neoantigens)","landscape_kpis":{"approvals":0,"comparable_trials":0,"sponsors":0},"mechanism_class":"allogeneic neoantigen-reactive T cell therapy","modality":"car_t","objectID":"24614","rationale_one_line":"Personalized allogeneic cell therapy expanding HLA-matched T cells reactive to tumor neoantigens; broad oncology indication outside the 11 supported enums; mapped to car_t as the closest cell therapy modality enum.","rnpv_envelope":{"cumulative_pos":0.008784,"engine_version":"1.0.0","fallback_profile_used":true,"peak_revenue_base_usd":600000000,"rnpv_base_usd":-13628878.41,"rnpv_high_usd":-7584475.1,"rnpv_low_usd":-16375283.85,"stages_assumed":[{"cost_usd":15000000,"duration_months":24,"name":"Preclinical","probability_of_success":0.07},{"cost_usd":60000000,"duration_months":18,"name":"Phase I","probability_of_success":0.55},{"cost_usd":130000000,"duration_months":30,"name":"Phase II","probability_of_success":0.4},{"cost_usd":320000000,"duration_months":36,"name":"Phase III","probability_of_success":0.62},{"cost_usd":14000000,"duration_months":12,"name":"NDA/BLA Review","probability_of_success":0.92}],"wacc_base":0.12},"rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/24614","subscores":{"clinical_relevance":0.8,"ira_exposure":0.9,"modality_pos":1,"whitespace":0.5},"target":"tumor neoantigens","title":"Personalized, Allogeneic Cell Therapy of Cancer"},{"biomarker_overlap":null,"composite_score":0.7119016957796761,"cr_rationale":"SYNGAP1-related ID has no approved therapy; gene replacement addresses root cause in severe unmet need.","description_excerpt":"Unmet Need: \r\nSYNGAP1-related Intellectual Disability (SRID, MRD5) is a severe neurodevelopmental disorder (NDD) characterized by encephalopathy, intellectual disability (ID), autism spectrum disorder (ASD), and epilepsy and accounts for 0.5-1% of all NDDs and ~1% of the ~200 million ID cases worldw","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"SYNGAP1-related Intellectual Disability (SRID, MRD5); severe neurodevelopmental disorder characterized by encephalopathy, intellectual disability, autism spectrum disorder, and epilepsy","landscape_kpis":{"approvals":0,"comparable_trials":0,"sponsors":0},"mechanism_class":"gene replacement / SYNGAP1 restoration","modality":"gene_therapy","objectID":"53583","rationale_one_line":"Taxonomy explicitly tags Gene Therapies and the description targets the SYNGAP1 gene in a rare neurodevelopmental disorder outside the 11 supported indications.","rnpv_envelope":{"cumulative_pos":0.006497,"engine_version":"1.0.0","fallback_profile_used":true,"peak_revenue_base_usd":600000000,"rnpv_base_usd":-14933010.9,"rnpv_high_usd":-10704126.44,"rnpv_low_usd":-16746357.83,"stages_assumed":[{"cost_usd":15000000,"duration_months":24,"name":"Preclinical","probability_of_success":0.07},{"cost_usd":60000000,"duration_months":18,"name":"Phase I","probability_of_success":0.5},{"cost_usd":130000000,"duration_months":30,"name":"Phase II","probability_of_success":0.34},{"cost_usd":320000000,"duration_months":36,"name":"Phase III","probability_of_success":0.6},{"cost_usd":14000000,"duration_months":12,"name":"NDA/BLA Review","probability_of_success":0.91}],"wacc_base":0.12},"rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53583","subscores":{"clinical_relevance":0.85,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"SYNGAP1","title":"Gene therapy for SYNGAP1 encephalopathy and \nSYNGAP1-related disorders"},{"biomarker_overlap":null,"composite_score":0.6919016957796762,"cr_rationale":"AAV NF1 replacement targets root cause where disease-modifying therapy is absent.","description_excerpt":"Value Proposition\r\n·      Targets direct genetic cause of NF1 rather than only symptoms.\r\n·      Improves therapeutic options for NF1 patients.\r\n·      AAV vector is one of the safest viral vectors for gene therapy.\r\n·      Market for NF1 gene therapies is quite open.\r\nUnmet Need\r\nNeurofibromatosis ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Neurofibromatosis type 1 (NF1)","landscape_kpis":{"approvals":0,"comparable_trials":0,"sponsors":0},"mechanism_class":"AAV gene replacement","modality":"gene_therapy","objectID":"60653","rationale_one_line":"AAV vector gene therapy targeting the NF1 genetic cause; NF1/neurofibromatosis not in the indication enum.","rnpv_envelope":{"cumulative_pos":0.006497,"engine_version":"1.0.0","fallback_profile_used":true,"peak_revenue_base_usd":600000000,"rnpv_base_usd":-14933010.9,"rnpv_high_usd":-10704126.44,"rnpv_low_usd":-16746357.83,"stages_assumed":[{"cost_usd":15000000,"duration_months":24,"name":"Preclinical","probability_of_success":0.07},{"cost_usd":60000000,"duration_months":18,"name":"Phase I","probability_of_success":0.5},{"cost_usd":130000000,"duration_months":30,"name":"Phase II","probability_of_success":0.34},{"cost_usd":320000000,"duration_months":36,"name":"Phase III","probability_of_success":0.6},{"cost_usd":14000000,"duration_months":12,"name":"NDA/BLA Review","probability_of_success":0.91}],"wacc_base":0.12},"rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/60653","subscores":{"clinical_relevance":0.8,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"NF1","title":"Gene therapy for neurofibromatosis type 1"},{"biomarker_overlap":"Nucleotide repeat expansion","composite_score":0.6919016957796762,"cr_rationale":"CRISPR editing of toxic repeat expansions addresses genetic root cause of disorders with no SoC.","description_excerpt":"Unmet Need / Invention Novelty: Expansions in nucleotide repeat elements have been linked to various neurological and neuromuscular disorders, with repeat-containing RNAs and/or their protein products being identified as important causes of pathogenic processes and associated diseases. There is an u","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Neurological and neuromuscular disorders caused by nucleotide repeat expansions","landscape_kpis":{"approvals":0,"comparable_trials":0,"sponsors":0},"mechanism_class":"CRISPR-Cas gene editing","modality":"gene_therapy","objectID":"47862","rationale_one_line":"Novel CRISPR-Cas therapeutic strategy to decrease toxic RNA/protein from nucleotide repeats in neurological/neuromuscular disorders; classified under Gene Therapies; indication not in enum.","rnpv_envelope":{"cumulative_pos":0.006497,"engine_version":"1.0.0","fallback_profile_used":true,"peak_revenue_base_usd":600000000,"rnpv_base_usd":-14933010.9,"rnpv_high_usd":-10704126.44,"rnpv_low_usd":-16746357.83,"stages_assumed":[{"cost_usd":15000000,"duration_months":24,"name":"Preclinical","probability_of_success":0.07},{"cost_usd":60000000,"duration_months":18,"name":"Phase I","probability_of_success":0.5},{"cost_usd":130000000,"duration_months":30,"name":"Phase II","probability_of_success":0.34},{"cost_usd":320000000,"duration_months":36,"name":"Phase III","probability_of_success":0.6},{"cost_usd":14000000,"duration_months":12,"name":"NDA/BLA Review","probability_of_success":0.91}],"wacc_base":0.12},"rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/47862","subscores":{"clinical_relevance":0.8,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Novel CRISPR-Cas based therapeutic strategy to decrease toxic RNA and protein products generated from nucleotide repeats"},{"biomarker_overlap":null,"composite_score":0.6919016957796762,"cr_rationale":"CF gene therapy targets unmet patients and sputum delivery barriers.","description_excerpt":"C11417: Synthetic Sputum-penetrating Gene Carriers\r\n\r\nNovelty: \r\n\r\nThe technology provides novel compositions and methods to deliver gene therapy to cystic fibrosis (CF) patients.\r\nValue Proposition: \r\nCF is one of the most common genetic disorders.  Currently, there are no aerosol gene delivery met","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"cystic fibrosis (gene therapy delivery through sputum)","landscape_kpis":{"approvals":0,"comparable_trials":0,"sponsors":0},"mechanism_class":"sputum-penetrating gene carrier","modality":"gene_therapy","objectID":"16927","rationale_one_line":"Description explicitly states 'deliver gene therapy to cystic fibrosis (CF) patients'; modality is gene_therapy; indication maps to 'other' as cystic fibrosis is outside the supported enum.","rnpv_envelope":{"cumulative_pos":0.006497,"engine_version":"1.0.0","fallback_profile_used":true,"peak_revenue_base_usd":600000000,"rnpv_base_usd":-14933010.9,"rnpv_high_usd":-10704126.44,"rnpv_low_usd":-16746357.83,"stages_assumed":[{"cost_usd":15000000,"duration_months":24,"name":"Preclinical","probability_of_success":0.07},{"cost_usd":60000000,"duration_months":18,"name":"Phase I","probability_of_success":0.5},{"cost_usd":130000000,"duration_months":30,"name":"Phase II","probability_of_success":0.34},{"cost_usd":320000000,"duration_months":36,"name":"Phase III","probability_of_success":0.6},{"cost_usd":14000000,"duration_months":12,"name":"NDA/BLA Review","probability_of_success":0.91}],"wacc_base":0.12},"rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/16927","subscores":{"clinical_relevance":0.8,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Engineering Synthetic Sputum-penetrating Gene Carriers"},{"biomarker_overlap":null,"composite_score":0.6719016957796762,"cr_rationale":"CRISPR CMV antiviral could clear latent reservoir not cured by ganciclovir.","description_excerpt":"Value Proposition - Novel Mechanism: Utilizes a Crispr/Cas9 system to target the viral genome to prevent production of the disease-causing protein 1E1 in CMV. - Widely Adaptable: Design allows modulation to fit a wide variety of other viral genomes to combat other infectious diseases. - Therapeutic ","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cytomegalovirus (CMV) and other viral infections","landscape_kpis":{"approvals":0,"comparable_trials":0,"sponsors":0},"mechanism_class":"CRISPR/Cas9 antiviral","modality":"gene_therapy","objectID":"59905","rationale_one_line":"CRISPR/Cas9 system targeting CMV viral genome to prevent IE1 protein production; gene_therapy modality; CMV/infectious disease not in indication enum.","rnpv_envelope":{"cumulative_pos":0.006497,"engine_version":"1.0.0","fallback_profile_used":true,"peak_revenue_base_usd":600000000,"rnpv_base_usd":-14933010.9,"rnpv_high_usd":-10704126.44,"rnpv_low_usd":-16746357.83,"stages_assumed":[{"cost_usd":15000000,"duration_months":24,"name":"Preclinical","probability_of_success":0.07},{"cost_usd":60000000,"duration_months":18,"name":"Phase I","probability_of_success":0.5},{"cost_usd":130000000,"duration_months":30,"name":"Phase II","probability_of_success":0.34},{"cost_usd":320000000,"duration_months":36,"name":"Phase III","probability_of_success":0.6},{"cost_usd":14000000,"duration_months":12,"name":"NDA/BLA Review","probability_of_success":0.91}],"wacc_base":0.12},"rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/59905","subscores":{"clinical_relevance":0.75,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"CMV IE1","title":"A CRISPR-based technology to treat cytomegalovirus (CMV) and other Viral Infections."},{"biomarker_overlap":null,"composite_score":0.6719016957796762,"cr_rationale":"AAV-mediated Muller glia reprogramming addresses retinal neurodegeneration where cell replacement SoC is unavailable.","description_excerpt":"Value Proposition\r\n·        Identifies targets for modulation of retinal Muller glia-derived neurogenesis.\r\n·        Demonstrates efficacy of adeno-associated virus induced retinal Muller glia-derived neurogenesis.\r\n·        Combines viral constructs and small molecules to generate specific subtypes","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Retinal neurodegeneration; conversion of retinal Muller glia into neurons for cell replacement therapy","landscape_kpis":{"approvals":0,"comparable_trials":0,"sponsors":0},"mechanism_class":"AAV-mediated retinal glia reprogramming","modality":"gene_therapy","objectID":"53418","rationale_one_line":"Source states adeno-associated virus induced retinal Muller glia-derived neurogenesis; AAV delivery maps to gene_therapy; retinal neurodegeneration is outside the 11 supported indications.","rnpv_envelope":{"cumulative_pos":0.006497,"engine_version":"1.0.0","fallback_profile_used":true,"peak_revenue_base_usd":600000000,"rnpv_base_usd":-14933010.9,"rnpv_high_usd":-10704126.44,"rnpv_low_usd":-16746357.83,"stages_assumed":[{"cost_usd":15000000,"duration_months":24,"name":"Preclinical","probability_of_success":0.07},{"cost_usd":60000000,"duration_months":18,"name":"Phase I","probability_of_success":0.5},{"cost_usd":130000000,"duration_months":30,"name":"Phase II","probability_of_success":0.34},{"cost_usd":320000000,"duration_months":36,"name":"Phase III","probability_of_success":0.6},{"cost_usd":14000000,"duration_months":12,"name":"NDA/BLA Review","probability_of_success":0.91}],"wacc_base":0.12},"rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53418","subscores":{"clinical_relevance":0.75,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":null,"title":"Conversion of retinal glia into neurons for cell replacement therapy"},{"biomarker_overlap":null,"composite_score":0.6719016957796762,"cr_rationale":"CFTR editing could help patients underserved by Trikafta mutation coverage.","description_excerpt":"Inventors: Jordan J. Green, Stephany Yi Tzeng, Garry R. Cutting, Erin W. Kavanagh \r\nUnmet Need\r\nCystic fibrosis (CF) is a progressive, genetic disease that affects the lungs, pancreas, and other organs. There are close to 40,000 children and adults living with cystic fibrosis in the United States (s","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Cystic fibrosis (CF); CFTR gene editing via polymer-nucleic acid nanoparticles","landscape_kpis":{"approvals":0,"comparable_trials":0,"sponsors":0},"mechanism_class":"polymer-nucleic acid nanoparticle gene editing (CFTR)","modality":"gene_therapy","objectID":"52676","rationale_one_line":"Taxonomy confirms Gene Therapies; source targets cystic fibrosis mutations in CFTR via gene editing nanoparticles; cystic fibrosis is outside the 11 supported indications.","rnpv_envelope":{"cumulative_pos":0.006497,"engine_version":"1.0.0","fallback_profile_used":true,"peak_revenue_base_usd":600000000,"rnpv_base_usd":-14933010.9,"rnpv_high_usd":-10704126.44,"rnpv_low_usd":-16746357.83,"stages_assumed":[{"cost_usd":15000000,"duration_months":24,"name":"Preclinical","probability_of_success":0.07},{"cost_usd":60000000,"duration_months":18,"name":"Phase I","probability_of_success":0.5},{"cost_usd":130000000,"duration_months":30,"name":"Phase II","probability_of_success":0.34},{"cost_usd":320000000,"duration_months":36,"name":"Phase III","probability_of_success":0.6},{"cost_usd":14000000,"duration_months":12,"name":"NDA/BLA Review","probability_of_success":0.91}],"wacc_base":0.12},"rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/52676","subscores":{"clinical_relevance":0.75,"ira_exposure":0.9,"modality_pos":0.7396723192655871,"whitespace":0.5},"target":"CFTR","title":"Polymer-Nucleic Acid Nanoparticles for Gene Editing"},{"biomarker_overlap":null,"composite_score":0.67,"cr_rationale":"VR-cell therapy may improve CAR-T safety, but superiority remains unproven.","description_excerpt":"Unmet Need\r\n·        Recent technological breakthroughs have highlighted the therapeutic potential of immunotherapy (e.g., CAR-T cells) and have focused attention and efforts on developing safe and effective immunotherapy modalities.\r\n·        Despite advances in the field, there remain several chal","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"Immuno-oncology broadly; improving CAR-T and immunotherapy safety and efficacy via multi-cytokine targeting","landscape_kpis":{"approvals":0,"comparable_trials":0,"sponsors":0},"mechanism_class":"VR-expressing cell therapy targeting multiple cytokines","modality":"car_t","objectID":"53237","rationale_one_line":"Source describes VR-Expressing Cells against Multiple Cytokines in an immuno-oncology context improving CAR-T safety; maps to car_t modality; broad immuno-oncology without specific cancer type maps to other.","rnpv_envelope":{"cumulative_pos":0.008784,"engine_version":"1.0.0","fallback_profile_used":true,"peak_revenue_base_usd":600000000,"rnpv_base_usd":-13628878.41,"rnpv_high_usd":-7584475.1,"rnpv_low_usd":-16375283.85,"stages_assumed":[{"cost_usd":15000000,"duration_months":24,"name":"Preclinical","probability_of_success":0.07},{"cost_usd":60000000,"duration_months":18,"name":"Phase I","probability_of_success":0.55},{"cost_usd":130000000,"duration_months":30,"name":"Phase II","probability_of_success":0.4},{"cost_usd":320000000,"duration_months":36,"name":"Phase III","probability_of_success":0.62},{"cost_usd":14000000,"duration_months":12,"name":"NDA/BLA Review","probability_of_success":0.92}],"wacc_base":0.12},"rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/53237","subscores":{"clinical_relevance":0.55,"ira_exposure":0.9,"modality_pos":1,"whitespace":0.5},"target":null,"title":"VR-Expressing Cells against Multiple Cytokines and Uses Thereof"},{"biomarker_overlap":"TDP-43 cryptic exon splicing","composite_score":0.6643988269794722,"cr_rationale":"ALS/FTD/LATE have no approved disease-modifying therapies; TDP-43 antibody targets unmet need directly.","description_excerpt":"Unmet Need: TDP-43 (Tar DNA-binding protein 43) acts as a guardian of the transcriptome by repressing the splicing of non-conserved, unannotated cryptic exons. Loss of TDP-43 function causes neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Limb","dev_stage":"unknown","exclusivity_status":"unknown","indication":"other","indication_free_text":"ALS, frontotemporal dementia (FTD), Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE), Alzheimer's Disease","landscape_kpis":{"approvals":0,"comparable_trials":0,"sponsors":0},"mechanism_class":"TDP-43 binding antibody","modality":"monoclonal_antibody","objectID":"51433","rationale_one_line":"Novel antibody targeting TDP-43 for neurodegenerative diseases (ALS, FTD, LATE, AD); classified under Proteins/therapeutic antibodies; none of these indications map to the 11 enums so maps to other.","rnpv_envelope":{"cumulative_pos":0.004521,"engine_version":"1.0.0","fallback_profile_used":true,"peak_revenue_base_usd":600000000,"rnpv_base_usd":-11241230.12,"rnpv_high_usd":-8258985.4,"rnpv_low_usd":-12532129.7,"stages_assumed":[{"cost_usd":12000000,"duration_months":24,"name":"Preclinical","probability_of_success":0.06},{"cost_usd":45000000,"duration_months":18,"name":"Phase I","probability_of_success":0.46},{"cost_usd":100000000,"duration_months":30,"name":"Phase II","probability_of_success":0.3},{"cost_usd":280000000,"duration_months":36,"name":"Phase III","probability_of_success":0.6},{"cost_usd":12000000,"duration_months":12,"name":"NDA/BLA Review","probability_of_success":0.91}],"wacc_base":0.12},"rubric_version":"rubric@2026-Q2-v3","source_url":"https://jhu.technologypublisher.com/technology/51433","subscores":{"clinical_relevance":0.9,"ira_exposure":0.85,"modality_pos":0.5146627565982402,"whitespace":0.5},"target":"TDP-43","title":"Novel Antibody and Assay for Early-stage Detection and Treatment Optimization of ALS, FTD, LATE and AD"}]}}